Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,966152,maximal rate of transport,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[mg] / [h],12,85,DB00563,Methotrexate
,966152,transport constant,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[mg] / [h],12,86,DB00563,Methotrexate
,966152,transport constant,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[mg] / [l],32,87,DB00563,Methotrexate
,966152,Michaelis constant,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[mg] / [l],32,88,DB00563,Methotrexate
,966152,Michaelis constant,"Values for the maximal rate of transport and a transport constant analogous to the Michaelis constant were 12 mg/hr and 32 mg/liter (7 x 10-5 M), respectively.",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),M,7 x,89,DB00563,Methotrexate
,966152,Ki,"The value of Ki, the dissociation constant for the transport carrier-inhibitor complex, was 23 mug/ml (8 x10-5 M).",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[μg] / [ml],23,90,DB00563,Methotrexate
,966152,dissociation constant,"The value of Ki, the dissociation constant for the transport carrier-inhibitor complex, was 23 mug/ml (8 x10-5 M).",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),[μg] / [ml],23,91,DB00563,Methotrexate
,966152,dissociation constant,"The value of Ki, the dissociation constant for the transport carrier-inhibitor complex, was 23 mug/ml (8 x10-5 M).",Biliary secretion of methotrexate in rats and its inhibition by probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966152/),M,8 x10-5,92,DB00563,Methotrexate
,17195068,total clearance (CL),"The following population parameters were obtained: total clearance (CL) = 8.8 l/h (inter-individual variability: 43%), initial volume of distribution (V1) = 17.3 l (48%), k12 = 0.0225 h(-1) (41%), and k21 = 0.0629 h(-1) (24%).",A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195068/),[l] / [h],8.8,1494,DB00563,Methotrexate
,17195068,initial volume of distribution (V1),"The following population parameters were obtained: total clearance (CL) = 8.8 l/h (inter-individual variability: 43%), initial volume of distribution (V1) = 17.3 l (48%), k12 = 0.0225 h(-1) (41%), and k21 = 0.0629 h(-1) (24%).",A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195068/),l,17.3,1495,DB00563,Methotrexate
,17195068,k12,"The following population parameters were obtained: total clearance (CL) = 8.8 l/h (inter-individual variability: 43%), initial volume of distribution (V1) = 17.3 l (48%), k12 = 0.0225 h(-1) (41%), and k21 = 0.0629 h(-1) (24%).",A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195068/),1/[h],0.0225,1496,DB00563,Methotrexate
,17195068,k21,"The following population parameters were obtained: total clearance (CL) = 8.8 l/h (inter-individual variability: 43%), initial volume of distribution (V1) = 17.3 l (48%), k12 = 0.0225 h(-1) (41%), and k21 = 0.0629 h(-1) (24%).",A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17195068/),1/[h],0.0629,1497,DB00563,Methotrexate
,21209239,Urinary excretion,"Urinary excretion of MTX and 7-OH-MTX was also similar with or without R788, averaging 58% to 69% and 4% to 5% of the MTX dose, respectively.","Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209239/),%,58,2858,DB00563,Methotrexate
,21209239,Urinary excretion,"Urinary excretion of MTX and 7-OH-MTX was also similar with or without R788, averaging 58% to 69% and 4% to 5% of the MTX dose, respectively.","Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209239/),%,69,2859,DB00563,Methotrexate
,21209239,Urinary excretion,"Urinary excretion of MTX and 7-OH-MTX was also similar with or without R788, averaging 58% to 69% and 4% to 5% of the MTX dose, respectively.","Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209239/),%,4,2860,DB00563,Methotrexate
,21209239,Urinary excretion,"Urinary excretion of MTX and 7-OH-MTX was also similar with or without R788, averaging 58% to 69% and 4% to 5% of the MTX dose, respectively.","Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209239/),%,5,2861,DB00563,Methotrexate
,21171585,circulatory half-life,"A generation 5 PEGylated (PEG 1100) polylysine dendrimer, conjugated via a stable amide linker to OtBu protected methotrexate (MTX), was previously shown to have a circulatory half-life of 2 days and to target solid tumors in both rats and mice.",Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21171585/),d,2,4416,DB00563,Methotrexate
,2809687,peak intra,"Using a fluorescence polarized immunoassay (TDx; Abbott, Dallas, TX), the median peak intraventricular CSF MTX concentration (CSF [MTX]) was 423 mumol/L. Median CSF [MTX] at 24 hours was 4.6 mumol/L, and at 48 hours was 1.05 mumol/L. Median MTX half-life (t1/2) was 5.7 hours.",Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2809687/),[μM] / [l],423,4899,DB00563,Methotrexate
,2809687,CSF [MTX],"Using a fluorescence polarized immunoassay (TDx; Abbott, Dallas, TX), the median peak intraventricular CSF MTX concentration (CSF [MTX]) was 423 mumol/L. Median CSF [MTX] at 24 hours was 4.6 mumol/L, and at 48 hours was 1.05 mumol/L. Median MTX half-life (t1/2) was 5.7 hours.",Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2809687/),[μM] / [l],4.6,4900,DB00563,Methotrexate
,2809687,CSF [MTX],"Using a fluorescence polarized immunoassay (TDx; Abbott, Dallas, TX), the median peak intraventricular CSF MTX concentration (CSF [MTX]) was 423 mumol/L. Median CSF [MTX] at 24 hours was 4.6 mumol/L, and at 48 hours was 1.05 mumol/L. Median MTX half-life (t1/2) was 5.7 hours.",Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2809687/),[μM] / [l],1.05,4901,DB00563,Methotrexate
,2809687,half-life (t1/2),"Using a fluorescence polarized immunoassay (TDx; Abbott, Dallas, TX), the median peak intraventricular CSF MTX concentration (CSF [MTX]) was 423 mumol/L. Median CSF [MTX] at 24 hours was 4.6 mumol/L, and at 48 hours was 1.05 mumol/L. Median MTX half-life (t1/2) was 5.7 hours.",Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2809687/),h,5.7,4902,DB00563,Methotrexate
greater,2809687,CSF [MTX],A CSF [MTX] greater than 1 mumol/L was maintained for 24 hours in all but one course and for 48 hours in half of the courses.,Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2809687/),[μM] / [l],1,4903,DB00563,Methotrexate
,2809687,minimum CSF [MTX],"A schedule for intraventricular MTX with an initial dose of 6 mg and supplemental doses of 6, 4, or 2 mg at 24 and 48 hours according to serial measurements of intraventricular [MTX] should be initiated to provide a minimum CSF [MTX] of 1 mumol/L for 72 hours.",Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2809687/),[μM] / [l],1,4904,DB00563,Methotrexate
,20030480,effluent rate,"The highest clearance rate among extracorporeal therapies was achieved by CVVHDF, with an effluent rate of 4950 ml/hour.",Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20030480/),[ml] / [h],4950,5192,DB00563,Methotrexate
,15853212,overall survival rate,The one-year overall survival rate was 50. 0%.,[Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853212/),%,50. 0,6170,DB00563,Methotrexate
,15853212,survival time,The median survival time was 311 days.,[Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853212/),d,311,6171,DB00563,Methotrexate
,627142,clearance,Plasma methotrexate clearance decreased from 79 ml/min 30 min into hemoperfusion to 28 ml/min at the conclusion.,Hemoperfusion for methotrexate removal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627142/),[ml] / [min],79,6665,DB00563,Methotrexate
,627142,clearance,Plasma methotrexate clearance decreased from 79 ml/min 30 min into hemoperfusion to 28 ml/min at the conclusion.,Hemoperfusion for methotrexate removal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/627142/),[ml] / [min],28,6666,DB00563,Methotrexate
,8929495,K1,"Baseline K1 values were 2.1 +/- 1.4 and 34.1 +/- 22.1 microl/minute/ml (+/- standard deviation) for brain and tumor, respectively.",Quantification and pharmacokinetics of blood-brain barrier disruption in humans. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929495/),[μl] / [min·ml],2.1,6793,DB00563,Methotrexate
,8929495,K1,"Baseline K1 values were 2.1 +/- 1.4 and 34.1 +/- 22.1 microl/minute/ml (+/- standard deviation) for brain and tumor, respectively.",Quantification and pharmacokinetics of blood-brain barrier disruption in humans. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929495/),[μl] / [min·ml],34.1,6794,DB00563,Methotrexate
,8929495,peak absolute increases,"The peak absolute increases in K1 following HBBBD were 20.8 +/- 11.7 and 19.7 +/- 10.7 microl/minute/ml for brain and tumor, corresponding to percentage increases of approximately 1000% in brain and approximately 60% in tumor.",Quantification and pharmacokinetics of blood-brain barrier disruption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929495/),[μl] / [min·ml],20.8,6795,DB00563,Methotrexate
,8929495,peak absolute increases,"The peak absolute increases in K1 following HBBBD were 20.8 +/- 11.7 and 19.7 +/- 10.7 microl/minute/ml for brain and tumor, corresponding to percentage increases of approximately 1000% in brain and approximately 60% in tumor.",Quantification and pharmacokinetics of blood-brain barrier disruption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929495/),[μl] / [min·ml],19.7,6796,DB00563,Methotrexate
,8929495,K1,"The peak absolute increases in K1 following HBBBD were 20.8 +/- 11.7 and 19.7 +/- 10.7 microl/minute/ml for brain and tumor, corresponding to percentage increases of approximately 1000% in brain and approximately 60% in tumor.",Quantification and pharmacokinetics of blood-brain barrier disruption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929495/),[μl] / [min·ml],20.8,6797,DB00563,Methotrexate
,8929495,K1,"The peak absolute increases in K1 following HBBBD were 20.8 +/- 11.7 and 19.7 +/- 10.7 microl/minute/ml for brain and tumor, corresponding to percentage increases of approximately 1000% in brain and approximately 60% in tumor.",Quantification and pharmacokinetics of blood-brain barrier disruption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929495/),[μl] / [min·ml],19.7,6798,DB00563,Methotrexate
,8929495,halftimes,"The halftimes for return of K1 to near baseline for brain and tumor were 8.1 +/- 3.8 and 4.2 +/- 1.2 minutes, respectively.",Quantification and pharmacokinetics of blood-brain barrier disruption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929495/),min,8.1,6799,DB00563,Methotrexate
,8929495,halftimes,"The halftimes for return of K1 to near baseline for brain and tumor were 8.1 +/- 3.8 and 4.2 +/- 1.2 minutes, respectively.",Quantification and pharmacokinetics of blood-brain barrier disruption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8929495/),min,4.2,6800,DB00563,Methotrexate
,34378331,clearance,Median clearance was similar across three dosing levels at 4.5-5.6 L/h and was consistent with linear PKs.,Propsective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34378331/),[l] / [h],4.5-5.6,7095,DB00563,Methotrexate
,23138519,flow rate,"The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×3 mm i.d., 4.6 µ) using methanol: 2 mM ammonium acetate buffer, pH 4.0 as mobile phase at a flow rate 1 mL/min in gradient mode.","Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138519/),[ml] / [min],1,7934,DB00563,Methotrexate
>,23138519,recoveries,The recoveries from spiked control samples were > 79% for all analytes and internal standard Intra- and Interday accuracy and precision of validated method were within the acceptable limits of < 15% at all concentration.,"Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138519/),%,79,7935,DB00563,Methotrexate
,33081266,droplet,"Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, -35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively.",Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081266/),nm,173.77,9812,DB00563,Methotrexate
,33081266,zeta potential,"Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, -35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively.",Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081266/),m,-,9813,DB00563,Methotrexate
,33081266,encapsulation efficiency,"Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, -35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively.",Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081266/),m,-,9814,DB00563,Methotrexate
,33081266,pH,"Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, -35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively.",Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081266/),,4.07,9815,DB00563,Methotrexate
,22169051,trough serum concentrations,"After SC golimumab administration, the serum golimumab concentration achieved steady state by ∼12 weeks with mean trough serum concentrations ranging from 1.15 to 1.24 μg/mL.","Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169051/),[μg] / [ml],1.15 to 1.24,10840,DB00563,Methotrexate
,22169051,clearance (CL),"After the final 30-minute IV infusion of golimumab 2 mg/kg, the mean (SD) clearance (CL) was 7.5 (2.6) mL/d/kg.","Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169051/),[ml] / [d·kg],7.5,10841,DB00563,Methotrexate
,22169051,terminal half-life,The mean terminal half-life after SC and IV administrations was ∼13 days.,"Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169051/),d,∼13,10842,DB00563,Methotrexate
,22169051,absolute bioavailability,The mean absolute bioavailability for SC golimumab was estimated to be 53%.,"Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169051/),%,53,10843,DB00563,Methotrexate
,22169051,CL/F,"The geometric mean of golimumab CL/F in patients with and without concomitant MTX use was 13.9 and 21.2 mL/d/kg, respectively, and the geometric mean ratio of CL/F was 65.5% (90% CI: 45.2%-94.9%, P = 0.06).","Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169051/),[ml] / [d·kg],13.9,10844,DB00563,Methotrexate
,22169051,CL/F,"The geometric mean of golimumab CL/F in patients with and without concomitant MTX use was 13.9 and 21.2 mL/d/kg, respectively, and the geometric mean ratio of CL/F was 65.5% (90% CI: 45.2%-94.9%, P = 0.06).","Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169051/),[ml] / [d·kg],21.2,10845,DB00563,Methotrexate
,30288039,zeta potential,The NPs had a zeta potential of +7.4-35.0 mV and MTX loading efficiency of 17.1%-18.4%.,Effects of PEG surface density and chain length on the pharmacokinetics and biodistribution of methotrexate-loaded chitosan nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30288039/),mv,7.4,11583,DB00563,Methotrexate
,30288039,zeta potential,The NPs had a zeta potential of +7.4-35.0 mV and MTX loading efficiency of 17.1%-18.4%.,Effects of PEG surface density and chain length on the pharmacokinetics and biodistribution of methotrexate-loaded chitosan nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30288039/),mv,35.0,11584,DB00563,Methotrexate
,30288039,loading efficiency,The NPs had a zeta potential of +7.4-35.0 mV and MTX loading efficiency of 17.1%-18.4%.,Effects of PEG surface density and chain length on the pharmacokinetics and biodistribution of methotrexate-loaded chitosan nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30288039/),%,17.1,11585,DB00563,Methotrexate
,30288039,loading efficiency,The NPs had a zeta potential of +7.4-35.0 mV and MTX loading efficiency of 17.1%-18.4%.,Effects of PEG surface density and chain length on the pharmacokinetics and biodistribution of methotrexate-loaded chitosan nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30288039/),%,18.4,11586,DB00563,Methotrexate
,2231218,Plasma clearance,"Plasma clearance of total MTX did not change significantly, whereas clearance of free MTX decreased significantly (from 12.5 +/- 4 to 7.6 +/- 1.5 ml/kg/min; p less than 0.05).",Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],12.5,13112,DB00563,Methotrexate
,2231218,clearance,"Plasma clearance of total MTX did not change significantly, whereas clearance of free MTX decreased significantly (from 12.5 +/- 4 to 7.6 +/- 1.5 ml/kg/min; p less than 0.05).",Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],12.5,13113,DB00563,Methotrexate
,2231218,clearance,"Plasma clearance of total MTX did not change significantly, whereas clearance of free MTX decreased significantly (from 12.5 +/- 4 to 7.6 +/- 1.5 ml/kg/min; p less than 0.05).",Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],7.6,13114,DB00563,Methotrexate
,2231218,renal clearance,There was a consistent decrease in the renal clearance of free MTX (from 12.1 +/- 6.8 to 5.6 +/- 2.4 ml/kg/min; p less than 0.05).,Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],12.1,13115,DB00563,Methotrexate
,2231218,renal clearance,There was a consistent decrease in the renal clearance of free MTX (from 12.1 +/- 6.8 to 5.6 +/- 2.4 ml/kg/min; p less than 0.05).,Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231218/),[ml] / [kg·min],5.6,13116,DB00563,Methotrexate
,8164303,AUC0-3,The mean AUC0-3 in the PD group was 43.6 +/- 3.9 micrograms/mL per hour compared with 15.8 +/- 1.1 micrograms/mL per hour in the control group (p < .001).,Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164303/),[μg] / [h·ml],43.6,13625,DB00563,Methotrexate
,8164303,AUC0-3,The mean AUC0-3 in the PD group was 43.6 +/- 3.9 micrograms/mL per hour compared with 15.8 +/- 1.1 micrograms/mL per hour in the control group (p < .001).,Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164303/),[μg] / [h·ml],15.8,13626,DB00563,Methotrexate
,30497012,zeta potential,"Optimized formulation depicted 223.6 ± 24.1 nm particle size, 0.243 ± 0.034 PDI, zeta potential -2.07 ± 0.51 mV and 15.03 ± 1.92%drug loading.",Lipid and TPGS based novel core-shell type nanocapsular sustained release system of methotrexate for intravenous application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30497012/),mv,2.07,13700,DB00563,Methotrexate
,15060739,Normalized clearance,Normalized clearance of MDAM was approximately 1.5 times that reported for MTX (125 vs 80 ml/min per m2) in adults.,Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060739/),[ml] / [m2·min],125,13873,DB00563,Methotrexate
,15060739,Normalized clearance,Normalized clearance of MDAM was approximately 1.5 times that reported for MTX (125 vs 80 ml/min per m2) in adults.,Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060739/),[ml] / [m2·min],80,13874,DB00563,Methotrexate
,7714737,Keq,The purified antibodies have been shown to have high affinity (Keq range: 1.8 x 10(8) to 8.75 x 10(9) M-1) and high selectivity for methotrexate.,"High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),1/[M],1.8 x 10(8),14733,DB00563,Methotrexate
,7714737,Keq,The purified antibodies have been shown to have high affinity (Keq range: 1.8 x 10(8) to 8.75 x 10(9) M-1) and high selectivity for methotrexate.,"High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),1/[M],8.75 x 10(9),14734,DB00563,Methotrexate
,7714737,steady state volume of distribution,"Preliminary pharmacokinetic studies of the purified antibodies in the rat following a 6 mg/kg intravenous infusion (n = 4) indicate a steady state volume of distribution of 38.0 +/- 11.2 mL kg-1, a systemic clearance of 0.92 +/- 0.67 mL kg-1 h-1 and an elimination half life of 28.9 +/- 7.9 h (mean +/- SD).","High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),[ml] / [kg],38.0,14735,DB00563,Methotrexate
,7714737,systemic clearance,"Preliminary pharmacokinetic studies of the purified antibodies in the rat following a 6 mg/kg intravenous infusion (n = 4) indicate a steady state volume of distribution of 38.0 +/- 11.2 mL kg-1, a systemic clearance of 0.92 +/- 0.67 mL kg-1 h-1 and an elimination half life of 28.9 +/- 7.9 h (mean +/- SD).","High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),[ml] / [h·kg],0.92,14736,DB00563,Methotrexate
,7714737,elimination half life,"Preliminary pharmacokinetic studies of the purified antibodies in the rat following a 6 mg/kg intravenous infusion (n = 4) indicate a steady state volume of distribution of 38.0 +/- 11.2 mL kg-1, a systemic clearance of 0.92 +/- 0.67 mL kg-1 h-1 and an elimination half life of 28.9 +/- 7.9 h (mean +/- SD).","High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714737/),h,28.9,14737,DB00563,Methotrexate
,21509569,clearance,"The population typical value of clearance was 7.43 L/h (inter-individual variability 43.9%), central compartment volume was 16.7 L (46.6%), peripheral compartment volume was 2.6 L (63.3%) and distribution clearance was 0.0952 L/h (66.6%).",Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21509569/),[l] / [h],7.43,15857,DB00563,Methotrexate
,21509569,central compartment volume,"The population typical value of clearance was 7.43 L/h (inter-individual variability 43.9%), central compartment volume was 16.7 L (46.6%), peripheral compartment volume was 2.6 L (63.3%) and distribution clearance was 0.0952 L/h (66.6%).",Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21509569/),l,16.7,15858,DB00563,Methotrexate
,21509569,peripheral compartment volume,"The population typical value of clearance was 7.43 L/h (inter-individual variability 43.9%), central compartment volume was 16.7 L (46.6%), peripheral compartment volume was 2.6 L (63.3%) and distribution clearance was 0.0952 L/h (66.6%).",Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21509569/),l,2.6,15859,DB00563,Methotrexate
,21509569,distribution clearance,"The population typical value of clearance was 7.43 L/h (inter-individual variability 43.9%), central compartment volume was 16.7 L (46.6%), peripheral compartment volume was 2.6 L (63.3%) and distribution clearance was 0.0952 L/h (66.6%).",Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21509569/),[l] / [h],0.0952,15860,DB00563,Methotrexate
,23187460,CSF,The CSF penetration rate of MTX was independent of the MTX dose [2.3% (95% confidence interval: 1.7-2.5%) vs. 2.8% (95% confidence interval: 2.4-3%)].,Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23187460/),%,2.3,15945,DB00563,Methotrexate
,23187460,penetration rate,The CSF penetration rate of MTX was independent of the MTX dose [2.3% (95% confidence interval: 1.7-2.5%) vs. 2.8% (95% confidence interval: 2.4-3%)].,Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23187460/),%,2.3,15946,DB00563,Methotrexate
,23187460,penetration rate,The CSF penetration rate of MTX was independent of the MTX dose [2.3% (95% confidence interval: 1.7-2.5%) vs. 2.8% (95% confidence interval: 2.4-3%)].,Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23187460/),%,2.8,15947,DB00563,Methotrexate
,6539365,half-life,These values were compared to a mean half-life of 2.83 (+/- 0.34) hours following 489 courses administered to 71 patients who had not received cisplatin.,The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539365/),h,2.83,16994,DB00563,Methotrexate
,10443172,polydispersity,The size was 70-76 nm and the polydispersity was 0.09-0.18.,Lipoprotein-mimicking biovectorized systems for methotrexate delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443172/),,0.09-0.18,17435,DB00563,Methotrexate
,10443172,zeta potential,The zeta potential was -63.2 which was reduced to -19.3 after p-PEG 4000 coating.,Lipoprotein-mimicking biovectorized systems for methotrexate delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443172/),,63.2,17436,DB00563,Methotrexate
,10443172,zeta potential,The zeta potential was -63.2 which was reduced to -19.3 after p-PEG 4000 coating.,Lipoprotein-mimicking biovectorized systems for methotrexate delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443172/),,19.3,17437,DB00563,Methotrexate
,10443172,Entrapment efficiency,Entrapment efficiency varied from 22.6% to 30.2%.,Lipoprotein-mimicking biovectorized systems for methotrexate delivery. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443172/),%,22.6,17438,DB00563,Methotrexate
,10443172,Entrapment efficiency,Entrapment efficiency varied from 22.6% to 30.2%.,Lipoprotein-mimicking biovectorized systems for methotrexate delivery. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443172/),%,30.2,17439,DB00563,Methotrexate
,10443172,Anchoring efficiency,Anchoring efficiency was 74.0 +/- 3.9%.,Lipoprotein-mimicking biovectorized systems for methotrexate delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443172/),%,74.0,17440,DB00563,Methotrexate
,16842380,clearance (CLMTX),"Values for MTX clearance (CLMTX) and 7-OH-MTX clearance (CL7-OH-MTX) were estimated at 8.85 and 2 L-1, respectively.",Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842380/),1/[l],8.85,17563,DB00563,Methotrexate
,16842380,clearance (CL7-OH-,"Values for MTX clearance (CLMTX) and 7-OH-MTX clearance (CL7-OH-MTX) were estimated at 8.85 and 2 L-1, respectively.",Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842380/),1/[l],2,17564,DB00563,Methotrexate
,16842380,plasma concentrations,"7-OH-MTX plasma concentrations were also significantly higher in patients with concurrent benzimidazoles as compared with patients without benzimidazoles at 24 h (4.47 micromol L-1vs. 2.52 micromol L-1, P=0.0009) and at 48 h (1.11 micromol L-1vs. 0.72 micromol L-1, P=0.031).",Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842380/),[μM] / [l],4.47,17565,DB00563,Methotrexate
,16842380,plasma concentrations,"7-OH-MTX plasma concentrations were also significantly higher in patients with concurrent benzimidazoles as compared with patients without benzimidazoles at 24 h (4.47 micromol L-1vs. 2.52 micromol L-1, P=0.0009) and at 48 h (1.11 micromol L-1vs. 0.72 micromol L-1, P=0.031).",Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842380/),[μM] / [l],2.52,17566,DB00563,Methotrexate
,16842380,plasma concentrations,"7-OH-MTX plasma concentrations were also significantly higher in patients with concurrent benzimidazoles as compared with patients without benzimidazoles at 24 h (4.47 micromol L-1vs. 2.52 micromol L-1, P=0.0009) and at 48 h (1.11 micromol L-1vs. 0.72 micromol L-1, P=0.031).",Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842380/),[μM] / [l],1.11,17567,DB00563,Methotrexate
,16842380,plasma concentrations,"7-OH-MTX plasma concentrations were also significantly higher in patients with concurrent benzimidazoles as compared with patients without benzimidazoles at 24 h (4.47 micromol L-1vs. 2.52 micromol L-1, P=0.0009) and at 48 h (1.11 micromol L-1vs. 0.72 micromol L-1, P=0.031).",Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842380/),[μM] / [l],0.72,17568,DB00563,Methotrexate
,9402310,tumor accumulation rates,Favorable tumor accumulation rates of about 14% were achieved for MTX(1)-RSA versus 0.04% for MTX.,Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402310/),%,14,17820,DB00563,Methotrexate
,9402310,tumor accumulation rates,Favorable tumor accumulation rates of about 14% were achieved for MTX(1)-RSA versus 0.04% for MTX.,Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402310/),%,0.04,17821,DB00563,Methotrexate
,23179005,blood flow rate,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],160-300,18219,DB00563,Methotrexate
,23179005,blood flow rate,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],0 and 4.3,18220,DB00563,Methotrexate
,23179005,clearances,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],1.1 and 3.4,18221,DB00563,Methotrexate
,23179005,Total amount of teriflunomide removed,Total amount of teriflunomide removed was 5.8-8.8 μg per dialysis session.,Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),μg,5.8-8.8,18222,DB00563,Methotrexate
,31152507,maximum observed concentrations (Cmax),"The results showed that the maximum observed concentrations (Cmax) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m2 6R,S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],3137.917,19100,DB00563,Methotrexate
,31152507,maximum observed concentrations (Cmax),"The results showed that the maximum observed concentrations (Cmax) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m2 6R,S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],1679.633,19101,DB00563,Methotrexate
,31152507,areas under the curve from the time of dosing to the last measurable concentration (AUC0-t),"The results showed that the maximum observed concentrations (Cmax) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m2 6R,S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],7504.883,19102,DB00563,Methotrexate
,31152507,areas under the curve from the time of dosing to the last measurable concentration (AUC0-t),"The results showed that the maximum observed concentrations (Cmax) of 6S-leucovorin and L-5-methyltetrahydrofolate were (3137.917±408.837) and (1679.633±244.132) μg/L, respectively, and the areas under the curve from the time of dosing to the last measurable concentration (AUC0-t) were (7504.883±1185.101) and (14001.214±2868.949) μg/L in the 125 mg/m2 6R,S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],14001.214,19103,DB00563,Methotrexate
,31152507,Cmax,"The Cmax values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m2 6S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],3187.917,19104,DB00563,Methotrexate
,31152507,Cmax,"The Cmax values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m2 6S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],1739.204,19105,DB00563,Methotrexate
,31152507,AUC0-t,"The Cmax values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m2 6S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],7426.664,19106,DB00563,Methotrexate
,31152507,AUC0-t,"The Cmax values of 6S-leucovorin and L-5-methyltetrahydrofolate were (3187.917±387.298) and (1739.204±224.755) μg/L, respectively, and AUC0-t values were (7426.664±854.825) and (14884.331±1843.353) μg/L in the 62.5 mg/m2 6S-leucovorin dose group.",[Simultaneous determination of leucovorin and 5-methyl-tetrahydrofolate diastereoisomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry coupled with ultrafiltration centrifugation-based pretreatment and its application to a pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152507/),[μg] / [l],14884.331,19107,DB00563,Methotrexate
,8584484,concentration ratios,The plasma/SF concentration ratios of 1.16 +/- 0.25 were maintained after the attainment of distribution equilibrium between the two compartments.,Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584484/),,1.16,20324,DB00563,Methotrexate
,8584484,t1/2,"The t1/2 values in the plasma (11.2 +/- 1.2 hr) and SF (12.7 +/- 3.7 hr) were similar during the elimination phase, while the MRT in SF (3.24 +/- 0.21 hr) was longer than that in plasma (2.56 +/- 0.20 hr), probably due to the slow distribution of MTX to SF.",Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584484/),h,11.2,20325,DB00563,Methotrexate
,8584484,t1/2,"The t1/2 values in the plasma (11.2 +/- 1.2 hr) and SF (12.7 +/- 3.7 hr) were similar during the elimination phase, while the MRT in SF (3.24 +/- 0.21 hr) was longer than that in plasma (2.56 +/- 0.20 hr), probably due to the slow distribution of MTX to SF.",Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584484/),h,12.7,20326,DB00563,Methotrexate
,8584484,MRT,"The t1/2 values in the plasma (11.2 +/- 1.2 hr) and SF (12.7 +/- 3.7 hr) were similar during the elimination phase, while the MRT in SF (3.24 +/- 0.21 hr) was longer than that in plasma (2.56 +/- 0.20 hr), probably due to the slow distribution of MTX to SF.",Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584484/),h,3.24,20327,DB00563,Methotrexate
,8584484,MRT,"The t1/2 values in the plasma (11.2 +/- 1.2 hr) and SF (12.7 +/- 3.7 hr) were similar during the elimination phase, while the MRT in SF (3.24 +/- 0.21 hr) was longer than that in plasma (2.56 +/- 0.20 hr), probably due to the slow distribution of MTX to SF.",Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584484/),h,2.56,20328,DB00563,Methotrexate
,8584484,bioavailability,"The bioavailability of MTX from the gel was 11.8 +/- 3.3% of the applied dose, but muscle tissues beneath the gel application site had significantly higher levels of MTX than untreated muscle tissues.",Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584484/),%,11.8,20329,DB00563,Methotrexate
,26150601,response rate,The ACR20 response rate at week 24 in the per-protocol set was 78.1% for SB4 and 80.3% for ETN.,"A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150601/),%,78.1,20731,DB00563,Methotrexate
,26150601,response rate,The ACR20 response rate at week 24 in the per-protocol set was 78.1% for SB4 and 80.3% for ETN.,"A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26150601/),%,80.3,20732,DB00563,Methotrexate
,25659459,time from diagnosis to HCT,"The median number of previous therapies was 3 (range, 1-8) and median time from diagnosis to HCT was 32 months (range, 4.5-177.5 months).",Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25659459/),month,32,21467,DB00563,Methotrexate
,25659459,overall survival,"Three-year progression-free and overall survival for all patients was 47.8% and 55%, respectively.",Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25659459/),,55,21468,DB00563,Methotrexate
,6369203,plasma halflife,"Despite the short plasma halflife of 5-Fluorouracil (16,8 min) distinct concentrations with peak levels up to 115 nmol/ml after 30 min were observed in the effusions.",[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6369203/),min,"16,8",22288,DB00563,Methotrexate
,6369203,t 1/2,"In consequence of the rapid elimination of 5-Fluorouracil from the plasma and the comparatively slow retrograde diffusion (t 1/2 55 min) from the pleural space, the drug levels persisted longer in the effusions, than in the blood.",[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6369203/),min,55,22289,DB00563,Methotrexate
,6369203,AUC,"Thus the area under the curve of the pleural level (AUC) reached 50% (27-85%) of the corresponding plasma AUC (10,9 +/- 2,3 mumol x min x ml-1).",[Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6369203/),[min·μM] / [ml],"10,9",22290,DB00563,Methotrexate
,3431592,overall response rates,"The overall response rates in 24 evaluable patients with head and neck cancer, 21 evaluable patients with bladder cancer, and 22 evaluable patients with cervical cancer were 54%, 57%, and 50%, respectively.",Cisplatin and dichloromethotrexate: a pharmacologically rational combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431592/),%,54,22586,DB00563,Methotrexate
,3431592,overall response rates,"The overall response rates in 24 evaluable patients with head and neck cancer, 21 evaluable patients with bladder cancer, and 22 evaluable patients with cervical cancer were 54%, 57%, and 50%, respectively.",Cisplatin and dichloromethotrexate: a pharmacologically rational combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431592/),%,57,22587,DB00563,Methotrexate
,3431592,overall response rates,"The overall response rates in 24 evaluable patients with head and neck cancer, 21 evaluable patients with bladder cancer, and 22 evaluable patients with cervical cancer were 54%, 57%, and 50%, respectively.",Cisplatin and dichloromethotrexate: a pharmacologically rational combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431592/),%,50,22588,DB00563,Methotrexate
,3431592,Complete response rates,"Complete response rates of 25%, 19%, and 36%, respectively, were observed.",Cisplatin and dichloromethotrexate: a pharmacologically rational combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431592/),%,25,22589,DB00563,Methotrexate
,3431592,Complete response rates,"Complete response rates of 25%, 19%, and 36%, respectively, were observed.",Cisplatin and dichloromethotrexate: a pharmacologically rational combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431592/),%,19,22590,DB00563,Methotrexate
,3431592,Complete response rates,"Complete response rates of 25%, 19%, and 36%, respectively, were observed.",Cisplatin and dichloromethotrexate: a pharmacologically rational combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431592/),%,36,22591,DB00563,Methotrexate
,2586358,Elimination T1/2,"Elimination T1/2 was between 1.34 and 5 hours (mean 2.16 +/- 0.23 hr, mean +/- SE).",Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2586358/),h,2.16,22653,DB00563,Methotrexate
,2586358,AUC,"There was a significantly larger AUC of 6MP achieved by a standardized dose in longer therapy (greater than 15 mo) vs. short therapy (less than 12 mo) (462 +/- 75 and 246 +/- 58 ng.ml-1.min.mg-1.m2, P less than 0.025).",Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2586358/),[m2·min·ng] / [mg·ml],462,22654,DB00563,Methotrexate
,2586358,AUC,"There was a significantly larger AUC of 6MP achieved by a standardized dose in longer therapy (greater than 15 mo) vs. short therapy (less than 12 mo) (462 +/- 75 and 246 +/- 58 ng.ml-1.min.mg-1.m2, P less than 0.025).",Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2586358/),[m2·min·ng] / [mg·ml],246,22655,DB00563,Methotrexate
,15987831,area under concentration-time curve (AUC)(brain)/AUC(plasma) ratio,The mean area under concentration-time curve (AUC)(brain)/AUC(plasma) ratio of unbound pemetrexed was 0.078 +/- 0.038 in the i.v. bolus study.,Distribution of the novel antifolate pemetrexed to the brain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987831/),,0.078,22824,DB00563,Methotrexate
,15987831,steady-state brain-to-plasma unbound concentration ratio,The pemetrexed steady-state brain-to-plasma unbound concentration ratio after i.v. infusion was 0.106 +/- 0.054.,Distribution of the novel antifolate pemetrexed to the brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987831/),,0.106,22825,DB00563,Methotrexate
,30835935,plasma MTX,"Moderately delayed MTX elimination was defined as 42-hour plasma MTX ≥ 4.0-9.9 μM, and severely delayed elimination was defined as 42-hour plasma MTX ≥ 10 μM.",Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30835935/),h,42,23549,DB00563,Methotrexate
≥,30835935,plasma MTX,"Moderately delayed MTX elimination was defined as 42-hour plasma MTX ≥ 4.0-9.9 μM, and severely delayed elimination was defined as 42-hour plasma MTX ≥ 10 μM.",Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30835935/),μM,4.0-9.9,23550,DB00563,Methotrexate
≥,30835935,plasma MTX,"Moderately delayed MTX elimination was defined as 42-hour plasma MTX ≥ 4.0-9.9 μM, and severely delayed elimination was defined as 42-hour plasma MTX ≥ 10 μM.",Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30835935/),μM,10,23551,DB00563,Methotrexate
,30835935,MTX,"Median 42-hour plasma MTX was 0.61 μM (interquartile range, 0.4-1.06 μM).",Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30835935/),μM,0.61,23552,DB00563,Methotrexate
,11103239,index,"However, the dialysis index was about 75 and 85% in the 3rd and 4th cycles, respectively.","[Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103239/),,75,24119,DB00563,Methotrexate
,11103239,index,"However, the dialysis index was about 75 and 85% in the 3rd and 4th cycles, respectively.","[Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103239/),,85,24120,DB00563,Methotrexate
,7273267,clearance,"Following oral administration, clearance values during the first 6 h were high at 257 +/- 8.3 (ml/Min), followed by a trough in clearance of 27.9 +/- 4.2 (ml/min) in the 20- to 30-h period.",Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273267/),[ml] / [Min],257,25547,DB00563,Methotrexate
,7273267,trough in clearance,"Following oral administration, clearance values during the first 6 h were high at 257 +/- 8.3 (ml/Min), followed by a trough in clearance of 27.9 +/- 4.2 (ml/min) in the 20- to 30-h period.",Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273267/),[ml] / [min],27.9,25548,DB00563,Methotrexate
,7273267,renal clearance,This was followed by a secondary rise of MTX renal clearance to 180.4 +/- 14.6 ml/min during the 68- to 84-h period and again to 84.9 +/- 17.1 ml/min between 84 and 112 h.,Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273267/),[ml] / [min],180.4,25549,DB00563,Methotrexate
,7273267,renal clearance,This was followed by a secondary rise of MTX renal clearance to 180.4 +/- 14.6 ml/min during the 68- to 84-h period and again to 84.9 +/- 17.1 ml/min between 84 and 112 h.,Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273267/),[ml] / [min],84.9,25550,DB00563,Methotrexate
,3500051,peak plasma concentration,"The patients received, first, two methotrexate intravenous bolus test doses (50 mg/m2) one with and one without concomitant administration of folinic acid (15 mg every 6 h) in a random sequence, and, second, an 8 h infusion, individualized to achieve a peak plasma concentration of 5 X 10(-4) M methotrexate (infusion rates greater than 1000 mg/h).",Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500051/),M,5 X 10(-4),28388,DB00563,Methotrexate
,7199304,absorption half-life,"The absorption half-life of 14C-TA was 5.3 min in the controls, 10.8 min in the methotrexate-intoxicated, 7.5 min in the fasted, and 5.3 min in the triparanol-intoxicated rats.",Intestinal absorption of tolfenamic acid at experimental malabsorption states in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199304/),min,5.3,28890,DB00563,Methotrexate
,7199304,absorption half-life,"The absorption half-life of 14C-TA was 5.3 min in the controls, 10.8 min in the methotrexate-intoxicated, 7.5 min in the fasted, and 5.3 min in the triparanol-intoxicated rats.",Intestinal absorption of tolfenamic acid at experimental malabsorption states in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199304/),min,10.8,28891,DB00563,Methotrexate
,7199304,absorption half-life,"The absorption half-life of 14C-TA was 5.3 min in the controls, 10.8 min in the methotrexate-intoxicated, 7.5 min in the fasted, and 5.3 min in the triparanol-intoxicated rats.",Intestinal absorption of tolfenamic acid at experimental malabsorption states in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199304/),min,7.5,28892,DB00563,Methotrexate
,7199304,absorbed fraction,The absorbed fraction of the intraduodenal 14C-TA dose was 100% in each experimental group as well as in the controls.,Intestinal absorption of tolfenamic acid at experimental malabsorption states in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199304/),%,100,28893,DB00563,Methotrexate
,27589009,volume of distribution (V),"In AS patients, volume of distribution (V) and elimination clearance (CL) were 5.4 L and 0.24 L/day, respectively.",The underlying inflammatory chronic disease influences infliximab pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27589009/),l,5.4,29968,DB00563,Methotrexate
,27589009,elimination clearance (CL),"In AS patients, volume of distribution (V) and elimination clearance (CL) were 5.4 L and 0.24 L/day, respectively.",The underlying inflammatory chronic disease influences infliximab pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27589009/),[l] / [d],0.24,29969,DB00563,Methotrexate
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,21,30243,DB00563,Methotrexate
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,66,30244,DB00563,Methotrexate
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,18,30245,DB00563,Methotrexate
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,74,30246,DB00563,Methotrexate
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30247,DB00563,Methotrexate
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30248,DB00563,Methotrexate
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30249,DB00563,Methotrexate
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,88,30250,DB00563,Methotrexate
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30251,DB00563,Methotrexate
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30252,DB00563,Methotrexate
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30253,DB00563,Methotrexate
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,71,30254,DB00563,Methotrexate
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.60,30255,DB00563,Methotrexate
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.57,30256,DB00563,Methotrexate
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.77,30257,DB00563,Methotrexate
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.86,30258,DB00563,Methotrexate
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.92,30259,DB00563,Methotrexate
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.96,30260,DB00563,Methotrexate
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4866.51,30261,DB00563,Methotrexate
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4980,30262,DB00563,Methotrexate
,8003056,AUC ratios,The median value of individual AUC ratios (MTX/MTX + CQ) was 1.6 (95% confidence interval 1.2-3.6).,Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8003056/),,1.6,30552,DB00563,Methotrexate
,27322715,clearance,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),[ml] / [m·min],110.7,31209,DB00563,Methotrexate
,27322715,clearance,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),[ml] / [m·min],108.2,31210,DB00563,Methotrexate
,27322715,42,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),μ,0.37,31211,DB00563,Methotrexate
,27322715,concentration,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),μ,0.37,31212,DB00563,Methotrexate
,27322715,concentration,"Among 176 patients (555 courses) on the low-risk arm (HDMTX=2.5 g/m/24 h), there was no difference in clearance (110.7 [1.8%] vs. 108.2 [0.9%] mL/min/m, P=0.3) nor in 42 hour methotrexate concentration (0.37 [5.1%] vs. 0.40 (5.0%) μM, P=0.23).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),μ,0.40,31213,DB00563,Methotrexate
,27322715,clearance,"Among 248 patients (830 courses) on the standard/high-risk arm (HDMTX ~5 g/m/24 h), there was slightly higher clearance (95.5 [1.4%] vs. 91.2 [0.8%] mL/min/m, P=0.005) in those receiving TMP/SMX, with no difference in the 42 hour methotrexate concentration (0.59 [4.1%] vs. 0.66 [4.2%] μM, P=0.06).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),[ml] / [m·min],95.5,31214,DB00563,Methotrexate
,27322715,clearance,"Among 248 patients (830 courses) on the standard/high-risk arm (HDMTX ~5 g/m/24 h), there was slightly higher clearance (95.5 [1.4%] vs. 91.2 [0.8%] mL/min/m, P=0.005) in those receiving TMP/SMX, with no difference in the 42 hour methotrexate concentration (0.59 [4.1%] vs. 0.66 [4.2%] μM, P=0.06).",Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27322715/),[ml] / [m·min],91.2,31215,DB00563,Methotrexate
,2970294,Terminal elimination half-lives,Terminal elimination half-lives were in the range of 5-14 h in patients represented by a triexponential model.,Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2970294/),h,5-14,31637,DB00563,Methotrexate
,22781384,perfusion rate,"The perfusion rate of 40 mL/h provoked perfusion-related symptoms, such as nausea/vomiting and insomnia, and revealed DLTs including encephalopathy in more than 1/3 of patients in both administration modes when the daily MTX dose of 40 mg was given.",Ventriculolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: a phase I study with pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22781384/),[ml] / [h],40,31862,DB00563,Methotrexate
,22781384,perfusion rate,This study disclosed the VLP chemotherapy with a perfusion rate of 20 mL/h and the daily MTX dose of 24 mg could be adopted for future study.,Ventriculolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: a phase I study with pharmacokinetic data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22781384/),[ml] / [h],20,31863,DB00563,Methotrexate
,2057988,terminal half-life,"However, a prolonged mean terminal half-life of 51.5 h was observed.",Methotrexate disposition following disruption of the blood-brain barrier. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057988/),h,51.5,32408,DB00563,Methotrexate
,17332143,renal clearance,"In dogs, DPC 333 administered orally at 1.7 mg/kg 15 min before the intravenous administration of [14C]MTX (0.5 mg/kg) did not alter the plasma concentration-time profile of MTX; however, the total amount of radioactivity excreted in urine increased from 58.7% to 92.2% of the dose, and the renal clearance increased from 1.8 ml/min/kg to 2.9 ml/min/kg, suggesting a decrease in MTX disposition via biliary excretion.","Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332143/),[ml] / [kg·min],1.8,33032,DB00563,Methotrexate
,17332143,renal clearance,"In dogs, DPC 333 administered orally at 1.7 mg/kg 15 min before the intravenous administration of [14C]MTX (0.5 mg/kg) did not alter the plasma concentration-time profile of MTX; however, the total amount of radioactivity excreted in urine increased from 58.7% to 92.2% of the dose, and the renal clearance increased from 1.8 ml/min/kg to 2.9 ml/min/kg, suggesting a decrease in MTX disposition via biliary excretion.","Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332143/),[ml] / [kg·min],2.9,33033,DB00563,Methotrexate
,8485020,terminal elimination half-lives,"The median terminal elimination half-lives of MTX and 7-OHMTX were 55 h and 116 h, respectively.",The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485020/),h,55,33437,DB00563,Methotrexate
,8485020,terminal elimination half-lives,"The median terminal elimination half-lives of MTX and 7-OHMTX were 55 h and 116 h, respectively.",The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485020/),h,116,33438,DB00563,Methotrexate
,2239280,area under the concentration versus time curve (AUC) 0-4 hours,"The mean area under the concentration versus time curve (AUC) 0-4 hours varied slightly from the start to the end of the MT (257 and 296 ng/ml.h, respectively).",The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239280/),[ng] / [h·ml],257,33584,DB00563,Methotrexate
,2239280,area under the concentration versus time curve (AUC) 0-4 hours,"The mean area under the concentration versus time curve (AUC) 0-4 hours varied slightly from the start to the end of the MT (257 and 296 ng/ml.h, respectively).",The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239280/),[ng] / [h·ml],296,33585,DB00563,Methotrexate
,2239280,plasma peak concentration,The mean plasma peak concentration increased from 98 ng/ml to 195 ng/ml (p less than 0.01) during the same period.,The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239280/),[ng] / [ml],98,33586,DB00563,Methotrexate
,2239280,plasma peak concentration,The mean plasma peak concentration increased from 98 ng/ml to 195 ng/ml (p less than 0.01) during the same period.,The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239280/),[ng] / [ml],195,33587,DB00563,Methotrexate
,9744775,Areas under the curve,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),[μM] / [min],4311,34196,DB00563,Methotrexate
,9744775,mean residence times,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),min,20,34197,DB00563,Methotrexate
,9744775,whole body clearances,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),min,20,34198,DB00563,Methotrexate
,9744775,whole body clearances,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),[ml] / [min],0.56,34199,DB00563,Methotrexate
,9744775,apparent distribution volumes,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),min,20,34200,DB00563,Methotrexate
,9744775,apparent distribution volumes,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),[ml] / [min],0.56,34201,DB00563,Methotrexate
,9744775,plasma protein binding,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),[ml] / [kg],532,34202,DB00563,Methotrexate
,9744775,plasma protein binding,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),[ml] / [kg],325,34203,DB00563,Methotrexate
,9744775,plasma protein binding,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),%,70,34204,DB00563,Methotrexate
,9744775,plasma protein binding,"Areas under the curve, mean residence times, whole body clearances, apparent distribution volumes, and plasma protein binding of PT523 vs methotrexate were, respectively, 4311 vs 6472 microM x min(-1); 20 vs 16 min; 0.56 vs 0.36 ml min(-1); 532 vs 325 ml x kg(-1); and 70% vs 30%.","Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9744775/),%,30,34205,DB00563,Methotrexate
,3565582,urinary clearance,"Under conditions of continuous infusion to attain plasma folate levels of 2.3-5.7 pmol/ml, the urinary clearance based on chromatographic analyses of plasma and urine after correction for plasma folate binding was 0.20 ml/min for folic acid, 0.37 ml/min for 5-CH3 THF, and 1.76 ml/min for methotrexate.",Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565582/),[ml] / [min],0.20,34277,DB00563,Methotrexate
,3565582,urinary clearance,"Under conditions of continuous infusion to attain plasma folate levels of 2.3-5.7 pmol/ml, the urinary clearance based on chromatographic analyses of plasma and urine after correction for plasma folate binding was 0.20 ml/min for folic acid, 0.37 ml/min for 5-CH3 THF, and 1.76 ml/min for methotrexate.",Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565582/),[ml] / [min],0.37,34278,DB00563,Methotrexate
,3565582,urinary clearance,"Under conditions of continuous infusion to attain plasma folate levels of 2.3-5.7 pmol/ml, the urinary clearance based on chromatographic analyses of plasma and urine after correction for plasma folate binding was 0.20 ml/min for folic acid, 0.37 ml/min for 5-CH3 THF, and 1.76 ml/min for methotrexate.",Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565582/),[ml] / [min],1.76,34279,DB00563,Methotrexate
,3565582,urinary clearance,Metabolites found after infusion of folic acid include 5-CH3 THF with a urinary clearance of 0.3 ml/min and an unknown with a urinary clearance of 0.8 ml/min.,Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565582/),[ml] / [min],0.3,34280,DB00563,Methotrexate
,3565582,urinary clearance,Metabolites found after infusion of folic acid include 5-CH3 THF with a urinary clearance of 0.3 ml/min and an unknown with a urinary clearance of 0.8 ml/min.,Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565582/),[ml] / [min],0.8,34281,DB00563,Methotrexate
,3565582,urinary clearance,Infusion of methotrexate was associated with the appearance of a metabolite with a urinary clearance of 2.5 ml/min.,Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3565582/),[ml] / [min],2.5,34282,DB00563,Methotrexate
,22546032,peak fourth ventricle CSF methotrexate levels,"In Group II, peak fourth ventricle CSF methotrexate levels ranged from 84.62 to 167.89 μmol/L (mean 115.53 ± 15.95 μmol/L [SD]).",Chemotherapy administration directly into the fourth ventricle in a nonhuman primate model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546032/),[μM] / [l],115.53,35215,DB00563,Methotrexate
,22546032,Trough levels,Trough levels ranged from 0.06 to 0.55 μmol/L (mean 0.22 ± 0.13 μmol/L).,Chemotherapy administration directly into the fourth ventricle in a nonhuman primate model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546032/),[μM] / [l],0.22,35216,DB00563,Methotrexate
,9754986,half-life,"The half-life of ACNU was very short (0.2-1.1 h), whereas the half-lives of MTX and Ara-C were relatively long (2.81-13.5 h and 1.84 6.25 h, respectively).","Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754986/),h,0.2-1.1,36316,DB00563,Methotrexate
,9754986,half-lives,"The half-life of ACNU was very short (0.2-1.1 h), whereas the half-lives of MTX and Ara-C were relatively long (2.81-13.5 h and 1.84 6.25 h, respectively).","Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754986/),h,2.81-13.5,36317,DB00563,Methotrexate
,9754986,half-lives,"The half-life of ACNU was very short (0.2-1.1 h), whereas the half-lives of MTX and Ara-C were relatively long (2.81-13.5 h and 1.84 6.25 h, respectively).","Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754986/),h,1.84,36318,DB00563,Methotrexate
,8173189,residual concentrations,"After administration of dl FA, the accumulation of d FA in plasma was confirmed: mean residual concentrations were 420 and 652 nM after 2 and 6 intakes respectively.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,420,36597,DB00563,Methotrexate
,8173189,residual concentrations,"After administration of dl FA, the accumulation of d FA in plasma was confirmed: mean residual concentrations were 420 and 652 nM after 2 and 6 intakes respectively.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,652,36598,DB00563,Methotrexate
,8173189,Total active folate concentrations,"Total active folate concentrations (1 FA + 5-MTHF) were similar between the two types of rescue: 92 and 100 nM respectively for dl FA rescue and 1 FA rescue after two intakes, 186 and 184 nM respectively for dl FA rescue and 1 FA rescue after six intakes.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,92,36599,DB00563,Methotrexate
,8173189,Total active folate concentrations,"Total active folate concentrations (1 FA + 5-MTHF) were similar between the two types of rescue: 92 and 100 nM respectively for dl FA rescue and 1 FA rescue after two intakes, 186 and 184 nM respectively for dl FA rescue and 1 FA rescue after six intakes.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,100,36600,DB00563,Methotrexate
,8173189,Total active folate concentrations,"Total active folate concentrations (1 FA + 5-MTHF) were similar between the two types of rescue: 92 and 100 nM respectively for dl FA rescue and 1 FA rescue after two intakes, 186 and 184 nM respectively for dl FA rescue and 1 FA rescue after six intakes.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,186,36601,DB00563,Methotrexate
,8173189,Total active folate concentrations,"Total active folate concentrations (1 FA + 5-MTHF) were similar between the two types of rescue: 92 and 100 nM respectively for dl FA rescue and 1 FA rescue after two intakes, 186 and 184 nM respectively for dl FA rescue and 1 FA rescue after six intakes.",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),nM,184,36602,DB00563,Methotrexate
,8173189,terminal half-lives,"For both types of rescue, MTX terminal half-lives were identical (average value 13.9 h).",[l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173189/),h,13.9,36603,DB00563,Methotrexate
,8281623,plasma half-life,"Depo/methotrexate increased the methotrexate plasma half-life by a factor of 190, from 0.53 to 100 h.",An extended-release formulation of methotrexate for subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8281623/),h,0,36704,DB00563,Methotrexate
,8281623,plasma half-life,"Depo/methotrexate increased the methotrexate plasma half-life by a factor of 190, from 0.53 to 100 h.",An extended-release formulation of methotrexate for subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8281623/),h,100,36705,DB00563,Methotrexate
,535133,half-life (t1/2),A significantly longer methotrexate half-life (t1/2) was found in nine partial responders (9.2 +/- 1.6 h) than in the nonresponders (3.8 +/- 0.7 h).,Bioavailability of methotrexate: implications for clinical use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/535133/),h,9.2,37195,DB00563,Methotrexate
,535133,half-life (t1/2),A significantly longer methotrexate half-life (t1/2) was found in nine partial responders (9.2 +/- 1.6 h) than in the nonresponders (3.8 +/- 0.7 h).,Bioavailability of methotrexate: implications for clinical use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/535133/),h,3.8,37196,DB00563,Methotrexate
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.38,37476,DB00563,Methotrexate
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.15,37477,DB00563,Methotrexate
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.13,37478,DB00563,Methotrexate
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.05,37479,DB00563,Methotrexate
,28801980,IC50,"Moreover, in vitro experiments demonstrated that PPIs (esomeprazole, lansoprazole, omeprazole and rabeprazole) inhibited hOAT3-mediated uptake of MTX in a concentration-dependent manner (IC50 values of 0.40-5.5 μ m), with a rank order of lansoprazole > esomeprazole > rabeprazole > omeprazole.",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),m·μ,0.40-5.5,37480,DB00563,Methotrexate
,2436760,terminal phase t1/2,The elimination of 50 mg/kg of 10-EdAM from the plasma of rats was triexponential with a terminal phase t1/2 of 18.5 h but a mean residence time of 0.7 h.,"Toxicity, elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2436760/),h,18.5,37558,DB00563,Methotrexate
,2436760,mean residence time,The elimination of 50 mg/kg of 10-EdAM from the plasma of rats was triexponential with a terminal phase t1/2 of 18.5 h but a mean residence time of 0.7 h.,"Toxicity, elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2436760/),h,0.7,37559,DB00563,Methotrexate
,2436760,terminal phase t1/2,The elimination of 10-EdAM from the plasma of dogs was also triexponential with a mean terminal phase t1/2 of 9.1 h and a mean residence time of 2.5 h; nonrenal clearance was the primary route of elimination.,"Toxicity, elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2436760/),h,9.1,37560,DB00563,Methotrexate
,2436760,mean residence time,The elimination of 10-EdAM from the plasma of dogs was also triexponential with a mean terminal phase t1/2 of 9.1 h and a mean residence time of 2.5 h; nonrenal clearance was the primary route of elimination.,"Toxicity, elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2436760/),h,2.5,37561,DB00563,Methotrexate
,16274945,B/P ratios,"A fold enhancement in the B/P ratios of 1.88 and 2.68 was observed at the 400 and 800 microg/kg doses respectively, when the protein was protected from metabolic degradation with PIs.","Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16274945/),,1.88,38447,DB00563,Methotrexate
,16274945,B/P ratios,"A fold enhancement in the B/P ratios of 1.88 and 2.68 was observed at the 400 and 800 microg/kg doses respectively, when the protein was protected from metabolic degradation with PIs.","Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16274945/),,2.68,38448,DB00563,Methotrexate
,17437161,distribution volume,"The means of distribution volume and elimination half-life (t (1/2)) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively.",A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437161/),[l] / [kg],0.05,39821,DB00563,Methotrexate
,17437161,elimination half-life (t (1/2)),"The means of distribution volume and elimination half-life (t (1/2)) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively.",A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437161/),d,9.5,39822,DB00563,Methotrexate
,30053381,zeta potential,The nano-formulation demonstrated an average particle size near 100 nm with a zeta potential of 18.65±1.77 mv.,in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30053381/),mv,18.65,39922,DB00563,Methotrexate
,30053381,Loading efficiency,Loading efficiency and loading capacity were calculated to be 65.46±7.66 and 3.02±0.34 respectively.,in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30053381/),,65.46,39923,DB00563,Methotrexate
,30053381,loading capacity,Loading efficiency and loading capacity were calculated to be 65.46±7.66 and 3.02±0.34 respectively.,in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30053381/),,3.02,39924,DB00563,Methotrexate
,30053381,drug targeting efficiency,"Moreover in in vivo studies, drug targeting efficiency and direct transport percentage for nanogel (test) and free drug solution (control) were 424.88% and 76.46% and 34842.15% and 99.71% respectively.",in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30053381/),%,424.88,39925,DB00563,Methotrexate
,30053381,drug targeting efficiency,"Moreover in in vivo studies, drug targeting efficiency and direct transport percentage for nanogel (test) and free drug solution (control) were 424.88% and 76.46% and 34842.15% and 99.71% respectively.",in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30053381/),%,76.46,39926,DB00563,Methotrexate
,30053381,drug targeting efficiency,"Moreover in in vivo studies, drug targeting efficiency and direct transport percentage for nanogel (test) and free drug solution (control) were 424.88% and 76.46% and 34842.15% and 99.71% respectively.",in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30053381/),%,34842.15,39927,DB00563,Methotrexate
,30053381,direct transport percentage,"Moreover in in vivo studies, drug targeting efficiency and direct transport percentage for nanogel (test) and free drug solution (control) were 424.88% and 76.46% and 34842.15% and 99.71% respectively.",in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30053381/),%,76.46,39928,DB00563,Methotrexate
,30053381,direct transport percentage,"Moreover in in vivo studies, drug targeting efficiency and direct transport percentage for nanogel (test) and free drug solution (control) were 424.88% and 76.46% and 34842.15% and 99.71% respectively.",in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30053381/),%,99.71,39929,DB00563,Methotrexate
,10912573,half-life,The mean half-life of CSF MTX was 8.7 +/- 3.4 h.,Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912573/),h,8.7,40639,DB00563,Methotrexate
,10912573,plasma clearance,The mean plasma clearance of MTX was not significantly different in patients with CNS disease (84 +/- 41 ml/min per m2) versus without CNS disease (59 +/- 38 ml/min per m2).,Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912573/),[ml] / [m2·min],84,40640,DB00563,Methotrexate
,10912573,plasma clearance,The mean plasma clearance of MTX was not significantly different in patients with CNS disease (84 +/- 41 ml/min per m2) versus without CNS disease (59 +/- 38 ml/min per m2).,Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912573/),[ml] / [m2·min],59,40641,DB00563,Methotrexate
,3698165,Total levels of TS (TStot),Total levels of TS (TStot) steadily increased from a pre-5-FU treatment level of 18.8 pmol to more than 40 pmol/g at 24 h.,Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698165/),pM,18.8,40655,DB00563,Methotrexate
more,3698165,Total levels of TS (TStot),Total levels of TS (TStot) steadily increased from a pre-5-FU treatment level of 18.8 pmol to more than 40 pmol/g at 24 h.,Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698165/),[pM] / [g],40,40656,DB00563,Methotrexate
,3199396,systemic bioavailability,The mean systemic bioavailability was 73% for the 15 mg oral dose.,Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199396/),%,73,41548,DB00563,Methotrexate
,19014836,Serum t((1/2)),Serum t((1/2)) ranged from 12 to 19 days.,"Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014836/),d,12 to 19,41795,DB00563,Methotrexate
,19014836,t((1/2)),The mean t((1/2)) ranged from 12 to 19 days.,"Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014836/),d,12 to 19,41796,DB00563,Methotrexate
,6974592,half-life (beta),The natural (l) isomer had a half-life (beta) of 47 +/- 4 (S.E.) min compared to 143 +/- 15 min for the unnatural (d) isomer.,Differences in the pharmacokinetics of the diastereoisomers of citrovorum factor in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6974592/),min,47,42467,DB00563,Methotrexate
,6974592,half-life (beta),The natural (l) isomer had a half-life (beta) of 47 +/- 4 (S.E.) min compared to 143 +/- 15 min for the unnatural (d) isomer.,Differences in the pharmacokinetics of the diastereoisomers of citrovorum factor in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6974592/),min,143,42468,DB00563,Methotrexate
,18851792,CSF,"The CSF concentration of MTX was significantly higher in 6-hour group than in 24-hour group (0.70 micromol/L vs. 0.49 micromol/L, P = 0.044).",[Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18851792/),[μM] / [l],0.70,42864,DB00563,Methotrexate
,18851792,CSF,"The CSF concentration of MTX was significantly higher in 6-hour group than in 24-hour group (0.70 micromol/L vs. 0.49 micromol/L, P = 0.044).",[Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18851792/),[μM] / [l],0.49,42865,DB00563,Methotrexate
,18851792,concentration,"The CSF concentration of MTX was significantly higher in 6-hour group than in 24-hour group (0.70 micromol/L vs. 0.49 micromol/L, P = 0.044).",[Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18851792/),[μM] / [l],0.70,42866,DB00563,Methotrexate
,18851792,concentration,"The CSF concentration of MTX was significantly higher in 6-hour group than in 24-hour group (0.70 micromol/L vs. 0.49 micromol/L, P = 0.044).",[Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18851792/),[μM] / [l],0.49,42867,DB00563,Methotrexate
,9551702,urinary excretion,"Within 48 h of drug administration, the urinary excretion of MTX was 46-99% of the dose, while that of 7-OH MTX was 1.5-8.6%.",Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551702/),%,46-99,42932,DB00563,Methotrexate
,9551702,urinary excretion,"Within 48 h of drug administration, the urinary excretion of MTX was 46-99% of the dose, while that of 7-OH MTX was 1.5-8.6%.",Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551702/),%,1.5-8.6,42933,DB00563,Methotrexate
,9551702,steady-state concentration,MTX concentrations in erythrocytes reached the steady-state concentration in the range 40.7-170 nmol.,Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9551702/),nM,40.7-170,42934,DB00563,Methotrexate
,21491447,elimination half-life,"The pharmacokinetic studies showed that elimination half-life of MTX-loaded plain PPI dendrimer (10.41 ± 2.12 h, p < 0.05) and MTX-loaded Lf-conjugated PPI dendrimer (12.23 ± 1.53 h, p < 0.01) was significantly higher than the free drug (5.85 ± 1.19 h).",Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491447/),h,10.41,43678,DB00563,Methotrexate
,21491447,elimination half-life,"The pharmacokinetic studies showed that elimination half-life of MTX-loaded plain PPI dendrimer (10.41 ± 2.12 h, p < 0.05) and MTX-loaded Lf-conjugated PPI dendrimer (12.23 ± 1.53 h, p < 0.01) was significantly higher than the free drug (5.85 ± 1.19 h).",Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491447/),h,12.23,43679,DB00563,Methotrexate
,21491447,elimination half-life,"The pharmacokinetic studies showed that elimination half-life of MTX-loaded plain PPI dendrimer (10.41 ± 2.12 h, p < 0.05) and MTX-loaded Lf-conjugated PPI dendrimer (12.23 ± 1.53 h, p < 0.01) was significantly higher than the free drug (5.85 ± 1.19 h).",Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491447/),h,5.85,43680,DB00563,Methotrexate
,21491447,accumulation,Organ distribution assessment of different formulations displayed significant (p <0.05) higher accumulation of drug in lungs by MTX-Lf-PPI (1329 ± 26.7 ng/g of tissue) as compared with MTX-PPI (721 ± 23.4 ng/g of tissue) and free MTX (575 ± 19.7 ng/g of tissue) after 6 h of administration.,Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491447/),[ng] / [g],1329,43681,DB00563,Methotrexate
,21491447,accumulation,Organ distribution assessment of different formulations displayed significant (p <0.05) higher accumulation of drug in lungs by MTX-Lf-PPI (1329 ± 26.7 ng/g of tissue) as compared with MTX-PPI (721 ± 23.4 ng/g of tissue) and free MTX (575 ± 19.7 ng/g of tissue) after 6 h of administration.,Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491447/),[ng] / [g],721,43682,DB00563,Methotrexate
,21491447,accumulation,Organ distribution assessment of different formulations displayed significant (p <0.05) higher accumulation of drug in lungs by MTX-Lf-PPI (1329 ± 26.7 ng/g of tissue) as compared with MTX-PPI (721 ± 23.4 ng/g of tissue) and free MTX (575 ± 19.7 ng/g of tissue) after 6 h of administration.,Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491447/),[ng] / [g],575,43683,DB00563,Methotrexate
,577895,half-lives,"After an initial rapid redistribution of the injected drug, the mean antifolate value in the lumbar CSF declined in a biphasic manner with half-lives of 4.5 and 14 hours.",Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577895/),h,4.5,44040,DB00563,Methotrexate
,577895,half-lives,"After an initial rapid redistribution of the injected drug, the mean antifolate value in the lumbar CSF declined in a biphasic manner with half-lives of 4.5 and 14 hours.",Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577895/),h,14,44041,DB00563,Methotrexate
,577895,half-lives,In the plasma the mean MTX concentration reached a peak of 2 X 10(-7) M between 3 and 12 hours after injection and decreased biexponentially thereafter with half-lives of 5.5 and 24 hours.,Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577895/),h,5.5,44042,DB00563,Methotrexate
,577895,half-lives,In the plasma the mean MTX concentration reached a peak of 2 X 10(-7) M between 3 and 12 hours after injection and decreased biexponentially thereafter with half-lives of 5.5 and 24 hours.,Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577895/),h,24,44043,DB00563,Methotrexate
,9117183,relative bioavailability,The relative bioavailability of the usual maintenance dose of MTX was reduced by 13.5% compared with the initial dose of 7.5 mg (P = 0.026).,Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117183/),,13,44513,DB00563,Methotrexate
,8721274,terminal elimination half-lives,"The mean terminal elimination half-lives of total and free MTX were 9.4 and 8.4 h, respectively, and the corresponding mean residence times, 8.5 and 9.2 h.",Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721274/),h,9.4,44520,DB00563,Methotrexate
,8721274,terminal elimination half-lives,"The mean terminal elimination half-lives of total and free MTX were 9.4 and 8.4 h, respectively, and the corresponding mean residence times, 8.5 and 9.2 h.",Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721274/),h,8.4,44521,DB00563,Methotrexate
,8721274,mean residence times,"The mean terminal elimination half-lives of total and free MTX were 9.4 and 8.4 h, respectively, and the corresponding mean residence times, 8.5 and 9.2 h.",Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721274/),h,8.5,44522,DB00563,Methotrexate
,8721274,mean residence times,"The mean terminal elimination half-lives of total and free MTX were 9.4 and 8.4 h, respectively, and the corresponding mean residence times, 8.5 and 9.2 h.",Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721274/),h,9.2,44523,DB00563,Methotrexate
,8721274,Total plasma clearance of the,Total plasma clearance of the free fraction averaged 215 ml/min.,Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721274/),[ml] / [min],215,44524,DB00563,Methotrexate
,8721274,plasma protein binding,Mean plasma protein binding ranged from 20 to 57% for these patients.,Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721274/),%,20 to 57,44525,DB00563,Methotrexate
,12537514,steady-state AUC(MTX),The results of this study suggest that a steady-state AUC(MTX) value of 700 nmol x h/L and higher are associated with a significantly better success rate of antipsoriatic therapy than lower values.,Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12537514/),[h·nM] / [l],700,45213,DB00563,Methotrexate
,27272171,terminal elimination half-life,"ABT-494 followed bi-exponential disposition, with a terminal elimination half-life of 6-16 h and a functional half-life, calculated from maximum observed plasma concentration (C max) to trough plasma concentration (C trough) ratio at steady state, of 3-4 h.","Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27272171/),h,6-16,45835,DB00563,Methotrexate
,27272171,half-life,"ABT-494 followed bi-exponential disposition, with a terminal elimination half-life of 6-16 h and a functional half-life, calculated from maximum observed plasma concentration (C max) to trough plasma concentration (C trough) ratio at steady state, of 3-4 h.","Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27272171/),h,3-4,45836,DB00563,Methotrexate
,27272171,trough plasma concentration (C trough) ratio,"ABT-494 followed bi-exponential disposition, with a terminal elimination half-life of 6-16 h and a functional half-life, calculated from maximum observed plasma concentration (C max) to trough plasma concentration (C trough) ratio at steady state, of 3-4 h.","Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27272171/),h,3-4,45837,DB00563,Methotrexate
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.7,45863,DB00563,Methotrexate
,2273487,elimination half-life,The mean MTX elimination half-life was prolonged when NSAID were coadministered (1.7 +/- 0.5 vs 1.2 +/- 0.1 h; p = 0.03).,Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),h,1.2,45864,DB00563,Methotrexate
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],10.6,45865,DB00563,Methotrexate
,2273487,apparent MTX clearance (CI),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[l] / [h],13.1,45866,DB00563,Methotrexate
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],2.1,45867,DB00563,Methotrexate
,2273487,area under the serum MTX concentration-time curve (Auc),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),[μM] / [h·l],1.5,45868,DB00563,Methotrexate
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,23.0,45869,DB00563,Methotrexate
,2273487,apparent volume of distribution (Vd),"However, neither the apparent MTX clearance (CI) (10.6 +/- 5.5 vs 13.1 +/- 3.5 l/h; p = 0.19), the area under the serum MTX concentration-time curve (Auc) (2.1 +/- 1.0 vs 1.5 +/- 0.6 mumol/l/h; p = 0.08) or the apparent volume of distribution (Vd) (23.0 +/- 6.2 vs 21.9 +/- 6.4 l; p = 0.53) was significantly altered by the administration of NSAID.",Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2273487/),l,21.9,45870,DB00563,Methotrexate
,6467500,bioavailability,The mean bioavailability for all the oral methods of administration was 28.2% +/- 3.7% compared with the same dose given IV.,"The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467500/),%,28.2,46272,DB00563,Methotrexate
,18031504,AUC(0-8 h),"The area under the concentration-time curve of plasma MTX in the interval 0-8 h post-dose (AUC(0-8 h)) was measured after a test bolus dose of 10 mg, and the starting weekly dose was individualized in order to achieve the target AUC(0-8 h) of 1800 nmol.h/L.",A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),[h·nM] / [l],1800,46582,DB00563,Methotrexate
,18031504,AUC(0-8 h ),"The AUC(0-8 h )achieved 1360 +/- 425 nmol.h/L (mean +/- SD: range, 778-2400 nmol.h/L).",A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),[h·nM] / [l],1360,46583,DB00563,Methotrexate
,18031504,steady-state concentration,"The mean (SD) steady-state concentration of total MTXPGs observed between days 85 to 110 reached 113 (34.6) nmol/L (range, 66.1-174 nmol/L).",A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),[nM] / [l],113,46584,DB00563,Methotrexate
,18031504,PASI,The PASI decreased from 24.0 +/- 8.0 (mean +/- SD) at baseline to 8.0 +/- 6.1 at day 110 (P < 0.001).,A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),,24.0,46585,DB00563,Methotrexate
,18031504,PASI,The PASI decreased from 24.0 +/- 8.0 (mean +/- SD) at baseline to 8.0 +/- 6.1 at day 110 (P < 0.001).,A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),,8.0,46586,DB00563,Methotrexate
,18031504,corpuscular volume,"Throughout the study period, there was a continuous increasing trend in the geometric mean values of the mean corpuscular volume from 92.6 to 96.4 fL (P < 0.001) and of plasma homocysteine from 9.5 to 12.3 micromol/L (P < 0.005).",A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),fl,92.6 to 96.4,46587,DB00563,Methotrexate
,2203580,terminal phase half-life,"Sustained release dosage forms are available, which may be beneficial due to the short terminal phase half-life of ketoprofen (1 to 3h).",Clinical pharmacokinetics of ketoprofen and its enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203580/),h,1 to 3,46734,DB00563,Methotrexate
,1473196,plasma clearance,There was a significant fall in methotrexate plasma clearance at night (from 5.6 +/- 3 ml/min/kg to 4.7 +/- 2.3 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],5.6,46800,DB00563,Methotrexate
,1473196,plasma clearance,There was a significant fall in methotrexate plasma clearance at night (from 5.6 +/- 3 ml/min/kg to 4.7 +/- 2.3 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],4.7,46801,DB00563,Methotrexate
,1473196,Renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],17.5,46802,DB00563,Methotrexate
,1473196,unbound renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],17.5,46803,DB00563,Methotrexate
,1473196,unbound renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],8.5,46804,DB00563,Methotrexate
,1473196,nonglomerular clearance,"Creatinine clearance did not exhibit diurnal variation, when comparing two 12-h collections, but there was a significant decrease in the nonglomerular clearance of methotrexate (from 14.8 +/- 5.2 to 6 +/- 4 ml/min/kg).",Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],14.8,46805,DB00563,Methotrexate
,1473196,nonglomerular clearance,"Creatinine clearance did not exhibit diurnal variation, when comparing two 12-h collections, but there was a significant decrease in the nonglomerular clearance of methotrexate (from 14.8 +/- 5.2 to 6 +/- 4 ml/min/kg).",Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],6,46806,DB00563,Methotrexate
,1933851,apparent rate of formation,"The apparent rate of formation of the nucleosides/tides in the tumor, K21, changed following methotrexate pretreatment, from a value of 6.4 +/- 2.4 to 15.5 +/- 5.0.","In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933851/),,6.4,47797,DB00563,Methotrexate
,1933851,apparent rate of formation,"The apparent rate of formation of the nucleosides/tides in the tumor, K21, changed following methotrexate pretreatment, from a value of 6.4 +/- 2.4 to 15.5 +/- 5.0.","In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933851/),,15.5,47798,DB00563,Methotrexate
,1933851,K21,The increase of the mean K21 value (2.4) estimated in vivo correlated favorably with the increase of the levels of the fluorinated nucleosides/nucleotides (2.2) observed by in vitro analysis.,"In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933851/),,2.4,47799,DB00563,Methotrexate
,1933851,K21,The increase of the mean K21 value (2.4) estimated in vivo correlated favorably with the increase of the levels of the fluorinated nucleosides/nucleotides (2.2) observed by in vitro analysis.,"In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933851/),,2.,47800,DB00563,Methotrexate
,7473485,elimination rate constant,"The mean elimination rate constant was 0.27 +/- 0.065, 0.26 +/- 0.067, and 0.25 +/- 0.11 h-1 after po fasting, po fed, and iv administration, respectively.",Influence of food on the bioavailability of oral methotrexate in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),1/[h],0.27,48004,DB00563,Methotrexate
,7473485,elimination rate constant,"The mean elimination rate constant was 0.27 +/- 0.065, 0.26 +/- 0.067, and 0.25 +/- 0.11 h-1 after po fasting, po fed, and iv administration, respectively.",Influence of food on the bioavailability of oral methotrexate in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),1/[h],0.26,48005,DB00563,Methotrexate
,7473485,elimination rate constant,"The mean elimination rate constant was 0.27 +/- 0.065, 0.26 +/- 0.067, and 0.25 +/- 0.11 h-1 after po fasting, po fed, and iv administration, respectively.",Influence of food on the bioavailability of oral methotrexate in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),1/[h],0.25,48006,DB00563,Methotrexate
,7473485,total area under the serum concentration vs time curve,"The total area under the serum concentration vs time curve was 1.87 +/- 0.83, 1.50 +/- 0.51, and 1.85 +/- 0.80 mumol/l.h after po fasting, po fed, and iv administration, respectively.",Influence of food on the bioavailability of oral methotrexate in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),[μM] / [h·l],1.87,48007,DB00563,Methotrexate
,7473485,total area under the serum concentration vs time curve,"The total area under the serum concentration vs time curve was 1.87 +/- 0.83, 1.50 +/- 0.51, and 1.85 +/- 0.80 mumol/l.h after po fasting, po fed, and iv administration, respectively.",Influence of food on the bioavailability of oral methotrexate in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),[μM] / [h·l],1.50,48008,DB00563,Methotrexate
,7473485,total area under the serum concentration vs time curve,"The total area under the serum concentration vs time curve was 1.87 +/- 0.83, 1.50 +/- 0.51, and 1.85 +/- 0.80 mumol/l.h after po fasting, po fed, and iv administration, respectively.",Influence of food on the bioavailability of oral methotrexate in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),[μM] / [h·l],1.85,48009,DB00563,Methotrexate
,7473485,maximum serum MTX concentration (Cmax),"The maximum serum MTX concentration (Cmax) was 0.65 +/- 0.33 and 0.39 +/- 0.18 mumol/l after po fasting and po fed administration, respectively (p = 0.0022).",Influence of food on the bioavailability of oral methotrexate in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),[μM] / [l],0.65,48010,DB00563,Methotrexate
,7473485,maximum serum MTX concentration (Cmax),"The maximum serum MTX concentration (Cmax) was 0.65 +/- 0.33 and 0.39 +/- 0.18 mumol/l after po fasting and po fed administration, respectively (p = 0.0022).",Influence of food on the bioavailability of oral methotrexate in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),[μM] / [l],0.39,48011,DB00563,Methotrexate
,7473485,time to Cmax,"The time to Cmax was 0.94 +/- 0.40 and 1.32 +/- 0.68 h after po fasting and po fed administration, respectively (p = 0.1464).",Influence of food on the bioavailability of oral methotrexate in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),h,0.94,48012,DB00563,Methotrexate
,7473485,time to Cmax,"The time to Cmax was 0.94 +/- 0.40 and 1.32 +/- 0.68 h after po fasting and po fed administration, respectively (p = 0.1464).",Influence of food on the bioavailability of oral methotrexate in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),h,1.32,48013,DB00563,Methotrexate
,7473485,bioavailability,"The bioavailability of oral MTX while fasting was 1.1 +/- 0.51, while that after a meal was 0.88 +/- 0.35 (p = 0.0211).",Influence of food on the bioavailability of oral methotrexate in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),,1.1,48014,DB00563,Methotrexate
,7473485,bioavailability,"The bioavailability of oral MTX while fasting was 1.1 +/- 0.51, while that after a meal was 0.88 +/- 0.35 (p = 0.0211).",Influence of food on the bioavailability of oral methotrexate in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7473485/),,0.88,48015,DB00563,Methotrexate
,10673736,steady-state concentration,"To achieve the target steady-state concentration of 65 microM, dosage adjustments were required in 14 patients, with doses ranging from 2854 to 6700 mg/m2 per course.",Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10673736/),μM,65,48267,DB00563,Methotrexate
,10673736,steady-state plasma concentration (Cpss),The mean steady-state plasma concentration (Cpss) of 68.0 microM was different (P = 0.025) than the predicted Cpss (mean = 87.4 microM; range 35.7-184 microM) had no adjustment in dose been made.,Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10673736/),μM,68.0,48268,DB00563,Methotrexate
,10673736,Cpss,The mean steady-state plasma concentration (Cpss) of 68.0 microM was different (P = 0.025) than the predicted Cpss (mean = 87.4 microM; range 35.7-184 microM) had no adjustment in dose been made.,Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10673736/),μM,87.4,48269,DB00563,Methotrexate
,3893694,total-body clearance,"The mean (+/- SD) parameters following iv MTX were as follows: total-body clearance, 124 (36) ml/minute; Vss, 0.56 (0.18) L/kg; V lambda, 0.69 (0.24) L/kg; and beta-half-life, 3.20 hours.",Methotrexate: bioavailability and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893694/),[ml] / [min],124,48691,DB00563,Methotrexate
,3893694,Vss,"The mean (+/- SD) parameters following iv MTX were as follows: total-body clearance, 124 (36) ml/minute; Vss, 0.56 (0.18) L/kg; V lambda, 0.69 (0.24) L/kg; and beta-half-life, 3.20 hours.",Methotrexate: bioavailability and pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893694/),[l] / [kg],0.56,48692,DB00563,Methotrexate
,3893694,V lambda,"The mean (+/- SD) parameters following iv MTX were as follows: total-body clearance, 124 (36) ml/minute; Vss, 0.56 (0.18) L/kg; V lambda, 0.69 (0.24) L/kg; and beta-half-life, 3.20 hours.",Methotrexate: bioavailability and pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893694/),[l] / [kg],0.69,48693,DB00563,Methotrexate
,3893694,beta-half-life,"The mean (+/- SD) parameters following iv MTX were as follows: total-body clearance, 124 (36) ml/minute; Vss, 0.56 (0.18) L/kg; V lambda, 0.69 (0.24) L/kg; and beta-half-life, 3.20 hours.",Methotrexate: bioavailability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893694/),h,3.20,48694,DB00563,Methotrexate
,3893694,absolute systemic bioavailability,The absolute systemic bioavailability of the oral tablets was 36% (+/- 10%).,Methotrexate: bioavailability and pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893694/),%,36,48695,DB00563,Methotrexate
,3893694,systemic bioavailability,"After im administration, the systemic bioavailability was 93% (+/- 14%).",Methotrexate: bioavailability and pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893694/),%,93,48696,DB00563,Methotrexate
,17112803,area under the curve from 36 to 48 hours,"The mean plasma methotrexate area under the curve from 36 to 48 hours after the start of the infusion was significantly 2-fold higher in female patients carrying at least 1 -24T allele as compared with all other patients (14.2+/-12.8 h.micromol/L versus 6.9+/-4.2 h.micromol/L, P<.001).",High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112803/),[h·μM] / [l],14.2,48756,DB00563,Methotrexate
,17112803,area under the curve from 36 to 48 hours,"The mean plasma methotrexate area under the curve from 36 to 48 hours after the start of the infusion was significantly 2-fold higher in female patients carrying at least 1 -24T allele as compared with all other patients (14.2+/-12.8 h.micromol/L versus 6.9+/-4.2 h.micromol/L, P<.001).",High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112803/),[h·μM] / [l],6.9,48757,DB00563,Methotrexate
,3836130,AUC,The differences were confirmed by determination of AUC for sera and tissue levels (1-4 h).,Tissue distribution of methotrexate in rats. A comparison between intravenous injection as bolus or drip infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3836130/),,1,49750,DB00563,Methotrexate
,25475953,t1/2,Stability and metabolic studies suggested that conjugate was stable at physiological pH (in Phosphate buffer pH 7.4 t1/2 is 70.25 ± 2.17 h and in plasma t1/2 is 193.57 ± 2.03 min) and circulated adequately to release MTX slowly in brain.,Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475953/),h,70.25,50105,DB00563,Methotrexate
,25475953,t1/2,Stability and metabolic studies suggested that conjugate was stable at physiological pH (in Phosphate buffer pH 7.4 t1/2 is 70.25 ± 2.17 h and in plasma t1/2 is 193.57 ± 2.03 min) and circulated adequately to release MTX slowly in brain.,Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475953/),min,193.57,50106,DB00563,Methotrexate
,12848626,AUC infinity,"The geometric mean AUC infinity values (95% confidence intervals) were 360 nmol x h/L (301-430 nmol x h/L), 261 nmol x h/L (214-318 nmol x h/L) and 281 nmol x h/L (209-377 nmol x h/L) per milligram of methotrexate administered for subcutaneous, oral and oral with folic acid administration, respectively (P < 0.05 and P < 0.01 for oral with folic acid and oral vs. subcutaneous administration, respectively).",Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848626/),[h·nM] / [l],360,50411,DB00563,Methotrexate
,12848626,AUC infinity,"The geometric mean AUC infinity values (95% confidence intervals) were 360 nmol x h/L (301-430 nmol x h/L), 261 nmol x h/L (214-318 nmol x h/L) and 281 nmol x h/L (209-377 nmol x h/L) per milligram of methotrexate administered for subcutaneous, oral and oral with folic acid administration, respectively (P < 0.05 and P < 0.01 for oral with folic acid and oral vs. subcutaneous administration, respectively).",Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848626/),[h·nM] / [l],261,50412,DB00563,Methotrexate
,12848626,AUC infinity,"The geometric mean AUC infinity values (95% confidence intervals) were 360 nmol x h/L (301-430 nmol x h/L), 261 nmol x h/L (214-318 nmol x h/L) and 281 nmol x h/L (209-377 nmol x h/L) per milligram of methotrexate administered for subcutaneous, oral and oral with folic acid administration, respectively (P < 0.05 and P < 0.01 for oral with folic acid and oral vs. subcutaneous administration, respectively).",Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848626/),[h·nM] / [l],281,50413,DB00563,Methotrexate
,12848626,relative bioavailabilities,"The geometric mean relative bioavailabilities (95% confidence intervals) were 0.73 (0.62-0.86) and 0.77 (0.60-0.99) for oral and oral with folic acid administration, respectively (difference not significant).",Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848626/),,0.73,50414,DB00563,Methotrexate
,12848626,relative bioavailabilities,"The geometric mean relative bioavailabilities (95% confidence intervals) were 0.73 (0.62-0.86) and 0.77 (0.60-0.99) for oral and oral with folic acid administration, respectively (difference not significant).",Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848626/),,0.,50415,DB00563,Methotrexate
,12848626,oral bioavailability,"In patients with stable Crohn's disease, the oral bioavailability of methotrexate is highly variable and averages 73% of that of subcutaneous administration.",Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848626/),%,73,50416,DB00563,Methotrexate
,8957036,plasma clearance,Mean plasma clearance of methotrexate during dialysis in these six patients was 92.1 +/- 10.3 mL/min.,Effective clearance of methotrexate using high-flux hemodialysis membranes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8957036/),[ml] / [min],92.1,50634,DB00563,Methotrexate
,6572562,peak levels,"Significant interindividual variability was noted in peak levels (range, 0.27 to 1.1 microM), time to peak (1 to 5 hr), area under the serum concentration-time curve (1.08 to 5.00 microM . hr), and the fraction of the dose absorbed (23 to 95%).",Pharmacokinetics of oral methotrexate in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6572562/),μM,0.27 to 1.1,53288,DB00563,Methotrexate
,6572562,time to peak,"Significant interindividual variability was noted in peak levels (range, 0.27 to 1.1 microM), time to peak (1 to 5 hr), area under the serum concentration-time curve (1.08 to 5.00 microM . hr), and the fraction of the dose absorbed (23 to 95%).",Pharmacokinetics of oral methotrexate in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6572562/),h,1 to 5,53289,DB00563,Methotrexate
,6572562,area under the serum concentration-time curve,"Significant interindividual variability was noted in peak levels (range, 0.27 to 1.1 microM), time to peak (1 to 5 hr), area under the serum concentration-time curve (1.08 to 5.00 microM . hr), and the fraction of the dose absorbed (23 to 95%).",Pharmacokinetics of oral methotrexate in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6572562/),h·μM,1.08 to 5.00,53290,DB00563,Methotrexate
,6714284,renal clearance,"At plasma concentrations below saturation, the renal clearance of methotrexate ranged from 52-102 ml/min (mean +/- SD, 83 +/- 19.4 ml/min).",Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714284/),[ml] / [min],52-102,53297,DB00563,Methotrexate
,6714284,renal clearance,"At plasma concentrations below saturation, the renal clearance of methotrexate ranged from 52-102 ml/min (mean +/- SD, 83 +/- 19.4 ml/min).",Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714284/),[ml] / [min],83,53298,DB00563,Methotrexate
,6368243,t1/2 (beta),In 4 patients (with a mean pretreatment creatinine clearance of 97 ml/min) there was no significant difference between the clearance of MTX when given alone [mean t1/2 (beta) 3.2 hr] and when given 2 weeks later with concurrent CDDP [mean t1/2 (beta) 2.9 hr].,The treatment of advanced bladder cancer with methotrexate and cis-platinum--a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6368243/),h,3.2,53879,DB00563,Methotrexate
,6368243,t1/2 (beta),In 4 patients (with a mean pretreatment creatinine clearance of 97 ml/min) there was no significant difference between the clearance of MTX when given alone [mean t1/2 (beta) 3.2 hr] and when given 2 weeks later with concurrent CDDP [mean t1/2 (beta) 2.9 hr].,The treatment of advanced bladder cancer with methotrexate and cis-platinum--a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6368243/),h,2.9,53880,DB00563,Methotrexate
,6368243,t1/2 (beta),In 1 patient with a pretreatment creatinine clearance of 52 ml/min the clearance of MTX when given alone (without hydration) was significantly delayed compared with the clearance of MTX when given 2 weeks later concurrently with CDDP and saline hydration [t1/2 (beta) 19 and 4.5 hr respectively].,The treatment of advanced bladder cancer with methotrexate and cis-platinum--a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6368243/),h,19,53881,DB00563,Methotrexate
,6368243,t1/2 (beta),In 1 patient with a pretreatment creatinine clearance of 52 ml/min the clearance of MTX when given alone (without hydration) was significantly delayed compared with the clearance of MTX when given 2 weeks later concurrently with CDDP and saline hydration [t1/2 (beta) 19 and 4.5 hr respectively].,The treatment of advanced bladder cancer with methotrexate and cis-platinum--a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6368243/),h,4.5,53882,DB00563,Methotrexate
≤,30580500,Time to serum methotrexate level,Time to serum methotrexate level ≤0.1 µmol/L was the primary outcome.,Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580500/),[μM] / [l],0.1,54137,DB00563,Methotrexate
,30580500,time to clearance,Median time to clearance for patients ≤18 years was 79 hours (range 63-116) compared to 120 hours (range 77-315) for patients >18 years (P < 0.001).,Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580500/),h,79,54138,DB00563,Methotrexate
,30580500,time to clearance,Median time to clearance for patients ≤18 years was 79 hours (range 63-116) compared to 120 hours (range 77-315) for patients >18 years (P < 0.001).,Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580500/),h,120,54139,DB00563,Methotrexate
,3209285,half-lives,The concentration-time decay of MTX in serum observed in 29/34 patients receiving 4 x 15 mg/m2/d p.o. leucovorin up to 5 days was biphasic with mean half-lives (+/- SD) of 2.42 +/- 0.45 h for t1/2 alpha and 19.9 +/- 7.6 h for t1/2 beta.,High-dose methotrexate: pharmacokinetics in children and young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),h,2.42,54422,DB00563,Methotrexate
,3209285,t1/2 beta,The concentration-time decay of MTX in serum observed in 29/34 patients receiving 4 x 15 mg/m2/d p.o. leucovorin up to 5 days was biphasic with mean half-lives (+/- SD) of 2.42 +/- 0.45 h for t1/2 alpha and 19.9 +/- 7.6 h for t1/2 beta.,High-dose methotrexate: pharmacokinetics in children and young adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),h,19.9,54423,DB00563,Methotrexate
,3209285,steady-state volume of distribution (Vss),The steady-state volume of distribution (Vss) was 0.56 +/- 0.18 l/kg and the total body clearance (CL) 71 +/- 20 ml/min/m2 (mean +/- SD).,High-dose methotrexate: pharmacokinetics in children and young adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),[l] / [kg],0.56,54424,DB00563,Methotrexate
,3209285,total body clearance (CL),The steady-state volume of distribution (Vss) was 0.56 +/- 0.18 l/kg and the total body clearance (CL) 71 +/- 20 ml/min/m2 (mean +/- SD).,High-dose methotrexate: pharmacokinetics in children and young adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),[ml] / [m2·min],71,54425,DB00563,Methotrexate
,3209285,Peak serum concentrations,"Peak serum concentrations ranged from 674-1778 mumol/l (mean +/- SD, 1201 +/- 293 mumol/l).",High-dose methotrexate: pharmacokinetics in children and young adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),[μM] / [l],674-1778,54426,DB00563,Methotrexate
,3209285,Peak serum concentrations,"Peak serum concentrations ranged from 674-1778 mumol/l (mean +/- SD, 1201 +/- 293 mumol/l).",High-dose methotrexate: pharmacokinetics in children and young adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),[μM] / [l],1201,54427,DB00563,Methotrexate
greater,3209285,elimination t1/2 alpha,In 5/34 patients who received a prolonged leucovorin rescue due to a delayed MTX elimination t1/2 alpha was greater than 3.1 h.,High-dose methotrexate: pharmacokinetics in children and young adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),h,3.1,54428,DB00563,Methotrexate
less,3209285,t1/2 alpha,"The data of this study suggest that patients with MTX serum concentrations of less than or equal to 6.3 mumol/l at 24 h, less than or equal to 0.77 mumol/l at 48 h, and less than or equal to 0.33 mumol/l at 72 h after the end of infusion, and a t1/2 alpha of less than or equal to 3.1 h (97.5th percentiles) are at low risk of toxicity.",High-dose methotrexate: pharmacokinetics in children and young adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209285/),h,3.1,54429,DB00563,Methotrexate
,9487560,Total clearance,"Total clearance (8.9 vs 6.5 ml-1.min-1.kg-1) and volume of distribution (4.0 vs 2.9 l.kg-1), however, tended to decrease in the tumor-bearing group.",Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487560/),1/[kg·min·ml],8.9,55072,DB00563,Methotrexate
,9487560,Total clearance,"Total clearance (8.9 vs 6.5 ml-1.min-1.kg-1) and volume of distribution (4.0 vs 2.9 l.kg-1), however, tended to decrease in the tumor-bearing group.",Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487560/),1/[kg·min·ml],6.5,55073,DB00563,Methotrexate
,9487560,volume of distribution,"Total clearance (8.9 vs 6.5 ml-1.min-1.kg-1) and volume of distribution (4.0 vs 2.9 l.kg-1), however, tended to decrease in the tumor-bearing group.",Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487560/),[l] / [kg],4.0,55074,DB00563,Methotrexate
,9487560,volume of distribution,"Total clearance (8.9 vs 6.5 ml-1.min-1.kg-1) and volume of distribution (4.0 vs 2.9 l.kg-1), however, tended to decrease in the tumor-bearing group.",Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487560/),[l] / [kg],2.9,55075,DB00563,Methotrexate
,9487560,/plasma AUC ratio,The ECF/plasma AUC ratio equaled 14.2 +/- 8.8% in muscle and 23.9 +/- 15.9% in tumor.,Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487560/),%,14.2,55076,DB00563,Methotrexate
,9487560,/plasma AUC ratio,The ECF/plasma AUC ratio equaled 14.2 +/- 8.8% in muscle and 23.9 +/- 15.9% in tumor.,Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9487560/),%,23.9,55077,DB00563,Methotrexate
,8207696,half-life of drug release,"In human plasma at 37 degrees C, the half-life of drug release was 40 days.",Sustained-release methotrexate for intracavitary chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8207696/),d,40,55149,DB00563,Methotrexate
,8207696,apparent half-life,"After intraperitoneal injection of Depo/methotrexate in mice, the intraperitoneal apparent half-life of free methotrexate was 39.6 h, in contrast to a half-life of 0.5 h for the unencapsulated standard methotrexate (std/methotrexate).",Sustained-release methotrexate for intracavitary chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8207696/),h,39.6,55150,DB00563,Methotrexate
,8207696,half-life,"After intraperitoneal injection of Depo/methotrexate in mice, the intraperitoneal apparent half-life of free methotrexate was 39.6 h, in contrast to a half-life of 0.5 h for the unencapsulated standard methotrexate (std/methotrexate).",Sustained-release methotrexate for intracavitary chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8207696/),h,0.5,55151,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,0.52,55195,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,1.30,55196,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,2.37,55197,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,3.57,55198,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,4.43,55199,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),,1.01,55200,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),,1.03,55201,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),,0.95,55202,DB00563,Methotrexate
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),,0.93,55203,DB00563,Methotrexate
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),min,4.75,55225,DB00563,Methotrexate
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),h,0.822,55226,DB00563,Methotrexate
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),h,18.9,55227,DB00563,Methotrexate
,6891324,total plasma clearance,The total plasma clearance of the parent drug ranged from 28.3 to 98.7 1/hr.,Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),[1] / [h],28.3 to 98.7,55228,DB00563,Methotrexate
,14755312,time to an absolute neutrophil count,"All patients engrafted rapidly; the median time to an absolute neutrophil count >0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count >20 x 10(9)/l was 16 days (range 6-30 days).",Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755312/),d,14,56589,DB00563,Methotrexate
>,14755312,time to a platelet count,"All patients engrafted rapidly; the median time to an absolute neutrophil count >0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count >20 x 10(9)/l was 16 days (range 6-30 days).",Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755312/),,20,56590,DB00563,Methotrexate
,14755312,time to a platelet count,"All patients engrafted rapidly; the median time to an absolute neutrophil count >0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count >20 x 10(9)/l was 16 days (range 6-30 days).",Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755312/),d,16,56591,DB00563,Methotrexate
,9515187,peak drug plasma concentrations (Cmax),"Significant inhibition of tumour growth was obtained in mice bearing human colon cancer xenografts and given intraperitoneal zidovudine 300 to 600 mg/kg weekly in combination with methotrexate 87.5 mg/kg or intraperitoneal fluorouracil 85 mg/kg, and in pharmacokinetic studies high peak drug plasma concentrations (Cmax) of zidovudine were obtained, ranging from 610.3 to 1698.8 mumol/L.",Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9515187/),[μM] / [l],610.3 to 1698.8,57087,DB00563,Methotrexate
,21741088,clearance (CL),"Based on the findings, in a typical child (who, based on the median values in REACH, weighs 42 kg, has a baseline serum albumin concentration [SAC] 3.8 mg/dL, and has not developed antibodies to infliximab [ATIs]) who is receiving infliximab and an immunomodulator, PK estimates (typical value [SE]) were as follows: clearance (CL), 5.43 (0.15) mL/kg/d; V(d) in the central compartment (V(1)), 54.2 (1.15) mL/kg; V(d) in the peripheral compartment (V(2)), 29.2 (2.03) mL/kg; and intercompartmental clearance (Q), 3.52 (0.71) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [d·kg],5.43,57365,DB00563,Methotrexate
,21741088,V(d) in the central compartment (V(1)),"Based on the findings, in a typical child (who, based on the median values in REACH, weighs 42 kg, has a baseline serum albumin concentration [SAC] 3.8 mg/dL, and has not developed antibodies to infliximab [ATIs]) who is receiving infliximab and an immunomodulator, PK estimates (typical value [SE]) were as follows: clearance (CL), 5.43 (0.15) mL/kg/d; V(d) in the central compartment (V(1)), 54.2 (1.15) mL/kg; V(d) in the peripheral compartment (V(2)), 29.2 (2.03) mL/kg; and intercompartmental clearance (Q), 3.52 (0.71) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [kg],54.2,57366,DB00563,Methotrexate
,21741088,V(d) in the peripheral compartment (V(2)),"Based on the findings, in a typical child (who, based on the median values in REACH, weighs 42 kg, has a baseline serum albumin concentration [SAC] 3.8 mg/dL, and has not developed antibodies to infliximab [ATIs]) who is receiving infliximab and an immunomodulator, PK estimates (typical value [SE]) were as follows: clearance (CL), 5.43 (0.15) mL/kg/d; V(d) in the central compartment (V(1)), 54.2 (1.15) mL/kg; V(d) in the peripheral compartment (V(2)), 29.2 (2.03) mL/kg; and intercompartmental clearance (Q), 3.52 (0.71) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [kg],29.2,57367,DB00563,Methotrexate
,21741088,intercompartmental clearance (Q),"Based on the findings, in a typical child (who, based on the median values in REACH, weighs 42 kg, has a baseline serum albumin concentration [SAC] 3.8 mg/dL, and has not developed antibodies to infliximab [ATIs]) who is receiving infliximab and an immunomodulator, PK estimates (typical value [SE]) were as follows: clearance (CL), 5.43 (0.15) mL/kg/d; V(d) in the central compartment (V(1)), 54.2 (1.15) mL/kg; V(d) in the peripheral compartment (V(2)), 29.2 (2.03) mL/kg; and intercompartmental clearance (Q), 3.52 (0.71) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [d·kg],3.52,57368,DB00563,Methotrexate
,21741088,CL,"Corresponding properties in a typical adult (weight, 68 kg; SAC, 4.1 mg/dL) were CL, 5.39 (0.13) mL/kg/d; V(1), 52.7 (0.49) mL/kg; V(2), 19.0 (1.53) mL/kg; and Q, 2.15 (0.39) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [d·kg],5.39,57369,DB00563,Methotrexate
,21741088,V(1),"Corresponding properties in a typical adult (weight, 68 kg; SAC, 4.1 mg/dL) were CL, 5.39 (0.13) mL/kg/d; V(1), 52.7 (0.49) mL/kg; V(2), 19.0 (1.53) mL/kg; and Q, 2.15 (0.39) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [kg],52.7,57370,DB00563,Methotrexate
,21741088,V(2),"Corresponding properties in a typical adult (weight, 68 kg; SAC, 4.1 mg/dL) were CL, 5.39 (0.13) mL/kg/d; V(1), 52.7 (0.49) mL/kg; V(2), 19.0 (1.53) mL/kg; and Q, 2.15 (0.39) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [kg],19.0,57371,DB00563,Methotrexate
,21741088,Q,"Corresponding properties in a typical adult (weight, 68 kg; SAC, 4.1 mg/dL) were CL, 5.39 (0.13) mL/kg/d; V(1), 52.7 (0.49) mL/kg; V(2), 19.0 (1.53) mL/kg; and Q, 2.15 (0.39) mL/kg/d.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),[ml] / [d·kg],2.15,57372,DB00563,Methotrexate
,21741088,t(1/2),"In the pediatric and adult patients, observed trough serum infliximab concentrations, median infliximab t(1/2) (in children, 13.2 days; and in adults, 12.4 days), and exploratory PK simulations predicted infliximab PK properties to be comparable between children and adults.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),d,13.2,57373,DB00563,Methotrexate
,21741088,t(1/2),"In the pediatric and adult patients, observed trough serum infliximab concentrations, median infliximab t(1/2) (in children, 13.2 days; and in adults, 12.4 days), and exploratory PK simulations predicted infliximab PK properties to be comparable between children and adults.",Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21741088/),d,12.4,57374,DB00563,Methotrexate
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],23.18,57930,DB00563,Methotrexate
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],5.66,57931,DB00563,Methotrexate
>,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57932,DB00563,Methotrexate
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57933,DB00563,Methotrexate
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57934,DB00563,Methotrexate
>,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57935,DB00563,Methotrexate
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57936,DB00563,Methotrexate
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57937,DB00563,Methotrexate
>,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57938,DB00563,Methotrexate
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57939,DB00563,Methotrexate
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57940,DB00563,Methotrexate
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.95,57941,DB00563,Methotrexate
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.05,57942,DB00563,Methotrexate
,6519167,steady state concentration,The mean steady state concentration of methotrexate in erythrocytes was 85 nmol/l and the mean erythrocyte folate concentration was 729 nmol/l.,Pharmacokinetics of methotrexate in erythrocytes in psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519167/),[nM] / [l],85,58820,DB00563,Methotrexate
,9808549,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.63 to 12,59168,DB00563,Methotrexate
,9808549,AUC,"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.11 to 8,59169,DB00563,Methotrexate
,31011346,T1/2,"In the current work, first the stability of MTX-PEG5000 was studied at 37 °C and the results indicated its high stability in plasma (T1/2 = 144 h) and a relatively rapid degradation in tissue homogenate (T1/2 = 24 h).",Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31011346/),h,144,59559,DB00563,Methotrexate
,31011346,T1/2,"In the current work, first the stability of MTX-PEG5000 was studied at 37 °C and the results indicated its high stability in plasma (T1/2 = 144 h) and a relatively rapid degradation in tissue homogenate (T1/2 = 24 h).",Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31011346/),h,24,59560,DB00563,Methotrexate
,31011346,T1/2 α,The results of pharmacokinetic studies in mice indicated that MTX-PEG5000 had longer plasma distribution and elimination half-lives compared to free MTX (T1/2 α 9.16 min for MTX-PEG5000 versus 2.45 min for MTX and T1/2 β 88.44 for MTX-PEG5000 versus 24.33 min for MTX).,Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31011346/),min,9.16,59561,DB00563,Methotrexate
,31011346,T1/2 α,The results of pharmacokinetic studies in mice indicated that MTX-PEG5000 had longer plasma distribution and elimination half-lives compared to free MTX (T1/2 α 9.16 min for MTX-PEG5000 versus 2.45 min for MTX and T1/2 β 88.44 for MTX-PEG5000 versus 24.33 min for MTX).,Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31011346/),min,2.45,59562,DB00563,Methotrexate
,31011346,T1/2 β,The results of pharmacokinetic studies in mice indicated that MTX-PEG5000 had longer plasma distribution and elimination half-lives compared to free MTX (T1/2 α 9.16 min for MTX-PEG5000 versus 2.45 min for MTX and T1/2 β 88.44 for MTX-PEG5000 versus 24.33 min for MTX).,Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31011346/),,88.44,59563,DB00563,Methotrexate
,31011346,T1/2 β,The results of pharmacokinetic studies in mice indicated that MTX-PEG5000 had longer plasma distribution and elimination half-lives compared to free MTX (T1/2 α 9.16 min for MTX-PEG5000 versus 2.45 min for MTX and T1/2 β 88.44 for MTX-PEG5000 versus 24.33 min for MTX).,Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31011346/),min,24.33,59564,DB00563,Methotrexate
,31011346,area under the curve (AUC),Pharmacokinetic parameters also showed higher area under the curve (AUC) of conjugate compared to parent drug (12.33 mg.,Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31011346/),,12,59565,DB00563,Methotrexate
,6492776,concentration multiplied by time (area under curve),Plasma MTX concentration multiplied by time (area under curve) was 131 g . hr/liter in 43 degrees C dogs compared with 73 g . hr/liter in 37 degrees C dogs (P less than 0.001).,Systemic thermochemotherapy: toxicity and plasma pharmacokinetics of methotrexate and doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492776/),[g·h] / [l],131,60455,DB00563,Methotrexate
,6492776,concentration multiplied by time (area under curve),Plasma MTX concentration multiplied by time (area under curve) was 131 g . hr/liter in 43 degrees C dogs compared with 73 g . hr/liter in 37 degrees C dogs (P less than 0.001).,Systemic thermochemotherapy: toxicity and plasma pharmacokinetics of methotrexate and doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492776/),[g·h] / [l],73,60456,DB00563,Methotrexate
,23494628,flow rate,"Chromatographic separation was accomplished by Agilent® Zorbax® SB-C18 column, with isocratic elution (5 mM ammonium acetate and methanol, 70:30, %v/v) at a flow rate of 300 μL/min.","Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494628/),[μl] / [min],300,61130,DB00563,Methotrexate
,23494628,total run time,"The limit of quantitation for both drugs was 15.6 ng/mL (plasma and brain) and 78.1 ng/mL (urine), with interday and intraday precision and accuracy ≤15% and a total run time of 6 min.","Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494628/),min,6,61131,DB00563,Methotrexate
,23456770,steady-state,"After multiple-doses, RBC MTX reached steady-state (82.4 nm) within 4 days.","Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23456770/),nm,82.4,61267,DB00563,Methotrexate
,23456770,I(maxd),Methotrexate showed modest (I(maxd) = 0.16) but sensitive (IC(50d) = 0.712 nm) effectiveness on paw edema.,"Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23456770/),,0.16,61268,DB00563,Methotrexate
,23456770,IC(50d),Methotrexate showed modest (I(maxd) = 0.16) but sensitive (IC(50d) = 0.712 nm) effectiveness on paw edema.,"Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23456770/),nm,0.712,61269,DB00563,Methotrexate
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,2.65,61642,DB00563,Methotrexate
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,3.52,61643,DB00563,Methotrexate
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,0.71,61644,DB00563,Methotrexate
,10864038,concentrations,"The mean total and free VPA concentrations in plasma were 78.0+/-0.8 and 10.9-0.3 microg/ml, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),[μg] / [ml],10.9-0.3,61645,DB00563,Methotrexate
> or =,12448653,T1/2,"Partial responses to 5-FU plus leucovorin therapy were seen only in patients with a long intratumoral half-life (trapping) of 5-FU (3 PR in 11 patients with T1/2 > or = 20 minutes, compared to 0 PR in 11 patients with T1/2 < 20 minutes).",Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12448653/),min,20,61844,DB00563,Methotrexate
<,12448653,T1/2,"Partial responses to 5-FU plus leucovorin therapy were seen only in patients with a long intratumoral half-life (trapping) of 5-FU (3 PR in 11 patients with T1/2 > or = 20 minutes, compared to 0 PR in 11 patients with T1/2 < 20 minutes).",Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12448653/),min,20,61845,DB00563,Methotrexate
greater,4047914,peripheral concentration,In oncochemotherapy with methotrexate (MTX) a peripheral concentration greater than 0.45 mg/l and a plasma concentration less than 45 mg/l must be maintained for 20 h.,Comparison of linear and tapered intravenous infusion of methotrexate in oncochemotherapy. A theoretical approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4047914/),[mg] / [l],0.45,63217,DB00563,Methotrexate
,15148625,clearance rate,The patient's normal initial MTX clearance rate (107 ml/min/m2) was consistent with his undetectable plasma level of MTX on day 9 after the infusion.,Late-onset delayed excretion of methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15148625/),[ml] / [m2·min],107,63556,DB00563,Methotrexate
,9552052,areas under the curve (AUC),The mean areas under the curve (AUC) for the i.v. (n = 14) and oral (n = 13) doses were 1.20 +/- 0.09 (SE) and 1.05 +/- 0.14 micromol x h/L respectively.,Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552052/),[h·μM] / [l],1.20,66052,DB00563,Methotrexate
,9552052,areas under the curve (AUC),The mean areas under the curve (AUC) for the i.v. (n = 14) and oral (n = 13) doses were 1.20 +/- 0.09 (SE) and 1.05 +/- 0.14 micromol x h/L respectively.,Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552052/),[h·μM] / [l],1.05,66053,DB00563,Methotrexate
,9552052,half-life,The half-life was 3.64 +/- 0.28 hours and the oral bioavailability in 12 matched subjects was 83.5% +/- 8.3%.,Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552052/),h,3.64,66054,DB00563,Methotrexate
,9552052,oral bioavailability,The half-life was 3.64 +/- 0.28 hours and the oral bioavailability in 12 matched subjects was 83.5% +/- 8.3%.,Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552052/),%,83.5,66055,DB00563,Methotrexate
,3153222,initial,"Both MTX and 7-OH-MTX elimination followed a biphasic curve, initial half-lives (t1/2(alpha] being 2.86 +/- 0.44 h and 5.14 +/- 0.46 h (mean +/- SD) and second-phase biological half-lives (t1/2(beta] being approximately 18 and 16 h, respectively.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153222/),h,2.86,67900,DB00563,Methotrexate
,3153222,half-lives (t1/2(alpha],"Both MTX and 7-OH-MTX elimination followed a biphasic curve, initial half-lives (t1/2(alpha] being 2.86 +/- 0.44 h and 5.14 +/- 0.46 h (mean +/- SD) and second-phase biological half-lives (t1/2(beta] being approximately 18 and 16 h, respectively.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153222/),h,2.86,67901,DB00563,Methotrexate
,3153222,half-lives (t1/2(alpha],"Both MTX and 7-OH-MTX elimination followed a biphasic curve, initial half-lives (t1/2(alpha] being 2.86 +/- 0.44 h and 5.14 +/- 0.46 h (mean +/- SD) and second-phase biological half-lives (t1/2(beta] being approximately 18 and 16 h, respectively.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153222/),h,5.14,67902,DB00563,Methotrexate
,3153222,second-phase biological half-lives (t1/2(beta],"Both MTX and 7-OH-MTX elimination followed a biphasic curve, initial half-lives (t1/2(alpha] being 2.86 +/- 0.44 h and 5.14 +/- 0.46 h (mean +/- SD) and second-phase biological half-lives (t1/2(beta] being approximately 18 and 16 h, respectively.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153222/),h,18,67903,DB00563,Methotrexate
,3153222,second-phase biological half-lives (t1/2(beta],"Both MTX and 7-OH-MTX elimination followed a biphasic curve, initial half-lives (t1/2(alpha] being 2.86 +/- 0.44 h and 5.14 +/- 0.46 h (mean +/- SD) and second-phase biological half-lives (t1/2(beta] being approximately 18 and 16 h, respectively.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153222/),h,16,67904,DB00563,Methotrexate
,3153222,apparent volume of distribution,"The apparent volume of distribution for MTX was 0.8 L/kg, whereas the corresponding value for 7-OH-MTX was threefold less.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after high-dose (33.6 g/m2) methotrexate therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153222/),[l] / [kg],0.8,67905,DB00563,Methotrexate
,34182802,retention time,Separation by chromatography was achieved with a Waters Phenyl Vanguard with a retention time of approximately 0.5 min.,A rapid LC-MS/MS assay for the measurement of serum methotrexate in patients who have received high doses for chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34182802/),min,0.5,69203,DB00563,Methotrexate
,34182802,recovery,"Mean recovery was 111% for three different concentrations of methotrexate spiked into seven different patient samples, with ion suppression <1%.",A rapid LC-MS/MS assay for the measurement of serum methotrexate in patients who have received high doses for chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34182802/),%,111,69204,DB00563,Methotrexate
above,20566424,maximum concentrations,The maximum concentrations during maintenance infusion in 31 courses (97%) were above 700 microM.,Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20566424/),μM,700,69207,DB00563,Methotrexate
,8406379,peak plasma levels,The plasma pharmacokinetics were described by a one-compartment open model with peak plasma levels of 6.9 +/- 2.5 micrograms/ml.,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),[μg] / [ml],6.9,69689,DB00563,Methotrexate
,8406379,relative oral bioavailability,Mean relative oral bioavailability was generally high (91 +/- 27 per cent).,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),%,91,69690,DB00563,Methotrexate
,15340127,AUC(0-t),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],108.0,70188,DB00563,Methotrexate
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],26.7,70189,DB00563,Methotrexate
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.5,70190,DB00563,Methotrexate
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70191,DB00563,Methotrexate
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70192,DB00563,Methotrexate
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],26.7,70193,DB00563,Methotrexate
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.5,70194,DB00563,Methotrexate
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70195,DB00563,Methotrexate
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70196,DB00563,Methotrexate
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,57.1,70197,DB00563,Methotrexate
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],110.2,70198,DB00563,Methotrexate
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],27.5,70199,DB00563,Methotrexate
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.0,70200,DB00563,Methotrexate
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,53.7,70201,DB00563,Methotrexate
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70202,DB00563,Methotrexate
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70203,DB00563,Methotrexate
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,57.0,70204,DB00563,Methotrexate
,9279889,steady state,"From previously published pharmacokinetic parameters with low-dose MTX therapy, and considering a 50 cm2 diffusional area, the target steady state in vitro TD flux for MTX was calculated to be 35 micrograms/cm2/hr.",Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279889/),[μg] / [cm2·h],35,70933,DB00563,Methotrexate
,9279889,TD flux,"From previously published pharmacokinetic parameters with low-dose MTX therapy, and considering a 50 cm2 diffusional area, the target steady state in vitro TD flux for MTX was calculated to be 35 micrograms/cm2/hr.",Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279889/),[μg] / [cm2·h],35,70934,DB00563,Methotrexate
> or =,9279889,fluxes,Target MTX fluxes of > or = 35 micrograms/cm2/hr were achievable only with 1-15% (v/v) Azone in propylene glycol (PG).,Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279889/),[μg] / [cm2·h],35,70935,DB00563,Methotrexate
,9279889,Flux,Flux of EDAM (85 micrograms/cm2/hr) was higher than MTX from an isopropyl alcohol (IPA)-5% (v/v) Azone system.,Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279889/),[μg] / [cm2·h],85,70936,DB00563,Methotrexate
,9279889,Area under the drug concentration-time curves (AUC0-24 hr),Area under the drug concentration-time curves (AUC0-24 hr) for MTX were 2379 and 3534 ng*hr/ml from PG-2.5% Azone and PG-7.5% Azone systems respectively.,Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279889/),[h·ng] / [ml],2379,70937,DB00563,Methotrexate
,9279889,Area under the drug concentration-time curves (AUC0-24 hr),Area under the drug concentration-time curves (AUC0-24 hr) for MTX were 2379 and 3534 ng*hr/ml from PG-2.5% Azone and PG-7.5% Azone systems respectively.,Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279889/),[h·ng] / [ml],3534,70938,DB00563,Methotrexate
,9279889,AUC0-24 hr,AUC0-24 hr of EDAM was 6893 ng*hr/ml using a PG-2.5% Azone system.,Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279889/),[h·ng] / [ml],6893,70939,DB00563,Methotrexate
,28744796,absolute subcutaneous bioavailability,ABT-122 absolute subcutaneous bioavailability was approximately 50% with maximum serum concentrations observed 3-4 days after dosing.,"Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),%,50,71247,DB00563,Methotrexate
,28744796,maximum serum concentration-to-trough concentration ratio,"ABT-122 maximum serum concentration-to-trough concentration ratio was 2.6 for every other week dosing and 1.3 for every week dosing, corresponding to an effective half-life of 10-18 days.","Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),,2.6,71248,DB00563,Methotrexate
,28744796,maximum serum concentration-to-trough concentration ratio,"ABT-122 maximum serum concentration-to-trough concentration ratio was 2.6 for every other week dosing and 1.3 for every week dosing, corresponding to an effective half-life of 10-18 days.","Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),,1.3,71249,DB00563,Methotrexate
,28744796,half-life,"ABT-122 maximum serum concentration-to-trough concentration ratio was 2.6 for every other week dosing and 1.3 for every week dosing, corresponding to an effective half-life of 10-18 days.","Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),d,10-18,71250,DB00563,Methotrexate
,28744796,area under the serum concentration-time curve accumulation ratio,ABT-122 median area under the serum concentration-time curve accumulation ratio was 3.8-4.8 with every week dosing.,"Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),,3.8-4.8,71251,DB00563,Methotrexate
,28744796,time to appearance of antidrug antibodies,Measureable antidrug antibodies were observed in all 48 subjects in Study 1 by day 15 post-dose and 19 of 31 ABT-122-treated patients in Studies 2 and 3 [median time to appearance of antidrug antibodies of 64 days (range 15-92 days)].,"Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28744796/),d,64,71252,DB00563,Methotrexate
,23782588,Cmax,"After final QW and Q2W dosing, mean ± SD for Cmax, Cmin and AUC0-168h/0-336h was 39.4 ± 18.1 and 10.7 ± 6.6 μg/ml, 27.9 ± 14.7 and 2.3 ± 3.2 μg/ml and 5,505 ± 2,632 and 2,332 ± 1,696 μg×h/ml.",Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782588/),[μg] / [ml],39.4,72086,DB00563,Methotrexate
,23782588,Cmin,"After final QW and Q2W dosing, mean ± SD for Cmax, Cmin and AUC0-168h/0-336h was 39.4 ± 18.1 and 10.7 ± 6.6 μg/ml, 27.9 ± 14.7 and 2.3 ± 3.2 μg/ml and 5,505 ± 2,632 and 2,332 ± 1,696 μg×h/ml.",Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782588/),[μg] / [ml],10.7,72087,DB00563,Methotrexate
,23782588,Cmin,"After final QW and Q2W dosing, mean ± SD for Cmax, Cmin and AUC0-168h/0-336h was 39.4 ± 18.1 and 10.7 ± 6.6 μg/ml, 27.9 ± 14.7 and 2.3 ± 3.2 μg/ml and 5,505 ± 2,632 and 2,332 ± 1,696 μg×h/ml.",Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782588/),[μg] / [ml],27.9,72088,DB00563,Methotrexate
,23782588,Cmin,"After final QW and Q2W dosing, mean ± SD for Cmax, Cmin and AUC0-168h/0-336h was 39.4 ± 18.1 and 10.7 ± 6.6 μg/ml, 27.9 ± 14.7 and 2.3 ± 3.2 μg/ml and 5,505 ± 2,632 and 2,332 ± 1,696 μg×h/ml.",Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782588/),[μg] / [ml],2.3,72089,DB00563,Methotrexate
,23782588,AUC0-168h/0-336h,"After final QW and Q2W dosing, mean ± SD for Cmax, Cmin and AUC0-168h/0-336h was 39.4 ± 18.1 and 10.7 ± 6.6 μg/ml, 27.9 ± 14.7 and 2.3 ± 3.2 μg/ml and 5,505 ± 2,632 and 2,332 ± 1,696 μg×h/ml.",Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782588/),[μg] / [ml],2.3,72090,DB00563,Methotrexate
,23782588,AUC0-168h/0-336h,"After final QW and Q2W dosing, mean ± SD for Cmax, Cmin and AUC0-168h/0-336h was 39.4 ± 18.1 and 10.7 ± 6.6 μg/ml, 27.9 ± 14.7 and 2.3 ± 3.2 μg/ml and 5,505 ± 2,632 and 2,332 ± 1,696 μg×h/ml.",Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782588/),[h·μg] / [ml],"5,505",72091,DB00563,Methotrexate
,23782588,AUC0-168h/0-336h,"After final QW and Q2W dosing, mean ± SD for Cmax, Cmin and AUC0-168h/0-336h was 39.4 ± 18.1 and 10.7 ± 6.6 μg/ml, 27.9 ± 14.7 and 2.3 ± 3.2 μg/ml and 5,505 ± 2,632 and 2,332 ± 1,696 μg×h/ml.",Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782588/),[h·μg] / [ml],"2,332",72092,DB00563,Methotrexate
,23782588,tmax,Median tmax was 2 - 3 days.,Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782588/),d,2 - 3,72093,DB00563,Methotrexate
,3477462,CSF/serum drug ratios,Individual CSF/serum drug ratios were not modified by the dose (1.1% for ID MTX versus 1.4% for HD MTX).,Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3477462/),,1,72930,DB00563,Methotrexate
,17655372,clinical response rates,"In controlled trials, clinical response rates of 20-40% have been achieved with such regimens in Crohn's disease and rheumatoid arthritis.",Clinical pharmacokinetics and use of infliximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),%,20-40,73675,DB00563,Methotrexate
,17655372,apparent volume of distribution,The apparent volume of distribution of the high-molecular-weight infliximab (149.1 kDa) is low (3-6L) and represents the intravascular space.,Clinical pharmacokinetics and use of infliximab. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),l,149.1,73676,DB00563,Methotrexate
,17655372,apparent volume of distribution,The apparent volume of distribution of the high-molecular-weight infliximab (149.1 kDa) is low (3-6L) and represents the intravascular space.,Clinical pharmacokinetics and use of infliximab. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),l,3-6,73677,DB00563,Methotrexate
,17655372,elimination half-life,"The long persistence in this compartment (elimination half-life 7-12 days, mean residence time 12-17 days) is due to the very low systemic clearance of about 11-15 mL/hour (0.18-0.25 mL/minute).",Clinical pharmacokinetics and use of infliximab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),d,7-12,73678,DB00563,Methotrexate
,17655372,mean residence time,"The long persistence in this compartment (elimination half-life 7-12 days, mean residence time 12-17 days) is due to the very low systemic clearance of about 11-15 mL/hour (0.18-0.25 mL/minute).",Clinical pharmacokinetics and use of infliximab. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),d,12-17,73679,DB00563,Methotrexate
,17655372,systemic clearance,"The long persistence in this compartment (elimination half-life 7-12 days, mean residence time 12-17 days) is due to the very low systemic clearance of about 11-15 mL/hour (0.18-0.25 mL/minute).",Clinical pharmacokinetics and use of infliximab. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),[ml] / [h],11-15,73680,DB00563,Methotrexate
above,17655372,trough concentrations,"When relating serum concentrations to the clinical response in patients with rheumatoid arthritis and patients with Crohn's disease, it can be assumed that trough concentrations above 1 microg/mL could be used as a kind of therapeutic target.",Clinical pharmacokinetics and use of infliximab. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655372/),[μg] / [ml],1,73681,DB00563,Methotrexate
,8325125,clearance,The clearance was fast at 158 +/- 81 ml/min/m2 and the elimination half-life (t1/2 beta) 3.0 +/- 0.7 h (mean +/- SD).,Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325125/),[ml] / [m2·min],158,74024,DB00563,Methotrexate
,8325125,elimination half-life (t1/2 beta),The clearance was fast at 158 +/- 81 ml/min/m2 and the elimination half-life (t1/2 beta) 3.0 +/- 0.7 h (mean +/- SD).,Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325125/),h,3.0,74025,DB00563,Methotrexate
,8325125,half-lives,The patients were at low risk for toxicity with a predicted MTX concentration at 39 h (5 half-lives) postinfusion of 0.28 +/- 0.10 mumol/l (mean +/- SD).,Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325125/),[μM] / [l],0.28,74026,DB00563,Methotrexate
,19576973,entrapment,The optimized emulsome (1:1.2 mole ratio of CA:PC) showed mean particle size of 160.3+/-10.2 nm and with 72.8+/-6.5% drug entrapment efficiency.,Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576973/),%,72.8,74155,DB00563,Methotrexate
,19576973,C(max),"The pharmacokinetic parameters C(max), t(max) and AUC(0-->12h) after duodenal administration of optimized emulsomal formulation and plain MTX solution were 7.1 and 2.4 microg/mL, 4 and 1 h, 40.45 and 7.2 h microg/mL respectively.",Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576973/),[μg] / [ml],7.1,74156,DB00563,Methotrexate
,19576973,t(max),"The pharmacokinetic parameters C(max), t(max) and AUC(0-->12h) after duodenal administration of optimized emulsomal formulation and plain MTX solution were 7.1 and 2.4 microg/mL, 4 and 1 h, 40.45 and 7.2 h microg/mL respectively.",Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576973/),[μg] / [ml],2.4,74157,DB00563,Methotrexate
,19576973,t(max),"The pharmacokinetic parameters C(max), t(max) and AUC(0-->12h) after duodenal administration of optimized emulsomal formulation and plain MTX solution were 7.1 and 2.4 microg/mL, 4 and 1 h, 40.45 and 7.2 h microg/mL respectively.",Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576973/),h,4,74158,DB00563,Methotrexate
,19576973,t(max),"The pharmacokinetic parameters C(max), t(max) and AUC(0-->12h) after duodenal administration of optimized emulsomal formulation and plain MTX solution were 7.1 and 2.4 microg/mL, 4 and 1 h, 40.45 and 7.2 h microg/mL respectively.",Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576973/),h,1,74159,DB00563,Methotrexate
,19576973,t(max),"The pharmacokinetic parameters C(max), t(max) and AUC(0-->12h) after duodenal administration of optimized emulsomal formulation and plain MTX solution were 7.1 and 2.4 microg/mL, 4 and 1 h, 40.45 and 7.2 h microg/mL respectively.",Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576973/),[h·μg] / [ml],40.45,74160,DB00563,Methotrexate
,19576973,AUC(0-->12h),"The pharmacokinetic parameters C(max), t(max) and AUC(0-->12h) after duodenal administration of optimized emulsomal formulation and plain MTX solution were 7.1 and 2.4 microg/mL, 4 and 1 h, 40.45 and 7.2 h microg/mL respectively.",Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19576973/),[h·μg] / [ml],7.2,74161,DB00563,Methotrexate
,10071016,trough blood level,"The mean trough blood level of MPA in 10 patients was 0.28 microg/ml, and 5.7 microg/ml for MPA glucoronide.",Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071016/),[μg] / [ml],0.28,74256,DB00563,Methotrexate
,10071016,trough blood level,"The mean trough blood level of MPA in 10 patients was 0.28 microg/ml, and 5.7 microg/ml for MPA glucoronide.",Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071016/),[μg] / [ml],5.7,74257,DB00563,Methotrexate
,20149329,bioavailability,"In four patients switched from oral to subcutaneous administration of the same dose, the bioavailability of oral MTX tended to be 11-15% lower when compared to subcutaneous route.",Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20149329/),%,11-15,74449,DB00563,Methotrexate
,6609105,duration of survival,The median duration of survival in the squamous group was 9 months and in the nonsquamous groups 6.5 months.,Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6609105/),month,9,75275,DB00563,Methotrexate
,6609105,duration of survival,The median duration of survival in the squamous group was 9 months and in the nonsquamous groups 6.5 months.,Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6609105/),month,6.5,75276,DB00563,Methotrexate
,3502454,terminal half-lives,The average terminal half-lives of methotrexate and 7-hydroxy-methotrexate in plasma were 15.02 and 15.19 hours respectively.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),h,15.02,75278,DB00563,Methotrexate
,3502454,terminal half-lives,The average terminal half-lives of methotrexate and 7-hydroxy-methotrexate in plasma were 15.02 and 15.19 hours respectively.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),h,15.19,75279,DB00563,Methotrexate
,3502454,area under concentration-time curve,The area under concentration-time curve was 723.8 +/- 196.4 microM x h for methotrexate and 598.1 +/- 212.5 microM x h for 7-hydroxy-methotrexate.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),h·μM,723.8,75280,DB00563,Methotrexate
,3502454,area under concentration-time curve,The area under concentration-time curve was 723.8 +/- 196.4 microM x h for methotrexate and 598.1 +/- 212.5 microM x h for 7-hydroxy-methotrexate.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),h·μM,598.1,75281,DB00563,Methotrexate
,3502454,urinary excretions,The total average urinary excretions of methotrexate and 7-hydroxy-methotrexate over a 96 hour period were 52% and 5.4% respectively.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),%,52,75282,DB00563,Methotrexate
,3502454,urinary excretions,The total average urinary excretions of methotrexate and 7-hydroxy-methotrexate over a 96 hour period were 52% and 5.4% respectively.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),%,5.4,75283,DB00563,Methotrexate
,3502454,Urinary clearance,Urinary clearance of methotrexate was 3.46 +/- 1.4 1/h.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3502454/),[1] / [h],3.46,75284,DB00563,Methotrexate
,12610799,half-life,The mean half-life of AG4263 was 12.5 h.,"Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610799/),h,12.5,76029,DB00563,Methotrexate
,19589239,maximal inhibition,"It was found that sodium cholate and sodium 12-monoketocholate decreased the AP-BL permeation of methotrexate at low concentrations (maximal inhibition at 0.25 and 1 mM, respectively) and increased it at higher concentrations.",Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589239/),mM,0.25,76328,DB00563,Methotrexate
,19589239,maximal inhibition,"It was found that sodium cholate and sodium 12-monoketocholate decreased the AP-BL permeation of methotrexate at low concentrations (maximal inhibition at 0.25 and 1 mM, respectively) and increased it at higher concentrations.",Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589239/),mM,1,76329,DB00563,Methotrexate
>,14735176,AUC(MTX),"In all, 22 patients were alive at a median follow-up of 31 months, with a 3-year OS of 40+/-9%; slow CL(crea) and AUC(MTX) >1100 micromol hl(-1) were independently associated with a better survival.",Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14735176/),[μM] / [hl],1100,77596,DB00563,Methotrexate
,9796964,clearance,Mean clearance and volume of distribution were 1.6 +/- 0.6 liters/h/m2 and 8.9 +/- 4.1 liters/m2.,Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796964/),[l] / [h·m2],1.6,78472,DB00563,Methotrexate
,9796964,volume of distribution,Mean clearance and volume of distribution were 1.6 +/- 0.6 liters/h/m2 and 8.9 +/- 4.1 liters/m2.,Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796964/),[l] / [m2],8.9,78473,DB00563,Methotrexate
,9796964,half-lives,"Mean half-lives were 0.23 +/- 0.1, 2.9 +/- 1.4, and 25.0 +/- 48.7 h.",Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796964/),h,0.23,78474,DB00563,Methotrexate
,9796964,half-lives,"Mean half-lives were 0.23 +/- 0.1, 2.9 +/- 1.4, and 25.0 +/- 48.7 h.",Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796964/),h,2.9,78475,DB00563,Methotrexate
,9796964,half-lives,"Mean half-lives were 0.23 +/- 0.1, 2.9 +/- 1.4, and 25.0 +/- 48.7 h.",Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796964/),h,25.0,78476,DB00563,Methotrexate
,16463431,bioavailability,The bioavailability of the split dose was 28% higher compared to the single dose (p = 0.007).,Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463431/),%,28,78667,DB00563,Methotrexate
,16463431,bioavailability,"The mean bioavailability after single-dose and split-dose MTX was 0.76 and 0.90, respectively, compared to subcutaneous administration.",Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463431/),,0.76,78668,DB00563,Methotrexate
,16463431,bioavailability,"The mean bioavailability after single-dose and split-dose MTX was 0.76 and 0.90, respectively, compared to subcutaneous administration.",Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463431/),,0.90,78669,DB00563,Methotrexate
,8231243,half-life,"In two of these patients, pharmacokinetic analysis demonstrated delayed terminal excretion of methotrexate with a half-life of 3-3.5 days, compared to a previously reported t1/2 of 8-15 hours in subjects with normal clearance.",Toxicity following concurrent intrathecal and moderate-dose intravenous methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8231243/),d,3-3.5,78930,DB00563,Methotrexate
,8231243,t1/2,"In two of these patients, pharmacokinetic analysis demonstrated delayed terminal excretion of methotrexate with a half-life of 3-3.5 days, compared to a previously reported t1/2 of 8-15 hours in subjects with normal clearance.",Toxicity following concurrent intrathecal and moderate-dose intravenous methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8231243/),h,8-15,78931,DB00563,Methotrexate
,4017160,terminal half-life,"In rabbits the IV kinetics of MTX (1.33, 4 and 12 mg/kg) could be described by a linear three-compartment model with a terminal half-life between 2.4 and 3.6 h.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017160/),h,2.4 and 3.6,79547,DB00563,Methotrexate
,4017160,terminal half-life,After short-term infusion of 7-OH-MTX (4 mg/kg) a biexponential decline of 7-OH-MTX plasma concentrations was observed with a terminal half-life of 0.45 h.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017160/),h,0.45,79548,DB00563,Methotrexate
,21586839,volume of distribution,The volume of distribution was calculated as 1.33 ml following intravitreal injection of 800 μg methotrexate.,Intravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586839/),ml,1.33,79656,DB00563,Methotrexate
,21586839,half life,Vitreous concentrations of the drug were found to be decreasing related to the specific mathematical equation; drug concentration= 1426.73 e -0.1182(time) and remained over effective dose by 81 hours with a half life of 5.9 hours.,Intravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586839/),h,5.9,79657,DB00563,Methotrexate
,7624260,clearance,"Methotrexate clearance (58-155 ml/min/m2) was significantly (p = 0.007) correlated with GFR, but GFR accounted for only 37% of the variability of methotrexate clearance.",Renal function and methotrexate clearance in children with newly diagnosed leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624260/),[ml] / [m2·min],58-155,79820,DB00563,Methotrexate
,34326772,clearance,The final population model demonstrated that the MTX clearance estimate in a typical child with body weight of 19 kg was 6.9 L/h and the central distribution of volume estimate was 20.7 L.,Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34326772/),[l] / [h],6.9,79864,DB00563,Methotrexate
,34326772,central distribution of volume,The final population model demonstrated that the MTX clearance estimate in a typical child with body weight of 19 kg was 6.9 L/h and the central distribution of volume estimate was 20.7 L.,Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34326772/),l,20.7,79865,DB00563,Methotrexate
,20843124,CL,"The population pharmacokinetic parameters CL ,V1,Q, V2,K,K12 and K21 generated in NONMEM, using the FO method were 3.5 L/h,1.25 L,8.43 L/h,6.45 L, 2.8,6.74 and 1.30 h-1 respectively.",Population pharmacokinetics of methotrexate in Indian cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20843124/),[l] / [h],3.5,80503,DB00563,Methotrexate
,20843124,K21,"The population pharmacokinetic parameters CL ,V1,Q, V2,K,K12 and K21 generated in NONMEM, using the FO method were 3.5 L/h,1.25 L,8.43 L/h,6.45 L, 2.8,6.74 and 1.30 h-1 respectively.",Population pharmacokinetics of methotrexate in Indian cancer patients. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20843124/),1/[h],6.74,80504,DB00563,Methotrexate
,20843124,K21,"The population pharmacokinetic parameters CL ,V1,Q, V2,K,K12 and K21 generated in NONMEM, using the FO method were 3.5 L/h,1.25 L,8.43 L/h,6.45 L, 2.8,6.74 and 1.30 h-1 respectively.",Population pharmacokinetics of methotrexate in Indian cancer patients. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20843124/),1/[h],1.30,80505,DB00563,Methotrexate
,2204007,F,Mean F was 0.85 +/- 0.22 (85% +/- 22%); in 1 patient F was 0.43 (43%).,Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.85,80611,DB00563,Methotrexate
,2204007,F,Mean F was 0.85 +/- 0.22 (85% +/- 22%); in 1 patient F was 0.43 (43%).,Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.43,80612,DB00563,Methotrexate
,2204007,F,"Furthermore, 3 patients treated with only p.o. CY had low estimated F values: 0.45, 0.49 and 0.50.",Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.45,80613,DB00563,Methotrexate
,2204007,F,"Furthermore, 3 patients treated with only p.o. CY had low estimated F values: 0.45, 0.49 and 0.50.",Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.49,80614,DB00563,Methotrexate
,2204007,F,"Furthermore, 3 patients treated with only p.o. CY had low estimated F values: 0.45, 0.49 and 0.50.",Bioavailability of cyclophosphamide in the CMF regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2204007/),,0.50,80615,DB00563,Methotrexate
,10348791,biliary clearance,"The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile ( approximately 0, approximately 0, 4.1 +/- 1.0, 12.6 +/- 2.2, and 56. 2 +/- 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99).",Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348791/),[ml] / [kg·min],4.1,82525,DB00563,Methotrexate
,10348791,biliary clearance,"The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile ( approximately 0, approximately 0, 4.1 +/- 1.0, 12.6 +/- 2.2, and 56. 2 +/- 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99).",Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348791/),[ml] / [kg·min],12.6,82526,DB00563,Methotrexate
,10348791,biliary clearance,"The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile ( approximately 0, approximately 0, 4.1 +/- 1.0, 12.6 +/- 2.2, and 56. 2 +/- 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99).",Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348791/),[ml] / [kg·min],56. 2,82527,DB00563,Methotrexate
,10348791,intrinsic,"The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile ( approximately 0, approximately 0, 4.1 +/- 1.0, 12.6 +/- 2.2, and 56. 2 +/- 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99).",Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348791/),[ml] / [kg·min],34.4,82528,DB00563,Methotrexate
,10348791,biliary clearance,"The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile ( approximately 0, approximately 0, 4.1 +/- 1.0, 12.6 +/- 2.2, and 56. 2 +/- 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99).",Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348791/),[ml] / [kg·min],0,82529,DB00563,Methotrexate
,10348791,biliary clearance,"The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile ( approximately 0, approximately 0, 4.1 +/- 1.0, 12.6 +/- 2.2, and 56. 2 +/- 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99).",Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348791/),[ml] / [kg·min],17.3,82530,DB00563,Methotrexate
,10348791,biliary clearance,"The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile ( approximately 0, approximately 0, 4.1 +/- 1.0, 12.6 +/- 2.2, and 56. 2 +/- 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99).",Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348791/),[ml] / [kg·min],34.4,82531,DB00563,Methotrexate
,10348791,biliary clearance,"The in vitro biliary clearance of inulin, salicylate, methotrexate, [D-pen2,5]enkephalin, and taurocholate, calculated as the ratio of the amount excreted into the bile canalicular networks and the area under the incubation medium concentration-time profile ( approximately 0, approximately 0, 4.1 +/- 1.0, 12.6 +/- 2.2, and 56. 2 +/- 6.0 ml/min/kg, respectively), correlated with their intrinsic in vivo biliary clearance (0.04, 0, 17.3, 34.4, and 116.9 ml/min/kg, respectively; r2 = 0.99).",Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348791/),[ml] / [kg·min],116.9,82532,DB00563,Methotrexate
,22950522,apparent terminal elimination half-life,"The absorption of GLPG0259 was slow, with a decrease in the absorption rate with increasing dose, and there was decreased elimination, with an apparent terminal elimination half-life of 26.0 hours.","Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22950522/),h,26.0,84353,DB00563,Methotrexate
,9423749,clearance rates,"Methotrexate clearance rates were 7.89 +/- 1.98 L/hr and 5.55 +/- 0.83 L/hr (p = 0.003), respectively.",Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423749/),[l] / [h],7.89,85355,DB00563,Methotrexate
,9423749,clearance rates,"Methotrexate clearance rates were 7.89 +/- 1.98 L/hr and 5.55 +/- 0.83 L/hr (p = 0.003), respectively.",Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423749/),[l] / [h],5.55,85356,DB00563,Methotrexate
,7349890,t1/2 alpha,"The serum half-life of 5-fluorouracil (5-FUra) in humans is best described as a biexponential decay function, with t1/2 alpha = 7.8 +/- 2.6 (S.E.) min and t1/2 beta = 36.8 +/- 13.5 min during initial courses of this drug alone.",Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349890/),min,7.8,85512,DB00563,Methotrexate
,7349890,t1/2 beta,"The serum half-life of 5-fluorouracil (5-FUra) in humans is best described as a biexponential decay function, with t1/2 alpha = 7.8 +/- 2.6 (S.E.) min and t1/2 beta = 36.8 +/- 13.5 min during initial courses of this drug alone.",Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7349890/),min,36.8,85513,DB00563,Methotrexate
,10468023,In vivo recovery,In vivo recovery (reverse dialysis) was 10.8 +/- 5.3%.,Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468023/),%,10.8,86221,DB00563,Methotrexate
,10993519,limit of detection,The limit of detection was 0.17 pmol which corresponds to a plasma concentration of 1.7 nmol/l.,High-performance liquid chromatographic assay for the determination of 5-methyltetrahydrofolate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993519/),pM,0.17,86781,DB00563,Methotrexate
,16867766,detection limits,The detection limits for plasma and urine samples were approximately 40 ng/ml (8.8 x 10(-8) M) for MTX and 100 ng/ml (2.1 x 10(-7) M) for 7-OH-MTX.,Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867766/),[ng] / [ml],40,87323,DB00563,Methotrexate
,16867766,detection limits,The detection limits for plasma and urine samples were approximately 40 ng/ml (8.8 x 10(-8) M) for MTX and 100 ng/ml (2.1 x 10(-7) M) for 7-OH-MTX.,Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867766/),M,8.8 x 10(-8),87324,DB00563,Methotrexate
,16867766,detection limits,The detection limits for plasma and urine samples were approximately 40 ng/ml (8.8 x 10(-8) M) for MTX and 100 ng/ml (2.1 x 10(-7) M) for 7-OH-MTX.,Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867766/),[ng] / [ml],100,87325,DB00563,Methotrexate
,16867766,detection limits,The detection limits for plasma and urine samples were approximately 40 ng/ml (8.8 x 10(-8) M) for MTX and 100 ng/ml (2.1 x 10(-7) M) for 7-OH-MTX.,Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867766/),M,2.1 x 10(-7),87326,DB00563,Methotrexate
,16867766,apparent half-life,"After the end of the infusion, the mean apparent half-life for the metabolite was 19.1 h, while that for MTX was 8.8 h.",Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867766/),h,19.1,87327,DB00563,Methotrexate
,16867766,apparent half-life,"After the end of the infusion, the mean apparent half-life for the metabolite was 19.1 h, while that for MTX was 8.8 h.",Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867766/),h,8.8,87328,DB00563,Methotrexate
,30610367,cerebrospinal fluid trough concentration,"For trastuzumab, the mean cerebrospinal fluid trough concentration of 53.4 mg/L reached relevant levels, enabling the stabilization of the metastases.",A successful compartmental approach for the treatment of breast cancer brain metastases. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610367/),[mg] / [l],53.4,87658,DB00563,Methotrexate
greater,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,500,87809,DB00563,Methotrexate
,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,15,87810,DB00563,Methotrexate
,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,23,87811,DB00563,Methotrexate
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.49,87812,DB00563,Methotrexate
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.27,87813,DB00563,Methotrexate
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.16,87814,DB00563,Methotrexate
,17112298,V(1),For children aged < or =10 years: CL (L/h) = 0.287 . TBW(0.876); V(1) (L) = 0.465 .,Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112298/),l,0.465,88231,DB00563,Methotrexate
>,25257727,trough concentrations,"Despite dose escalation in 90 % of patients, only 17 (57 %) patients ever achieved MPA trough concentrations >50 ng/ml.",A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25257727/),[ng] / [ml],50,89376,DB00563,Methotrexate
,309355,half-life,CPDG1 rescue resulted in a prolonged CSF-MTX half-life of 16.5-23 hours in comparison with CF rescue where the CSF-MTX half-life was 6.5-7.2 hours.,Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/309355/),h,16.5-23,89411,DB00563,Methotrexate
,309355,half-life,CPDG1 rescue resulted in a prolonged CSF-MTX half-life of 16.5-23 hours in comparison with CF rescue where the CSF-MTX half-life was 6.5-7.2 hours.,Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/309355/),h,6.5-7.2,89412,DB00563,Methotrexate
,16372823,acid dissociation constant [pKa],"Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors.",Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),,4.7,89509,DB00563,Methotrexate
,16372823,oral bioavailability,Lumiracoxib has good oral bioavailability (74%).,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),%,74,89510,DB00563,Methotrexate
,16372823,elimination half-life,Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),h,4,89511,DB00563,Methotrexate
,9210979,elimination half-life,"In rabbits, MTX concentrations in the plasma increased steadily toward the peak (5.9 +/- 2.8 ng mL-1) which appeared at approximately 2 h postdose and declined with the elimination half-life of 4.48 +/- 1.74 h.",Percutaneous absorption and disposition studies of methotrexate in rabbits and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210979/),h,4.48,90096,DB00563,Methotrexate
,9210979,recovery,"quantitation limit of 0.5 ng mL-1, and mean recovery of approximately 87% was used for the quantitation of MTX in the tissue and fluid samples.",Percutaneous absorption and disposition studies of methotrexate in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210979/),%,87,90097,DB00563,Methotrexate
,18282,half-life,The half-life of MTX in the CSF (11.95 hours) is twice as long as the serum half-life.,Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282/),h,11.95,90825,DB00563,Methotrexate
,2328562,systemic clearance,"In twelve patients who completed the study, methotrexate systemic clearance was not statistically different with naproxen (103.3 +/- 35.0 ml/min) versus without naproxen (113.4 +/- 48.3 ml/min; p = 0.37).",Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328562/),[ml] / [min],103.3,91779,DB00563,Methotrexate
,2328562,systemic clearance,"In twelve patients who completed the study, methotrexate systemic clearance was not statistically different with naproxen (103.3 +/- 35.0 ml/min) versus without naproxen (113.4 +/- 48.3 ml/min; p = 0.37).",Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328562/),[ml] / [min],113.4,91780,DB00563,Methotrexate
,2328562,Oral clearance,Oral clearance of methotrexate was not statistically different with naproxen (161.7 +/- 55.0 ml/min) versus without naproxen (176.7 +/- 68.3 ml/min; p = 0.14).,Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328562/),[ml] / [min],161.7,91781,DB00563,Methotrexate
,2328562,Oral clearance,Oral clearance of methotrexate was not statistically different with naproxen (161.7 +/- 55.0 ml/min) versus without naproxen (176.7 +/- 68.3 ml/min; p = 0.14).,Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328562/),[ml] / [min],176.7,91782,DB00563,Methotrexate
,3416310,alpha,"Elimination was independent of dose over the range tested, with mean plasma half-lives of: alpha = 12.9 min, beta = 1.5 h, and gamma = 11.9 h.",Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416310/),min,12.9,91898,DB00563,Methotrexate
,3416310,beta,"Elimination was independent of dose over the range tested, with mean plasma half-lives of: alpha = 12.9 min, beta = 1.5 h, and gamma = 11.9 h.",Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416310/),h,1.5,91899,DB00563,Methotrexate
,3416310,gamma,"Elimination was independent of dose over the range tested, with mean plasma half-lives of: alpha = 12.9 min, beta = 1.5 h, and gamma = 11.9 h.",Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416310/),h,11.9,91900,DB00563,Methotrexate
,3416310,Cumulative,Cumulative urinary excretion of the drug ranged from 13 to 55% of the administered dose (mean = 33%); 88% of the urinary drug appeared within the first 4 h following drug administration.,Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416310/),%,33,91901,DB00563,Methotrexate
,3416310,urinary excretion,Cumulative urinary excretion of the drug ranged from 13 to 55% of the administered dose (mean = 33%); 88% of the urinary drug appeared within the first 4 h following drug administration.,Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416310/),,13 to 55%,91902,DB00563,Methotrexate
,3416310,urinary excretion,Cumulative urinary excretion of the drug ranged from 13 to 55% of the administered dose (mean = 33%); 88% of the urinary drug appeared within the first 4 h following drug administration.,Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416310/),%,33,91903,DB00563,Methotrexate
,3471936,bioavailability,"Mean bioavailability, as determined by comparing the area under the concentration-time curve after oral or intramuscular administration with that produced by the same dosage given intravenously, was 33% (range 13% to 76%) for oral (n = 11) and 76% (54% to 112%) for intramuscular (n = 7) administration (P less than 0.01).",Methotrexate bioavailability after oral and intramuscular administration in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471936/),%,33,92371,DB00563,Methotrexate
,3471936,bioavailability,"Mean bioavailability, as determined by comparing the area under the concentration-time curve after oral or intramuscular administration with that produced by the same dosage given intravenously, was 33% (range 13% to 76%) for oral (n = 11) and 76% (54% to 112%) for intramuscular (n = 7) administration (P less than 0.01).",Methotrexate bioavailability after oral and intramuscular administration in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471936/),%,76,92372,DB00563,Methotrexate
,3471936,bioavailability,"Median bioavailability (with orally administered dosages less than or equal to 40 mg/m2 (range 13 to 40 mg/m2) was 42% (19% to 76%); at dosages greater than 40 mg/m2 (43 to 76 mg/m2), bioavailability was significantly lower, 17.5% (12.7% to 22.3%, p less than 0.02).",Methotrexate bioavailability after oral and intramuscular administration in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471936/),%,42,92373,DB00563,Methotrexate
,3471936,bioavailability,"Median bioavailability (with orally administered dosages less than or equal to 40 mg/m2 (range 13 to 40 mg/m2) was 42% (19% to 76%); at dosages greater than 40 mg/m2 (43 to 76 mg/m2), bioavailability was significantly lower, 17.5% (12.7% to 22.3%, p less than 0.02).",Methotrexate bioavailability after oral and intramuscular administration in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471936/),%,17.5,92374,DB00563,Methotrexate
,3471936,bioavailability,"Median bioavailability (with orally administered dosages less than or equal to 40 mg/m2 (range 13 to 40 mg/m2) was 42% (19% to 76%); at dosages greater than 40 mg/m2 (43 to 76 mg/m2), bioavailability was significantly lower, 17.5% (12.7% to 22.3%, p less than 0.02).",Methotrexate bioavailability after oral and intramuscular administration in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3471936/),%,22.3,92375,DB00563,Methotrexate
,6433796,peak ventricular concentration,"The peak ventricular concentration of MTX, which was administered by Ommaya reservoir, at a dose of 15mg/m2, was 2.5 +/- 0.9 X 10(-4)M, and remained as a level of 10(-6)M for 72 hours with a half-life of 10.5 hours.",[Pharmacokinetics of intrathecal chemotherapy and clinical problems]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6433796/),M,2.5,93257,DB00563,Methotrexate
,6433796,half-life,"The peak ventricular concentration of MTX, which was administered by Ommaya reservoir, at a dose of 15mg/m2, was 2.5 +/- 0.9 X 10(-4)M, and remained as a level of 10(-6)M for 72 hours with a half-life of 10.5 hours.",[Pharmacokinetics of intrathecal chemotherapy and clinical problems]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6433796/),h,10.5,93258,DB00563,Methotrexate
,9556164,maximum CSF concentration,The maximum CSF concentration of THP was 0.97% of plasma in patient A and 0.89% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),,0,95277,DB00563,Methotrexate
,9556164,AUC,The CSF AUC of THP was 28.4% of plasma in patient A and 13.1% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),%,28.4,95278,DB00563,Methotrexate
,9556164,AUC,The CSF AUC of THP was 28.4% of plasma in patient A and 13.1% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),%,13.1,95279,DB00563,Methotrexate
,31729053,time to methotrexate clearance,"The mean time to methotrexate clearance was 82.5 hours (SD, 51.2; 95% confidence interval, 69.4-95.7) in the concomitant levetiracetam group and 72.4 hours (SD, 31.2; 95% confidence interval, 61.7-83.0) in the nonlevetiracetam group, which was not significantly different (P > .05), even in the subgroup receiving methotrexate doses >3500 mg/m2 .",Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31729053/),h,82.5,95819,DB00563,Methotrexate
,31729053,time to methotrexate clearance,"The mean time to methotrexate clearance was 82.5 hours (SD, 51.2; 95% confidence interval, 69.4-95.7) in the concomitant levetiracetam group and 72.4 hours (SD, 31.2; 95% confidence interval, 61.7-83.0) in the nonlevetiracetam group, which was not significantly different (P > .05), even in the subgroup receiving methotrexate doses >3500 mg/m2 .",Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31729053/),h,72.4,95820,DB00563,Methotrexate
,15831771,time to peak concentration,"Etanercept is absorbed slowly from the site of subcutaneous injection, with time to peak concentration at approximately 48 to 60 hours, and is cleared slowly from the body with a t(1/2) of 70 to 100 hours.",Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),h,48 to 60,95896,DB00563,Methotrexate
,15831771,t(1/2),"Etanercept is absorbed slowly from the site of subcutaneous injection, with time to peak concentration at approximately 48 to 60 hours, and is cleared slowly from the body with a t(1/2) of 70 to 100 hours.",Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),h,70 to 100,95897,DB00563,Methotrexate
,15831771,absolute bioavailability,The absolute bioavailability of etanercept was 58% in healthy subjects following subcutaneous administration.,Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15831771/),%,58,95898,DB00563,Methotrexate
,20695463,50% growth inhibitory concentration,MTX showed a significant inhibitory effect on the in vitro growth of 9L glioma cells with 50% growth inhibitory concentration at 7.99 ng/mL.,Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20695463/),[ng] / [ml],7.99,96781,DB00563,Methotrexate
,31284483,encapsulation efficiency,"Mean particle size and encapsulation efficiency of NPs were 163.7 ± 10.25 nm and 93.3 ± 0.5%, respectively.",Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31284483/),%,93.3,97047,DB00563,Methotrexate
,25563323,CL1,"The PPK parameters (RSD%) were CL1, V1, CL2 and V2 with values of 6.20 L/h (8.48%), 19.6 L (extremely small), 0.0172 L/h (50.9%) and 0.515 L (39.1%), respectively.",Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563323/),[l] / [h],6.20,97080,DB00563,Methotrexate
,25563323,V2,"The PPK parameters (RSD%) were CL1, V1, CL2 and V2 with values of 6.20 L/h (8.48%), 19.6 L (extremely small), 0.0172 L/h (50.9%) and 0.515 L (39.1%), respectively.",Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25563323/),l,0.515,97081,DB00563,Methotrexate
,29402521,time to steady-state,"The mean time to steady-state MTX PG concentration was increased with MTX dose, from 8 to >26 weeks, depending on PG chain length.","Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29402521/),weeks,8,97152,DB00563,Methotrexate
>,29402521,time to steady-state,"The mean time to steady-state MTX PG concentration was increased with MTX dose, from 8 to >26 weeks, depending on PG chain length.","Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29402521/),weeks,26,97153,DB00563,Methotrexate
,2363742,bioavailability,"The results, however, demonstrated a change in the bioavailability of the drug (decreasing from 84.7% to 38.9%).",Biliary elimination of low-dose methotrexate in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363742/),%,84.7,97684,DB00563,Methotrexate
,2363742,bioavailability,"The results, however, demonstrated a change in the bioavailability of the drug (decreasing from 84.7% to 38.9%).",Biliary elimination of low-dose methotrexate in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363742/),%,38.9,97685,DB00563,Methotrexate
,22105588,CL(filt),"For a typical 70 kg man of 18 years or older, the parameter estimates for the final model were CL(filt) = 2.69 L/h/70 kg, CL(sec) = 10.9 L/h/70 kg, V₁ = 74.3 L/70 kg, Q = 0.110 L/h/70 kg, and V₂ = 4.10 L/70 kg.",A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105588/),[l] / [70·h·kg],2.69,98103,DB00563,Methotrexate
,22105588,CL(sec),"For a typical 70 kg man of 18 years or older, the parameter estimates for the final model were CL(filt) = 2.69 L/h/70 kg, CL(sec) = 10.9 L/h/70 kg, V₁ = 74.3 L/70 kg, Q = 0.110 L/h/70 kg, and V₂ = 4.10 L/70 kg.",A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105588/),[l] / [70·h·kg],10.9,98104,DB00563,Methotrexate
,22105588,V₁,"For a typical 70 kg man of 18 years or older, the parameter estimates for the final model were CL(filt) = 2.69 L/h/70 kg, CL(sec) = 10.9 L/h/70 kg, V₁ = 74.3 L/70 kg, Q = 0.110 L/h/70 kg, and V₂ = 4.10 L/70 kg.",A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105588/),[l] / [70·kg],74.3,98105,DB00563,Methotrexate
,22105588,Q,"For a typical 70 kg man of 18 years or older, the parameter estimates for the final model were CL(filt) = 2.69 L/h/70 kg, CL(sec) = 10.9 L/h/70 kg, V₁ = 74.3 L/70 kg, Q = 0.110 L/h/70 kg, and V₂ = 4.10 L/70 kg.",A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105588/),[l] / [70·h·kg],0.110,98106,DB00563,Methotrexate
,22105588,V₂,"For a typical 70 kg man of 18 years or older, the parameter estimates for the final model were CL(filt) = 2.69 L/h/70 kg, CL(sec) = 10.9 L/h/70 kg, V₁ = 74.3 L/70 kg, Q = 0.110 L/h/70 kg, and V₂ = 4.10 L/70 kg.",A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105588/),[l] / [70·kg],4.10,98107,DB00563,Methotrexate
,580447,half life,"MTX was accumulated in liver after both modes of administration with a half life 6.1 hr after intraperitoneal injection and 12.4 hr after the localized chemotherpay, respectively.",Distribution and pharmacokinetics of methotrexate in localized chemotherapy of solid Gardner's lymphosarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580447/),h,6.1,98227,DB00563,Methotrexate
,580447,half life,"MTX was accumulated in liver after both modes of administration with a half life 6.1 hr after intraperitoneal injection and 12.4 hr after the localized chemotherpay, respectively.",Distribution and pharmacokinetics of methotrexate in localized chemotherapy of solid Gardner's lymphosarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580447/),h,12.4,98228,DB00563,Methotrexate
,9803986,relative bioavailability,"The final model describing the biexponential disposition of methotrexate was clearance(CL, 1 h(-1)) = (0.0810*BW + 0.257*CL(CR))*(1-(0.167*GEN); central volume (Vc, 1) = 0.311*BW; peripheral volume (Vp, 1) = 0.469*BW-0.169*AGE; intercompartmental clearance (Q, 1 h(-1)) = 4.27*(1-0.355*GEN); oral absorption rate constant (ka(p.o.), h(-1)) = 4.70-0.0439*DOSE*(1-0.507*FED); intramuscular absorption rate constant (ka(i.m.), h(-1)) = 0.122*DOSE; relative bioavailability (F) = 93.4%; and oral absorption lag time (LAG(p.o.), min) = 13.5.",The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803986/),%,93.4,98284,DB00563,Methotrexate
,9803986,CL,"Pharmacokinetic parameters (%CV) for a typical fasted male subject in this study were CL, 7.341 h(-1) (27%); Vc, 23.51 (28%); Vp, 25.31 (31%); Q, 4.25 1 h(-1) (41%); ka(p.o.), 3.67 h(-1) (77%); and ka(i.m.), 3.09 h(-1) (44%).",The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803986/),1/[h],7.341,98285,DB00563,Methotrexate
,9803986,Vc,"Pharmacokinetic parameters (%CV) for a typical fasted male subject in this study were CL, 7.341 h(-1) (27%); Vc, 23.51 (28%); Vp, 25.31 (31%); Q, 4.25 1 h(-1) (41%); ka(p.o.), 3.67 h(-1) (77%); and ka(i.m.), 3.09 h(-1) (44%).",The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803986/),,23.51,98286,DB00563,Methotrexate
,9803986,Vp,"Pharmacokinetic parameters (%CV) for a typical fasted male subject in this study were CL, 7.341 h(-1) (27%); Vc, 23.51 (28%); Vp, 25.31 (31%); Q, 4.25 1 h(-1) (41%); ka(p.o.), 3.67 h(-1) (77%); and ka(i.m.), 3.09 h(-1) (44%).",The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803986/),,25.31,98287,DB00563,Methotrexate
,9803986,Q,"Pharmacokinetic parameters (%CV) for a typical fasted male subject in this study were CL, 7.341 h(-1) (27%); Vc, 23.51 (28%); Vp, 25.31 (31%); Q, 4.25 1 h(-1) (41%); ka(p.o.), 3.67 h(-1) (77%); and ka(i.m.), 3.09 h(-1) (44%).",The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803986/),[1] / [h],4.25,98288,DB00563,Methotrexate
,9803986,ka,"Pharmacokinetic parameters (%CV) for a typical fasted male subject in this study were CL, 7.341 h(-1) (27%); Vc, 23.51 (28%); Vp, 25.31 (31%); Q, 4.25 1 h(-1) (41%); ka(p.o.), 3.67 h(-1) (77%); and ka(i.m.), 3.09 h(-1) (44%).",The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803986/),1/[h],3.67,98289,DB00563,Methotrexate
,9803986,ka,"Pharmacokinetic parameters (%CV) for a typical fasted male subject in this study were CL, 7.341 h(-1) (27%); Vc, 23.51 (28%); Vp, 25.31 (31%); Q, 4.25 1 h(-1) (41%); ka(p.o.), 3.67 h(-1) (77%); and ka(i.m.), 3.09 h(-1) (44%).",The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9803986/),1/[h],3.09,98290,DB00563,Methotrexate
,9204775,volume doubling time,Antitumor efficacy in Sarcoma-180 tumor bearing mice exhibited increased volume doubling time (18 +/- 2.7 days) compared to plain subcutaneous injection of methotrexate (8 +/- 0.7 days).,In vitro characterization of methotrexate loaded poly(lactic-co-glycolic) acid microspheres and antitumor efficacy in Sarcoma-180 mice bearing tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204775/),d,18,99013,DB00563,Methotrexate
,9204775,volume doubling time,Antitumor efficacy in Sarcoma-180 tumor bearing mice exhibited increased volume doubling time (18 +/- 2.7 days) compared to plain subcutaneous injection of methotrexate (8 +/- 0.7 days).,In vitro characterization of methotrexate loaded poly(lactic-co-glycolic) acid microspheres and antitumor efficacy in Sarcoma-180 mice bearing tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204775/),d,8,99014,DB00563,Methotrexate
,7363401,renal clearance rate,"During this period the methotrexate renal clearance rate was 37 ml . min-1, increasing to 97 ml . min-1 when vomiting and diarrhoea ceased.",Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363401/),[ml] / [min],37,101378,DB00563,Methotrexate
,7363401,renal clearance rate,"During this period the methotrexate renal clearance rate was 37 ml . min-1, increasing to 97 ml . min-1 when vomiting and diarrhoea ceased.",Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363401/),[ml] / [min],97,101379,DB00563,Methotrexate
,7363401,plasma clearance,"Only 26% of the administered dose was recovered in the urine up to 48 h after treatment, whilst the plasma clearance of methotrexate assessed over the same period was 208 ml . min-1.",Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363401/),[ml] / [min],208,101380,DB00563,Methotrexate
,17766699,terminal half-life,The mean terminal half-life of rituximab was 19 to 22 days; pharmacokinetic parameters were similar whether rituximab was administered alone or with methotrexate or cyclophosphamide.,Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17766699/),d,19 to 22,102044,DB00563,Methotrexate
,7838036,total clearance,"Steady-state levels and AUC were from 60% higher to more than double and the total clearance of the compound, expressed either per square meter surface area or per kg body weight, in each cycle was significantly lower in adolescents > 10 years of age, sometimes being only one-third of the clearance in infants (0.2 vs. 0.6 1/h/kg and 6.6 vs. 10.7 1/h/sq.m).","Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7838036/),[1] / [h·kg],0.2,102138,DB00563,Methotrexate
,7838036,total clearance,"Steady-state levels and AUC were from 60% higher to more than double and the total clearance of the compound, expressed either per square meter surface area or per kg body weight, in each cycle was significantly lower in adolescents > 10 years of age, sometimes being only one-third of the clearance in infants (0.2 vs. 0.6 1/h/kg and 6.6 vs. 10.7 1/h/sq.m).","Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7838036/),[1] / [h·kg],0.6,102139,DB00563,Methotrexate
,7838036,total clearance,"Steady-state levels and AUC were from 60% higher to more than double and the total clearance of the compound, expressed either per square meter surface area or per kg body weight, in each cycle was significantly lower in adolescents > 10 years of age, sometimes being only one-third of the clearance in infants (0.2 vs. 0.6 1/h/kg and 6.6 vs. 10.7 1/h/sq.m).","Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7838036/),[1] / [h·m·sq],6.6,102140,DB00563,Methotrexate
,7838036,total clearance,"Steady-state levels and AUC were from 60% higher to more than double and the total clearance of the compound, expressed either per square meter surface area or per kg body weight, in each cycle was significantly lower in adolescents > 10 years of age, sometimes being only one-third of the clearance in infants (0.2 vs. 0.6 1/h/kg and 6.6 vs. 10.7 1/h/sq.m).","Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7838036/),[1] / [h·m·sq],10.7,102141,DB00563,Methotrexate
,7838036,clearance,"Steady-state levels and AUC were from 60% higher to more than double and the total clearance of the compound, expressed either per square meter surface area or per kg body weight, in each cycle was significantly lower in adolescents > 10 years of age, sometimes being only one-third of the clearance in infants (0.2 vs. 0.6 1/h/kg and 6.6 vs. 10.7 1/h/sq.m).","Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7838036/),[1] / [h·kg],0.2,102142,DB00563,Methotrexate
,7838036,clearance,"Steady-state levels and AUC were from 60% higher to more than double and the total clearance of the compound, expressed either per square meter surface area or per kg body weight, in each cycle was significantly lower in adolescents > 10 years of age, sometimes being only one-third of the clearance in infants (0.2 vs. 0.6 1/h/kg and 6.6 vs. 10.7 1/h/sq.m).","Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7838036/),[1] / [h·kg],0.6,102143,DB00563,Methotrexate
,7838036,clearance,"Steady-state levels and AUC were from 60% higher to more than double and the total clearance of the compound, expressed either per square meter surface area or per kg body weight, in each cycle was significantly lower in adolescents > 10 years of age, sometimes being only one-third of the clearance in infants (0.2 vs. 0.6 1/h/kg and 6.6 vs. 10.7 1/h/sq.m).","Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7838036/),[1] / [h·m·sq],6.6,102144,DB00563,Methotrexate
,7838036,clearance,"Steady-state levels and AUC were from 60% higher to more than double and the total clearance of the compound, expressed either per square meter surface area or per kg body weight, in each cycle was significantly lower in adolescents > 10 years of age, sometimes being only one-third of the clearance in infants (0.2 vs. 0.6 1/h/kg and 6.6 vs. 10.7 1/h/sq.m).","Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7838036/),[1] / [h·m·sq],10.7,102145,DB00563,Methotrexate
,3876873,t1/2,"The levels declined rapidly with a two-phase elimination pattern (t1/2 = 1.2-2.5 hours, t1/2 = 18-32 hours).",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),h,1.2-2.5,104192,DB00563,Methotrexate
,3876873,t1/2,"The levels declined rapidly with a two-phase elimination pattern (t1/2 = 1.2-2.5 hours, t1/2 = 18-32 hours).",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),h,18-32,104193,DB00563,Methotrexate
,3876873,folate level,"The folate level in the plasma ranged from 5 X 10(-7) M to 1.4 X 10(-6) M when CF was administered every six hours or every three hours, respectively.",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),M,5 X 10(-7),104194,DB00563,Methotrexate
,3876873,folate level,"The folate level in the plasma ranged from 5 X 10(-7) M to 1.4 X 10(-6) M when CF was administered every six hours or every three hours, respectively.",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),,1.4 X 10(-6),104195,DB00563,Methotrexate
,32246190,clearance (CL),"A two-compartment model adequately described the data, and the estimated mean MTX clearance (CL) was 6.03 L/h (9%).",Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32246190/),[l] / [h],6.03,104423,DB00563,Methotrexate
,19617465,apparent clearance,"For a patient of standard weight (70 kg), the population estimates (typical value +/- standard error) for golimumab pharmacokinetic parameters were as follows: apparent clearance = 1.38 +/- 0.04 L/d, apparent volume of distribution = 24.9 +/- 1.04 L, and absorption rate constant = 0.908 +/- 0.121 per day.","Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19617465/),[l] / [d],1.38,104587,DB00563,Methotrexate
,19617465,apparent volume of distribution,"For a patient of standard weight (70 kg), the population estimates (typical value +/- standard error) for golimumab pharmacokinetic parameters were as follows: apparent clearance = 1.38 +/- 0.04 L/d, apparent volume of distribution = 24.9 +/- 1.04 L, and absorption rate constant = 0.908 +/- 0.121 per day.","Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19617465/),l,24.9,104588,DB00563,Methotrexate
,19617465,absorption rate constant,"For a patient of standard weight (70 kg), the population estimates (typical value +/- standard error) for golimumab pharmacokinetic parameters were as follows: apparent clearance = 1.38 +/- 0.04 L/d, apparent volume of distribution = 24.9 +/- 1.04 L, and absorption rate constant = 0.908 +/- 0.121 per day.","Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19617465/),1/[d],0.908,104589,DB00563,Methotrexate
,23190184,AUC,The mean AUC values were 3375 ng/mL × h (PO MTX) and 3985 ng/mL × h (SC MTX).,Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23190184/),[ng] / [h·ml],3375,105500,DB00563,Methotrexate
,23190184,AUC,The mean AUC values were 3375 ng/mL × h (PO MTX) and 3985 ng/mL × h (SC MTX).,Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23190184/),[ng] / [h·ml],3985,105501,DB00563,Methotrexate
,23190184,AUC ratio,The mean AUC ratio (PO/SC) was 0.86 (0.62-1.08).,Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23190184/),,0.86,105502,DB00563,Methotrexate
,23190184,bioavailability,This correlates with a relative PO bioavailability of 86% in comparison to SC.,Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23190184/),%,86,105503,DB00563,Methotrexate
,18343249,apparent t(1/2),Peak plasma concentrations occurred between 1 to 2.5 hours after administration and the apparent t(1/2) was approximately 3 hours.,"Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343249/),h,3,105585,DB00563,Methotrexate
,26696583,elimination half-life,The median MTX elimination half-life was 21.7 h (range 9.4-204.4).,The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696583/),h,21.7,105605,DB00563,Methotrexate
,29259050,response rates,ACR20 response rates at week 24 were similar between the groups (LBEC0101 93.3% vs ETN-RP 86.7%).,"Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29259050/),%,93.3,105788,DB00563,Methotrexate
,29259050,response rates,ACR20 response rates at week 24 were similar between the groups (LBEC0101 93.3% vs ETN-RP 86.7%).,"Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29259050/),%,86.7,105789,DB00563,Methotrexate
,23151940,area under the curve,"Mean MTX area under the curve associated with CH administration was 1,134 µmol hours/L, compared to 608 µmol hours/L after discontinuation of CH.",Pharmacokinetic interaction between methotrexate and chloral hydrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23151940/),[h·μM] / [l],"1,134",107659,DB00563,Methotrexate
,23151940,area under the curve,"Mean MTX area under the curve associated with CH administration was 1,134 µmol hours/L, compared to 608 µmol hours/L after discontinuation of CH.",Pharmacokinetic interaction between methotrexate and chloral hydrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23151940/),[h·μM] / [l],608,107660,DB00563,Methotrexate
,10945838,peak plasma DAMPA concentration,The mean peak plasma DAMPA concentration was 51 microM and the plasma disposition was described by a three-compartment open model with first order elimination.,"Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945838/),μM,51,108695,DB00563,Methotrexate
,10945838,clearance,The mean clearance of DAMPA was 1.9 l/kg/h and the mean terminal half-life was 51 min.,"Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945838/),[l] / [h·kg],1.9,108696,DB00563,Methotrexate
,10945838,terminal half-life,The mean clearance of DAMPA was 1.9 l/kg/h and the mean terminal half-life was 51 min.,"Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945838/),min,51,108697,DB00563,Methotrexate
,3479231,systemic clearance,Relapsed children (n = 25) had a systemic clearance of MTX 122.5 +/- 55.5 ml/minute/m2 versus 71.8 +/- 25.8 ml/minute/m2 found in the CCR patients (n = 33) when the dosage of MTX was 0.5 to 1.0 g/m2.,Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479231/),[ml] / [m2·min],122.5,108951,DB00563,Methotrexate
,3479231,systemic clearance,Relapsed children (n = 25) had a systemic clearance of MTX 122.5 +/- 55.5 ml/minute/m2 versus 71.8 +/- 25.8 ml/minute/m2 found in the CCR patients (n = 33) when the dosage of MTX was 0.5 to 1.0 g/m2.,Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479231/),[ml] / [m2·min],71.8,108952,DB00563,Methotrexate
,3479231,clearance,"When the dose was 6.0 to 8.0 g/m2 the clearance values were 93.27 +/- 32.6 versus 61.8 +/- 24.5 ml/minute/m2, respectively.",Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479231/),[ml] / [m2·min],93.27,108953,DB00563,Methotrexate
,3479231,clearance,"When the dose was 6.0 to 8.0 g/m2 the clearance values were 93.27 +/- 32.6 versus 61.8 +/- 24.5 ml/minute/m2, respectively.",Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479231/),[ml] / [m2·min],61.8,108954,DB00563,Methotrexate
,9613341,t1/2 eliminations,"For total and free MTX, t1/2 eliminations were 22.7 hours in group 1, 13.5 hours in group 2, 12 hours in group 3, and 11 hours in group 4.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),h,22.7,109004,DB00563,Methotrexate
,9613341,t1/2 eliminations,"For total and free MTX, t1/2 eliminations were 22.7 hours in group 1, 13.5 hours in group 2, 12 hours in group 3, and 11 hours in group 4.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),h,13.5,109005,DB00563,Methotrexate
,9613341,t1/2 eliminations,"For total and free MTX, t1/2 eliminations were 22.7 hours in group 1, 13.5 hours in group 2, 12 hours in group 3, and 11 hours in group 4.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),h,12,109006,DB00563,Methotrexate
,9613341,t1/2 eliminations,"For total and free MTX, t1/2 eliminations were 22.7 hours in group 1, 13.5 hours in group 2, 12 hours in group 3, and 11 hours in group 4.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),h,11,109007,DB00563,Methotrexate
,9613341,Clearance,"Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[ml] / [min],64,109008,DB00563,Methotrexate
,9613341,Clearance,"Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[ml] / [min],92,109009,DB00563,Methotrexate
,9613341,Clearance,"Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[ml] / [min],96,109010,DB00563,Methotrexate
,9613341,Clearance,"Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[ml] / [min],115,109011,DB00563,Methotrexate
,9613341,Clearance,"Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[ml] / [min],118,109012,DB00563,Methotrexate
,9613341,Clearance,"Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[ml] / [min],163,109013,DB00563,Methotrexate
,9613341,Clearance,"Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[ml] / [min],171,109014,DB00563,Methotrexate
,9613341,Clearance,"Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[ml] / [min],206,109015,DB00563,Methotrexate
,9613341,Volume of distribution,"Volume of distribution averaged 2.16 l/kg in group 1, 1.92 l/kg in group 2, 1.61 l/kg in group 3, and 1.56 l/kg in group 4.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[l] / [kg],2.16,109016,DB00563,Methotrexate
,9613341,Volume of distribution,"Volume of distribution averaged 2.16 l/kg in group 1, 1.92 l/kg in group 2, 1.61 l/kg in group 3, and 1.56 l/kg in group 4.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[l] / [kg],1.92,109017,DB00563,Methotrexate
,9613341,Volume of distribution,"Volume of distribution averaged 2.16 l/kg in group 1, 1.92 l/kg in group 2, 1.61 l/kg in group 3, and 1.56 l/kg in group 4.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[l] / [kg],1.61,109018,DB00563,Methotrexate
,9613341,Volume of distribution,"Volume of distribution averaged 2.16 l/kg in group 1, 1.92 l/kg in group 2, 1.61 l/kg in group 3, and 1.56 l/kg in group 4.",Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9613341/),[l] / [kg],1.56,109019,DB00563,Methotrexate
,3757156,T1/2 alpha,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),min,12,110106,DB00563,Methotrexate
,3757156,T1/2 beta,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),min,93,110107,DB00563,Methotrexate
,3757156,slow elimination phase,"The time-concentration curves of i.v.-treated patients (15 mg/m2 over 30 min) correspond to a three-compartment model with a T1/2 alpha of 12 min, a T1/2 beta of 93 min, and a slow elimination phase of 36 h.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),h,36,110108,DB00563,Methotrexate
,3757156,central compartment volume,"The central compartment volume was 26.22 and the distribution volume, 1381.9.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),,26.22,110109,DB00563,Methotrexate
,3757156,distribution volume,"The central compartment volume was 26.22 and the distribution volume, 1381.9.",Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757156/),,1381.9,110110,DB00563,Methotrexate
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],299,110190,DB00563,Methotrexate
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],384,110191,DB00563,Methotrexate
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],245,110192,DB00563,Methotrexate
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],321,110193,DB00563,Methotrexate
,23802659,troughs,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110194,DB00563,Methotrexate
,23802659,t½,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110195,DB00563,Methotrexate
,12739768,recovery,"The mean probe recovery and unbound fraction of MTX in SF were 46.8% and 44.8%, respectively.",Development of a dog microdialysis model for determining synovial fluid pharmacokinetics of anti-arthritis compounds exemplified by methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739768/),%,46.8,110274,DB00563,Methotrexate
,12739768,unbound fraction,"The mean probe recovery and unbound fraction of MTX in SF were 46.8% and 44.8%, respectively.",Development of a dog microdialysis model for determining synovial fluid pharmacokinetics of anti-arthritis compounds exemplified by methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739768/),%,44.8,110275,DB00563,Methotrexate
,12739768,unbound fraction,The unbound fraction of MTX was 44% in synovial fluid.,Development of a dog microdialysis model for determining synovial fluid pharmacokinetics of anti-arthritis compounds exemplified by methotrexate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739768/),%,44,110276,DB00563,Methotrexate
,12739768,maximal concentrations,"MTX penetrated into the joint space rapidly, with maximal concentrations of 6.6 microM reached at approximately 1 h postdose.",Development of a dog microdialysis model for determining synovial fluid pharmacokinetics of anti-arthritis compounds exemplified by methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739768/),μM,6.6,110277,DB00563,Methotrexate
,10873078,MTD,"In conclusion, the MTD of this schedule is 10 mg/day and the DLTs are neutropenia and diarrhea.",Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873078/),,10,110284,DB00563,Methotrexate
,21410944,maximum concentration (C(max)),"The maximum concentration (C(max)) was 160-200 nM and after 6 hours, the effective concentration (C(eff)) was <150 nM.",A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21410944/),nM,160-200,110443,DB00563,Methotrexate
<,21410944,effective concentration (C(eff)),"The maximum concentration (C(max)) was 160-200 nM and after 6 hours, the effective concentration (C(eff)) was <150 nM.",A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21410944/),nM,150,110444,DB00563,Methotrexate
,21410944,C(eff),"However, methotrexate blood levels did not reach the desirable C(eff) of 250-400-nM required to clear malaria infection in vivo.",A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21410944/),nM,250-400-,110445,DB00563,Methotrexate
,8085278,duration of fever,Mean duration of fever in the TDM group (2.8 +/- 2.4 days) was significantly shorter than that in the non-TDM group (9.0 +/- 8.8 days) (p < 0.001).,Challenges in comparing treatment outcome from a prospective with that of a retrospective study: assessing the merit of gentamicin therapeutic drug monitoring in pediatric oncology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085278/),d,2.8,111531,DB00563,Methotrexate
,8085278,duration of fever,Mean duration of fever in the TDM group (2.8 +/- 2.4 days) was significantly shorter than that in the non-TDM group (9.0 +/- 8.8 days) (p < 0.001).,Challenges in comparing treatment outcome from a prospective with that of a retrospective study: assessing the merit of gentamicin therapeutic drug monitoring in pediatric oncology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085278/),d,9.0,111532,DB00563,Methotrexate
<,14752795,AUC,"The group of 11 patients who were the least exposed to MTX (AUC <2,400 micromol/L hr) presented a high DFS, probably due to the shorter interval of time between MTX courses that led to a higher dose density.",Methotrexate pharmacokinetics and survival in osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752795/),[μM] / [h·l],"2,400",112176,DB00563,Methotrexate
>,14752795,AUC,"In patients with AUC >2,400 micromol/L hr, an increase in the AUC was related to an increase in the DFS.",Methotrexate pharmacokinetics and survival in osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752795/),[μM] / [h·l],"2,400",112177,DB00563,Methotrexate
below,14752795,AUC,"Significant differences were observed in the DFS between patients whose mean AUC was below or above 4,000 micromol/L hr (P=0.024), such that 4,000 micromol/L hr was considered as the minimum AUC to be aimed at for future patients.",Methotrexate pharmacokinetics and survival in osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752795/),[μM] / [h·l],"4,000",112178,DB00563,Methotrexate
,14752795,minimum AUC,"Significant differences were observed in the DFS between patients whose mean AUC was below or above 4,000 micromol/L hr (P=0.024), such that 4,000 micromol/L hr was considered as the minimum AUC to be aimed at for future patients.",Methotrexate pharmacokinetics and survival in osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752795/),[μM] / [h·l],"4,000",112179,DB00563,Methotrexate
higher,14752795,AUC,"In order to improve the response to osteosarcoma in children, it is recommended that the dose of MTX to be increased such as to obtain an AUC higher than 4,000 micromol/L hr.",Methotrexate pharmacokinetics and survival in osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752795/),[μM] / [h·l],"4,000",112180,DB00563,Methotrexate
,2834981,resolution factors,"Baseline separation was achieved using 5 and 25 mM sodium phosphate buffers (pH 7.4) as the mobile phase with resolution factors of 1.65 for LV and 2.31 for MeTHF, respectively.",Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834981/),,1.65,113273,DB00563,Methotrexate
,2834981,resolution factors,"Baseline separation was achieved using 5 and 25 mM sodium phosphate buffers (pH 7.4) as the mobile phase with resolution factors of 1.65 for LV and 2.31 for MeTHF, respectively.",Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2834981/),,2.31,113274,DB00563,Methotrexate
,7788170,Plasma protein binding,Plasma protein binding ranged from 25 to 55%.,"Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7788170/),%,25 to 55,113592,DB00563,Methotrexate
,7788170,Total clearance,"Total clearance of MTX was not statistically different with piroxicam (8.0 l/h for total MTX, 13.7 l/h for free MTX) vs without piroxicam.","Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7788170/),[l] / [h],8.0,113593,DB00563,Methotrexate
,7788170,Total clearance,"Total clearance of MTX was not statistically different with piroxicam (8.0 l/h for total MTX, 13.7 l/h for free MTX) vs without piroxicam.","Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7788170/),[l] / [h],13.7,113594,DB00563,Methotrexate
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.90,115460,DB00563,Methotrexate
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.52,115461,DB00563,Methotrexate
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.84,115462,DB00563,Methotrexate
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.01,115463,DB00563,Methotrexate
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.02,115464,DB00563,Methotrexate
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.27,115465,DB00563,Methotrexate
,2674426,Peak concentrations,"Peak concentrations varied considerably, ranging from 0.31-0.72 microM.",Methotrexate pharmacokinetics in patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674426/),μM,0.31-0.72,116046,DB00563,Methotrexate
,2674426,CL/F-MTX,CL/F-MTX = 145 +/- 52 ml/min/1.73 m2 and elimination half-life was 4.5 +/- 0.89 h.,Methotrexate pharmacokinetics in patients with rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674426/),[ml] / [1.73·m2·min],145,116047,DB00563,Methotrexate
,2674426,elimination half-life,CL/F-MTX = 145 +/- 52 ml/min/1.73 m2 and elimination half-life was 4.5 +/- 0.89 h.,Methotrexate pharmacokinetics in patients with rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674426/),h,4.5,116048,DB00563,Methotrexate
,2785400,AUC (area under the curve) ratios,"Considering FA plus 5-MTHF together, the AUC (area under the curve) ratios between CSF and plasma were close to 1%.",Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785400/),%,1,117185,DB00563,Methotrexate
,2785400,t 1/2,5-MTHF was cleared very slowly from CSF (t 1/2 = 85 h).,Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785400/),h,85,117186,DB00563,Methotrexate
,33461449,encapsulation rate,"Based on the optimized formula, MTX-M-NPs were prepared with a particle size of 188.17 ± 1.71 nm and an encapsulation rate of 95.55 ± 0.33%.",Preparation and Formulation Optimization of Methotrexate-loaded Human Serum Albumin Nanoparticles Modified by Mannose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33461449/),%,95.55,117275,DB00563,Methotrexate
,8500221,half-life,The half-life of methotrexate in CSF after an intracisternal injection of Depo/methotrexate was 5.4 days compared to 0.30 days for unencapsulated methotrexate.,A slow-release methotrexate formulation for intrathecal chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500221/),d,5.4,118907,DB00563,Methotrexate
,8500221,half-life,The half-life of methotrexate in CSF after an intracisternal injection of Depo/methotrexate was 5.4 days compared to 0.30 days for unencapsulated methotrexate.,A slow-release methotrexate formulation for intrathecal chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500221/),d,0.30,118908,DB00563,Methotrexate
,3828961,half-life time (t0.5),"The mean phenazone half-life time (t0.5) was significantly shorter in patients with breast cancer (8.880 +/- 2.5585 h) than in healthy persons (12.024 +/- 3.8486 h, P less than 0.001).",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),h,8.880,120567,DB00563,Methotrexate
,3828961,half-life time (t0.5),"The mean phenazone half-life time (t0.5) was significantly shorter in patients with breast cancer (8.880 +/- 2.5585 h) than in healthy persons (12.024 +/- 3.8486 h, P less than 0.001).",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),h,12.024,120568,DB00563,Methotrexate
,3828961,elimination rate constant (K,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),1/[h],0.063,120569,DB00563,Methotrexate
,3828961,metabolic clearance rate (MCR,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),[ml] / [min],54.968,120570,DB00563,Methotrexate
,3828961,K,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),1/[h],0.063,120571,DB00563,Methotrexate
,3828961,MCR,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),[ml] / [min],41.832,120572,DB00563,Methotrexate
,18975321,times to reach steady state,"The median times to reach steady state in RBCs (defined as 90% of the maximum concentration) were 6.2, 10.6, 41.2, 149, and 139.8 weeks, respectively, for MTXGlu1, MTXGlu2, MTXGlu3, MTXGlu4, and MTXGlu5.",Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,6.2,121001,DB00563,Methotrexate
,18975321,times to reach steady state,"The median times to reach steady state in RBCs (defined as 90% of the maximum concentration) were 6.2, 10.6, 41.2, 149, and 139.8 weeks, respectively, for MTXGlu1, MTXGlu2, MTXGlu3, MTXGlu4, and MTXGlu5.",Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,10.6,121002,DB00563,Methotrexate
,18975321,times to reach steady state,"The median times to reach steady state in RBCs (defined as 90% of the maximum concentration) were 6.2, 10.6, 41.2, 149, and 139.8 weeks, respectively, for MTXGlu1, MTXGlu2, MTXGlu3, MTXGlu4, and MTXGlu5.",Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,41.2,121003,DB00563,Methotrexate
,18975321,times to reach steady state,"The median times to reach steady state in RBCs (defined as 90% of the maximum concentration) were 6.2, 10.6, 41.2, 149, and 139.8 weeks, respectively, for MTXGlu1, MTXGlu2, MTXGlu3, MTXGlu4, and MTXGlu5.",Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,149,121004,DB00563,Methotrexate
,18975321,times to reach steady state,"The median times to reach steady state in RBCs (defined as 90% of the maximum concentration) were 6.2, 10.6, 41.2, 149, and 139.8 weeks, respectively, for MTXGlu1, MTXGlu2, MTXGlu3, MTXGlu4, and MTXGlu5.",Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,139.8,121005,DB00563,Methotrexate
,18975321,half-life of accumulation,The median half-life of accumulation for RBC MTXGlu1-5 ranged from 1.9 weeks to 45.2 weeks.,Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,1.9,121006,DB00563,Methotrexate
,18975321,half-life of accumulation,The median half-life of accumulation for RBC MTXGlu1-5 ranged from 1.9 weeks to 45.2 weeks.,Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,45.2,121007,DB00563,Methotrexate
,18975321,half-life of elimination,The median half-life of elimination for RBC MTXGlu1-5 ranged from 1.2 weeks to 4.3 weeks.,Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,1.2,121008,DB00563,Methotrexate
,18975321,half-life of elimination,The median half-life of elimination for RBC MTXGlu1-5 ranged from 1.2 weeks to 4.3 weeks.,Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18975321/),weeks,4.3,121009,DB00563,Methotrexate
,24969912,overall response rate,"Of the 8 PCNSL patients, 4 (50%) achieved CR and 3 (38%) PR, an overall response rate of 88%.","Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24969912/),%,88,121433,DB00563,Methotrexate
,24969912,overall response rate,Of the 8 SCNSL patients the overall response rate was 63% (CR+PR:38%+25%).,"Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24969912/),%,63,121434,DB00563,Methotrexate
,24969912,overall response rate,Of the 8 SCNSL patients the overall response rate was 63% (CR+PR:38%+25%).,"Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24969912/),%,38,121435,DB00563,Methotrexate
,1874877,percentage recovery,The percentage recovery with this method compared with others was high (90 versus 70%).,High-performance liquid chromatography method for serum methotrexate levels in children with severe steroid-dependent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874877/),%,90,121633,DB00563,Methotrexate
,1874877,percentage recovery,The percentage recovery with this method compared with others was high (90 versus 70%).,High-performance liquid chromatography method for serum methotrexate levels in children with severe steroid-dependent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874877/),%,70,121634,DB00563,Methotrexate
,1874877,retention time,The retention time for MTX was 14.7 min.,High-performance liquid chromatography method for serum methotrexate levels in children with severe steroid-dependent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874877/),min,14.7,121635,DB00563,Methotrexate
,1874877,half-life,"Following administration, the serum disappearance was monophasic with a half-life of 5 h.",High-performance liquid chromatography method for serum methotrexate levels in children with severe steroid-dependent asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874877/),h,5,121636,DB00563,Methotrexate
,433624,sensitivity,A sensitive (sensitivity 2.2 X 10(-9) mol/l) and specific (practically no cross-reaction with circulating folates) radioimmunoassay for the determination of methotrexate concentrations in biological fluids in described and compared with a commercial competitive protein binding assay.,Methotrexate concentrations in biological fluids: comparison of results obtained by radioimmunoassay and direct ligand binding radioassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/433624/),,2.2,121702,DB00563,Methotrexate
,28990296,C/D ratios,"The C/D ratios of MTX at 24 and 42 h for the TTC/TTC-A/A haplotype carriers (11.74 and 0.07 μmol/l per g/m2 , respectively) were significantly lower than those in DEL/DEL-G/G or DEL/TTC-G/G haplotype carriers (12.49 and 0.09 μmol/l per g/m2 , respectively; p < 0.05).",Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28990296/),[μM] / [g·l·m2],11.74,121792,DB00563,Methotrexate
,28990296,C/D ratios,"The C/D ratios of MTX at 24 and 42 h for the TTC/TTC-A/A haplotype carriers (11.74 and 0.07 μmol/l per g/m2 , respectively) were significantly lower than those in DEL/DEL-G/G or DEL/TTC-G/G haplotype carriers (12.49 and 0.09 μmol/l per g/m2 , respectively; p < 0.05).",Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28990296/),[μM] / [g·l·m2],0.07,121793,DB00563,Methotrexate
,28990296,C/D ratios,"The C/D ratios of MTX at 24 and 42 h for the TTC/TTC-A/A haplotype carriers (11.74 and 0.07 μmol/l per g/m2 , respectively) were significantly lower than those in DEL/DEL-G/G or DEL/TTC-G/G haplotype carriers (12.49 and 0.09 μmol/l per g/m2 , respectively; p < 0.05).",Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28990296/),[μM] / [g·l·m2],12.49,121794,DB00563,Methotrexate
,28990296,C/D ratios,"The C/D ratios of MTX at 24 and 42 h for the TTC/TTC-A/A haplotype carriers (11.74 and 0.07 μmol/l per g/m2 , respectively) were significantly lower than those in DEL/DEL-G/G or DEL/TTC-G/G haplotype carriers (12.49 and 0.09 μmol/l per g/m2 , respectively; p < 0.05).",Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28990296/),[μM] / [g·l·m2],0.09,121795,DB00563,Methotrexate
exceeded,7081435,In ratio,"The stop-flow pattern of MTX excretion was similar, except the base-line flow pattern of MTX excretion was similar, except the base-line (U/P)MTX/(U/P)In ratio exceeded 1.0, indicating net secretion during both free-flow and stopped-flow periods.",Renal tubular transport of folic acid and methotrexate in the monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7081435/),,1.0,123413,DB00563,Methotrexate
,30556906,execution time,"Compared to calling a NONMEM execution and reading its output, estimating individual parameters within R reduces the execution time from 8.7-12.8 seconds to 0.4-1.0 second.",Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30556906/),seconds,8.7-12.8,124335,DB00563,Methotrexate
,30556906,execution time,"Compared to calling a NONMEM execution and reading its output, estimating individual parameters within R reduces the execution time from 8.7-12.8 seconds to 0.4-1.0 second.",Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30556906/),second,0.4-1.0,124336,DB00563,Methotrexate
,6760471,Recovery,Recovery ranges from 78.3 to 84.9% for MTX and 67.6 to 76.1% for 7OH-MTX.,Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),%,78.3 to 84.9,124621,DB00563,Methotrexate
,6760471,Recovery,Recovery ranges from 78.3 to 84.9% for MTX and 67.6 to 76.1% for 7OH-MTX.,Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),%,67.6 to 76.1,124622,DB00563,Methotrexate
,6760471,beta half-lives,"After receiving 218.2 mg/kg and 148.5 mg/kg MTX in a 6-h infusion, their beta half-lives for MTX were 2.6 and 2.0 h, while their gamma half-lives were 26.2 and 42.9 h, respectively.",Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),h,2.6,124623,DB00563,Methotrexate
,6760471,beta half-lives,"After receiving 218.2 mg/kg and 148.5 mg/kg MTX in a 6-h infusion, their beta half-lives for MTX were 2.6 and 2.0 h, while their gamma half-lives were 26.2 and 42.9 h, respectively.",Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),h,2.0,124624,DB00563,Methotrexate
,6760471,gamma half-lives,"After receiving 218.2 mg/kg and 148.5 mg/kg MTX in a 6-h infusion, their beta half-lives for MTX were 2.6 and 2.0 h, while their gamma half-lives were 26.2 and 42.9 h, respectively.",Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),h,26.2,124625,DB00563,Methotrexate
,6760471,gamma half-lives,"After receiving 218.2 mg/kg and 148.5 mg/kg MTX in a 6-h infusion, their beta half-lives for MTX were 2.6 and 2.0 h, while their gamma half-lives were 26.2 and 42.9 h, respectively.",Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),h,42.9,124626,DB00563,Methotrexate
,6760471,beta half-lives,"The 7OH-MTX beta half-lives were 5.8 and 4.0 h, and the gamma half-lives were 10.2 and 15.8 h.",Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),h,5.8,124627,DB00563,Methotrexate
,6760471,beta half-lives,"The 7OH-MTX beta half-lives were 5.8 and 4.0 h, and the gamma half-lives were 10.2 and 15.8 h.",Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),h,4.0,124628,DB00563,Methotrexate
,6760471,gamma half-lives,"The 7OH-MTX beta half-lives were 5.8 and 4.0 h, and the gamma half-lives were 10.2 and 15.8 h.",Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),h,10.2,124629,DB00563,Methotrexate
,6760471,gamma half-lives,"The 7OH-MTX beta half-lives were 5.8 and 4.0 h, and the gamma half-lives were 10.2 and 15.8 h.",Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),h,15.8,124630,DB00563,Methotrexate
,6760471,Plasma concentration ratios,Plasma concentration ratios of 7OH-MTX to MTX were 28.5 and 18.1 at 24 h after MTX infusion.,Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),,28.5,124631,DB00563,Methotrexate
,6760471,Plasma concentration ratios,Plasma concentration ratios of 7OH-MTX to MTX were 28.5 and 18.1 at 24 h after MTX infusion.,Analysis of methotrexate and 7-hydroxymethotrexate by high-performance liquid chromatography and preliminary clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6760471/),,18.1,124632,DB00563,Methotrexate
,32164493,time to methotrexate clearance,The average time to methotrexate clearance between the two cohorts was similar (parenteral 88 h vs. enteral 98 h p = 0.06).,Evaluation of methotrexate clearance with an enteral urine alkalinization protocol for patients receiving high-dose methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32164493/),h,88,125227,DB00563,Methotrexate
,32164493,time to methotrexate clearance,The average time to methotrexate clearance between the two cohorts was similar (parenteral 88 h vs. enteral 98 h p = 0.06).,Evaluation of methotrexate clearance with an enteral urine alkalinization protocol for patients receiving high-dose methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32164493/),h,98,125228,DB00563,Methotrexate
,16528531,total body clearance CL,"The population pharmacokinetic parameters and the inter-subject variablities expressed as coefficient of variation were: the total body clearance CL, 7.1 l h-1 (22%), the volume of the central and peripheral compartments V1, 25.1 l (22.5%), V2, 2.7 l (64%), respectively, and the transfer constant Q, 2.7 (51%) l h-1.",Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528531/),[l] / [h],7.1,125744,DB00563,Methotrexate
,16528531,volume of the central,"The population pharmacokinetic parameters and the inter-subject variablities expressed as coefficient of variation were: the total body clearance CL, 7.1 l h-1 (22%), the volume of the central and peripheral compartments V1, 25.1 l (22.5%), V2, 2.7 l (64%), respectively, and the transfer constant Q, 2.7 (51%) l h-1.",Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528531/),l,25.1,125745,DB00563,Methotrexate
,16528531,V2,"The population pharmacokinetic parameters and the inter-subject variablities expressed as coefficient of variation were: the total body clearance CL, 7.1 l h-1 (22%), the volume of the central and peripheral compartments V1, 25.1 l (22.5%), V2, 2.7 l (64%), respectively, and the transfer constant Q, 2.7 (51%) l h-1.",Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528531/),l,2.7,125746,DB00563,Methotrexate
,16528531,transfer constant Q,"The population pharmacokinetic parameters and the inter-subject variablities expressed as coefficient of variation were: the total body clearance CL, 7.1 l h-1 (22%), the volume of the central and peripheral compartments V1, 25.1 l (22.5%), V2, 2.7 l (64%), respectively, and the transfer constant Q, 2.7 (51%) l h-1.",Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528531/),[l] / [h],2.7,125747,DB00563,Methotrexate
,10999734,area under the curve,"At that dose level, the mean area under the curve was 20.6 micromol x h, and the mean terminal half-life was 8 h.","Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999734/),h·μM,20.6,125826,DB00563,Methotrexate
,10999734,terminal half-life,"At that dose level, the mean area under the curve was 20.6 micromol x h, and the mean terminal half-life was 8 h.","Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999734/),h,8,125827,DB00563,Methotrexate
,22456893,peak serum levels [C (max),"Dose normalized MTX peak serum levels [C (max), μmol/L g] and dose normalized area under the curve [AUC(dn), μmol h/L g] were higher in females than in males, respectively [59.4 (f) vs. 48.1 (m), P<0.001; 373.2 (f) vs. 271.9 (m), P=0.008].",The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456893/),,59.4,125929,DB00563,Methotrexate
,22456893,dose normalized area under the curve [AUC(dn),"Dose normalized MTX peak serum levels [C (max), μmol/L g] and dose normalized area under the curve [AUC(dn), μmol h/L g] were higher in females than in males, respectively [59.4 (f) vs. 48.1 (m), P<0.001; 373.2 (f) vs. 271.9 (m), P=0.008].",The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456893/),,48.1,125930,DB00563,Methotrexate
,22456893,dose normalized area under the curve [AUC(dn),"Dose normalized MTX peak serum levels [C (max), μmol/L g] and dose normalized area under the curve [AUC(dn), μmol h/L g] were higher in females than in males, respectively [59.4 (f) vs. 48.1 (m), P<0.001; 373.2 (f) vs. 271.9 (m), P=0.008].",The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456893/),,373.2,125931,DB00563,Methotrexate
,22456893,dose normalized area under the curve [AUC(dn),"Dose normalized MTX peak serum levels [C (max), μmol/L g] and dose normalized area under the curve [AUC(dn), μmol h/L g] were higher in females than in males, respectively [59.4 (f) vs. 48.1 (m), P<0.001; 373.2 (f) vs. 271.9 (m), P=0.008].",The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456893/),,271.9,125932,DB00563,Methotrexate
above,22456893,AUC,"AUC values above 2,126 h μmol/L were independently associated with shorter overall and progression-free survival [hazard ratio (HR), 4.56, 95 % CI 1.74-11.94; HR 2.87, 95 % CI 1.18-7.00].",The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456893/),[h·μM] / [l],"2,126",125933,DB00563,Methotrexate
,1761069,plasma clearance,In 6 children with leukaemia there was a significant fall in methotrexate plasma clearance at night (from 5.6 to 4.7 ml.kg-1.min-1).,Diurnal variation of methotrexate disposition in children with acute leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761069/),[ml] / [kg·min],5.6,127617,DB00563,Methotrexate
,1761069,plasma clearance,In 6 children with leukaemia there was a significant fall in methotrexate plasma clearance at night (from 5.6 to 4.7 ml.kg-1.min-1).,Diurnal variation of methotrexate disposition in children with acute leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761069/),[ml] / [kg·min],4.7,127618,DB00563,Methotrexate
,1761069,unbound renal clearance,Renal clearance of methotrexate tended to fall at night and unbound renal clearance fell significantly (from 17.5 to 8.5 ml.min-1.kg-1 P less than 0.05).,Diurnal variation of methotrexate disposition in children with acute leukaemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761069/),[ml] / [kg·min],17.5,127619,DB00563,Methotrexate
,1761069,unbound renal clearance,Renal clearance of methotrexate tended to fall at night and unbound renal clearance fell significantly (from 17.5 to 8.5 ml.min-1.kg-1 P less than 0.05).,Diurnal variation of methotrexate disposition in children with acute leukaemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761069/),[ml] / [kg·min],8.5,127620,DB00563,Methotrexate
,1761069,non-g,"Creatinine clearance did not exhibit diurnal variation, whereas there was a significant fall in the non-glomerular clearance of methotrexate (from 14.8 to 6 ml.min-1.kg-1).",Diurnal variation of methotrexate disposition in children with acute leukaemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761069/),[ml] / [kg·min],14.8,127621,DB00563,Methotrexate
,1761069,non-g,"Creatinine clearance did not exhibit diurnal variation, whereas there was a significant fall in the non-glomerular clearance of methotrexate (from 14.8 to 6 ml.min-1.kg-1).",Diurnal variation of methotrexate disposition in children with acute leukaemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761069/),[ml] / [kg·min],6,127622,DB00563,Methotrexate
,2143500,terminal half-life,The drug had a mean terminal half-life of 13 hours.,A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2143500/),h,13,128273,DB00563,Methotrexate
,23760811,steady-state plasma concentration (Cpss),"Doses were individualized to achieve a steady-state plasma concentration (Cpss) of 33 or 65 μM (approximately 2.5 or 5 g/m(2)/day) for low- and standard-/high-risk patients, respectively.",Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760811/),μM,33,128682,DB00563,Methotrexate
,23760811,steady-state plasma concentration (Cpss),"Doses were individualized to achieve a steady-state plasma concentration (Cpss) of 33 or 65 μM (approximately 2.5 or 5 g/m(2)/day) for low- and standard-/high-risk patients, respectively.",Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760811/),μM,65,128683,DB00563,Methotrexate
,33564926,run time,"The lower limit of quantification was 0.100 ng/ml, and the run time was only 3 min.",Studies on the intracellular accumulation process of methotrexate and its correlation with the key protein using an LC-MS/MS method: a novel way to realize prospective individualized medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33564926/),min,3,128743,DB00563,Methotrexate
,8896045,volume of distribution at steady state,"In the SIDM rats, the volume of distribution at steady state was significantly higher (1010 versus 265 ml/kg) than that in the control rats, and this was due to the significantly increased unbound fraction of MTX (73.0 versus 58.1%) in serum of SIDM rats.",Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896045/),[ml] / [kg],1010,130361,DB00563,Methotrexate
,8896045,volume of distribution at steady state,"In the SIDM rats, the volume of distribution at steady state was significantly higher (1010 versus 265 ml/kg) than that in the control rats, and this was due to the significantly increased unbound fraction of MTX (73.0 versus 58.1%) in serum of SIDM rats.",Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896045/),[ml] / [kg],265,130362,DB00563,Methotrexate
,8896045,unbound fraction,"In the SIDM rats, the volume of distribution at steady state was significantly higher (1010 versus 265 ml/kg) than that in the control rats, and this was due to the significantly increased unbound fraction of MTX (73.0 versus 58.1%) in serum of SIDM rats.",Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896045/),%,73.0,130363,DB00563,Methotrexate
,8896045,unbound fraction,"In the SIDM rats, the volume of distribution at steady state was significantly higher (1010 versus 265 ml/kg) than that in the control rats, and this was due to the significantly increased unbound fraction of MTX (73.0 versus 58.1%) in serum of SIDM rats.",Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896045/),%,58.1,130364,DB00563,Methotrexate
,8896045,mean residence time,This resulted in a significantly increased mean residence time (53.2 versus 13.8 min) in the SIDM rats.,Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896045/),min,53.2,130365,DB00563,Methotrexate
,8896045,mean residence time,This resulted in a significantly increased mean residence time (53.2 versus 13.8 min) in the SIDM rats.,Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896045/),min,13.8,130366,DB00563,Methotrexate
,2403095,Elimination half-life,"Elimination half-life of mercaptopurine was significantly longer in the evening than during the day (423 +/- 142 minutes vs 176 +/- 22 minutes, mean +/- SEM).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),min,423,131184,DB00563,Methotrexate
,2403095,Elimination half-life,"Elimination half-life of mercaptopurine was significantly longer in the evening than during the day (423 +/- 142 minutes vs 176 +/- 22 minutes, mean +/- SEM).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),min,176,131185,DB00563,Methotrexate
,2403095,area under the concentration-time curve (AUC0-infinity),"The area under the concentration-time curve (AUC0-infinity) was significantly larger in the evening (24,713 +/- 3536 ng/mL per minute vs 17,120 +/- 1474 ng/mL per minute).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],"24,713",131186,DB00563,Methotrexate
,2403095,area under the concentration-time curve (AUC0-infinity),"The area under the concentration-time curve (AUC0-infinity) was significantly larger in the evening (24,713 +/- 3536 ng/mL per minute vs 17,120 +/- 1474 ng/mL per minute).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],"17,120",131187,DB00563,Methotrexate
,2403095,area under the curve,"These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 min-infinity, 7724 +/- 2955 ng/mL per minute in the evening vs 2597 +/- 712 ng/mL per minute during the day).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],7724,131188,DB00563,Methotrexate
,2403095,area under the curve,"These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 min-infinity, 7724 +/- 2955 ng/mL per minute in the evening vs 2597 +/- 712 ng/mL per minute during the day).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],2597,131189,DB00563,Methotrexate
,2403095,AUC300 min-infinity,"These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 min-infinity, 7724 +/- 2955 ng/mL per minute in the evening vs 2597 +/- 712 ng/mL per minute during the day).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],7724,131190,DB00563,Methotrexate
,2403095,AUC300 min-infinity,"These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 min-infinity, 7724 +/- 2955 ng/mL per minute in the evening vs 2597 +/- 712 ng/mL per minute during the day).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],2597,131191,DB00563,Methotrexate
,8596147,renal clearance,When patients received usual maintenance doses of MTX the renal clearance of MTX NSAID was 91.7 (26.4) ml/min versus 115.3 (34.4) ml/min without NSAID (p = 0.004).,The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8596147/),[ml] / [min],91.7,131999,DB00563,Methotrexate
,8596147,renal clearance,When patients received usual maintenance doses of MTX the renal clearance of MTX NSAID was 91.7 (26.4) ml/min versus 115.3 (34.4) ml/min without NSAID (p = 0.004).,The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8596147/),[ml] / [min],115.3,132000,DB00563,Methotrexate
,8596147,clearance,Creatinine clearance in patients taking usual maintenance doses increased from 77.5 (13.9) ml/min with NSAID to 95.3 (26.3) ml/min without NSAID (p = 0.05).,The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8596147/),,95.3,132001,DB00563,Methotrexate
,383286,plasma AMT,Nephrotoxic drug courses were associated with 24-hr plasma AMT levels [3.6 +/- 2.0 (S.D.) X 10(-6) M] which were significantly higher than nonnephrotoxic courses (1.6 +/- 1.0 x 10(-6) M) (p less than 0.05).,A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/383286/),M,3.6,132364,DB00563,Methotrexate
,383286,plasma AMT,Nephrotoxic drug courses were associated with 24-hr plasma AMT levels [3.6 +/- 2.0 (S.D.) X 10(-6) M] which were significantly higher than nonnephrotoxic courses (1.6 +/- 1.0 x 10(-6) M) (p less than 0.05).,A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/383286/),M,1.6,132365,DB00563,Methotrexate
,383286,t1/2 alpha,"In nonnephrotoxic courses, serum elimination pharmacokinetics appeared to be biphasic with a t1/2 alpha of 1.08 +/- 0.01 hr and t1/2 beta of 12.31 +/- 0.06 hr.",A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/383286/),h,1.08,132366,DB00563,Methotrexate
,383286,t1/2 beta,"In nonnephrotoxic courses, serum elimination pharmacokinetics appeared to be biphasic with a t1/2 alpha of 1.08 +/- 0.01 hr and t1/2 beta of 12.31 +/- 0.06 hr.",A Phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/383286/),h,12.31,132367,DB00563,Methotrexate
,19834958,clearance,"Methotrexate clearance was significantly higher (median, 117.1 mL/minute/m(2) vs 91.1 mL/minute/m(2); P = .019) in patients who received urate oxidase.",Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834958/),[min·ml] / [m(2],117.1,132385,DB00563,Methotrexate
,19834958,clearance,"Methotrexate clearance was significantly higher (median, 117.1 mL/minute/m(2) vs 91.1 mL/minute/m(2); P = .019) in patients who received urate oxidase.",Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834958/),[min·ml] / [m(2],91.1,132386,DB00563,Methotrexate
,32261815,encapsulation efficiency,"The prepared drug delivery systems present a spherical shape, a small particle size (219.6 ± 2.1 nm) with narrow particle size distribution, high MMC encapsulation efficiency (90.5 ± 3.0%) and a sustained and pH-controlled MMC release.",Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32261815/),%,90.5,133635,DB00563,Methotrexate
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],48.0,134416,DB00563,Methotrexate
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],38.9,134417,DB00563,Methotrexate
,28402673,entrapment,"The entrapment and loading efficiency of MTX and ACL was calculated as 85-90% and 10-12%, respectively.",Functionalized Lipid-Polymer Hybrid Nanoparticles Mediated Codelivery of Methotrexate and Aceclofenac: A Synergistic Effect in Breast Cancer with Improved Pharmacokinetics Attributes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28402673/),%,85-90,135156,DB00563,Methotrexate
,28402673,loading efficiency,"The entrapment and loading efficiency of MTX and ACL was calculated as 85-90% and 10-12%, respectively.",Functionalized Lipid-Polymer Hybrid Nanoparticles Mediated Codelivery of Methotrexate and Aceclofenac: A Synergistic Effect in Breast Cancer with Improved Pharmacokinetics Attributes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28402673/),%,10-12,135157,DB00563,Methotrexate
,8897267,area under the total MTX concentration vs time curve,"Pharmacokinetic studies revealed that intravenous anti-methotrexate immunoglobulin G (anti-MTX IgG) and anti-methotrexate Fab (anti-MTX Fab) administration produced dramatic alterations in the plasma pharmacokinetics of methotrexate (MTX), following intraperitoneal MTX administration (area under the total MTX concentration vs time curve for anti-MTX IgG relative to control, 420 +/- 90 (p < 0.05); for anti-MTX Fab relative to control, 46 +/- 6.1 (p < 0.05); area under the free MTX concentration vs time curve for anti-MTX IgG relative to control, 0.64 +/- 0.16; for anti-MTX Fab relative to control, 0.45 +/- 0.20 (p < 0.05)).",Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897267/),,420,135477,DB00563,Methotrexate
,8897267,area under the total MTX concentration vs time curve,"Pharmacokinetic studies revealed that intravenous anti-methotrexate immunoglobulin G (anti-MTX IgG) and anti-methotrexate Fab (anti-MTX Fab) administration produced dramatic alterations in the plasma pharmacokinetics of methotrexate (MTX), following intraperitoneal MTX administration (area under the total MTX concentration vs time curve for anti-MTX IgG relative to control, 420 +/- 90 (p < 0.05); for anti-MTX Fab relative to control, 46 +/- 6.1 (p < 0.05); area under the free MTX concentration vs time curve for anti-MTX IgG relative to control, 0.64 +/- 0.16; for anti-MTX Fab relative to control, 0.45 +/- 0.20 (p < 0.05)).",Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897267/),,46,135478,DB00563,Methotrexate
,8897267,area under the free MTX concentration vs time curve,"Pharmacokinetic studies revealed that intravenous anti-methotrexate immunoglobulin G (anti-MTX IgG) and anti-methotrexate Fab (anti-MTX Fab) administration produced dramatic alterations in the plasma pharmacokinetics of methotrexate (MTX), following intraperitoneal MTX administration (area under the total MTX concentration vs time curve for anti-MTX IgG relative to control, 420 +/- 90 (p < 0.05); for anti-MTX Fab relative to control, 46 +/- 6.1 (p < 0.05); area under the free MTX concentration vs time curve for anti-MTX IgG relative to control, 0.64 +/- 0.16; for anti-MTX Fab relative to control, 0.45 +/- 0.20 (p < 0.05)).",Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897267/),,0.64,135479,DB00563,Methotrexate
,8897267,area under the free MTX concentration vs time curve,"Pharmacokinetic studies revealed that intravenous anti-methotrexate immunoglobulin G (anti-MTX IgG) and anti-methotrexate Fab (anti-MTX Fab) administration produced dramatic alterations in the plasma pharmacokinetics of methotrexate (MTX), following intraperitoneal MTX administration (area under the total MTX concentration vs time curve for anti-MTX IgG relative to control, 420 +/- 90 (p < 0.05); for anti-MTX Fab relative to control, 46 +/- 6.1 (p < 0.05); area under the free MTX concentration vs time curve for anti-MTX IgG relative to control, 0.64 +/- 0.16; for anti-MTX Fab relative to control, 0.45 +/- 0.20 (p < 0.05)).",Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897267/),,0.45,135480,DB00563,Methotrexate
,1635087,residual concentrations,"Considering total active folate levels (l-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue.","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),nM,92,136316,DB00563,Methotrexate
,1635087,residual concentrations,"Considering total active folate levels (l-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue.","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),nM,186,136317,DB00563,Methotrexate
,1635087,residual concentrations,"Considering total active folate levels (l-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue.","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),nM,100,136318,DB00563,Methotrexate
,1635087,residual concentrations,"Considering total active folate levels (l-FA + 5-MTHF), mean residual concentrations were similar for rescue by d,l-FA and l-FA, after two and six intakes, respectively: 92 and 186 nM for d,l-FA rescue versus 100 and 184 nM for l-FA rescue.","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),nM,184,136319,DB00563,Methotrexate
,1635087,terminal half-lives,"For both types of FA rescue, MTX terminal half-lives were identical (average value, 13.9 hours).","l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1635087/),h,13.9,136320,DB00563,Methotrexate
,1754988,AUC0-infinity,"After IM administration, AUC0-infinity is significantly (p 0.01) increased i.e., 15.1 +/- 4.1 mumol.h/l versus 11.2 +/- 4.8 after IS injection.",[Pharmacokinetics of methotrexate and clinical response associated in the medical treatment of ectopic pregnancies]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1754988/),[h·μM] / [l],15.1,137154,DB00563,Methotrexate
,1754988,AUC0-infinity,"After IM administration, AUC0-infinity is significantly (p 0.01) increased i.e., 15.1 +/- 4.1 mumol.h/l versus 11.2 +/- 4.8 after IS injection.",[Pharmacokinetics of methotrexate and clinical response associated in the medical treatment of ectopic pregnancies]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1754988/),,11.2,137155,DB00563,Methotrexate
,1754988,T1/2 lambda z,"T1/2 lambda z and MRT remained unchanged whatever the route is i.e., 11.3 +/- 4.9 h and 8.6 +/- 3.9 h (IS) versus 12.1 +/- 5.9 h and 7.3 +/- 1.8 h (IM).",[Pharmacokinetics of methotrexate and clinical response associated in the medical treatment of ectopic pregnancies]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1754988/),h,11.3,137156,DB00563,Methotrexate
,1754988,T1/2 lambda z,"T1/2 lambda z and MRT remained unchanged whatever the route is i.e., 11.3 +/- 4.9 h and 8.6 +/- 3.9 h (IS) versus 12.1 +/- 5.9 h and 7.3 +/- 1.8 h (IM).",[Pharmacokinetics of methotrexate and clinical response associated in the medical treatment of ectopic pregnancies]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1754988/),h,12.1,137157,DB00563,Methotrexate
,1754988,MRT,"T1/2 lambda z and MRT remained unchanged whatever the route is i.e., 11.3 +/- 4.9 h and 8.6 +/- 3.9 h (IS) versus 12.1 +/- 5.9 h and 7.3 +/- 1.8 h (IM).",[Pharmacokinetics of methotrexate and clinical response associated in the medical treatment of ectopic pregnancies]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1754988/),h,8.6,137158,DB00563,Methotrexate
,1754988,MRT,"T1/2 lambda z and MRT remained unchanged whatever the route is i.e., 11.3 +/- 4.9 h and 8.6 +/- 3.9 h (IS) versus 12.1 +/- 5.9 h and 7.3 +/- 1.8 h (IM).",[Pharmacokinetics of methotrexate and clinical response associated in the medical treatment of ectopic pregnancies]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1754988/),h,7.3,137159,DB00563,Methotrexate
,14639053,bioavailability,"The population estimate of bioavailability of 0.75 (0.07), n = 9, was consistent with literature values.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),,0.75,137772,DB00563,Methotrexate
,14639053,Cl,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),[l] / [h],9.9,137773,DB00563,Methotrexate
,14639053,V,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),l,605,137774,DB00563,Methotrexate
,14639053,ka,"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),1/[hours],0.77,137775,DB00563,Methotrexate
,14639053,t(tag),"The parameter values from the final model were: Cl = 9.9 +/- 0.4 L/h, V = 605 +/- 91 L, ka = 0.77 +/- 0.22 hours(-1), t(tag) = 0.44 +/- 0.02 hours.",Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639053/),h,0.44,137776,DB00563,Methotrexate
,2076721,steady-state concentration,The median steady-state concentration of MTX was 66 mumol.l-1.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),[μM] / [l],66,138790,DB00563,Methotrexate
,2076721,elimination half-lifes,"Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,1.8,138791,DB00563,Methotrexate
,2076721,elimination half-lifes,"Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,6.4,138792,DB00563,Methotrexate
,2076721,elimination half-lifes,"Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,15,138793,DB00563,Methotrexate
,2076721,terminal,"Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,15,138794,DB00563,Methotrexate
,2076721,systemic MTX clearance,The median systemic MTX clearance was 110 mg.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),mg,110,138795,DB00563,Methotrexate
,2076721,Cmax,The 7-OHMTX level increased during each infusion and a Cmax of 19 mumol.l-1 was achieved at the end.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),[μM] / [l],19,138796,DB00563,Methotrexate
,2076721,initial half-life,Its initial half-life was 5 h and the terminal half-life was 12 h.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,5,138797,DB00563,Methotrexate
,2076721,terminal half-life,Its initial half-life was 5 h and the terminal half-life was 12 h.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),h,12,138798,DB00563,Methotrexate
,2076721,ratios of folinic acid to MTX,"The median folinic acid level during rescue, 48 h after starting the infusion, was 7.0 mumol.l-1 and 18 h following the last dose of LCV it was 0.44 mumol.l-1, leading to ratios of folinic acid to MTX of 31 and 6, respectively.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),,31,138799,DB00563,Methotrexate
,2076721,ratios of folinic acid to MTX,"The median folinic acid level during rescue, 48 h after starting the infusion, was 7.0 mumol.l-1 and 18 h following the last dose of LCV it was 0.44 mumol.l-1, leading to ratios of folinic acid to MTX of 31 and 6, respectively.","Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),,6,138800,DB00563,Methotrexate
,2076721,ratio of,The median 5-MTHF level during rescue was 0.44 mumol.l-1 with a median ratio of 5-MTHF to MTX of 2.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),,2,138801,DB00563,Methotrexate
,2076721,ratio of,Only one patient with a 48 h MTX concentration of 5.5 mumol.l-1 and a ratio of 5-MTHF to MTX of 0.08 suffered from ulcerating mucositis and septicaemia despite increased and prolonged LCV rescue.,"Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076721/),,0.08,138802,DB00563,Methotrexate
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],80,139441,DB00563,Methotrexate
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],103,139442,DB00563,Methotrexate
,8864317,AUC,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[ng] / [ml],673,142186,DB00563,Methotrexate
,8864317,AUC,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[ng] / [ml],628,142187,DB00563,Methotrexate
,8864317,MRT,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),h,5.2,142188,DB00563,Methotrexate
,8864317,MRT,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),h,5.2,142189,DB00563,Methotrexate
,8864317,"t1/2,z","3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),h,4.3,142190,DB00563,Methotrexate
,8864317,"t1/2,z","3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),h,4.2,142191,DB00563,Methotrexate
,8864317,V/F,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),1,59.3,142192,DB00563,Methotrexate
,8864317,V/F,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),1,65.5,142193,DB00563,Methotrexate
,8864317,CL/F,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[1] / [h],12.3,142194,DB00563,Methotrexate
,8864317,CL/F,"3. Pharmacokinetics of MTX without vs with SASP, means +/- s.d. were follows: AUC: 673 +/- 179 vs 628 +/- 210 (95% confidence interval [CI] of the difference was -71 to 159) ng ml-1, MRT: 5.2 +/- 1.3 vs 5.2 +/- 1.1 (95% CI -0.4 to 0.4) h, t1/2,z: 4.3 +/- 1.1 vs 4.2 +/- 1.1 (95% CI -0.3 to 0.5) h, V/F: 59.3 +/- 29.3 vs 65.5 +/- 25.3 (95% -23.8 to 11.4) 1, CL/F: 12.3 +/- 5.0 vs 13.5 +/- 4.8 (95% CI -4.5 to 2.3) 1 h-1.",Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[1] / [h],13.5,142195,DB00563,Methotrexate
,8864317,CLR/F,CLR/F: 6.2 +/- 1.3 vs 6.3 +/- 2.1 (95% CI -1.3 to 1.1) l h-1.,Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[l] / [h],6.2,142196,DB00563,Methotrexate
,8864317,CLR/F,CLR/F: 6.2 +/- 1.3 vs 6.3 +/- 2.1 (95% CI -1.3 to 1.1) l h-1.,Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864317/),[l] / [h],6.3,142197,DB00563,Methotrexate
,1498265,elimination half-life (t1/2 beta),The elimination half-life (t1/2 beta) calculated during the washout interval (mean +/- SD) was 47 x 4 +/- 21 x 5 min which is close to that calculated in a reference group of rabbits.,Effect of indomethacin on the pharmacokinetics of methotrexate in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1498265/),min,47 x 4,142272,DB00563,Methotrexate
,7902243,apparent Ki,Their estimated apparent Ki values ranged from 0.3 mM for navelbine to 9.8 mM for methotrexate.,Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902243/),mM,0.3,142868,DB00563,Methotrexate
,7902243,apparent Ki,Their estimated apparent Ki values ranged from 0.3 mM for navelbine to 9.8 mM for methotrexate.,Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902243/),mM,9.8,142869,DB00563,Methotrexate
,28824272,ion transitions (m/z),"The ion transitions (m/z) monitored were 455.2→308.1, 471.1→324.1, and 326.2→175.1 for MTX, 7-OHMTX, and DAMPA respectively.","Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28824272/),,455.2,144084,DB00563,Methotrexate
,28824272,ion transitions (m/z),"The ion transitions (m/z) monitored were 455.2→308.1, 471.1→324.1, and 326.2→175.1 for MTX, 7-OHMTX, and DAMPA respectively.","Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28824272/),,308.1,144085,DB00563,Methotrexate
,28824272,ion transitions (m/z),"The ion transitions (m/z) monitored were 455.2→308.1, 471.1→324.1, and 326.2→175.1 for MTX, 7-OHMTX, and DAMPA respectively.","Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28824272/),,471.1,144086,DB00563,Methotrexate
,28824272,ion transitions (m/z),"The ion transitions (m/z) monitored were 455.2→308.1, 471.1→324.1, and 326.2→175.1 for MTX, 7-OHMTX, and DAMPA respectively.","Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28824272/),,324.1,144087,DB00563,Methotrexate
,28824272,ion transitions (m/z),"The ion transitions (m/z) monitored were 455.2→308.1, 471.1→324.1, and 326.2→175.1 for MTX, 7-OHMTX, and DAMPA respectively.","Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28824272/),,326.2,144088,DB00563,Methotrexate
,28824272,ion transitions (m/z),"The ion transitions (m/z) monitored were 455.2→308.1, 471.1→324.1, and 326.2→175.1 for MTX, 7-OHMTX, and DAMPA respectively.","Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28824272/),,175.1,144089,DB00563,Methotrexate
≥,25342291,(MTX),Delayed plasma excretion was defined as (MTX) ≥1 μM at 42 hours (h).,Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342291/),μM,1,144930,DB00563,Methotrexate
<,25342291,MTX),Leucovorin was administered at 42 h and then every 6 h until (MTX) <0.1 μM.,Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342291/),μM,0.1,144931,DB00563,Methotrexate
,25342291,clearance,Population average (inter-individual variation) MTX clearance was 96.0 ml/min/m² (41.1 CV %) and increased with age.,Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25342291/),[ml] / [min·m²],96.0,144932,DB00563,Methotrexate
,18021335,Cmax,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),nm,455.00,145177,DB00563,Methotrexate
,18021335,Cmax,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),nm,425.00,145178,DB00563,Methotrexate
,18021335,AUC,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),[nm] / [h],1469.92,145179,DB00563,Methotrexate
,18021335,AUC,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),[nm] / [h],1560.73,145180,DB00563,Methotrexate
,8054251,oral clearance (CLo),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],11.0,145184,DB00563,Methotrexate
,8054251,renal clearance (CLR),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],7.9,145185,DB00563,Methotrexate
,8054251,percent excreted unchanged,"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),%,72,145186,DB00563,Methotrexate
,8054251,fraction unbound (fu),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),,0.54,145187,DB00563,Methotrexate
,7312939,terminal half-life,"Plasma pharmacokinetics were described by a triexponential function, with a terminal half-life of 4.2 h.",Pharmacokinetics and organ distribution of methotrexate in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312939/),h,4.2,145219,DB00563,Methotrexate
,7312939,terminal half-life,"The terminal half-life of MTX in bone marrow was greatly prolonged (37 h), while MTX remained nearly constant in liver (0.57 microgram/ml) and kidney (0.53 microgram/ml) from 6 h to 23 days.",Pharmacokinetics and organ distribution of methotrexate in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312939/),h,37,145220,DB00563,Methotrexate
,7312939,terminal half-life,"The terminal half-life of MTX in bone marrow was greatly prolonged (37 h), while MTX remained nearly constant in liver (0.57 microgram/ml) and kidney (0.53 microgram/ml) from 6 h to 23 days.",Pharmacokinetics and organ distribution of methotrexate in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312939/),[μg] / [ml],0.57,145221,DB00563,Methotrexate
,7312939,terminal half-life,"The terminal half-life of MTX in bone marrow was greatly prolonged (37 h), while MTX remained nearly constant in liver (0.57 microgram/ml) and kidney (0.53 microgram/ml) from 6 h to 23 days.",Pharmacokinetics and organ distribution of methotrexate in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312939/),[μg] / [ml],0.53,145222,DB00563,Methotrexate
,7312939,terminal half-life,"The terminal half-life of MTX in bone marrow was greatly prolonged (37 h), while MTX remained nearly constant in liver (0.57 microgram/ml) and kidney (0.53 microgram/ml) from 6 h to 23 days.",Pharmacokinetics and organ distribution of methotrexate in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312939/),h,6,145223,DB00563,Methotrexate
,7312939,terminal half-life,"The terminal half-life of MTX in bone marrow was greatly prolonged (37 h), while MTX remained nearly constant in liver (0.57 microgram/ml) and kidney (0.53 microgram/ml) from 6 h to 23 days.",Pharmacokinetics and organ distribution of methotrexate in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7312939/),d,23,145224,DB00563,Methotrexate
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,13,145395,DB00563,Methotrexate
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,36,145396,DB00563,Methotrexate
,6956440,distribution volume,The distribution volume of MTX was 0.186 +/- 0.062 liter/kg.,Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6956440/),[l] / [kg],0.186,145638,DB00563,Methotrexate
,6956440,Peak plasma levels,Peak plasma levels ranged from 540 to 1700 microM for MTX and from 12 to 560 mu M for 7-OH-MTX.,Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6956440/),μM,540 to 1700,145639,DB00563,Methotrexate
,6956440,Peak plasma levels,Peak plasma levels ranged from 540 to 1700 microM for MTX and from 12 to 560 mu M for 7-OH-MTX.,Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6956440/),M·mu,12 to 560,145640,DB00563,Methotrexate
,6956440,terminal half-life,"Plasma disappearance of MTX was biphasic, with a terminal half-life of 2.1 +/- 0.6 hours (mean +/- SE).",Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6956440/),h,2.1,145641,DB00563,Methotrexate
,6956440,half-life,"Plasma decay of 7-OH-MTX was mainly monoexponential, with a half-life of 23.8 +/- 15.2 hours.",Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6956440/),h,23.8,145642,DB00563,Methotrexate
,6956440,renal clearance,The renal clearance of MTX (0.0623 +/- 0.0232 liter/kg/hour) accounted for about 84% of the total clearance of MTX (0.0742 +/- 0.0288 liter/kg/hour).,Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6956440/),[l] / [h·kg],0.0623,145643,DB00563,Methotrexate
,6956440,total clearance,The renal clearance of MTX (0.0623 +/- 0.0232 liter/kg/hour) accounted for about 84% of the total clearance of MTX (0.0742 +/- 0.0288 liter/kg/hour).,Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6956440/),[l] / [h·kg],0.0742,145644,DB00563,Methotrexate
,6956440,renal clearance,The renal clearance of 7-OH-MTX was in the range of 0.0173 +/- 0.0149 liter/kg/hour.,Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6956440/),[l] / [h·kg],0.0173,145645,DB00563,Methotrexate
,3469802,peak serum MTX concentration,"Mean peak serum MTX concentration 1/2 h following a bolus of 167 mg/m2 MTX (1/3 total dose) was 25.9 X 10(-6) M, mean plateau serum MTX concentration was 7 X 10(-6) M (over 8-24 h), and mean MTX clearance was 74 ml/min/m2.",Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3469802/),M,25.9 X 10(-6),145677,DB00563,Methotrexate
,3469802,plateau serum MTX concentration,"Mean peak serum MTX concentration 1/2 h following a bolus of 167 mg/m2 MTX (1/3 total dose) was 25.9 X 10(-6) M, mean plateau serum MTX concentration was 7 X 10(-6) M (over 8-24 h), and mean MTX clearance was 74 ml/min/m2.",Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3469802/),M,7 X 10(-6),145678,DB00563,Methotrexate
,3469802,clearance,"Mean peak serum MTX concentration 1/2 h following a bolus of 167 mg/m2 MTX (1/3 total dose) was 25.9 X 10(-6) M, mean plateau serum MTX concentration was 7 X 10(-6) M (over 8-24 h), and mean MTX clearance was 74 ml/min/m2.",Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3469802/),[ml] / [m2·min],74,145679,DB00563,Methotrexate
exceeded,12655445,time,"The time during which MTX plasma concentrations exceeded 0.1 microM was significantly longer in regimen A than in regimen B (A 3.83+/-0.18 vs B 3.13+/-0.06 days, P=0.001).",Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12655445/),d,0,145809,DB00563,Methotrexate
,12655445,time,"The time during which MTX plasma concentrations exceeded 0.1 microM was significantly longer in regimen A than in regimen B (A 3.83+/-0.18 vs B 3.13+/-0.06 days, P=0.001).",Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12655445/),d,3.83,145810,DB00563,Methotrexate
,12655445,time,"The time during which MTX plasma concentrations exceeded 0.1 microM was significantly longer in regimen A than in regimen B (A 3.83+/-0.18 vs B 3.13+/-0.06 days, P=0.001).",Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12655445/),d,3.13,145811,DB00563,Methotrexate
exceeded,12655445,plasma concentrations,"The time during which MTX plasma concentrations exceeded 0.1 microM was significantly longer in regimen A than in regimen B (A 3.83+/-0.18 vs B 3.13+/-0.06 days, P=0.001).",Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12655445/),d,0,145812,DB00563,Methotrexate
,12655445,plasma concentrations,"The time during which MTX plasma concentrations exceeded 0.1 microM was significantly longer in regimen A than in regimen B (A 3.83+/-0.18 vs B 3.13+/-0.06 days, P=0.001).",Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12655445/),d,3.83,145813,DB00563,Methotrexate
,12655445,plasma concentrations,"The time during which MTX plasma concentrations exceeded 0.1 microM was significantly longer in regimen A than in regimen B (A 3.83+/-0.18 vs B 3.13+/-0.06 days, P=0.001).",Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12655445/),d,3.13,145814,DB00563,Methotrexate
,26289435,drug release,"In vitro drug release in PBS (pH 7.4) from pristine MWCNTs and folate conjugated MWCNTs formulation was found to be 66.35 ± 2.3 and 56.88 ± 1.9% in 24 h, respectively.",Drug targeting to arthritic region via folic acid appended surface-engineered multi-walled carbon nanotubes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26289435/),%,66.35,145896,DB00563,Methotrexate
,26289435,drug release,"In vitro drug release in PBS (pH 7.4) from pristine MWCNTs and folate conjugated MWCNTs formulation was found to be 66.35 ± 2.3 and 56.88 ± 1.9% in 24 h, respectively.",Drug targeting to arthritic region via folic acid appended surface-engineered multi-walled carbon nanotubes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26289435/),%,56.88,145897,DB00563,Methotrexate
,2525077,t.1/2 alpha,"Plasma TMTX elimination was biexponential, with a mean t.1/2 alpha of 0.23 h and a t.1/2 beta of 16.7 h.",Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525077/),h,0.23,145968,DB00563,Methotrexate
,2525077,t.1/2 beta,"Plasma TMTX elimination was biexponential, with a mean t.1/2 alpha of 0.23 h and a t.1/2 beta of 16.7 h.",Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525077/),h,16.7,145969,DB00563,Methotrexate
,2525077,Total plasma TMTX clearance,Total plasma TMTX clearance (mean +/- SD) was 14.3 +/- 5.9 ml/min per m2.,Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2525077/),[ml] / [m2·min],14.3,145970,DB00563,Methotrexate
,18548509,steady-state plasma concentration,The mean steady-state plasma concentration of 1.7+/-0.1 micromol/l was reached and the total clearance achieved 17.7+/-1.0 ml/min/kg.,Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18548509/),[μM] / [l],1.7,147060,DB00563,Methotrexate
,18548509,total clearance,The mean steady-state plasma concentration of 1.7+/-0.1 micromol/l was reached and the total clearance achieved 17.7+/-1.0 ml/min/kg.,Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18548509/),[ml] / [kg·min],17.7,147061,DB00563,Methotrexate
,19132729,steady-state MTX concentration,The median steady-state MTX concentration at the end of the 24-hr infusion was 57.8 microM (range 9.5-313).,Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132729/),μM,57.8,147381,DB00563,Methotrexate
,19132729,systemic clearance,"The median systemic clearance was 6.22 L/hr/m(2) BSA, and tended to increase with age (P = 0.099).",Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132729/),[h·l] / [m(2],6.22,147382,DB00563,Methotrexate
,19132729,clearance,"Boys had higher clearance than girls, 6.77 and 5.28 L/hr/m(2) (P = 0.030), and tended to have lower median MTX concentration at 24 hr.",Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132729/),[h·l] / [m(2],6.77,147383,DB00563,Methotrexate
,19132729,clearance,"Boys had higher clearance than girls, 6.77 and 5.28 L/hr/m(2) (P = 0.030), and tended to have lower median MTX concentration at 24 hr.",Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132729/),[h·l] / [m(2],5.28,147384,DB00563,Methotrexate
,3193470,plasma clearance,"The elimination kinetics were linear, with a mean plasma clearance of 294 mL/min (range, 128-715).",Clinical and pharmacologic reappraisal of dichloromethotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3193470/),[ml] / [min],294,147402,DB00563,Methotrexate
,11413676,Cl/Cl,Renal clearance of MTX was higher than that of inuline (Cl/Cl = 1.50 (0.095 ml/min.kg).,[Renal excretion of methotrexate in an in vivo model in minipigs]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413676/),[ml] / [kg·min],1.50,149914,DB00563,Methotrexate
,11413676,renal clearance,The renal clearance of MTX varied from 1.36 ml/min.kg (measured at pH 6.0) to 3.2 ml/min.kg (measured at pH 7.0).,[Renal excretion of methotrexate in an in vivo model in minipigs]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413676/),[ml] / [kg·min],1.36,149915,DB00563,Methotrexate
,11413676,renal clearance,The renal clearance of MTX varied from 1.36 ml/min.kg (measured at pH 6.0) to 3.2 ml/min.kg (measured at pH 7.0).,[Renal excretion of methotrexate in an in vivo model in minipigs]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413676/),[ml] / [kg·min],3.2,149916,DB00563,Methotrexate
,7647480,total serum clearance,"There was a 25% decrease in mean methotrexate total serum clearance in the GLN group compared with the control group (0.63 +/- 0.09 L.h-1.kg-1 and 0.47 +/- 0.13 L.h-1.kg-1, respectively, p = 0.01).",A significant methotrexate-glutamine pharmacokinetic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7647480/),[l] / [h·kg],0.63,150291,DB00563,Methotrexate
,7647480,total serum clearance,"There was a 25% decrease in mean methotrexate total serum clearance in the GLN group compared with the control group (0.63 +/- 0.09 L.h-1.kg-1 and 0.47 +/- 0.13 L.h-1.kg-1, respectively, p = 0.01).",A significant methotrexate-glutamine pharmacokinetic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7647480/),[l] / [h·kg],0.47,150292,DB00563,Methotrexate
,8857074,CL,"The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%).",A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857074/),[center·dot·l] / [h],6.94,151541,DB00563,Methotrexate
,8857074,V,"The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%).",A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857074/),l,34.8,151542,DB00563,Methotrexate
,8857074,k12,"The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%).",A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857074/),1/[h],0.0838,151543,DB00563,Methotrexate
,8857074,k21,"The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%).",A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857074/),1/[h],0.0769,151544,DB00563,Methotrexate
,8857074,ka,"The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%).",A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857074/),1/[h],4.31,151545,DB00563,Methotrexate
,8857074,Emax,"The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%).",A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857074/),[center·dot·mol·mu] / [l],1.12,151546,DB00563,Methotrexate
,8857074,gamma,"The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%).",A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857074/),,0.932,151547,DB00563,Methotrexate
,8857074,EC50,"The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%).",A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857074/),[center·dot·mol·mu] / [l],2.14,151548,DB00563,Methotrexate
,21265469,clearance (CL),"At the steady-state, the clearance (CL) of MTX (6.28 +/- 2.79 l h(-1)) was correlated with its CL(R) (r(s) = 0.79, p < 0.0001) which accounted for 61% (SD 26%) of the former.",High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21265469/),[l] / [h],6.28,151559,DB00563,Methotrexate
,29626002,plasma half-life,"The plasma half-life is 4-8 hours, though the pharmacologic effects of acetazolamide last longer.",Evaluating off-label uses of acetazolamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626002/),h,4-8,151569,DB00563,Methotrexate
,10520733,CL,"The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%).",Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520733/),[l] / [h],3.51,151916,DB00563,Methotrexate
,10520733,Vd,"The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%).",Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520733/),l,8.67,151917,DB00563,Methotrexate
,10520733,k12,"The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%).",Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520733/),1/[h],0.0044,151918,DB00563,Methotrexate
,10520733,k21,"The following population parameters were obtained using a two-compartment model: CL = 3.51 L/h (inter-individual variability: 66%), Vd = 8.67 L (58%), k12 = 0.0044 h(-1)(105%), k21 = 0.039 h(-1)(25%).",Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520733/),1/[h],0.039,151919,DB00563,Methotrexate
,28265691,half-life,"BMS-986142 was rapidly absorbed with peak concentrations occurring within 2 h, and was eliminated with a mean half-life ranging from 7 to 11 h.","Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28265691/),h,7 to 11,152534,DB00563,Methotrexate
,31026092,elimination rate constant,The elimination rate constant (% relative standard error) of rituximab effect decay was 0.036 (22.7%) days-1 and CD19+ turnover was 0.02 (41%) days-1 corresponding to half-lives of 19 and 35 days respectively.,Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31026092/),1/[d],0.036,153268,DB00563,Methotrexate
,31026092,turnover,The elimination rate constant (% relative standard error) of rituximab effect decay was 0.036 (22.7%) days-1 and CD19+ turnover was 0.02 (41%) days-1 corresponding to half-lives of 19 and 35 days respectively.,Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31026092/),%,0.02,153269,DB00563,Methotrexate
,31026092,half-lives,The elimination rate constant (% relative standard error) of rituximab effect decay was 0.036 (22.7%) days-1 and CD19+ turnover was 0.02 (41%) days-1 corresponding to half-lives of 19 and 35 days respectively.,Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31026092/),d,19,153270,DB00563,Methotrexate
,31026092,half-lives,The elimination rate constant (% relative standard error) of rituximab effect decay was 0.036 (22.7%) days-1 and CD19+ turnover was 0.02 (41%) days-1 corresponding to half-lives of 19 and 35 days respectively.,Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31026092/),d,35,153271,DB00563,Methotrexate
,10930807,Maximum MTX concentrations,"Maximum MTX concentrations ranged between 178 and 294 microgram/ml (i.v. bolus), and between 11 and 24 microgram/ml (i.v. infusion) in plasma.",Influence of schedule of administration on methotrexate penetration in brain tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930807/),[μg] / [ml],178 and 294,154123,DB00563,Methotrexate
,10930807,Maximum MTX concentrations,"Maximum MTX concentrations ranged between 178 and 294 microgram/ml (i.v. bolus), and between 11 and 24 microgram/ml (i.v. infusion) in plasma.",Influence of schedule of administration on methotrexate penetration in brain tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930807/),[μg] / [ml],11 and 24,154124,DB00563,Methotrexate
,8137220,survival time,"Median duration of CR was 10 months (range, 4-27 months), and median survival time for patients achieving complete response was 30.5 months (range, 28-33 months).","Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137220/),month,30.5,154539,DB00563,Methotrexate
,9231507,fraction of oral methotrexate,"The fraction of oral methotrexate (MTX) absorbed averages 70 per cent at low doses (< or = 10 mg/m2), both fasting and after food.",[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231507/),%,70,155681,DB00563,Methotrexate
,9231507,binding,The mean binding of MTX to serum albumin is 42-57 per cent.,[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231507/),%,42-57,155682,DB00563,Methotrexate
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,2.7,155899,DB00563,Methotrexate
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,6.5,155900,DB00563,Methotrexate
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,4.2,155901,DB00563,Methotrexate
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,9.9,155902,DB00563,Methotrexate
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,43,155903,DB00563,Methotrexate
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,58,155904,DB00563,Methotrexate
,19746402,clearance CL,"The pharmacokinetic parameters and the inter-individual variability were as follows: the clearance CL, 7.45 L.h(-1) (inter-individual variability 50.6%), the volume of the central and peripheral compartment V(1), 25.9 L (22.5%), V(2), 9.23 L (97.8%), respectively, and the intercompartmental clearance Q, 0.333 L.h(-1) (70.4%).",High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746402/),[l] / [h],7.45,158814,DB00563,Methotrexate
,19746402,volume of the central,"The pharmacokinetic parameters and the inter-individual variability were as follows: the clearance CL, 7.45 L.h(-1) (inter-individual variability 50.6%), the volume of the central and peripheral compartment V(1), 25.9 L (22.5%), V(2), 9.23 L (97.8%), respectively, and the intercompartmental clearance Q, 0.333 L.h(-1) (70.4%).",High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746402/),l,25.9,158815,DB00563,Methotrexate
,19746402,V(2),"The pharmacokinetic parameters and the inter-individual variability were as follows: the clearance CL, 7.45 L.h(-1) (inter-individual variability 50.6%), the volume of the central and peripheral compartment V(1), 25.9 L (22.5%), V(2), 9.23 L (97.8%), respectively, and the intercompartmental clearance Q, 0.333 L.h(-1) (70.4%).",High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746402/),l,9.23,158816,DB00563,Methotrexate
,19746402,intercompartmental clearance Q,"The pharmacokinetic parameters and the inter-individual variability were as follows: the clearance CL, 7.45 L.h(-1) (inter-individual variability 50.6%), the volume of the central and peripheral compartment V(1), 25.9 L (22.5%), V(2), 9.23 L (97.8%), respectively, and the intercompartmental clearance Q, 0.333 L.h(-1) (70.4%).",High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19746402/),[l] / [h],0.333,158817,DB00563,Methotrexate
,17667799,venous/capillary plasma concentration ratio,"The venous/capillary plasma concentration ratio was 1.00 [median value; interquartile range (IQR): 0.882-1.094]; for 85% of the data points the ratio was 0.8 to 1.2, independent of drug concentration.",Therapeutic drug monitoring of methotrexate on the pediatric oncology ward: can blood sampling from central venous accesses substitute for capillary finger punctures? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667799/),,1,160432,DB00563,Methotrexate
,20353751,AUC(0-t),"After administering a single dose of 20 mg of each leflunomide formulation, the mean AUC(0-t) and Cmax values of A771726 were 487.3 +/- 167.6 microg*h/ml and 2.24 +/- 0.85 microg/ml for the reference formulation and 468.5 +/- 148.6 microg*h/ml and 1.98 +/- 0.45 microg/ml for the test formulation, respectively.","Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20353751/),[h·μg] / [ml],487.3,160781,DB00563,Methotrexate
,20353751,AUC(0-t),"After administering a single dose of 20 mg of each leflunomide formulation, the mean AUC(0-t) and Cmax values of A771726 were 487.3 +/- 167.6 microg*h/ml and 2.24 +/- 0.85 microg/ml for the reference formulation and 468.5 +/- 148.6 microg*h/ml and 1.98 +/- 0.45 microg/ml for the test formulation, respectively.","Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20353751/),[h·μg] / [ml],468.5,160782,DB00563,Methotrexate
,20353751,Cmax,"After administering a single dose of 20 mg of each leflunomide formulation, the mean AUC(0-t) and Cmax values of A771726 were 487.3 +/- 167.6 microg*h/ml and 2.24 +/- 0.85 microg/ml for the reference formulation and 468.5 +/- 148.6 microg*h/ml and 1.98 +/- 0.45 microg/ml for the test formulation, respectively.","Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20353751/),[μg] / [ml],2.24,160783,DB00563,Methotrexate
,20353751,Cmax,"After administering a single dose of 20 mg of each leflunomide formulation, the mean AUC(0-t) and Cmax values of A771726 were 487.3 +/- 167.6 microg*h/ml and 2.24 +/- 0.85 microg/ml for the reference formulation and 468.5 +/- 148.6 microg*h/ml and 1.98 +/- 0.45 microg/ml for the test formulation, respectively.","Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20353751/),[μg] / [ml],1.98,160784,DB00563,Methotrexate
,32239519,peak MTX concentrations,"Although peak MTX concentrations were within the expected range (308-368 µmol/L), MTX concentrations after 24 hours or later were markedly increased (97, 52, and 19 µmol/L, respectively).",Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32239519/),[μM] / [l],308-368,161967,DB00563,Methotrexate
,32239519,peak MTX concentrations,"Although peak MTX concentrations were within the expected range (308-368 µmol/L), MTX concentrations after 24 hours or later were markedly increased (97, 52, and 19 µmol/L, respectively).",Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32239519/),[μM] / [l],97,161968,DB00563,Methotrexate
,32239519,peak MTX concentrations,"Although peak MTX concentrations were within the expected range (308-368 µmol/L), MTX concentrations after 24 hours or later were markedly increased (97, 52, and 19 µmol/L, respectively).",Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32239519/),[μM] / [l],52,161969,DB00563,Methotrexate
,32239519,peak MTX concentrations,"Although peak MTX concentrations were within the expected range (308-368 µmol/L), MTX concentrations after 24 hours or later were markedly increased (97, 52, and 19 µmol/L, respectively).",Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32239519/),[μM] / [l],19,161970,DB00563,Methotrexate
,32239519,volume of distribution,"Glucarpidase is a highly hydrophilic molecule with a volume of distribution of 3.6 L, representing the intravascular volume of an adult.",Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32239519/),l,3.6,161971,DB00563,Methotrexate
,30945116,apparent oral clearance,"Population estimates of upadacitinib apparent oral clearance and steady-state volume of distribution in healthy volunteers for the ER formulation were 53.7 L/h and 294 L, respectively.",Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30945116/),[l] / [h],53.7,162883,DB00563,Methotrexate
,30945116,steady-state volume of distribution,"Population estimates of upadacitinib apparent oral clearance and steady-state volume of distribution in healthy volunteers for the ER formulation were 53.7 L/h and 294 L, respectively.",Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30945116/),l,294,162884,DB00563,Methotrexate
,30945116,relative bioavailability,The relative bioavailability of the ER formulation compared with the IR formulation was estimated to be 76.2%.,Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30945116/),%,76.2,162885,DB00563,Methotrexate
,6326682,total body clearance,"The mean values of total body clearance, when administered at doses 50 mg and 100 mg per kg body weight, were 0.369 and 0.402 (l/h) per kg, respectively.",[Effect of IV hydration with sodium bicarbonate on high-dose methotrexate disposition kinetics]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326682/),[l] / [h)·kg],0.369,164320,DB00563,Methotrexate
,6326682,total body clearance,"The mean values of total body clearance, when administered at doses 50 mg and 100 mg per kg body weight, were 0.369 and 0.402 (l/h) per kg, respectively.",[Effect of IV hydration with sodium bicarbonate on high-dose methotrexate disposition kinetics]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326682/),[l] / [h)·kg],0.402,164321,DB00563,Methotrexate
,8782127,dose normalized area under the serum concentration time curve,"However, some significant changes were observed in the pharmacokinetics of 7-hydroxymethotrexate: a 30% increase in dose normalized area under the serum concentration time curve (mean +/- SD) to 3102 +/- 1397 micrograms.h/l and a 16% decrease in renal clearance to 10.0 +/- 6.7 ml/h/kg.",Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8782127/),[h·μg] / [l],3102,164424,DB00563,Methotrexate
,8782127,renal clearance,"However, some significant changes were observed in the pharmacokinetics of 7-hydroxymethotrexate: a 30% increase in dose normalized area under the serum concentration time curve (mean +/- SD) to 3102 +/- 1397 micrograms.h/l and a 16% decrease in renal clearance to 10.0 +/- 6.7 ml/h/kg.",Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8782127/),[ml] / [h·kg],10.0,164425,DB00563,Methotrexate
,8823490,total body clearance,"The mean total body clearance and volume of distribution at steady state of MTX varied from 0.90 +/- 0.3 to 0.24 +/- 0.02 l h-1 kg-1 (P < 0.05) and from 0.58 +/- 0.24 to 0.21 +/- 0.16 l kg-1 (P < 0.05) in control and tumor rats, respectively.",In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823490/),[l] / [h·kg],0.90,164640,DB00563,Methotrexate
,8823490,volume of distribution at steady state,"The mean total body clearance and volume of distribution at steady state of MTX varied from 0.90 +/- 0.3 to 0.24 +/- 0.02 l h-1 kg-1 (P < 0.05) and from 0.58 +/- 0.24 to 0.21 +/- 0.16 l kg-1 (P < 0.05) in control and tumor rats, respectively.",In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823490/),[l] / [kg],0.58,164641,DB00563,Methotrexate
,8823490,volume of distribution at steady state,"The mean total body clearance and volume of distribution at steady state of MTX varied from 0.90 +/- 0.3 to 0.24 +/- 0.02 l h-1 kg-1 (P < 0.05) and from 0.58 +/- 0.24 to 0.21 +/- 0.16 l kg-1 (P < 0.05) in control and tumor rats, respectively.",In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823490/),[l] / [kg],0.21,164642,DB00563,Methotrexate
,8823490,area under the interstitial fluid concentration-time curve (AUC),The mean MTX area under the interstitial fluid concentration-time curve (AUC) was 171.6 +/- 69.14 micrograms min ml-1(control) and 583.5 +/- 296.7 micrograms min ml-1 (brain tumor-bearing rats).,In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823490/),[min·μg] / [ml],171.6,164643,DB00563,Methotrexate
,8823490,area under the interstitial fluid concentration-time curve (AUC),The mean MTX area under the interstitial fluid concentration-time curve (AUC) was 171.6 +/- 69.14 micrograms min ml-1(control) and 583.5 +/- 296.7 micrograms min ml-1 (brain tumor-bearing rats).,In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823490/),[min·μg] / [ml],583.5,164644,DB00563,Methotrexate
,27129122,plasma Cmax,"Geometric mean values for plasma Cmax (ng/mL) were 4.1, 15.7, 26.5, and 51.2 for doses of 0.15, 0.45, 0.90, and 1.5 µg/kg, respectively.","PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129122/),[ng] / [ml],4.1,166127,DB00563,Methotrexate
,27129122,plasma Cmax,"Geometric mean values for plasma Cmax (ng/mL) were 4.1, 15.7, 26.5, and 51.2 for doses of 0.15, 0.45, 0.90, and 1.5 µg/kg, respectively.","PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129122/),[ng] / [ml],15.7,166128,DB00563,Methotrexate
,27129122,plasma Cmax,"Geometric mean values for plasma Cmax (ng/mL) were 4.1, 15.7, 26.5, and 51.2 for doses of 0.15, 0.45, 0.90, and 1.5 µg/kg, respectively.","PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129122/),[ng] / [ml],26.5,166129,DB00563,Methotrexate
,27129122,plasma Cmax,"Geometric mean values for plasma Cmax (ng/mL) were 4.1, 15.7, 26.5, and 51.2 for doses of 0.15, 0.45, 0.90, and 1.5 µg/kg, respectively.","PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129122/),[ng] / [ml],51.2,166130,DB00563,Methotrexate
,27310327,half-life,The half-life of ASP2409 increased dose dependently and ranged from 1.57 to 6.68 days.,"A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310327/),d,1.57 to 6.68,166709,DB00563,Methotrexate
,1599518,peak concentration,"Food reduced the peak concentration, from a mean of 0.71 mumoles/liter to 0.49 mumoles/liter (P less than 0.02), and slightly increased the time to peak concentration, from a mean of 1.3 hours to 2.0 hours.",Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599518/),[mumoles] / [l],0.71,167179,DB00563,Methotrexate
,1599518,peak concentration,"Food reduced the peak concentration, from a mean of 0.71 mumoles/liter to 0.49 mumoles/liter (P less than 0.02), and slightly increased the time to peak concentration, from a mean of 1.3 hours to 2.0 hours.",Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599518/),[mumoles] / [l],0.49,167180,DB00563,Methotrexate
,1599518,time to peak concentration,"Food reduced the peak concentration, from a mean of 0.71 mumoles/liter to 0.49 mumoles/liter (P less than 0.02), and slightly increased the time to peak concentration, from a mean of 1.3 hours to 2.0 hours.",Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599518/),h,1.3,167181,DB00563,Methotrexate
,1599518,time to peak concentration,"Food reduced the peak concentration, from a mean of 0.71 mumoles/liter to 0.49 mumoles/liter (P less than 0.02), and slightly increased the time to peak concentration, from a mean of 1.3 hours to 2.0 hours.",Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599518/),h,2.0,167182,DB00563,Methotrexate
,1599518,Bioavailability,Bioavailability was highly variable (range 28-94%) but was not affected by food intake.,Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1599518/),%,28-94,167183,DB00563,Methotrexate
,7468228,systemic availability,"The systemic availability of oral antipyrine after cyclophosphamide pretreatment (0.88) was not changed, but the metabolic clearance of the drug was reduced.",The effect of antineoplastic drugs on the pharmacokinetics of antipyrine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7468228/),,0.88,167737,DB00563,Methotrexate
,15628946,alpha,Pharmacokinetic parameters obtained for group I included: alpha (h(-1)) = 0.38 +/- 0.12; beta (h(-1)) = 0.07 +/- 0.03; K12 (h(-1)) = 0.02 +/- 0.02; K21 (h(-1)) = 0.09 +/- 0.09; K13 (h(-1)) = 0.34 +/- 0.12; Vc (l/kg) = 0.53 +/- 0.23; Vss (l/kg) = 0.62 +/- 0.26; Cl (l/kg.h) = 0.16 +/- 0.06.,[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),1/[h],0.38,168393,DB00563,Methotrexate
,15628946,beta,Pharmacokinetic parameters obtained for group I included: alpha (h(-1)) = 0.38 +/- 0.12; beta (h(-1)) = 0.07 +/- 0.03; K12 (h(-1)) = 0.02 +/- 0.02; K21 (h(-1)) = 0.09 +/- 0.09; K13 (h(-1)) = 0.34 +/- 0.12; Vc (l/kg) = 0.53 +/- 0.23; Vss (l/kg) = 0.62 +/- 0.26; Cl (l/kg.h) = 0.16 +/- 0.06.,[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),1/[h],0.07,168394,DB00563,Methotrexate
,15628946,K12,Pharmacokinetic parameters obtained for group I included: alpha (h(-1)) = 0.38 +/- 0.12; beta (h(-1)) = 0.07 +/- 0.03; K12 (h(-1)) = 0.02 +/- 0.02; K21 (h(-1)) = 0.09 +/- 0.09; K13 (h(-1)) = 0.34 +/- 0.12; Vc (l/kg) = 0.53 +/- 0.23; Vss (l/kg) = 0.62 +/- 0.26; Cl (l/kg.h) = 0.16 +/- 0.06.,[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),1/[h],0.02,168395,DB00563,Methotrexate
,15628946,K21,Pharmacokinetic parameters obtained for group I included: alpha (h(-1)) = 0.38 +/- 0.12; beta (h(-1)) = 0.07 +/- 0.03; K12 (h(-1)) = 0.02 +/- 0.02; K21 (h(-1)) = 0.09 +/- 0.09; K13 (h(-1)) = 0.34 +/- 0.12; Vc (l/kg) = 0.53 +/- 0.23; Vss (l/kg) = 0.62 +/- 0.26; Cl (l/kg.h) = 0.16 +/- 0.06.,[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),1/[h],0.09,168396,DB00563,Methotrexate
,15628946,K13,Pharmacokinetic parameters obtained for group I included: alpha (h(-1)) = 0.38 +/- 0.12; beta (h(-1)) = 0.07 +/- 0.03; K12 (h(-1)) = 0.02 +/- 0.02; K21 (h(-1)) = 0.09 +/- 0.09; K13 (h(-1)) = 0.34 +/- 0.12; Vc (l/kg) = 0.53 +/- 0.23; Vss (l/kg) = 0.62 +/- 0.26; Cl (l/kg.h) = 0.16 +/- 0.06.,[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),1/[h],0.34,168397,DB00563,Methotrexate
,15628946,Vc,Pharmacokinetic parameters obtained for group I included: alpha (h(-1)) = 0.38 +/- 0.12; beta (h(-1)) = 0.07 +/- 0.03; K12 (h(-1)) = 0.02 +/- 0.02; K21 (h(-1)) = 0.09 +/- 0.09; K13 (h(-1)) = 0.34 +/- 0.12; Vc (l/kg) = 0.53 +/- 0.23; Vss (l/kg) = 0.62 +/- 0.26; Cl (l/kg.h) = 0.16 +/- 0.06.,[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),[l] / [kg],0.53,168398,DB00563,Methotrexate
,15628946,Vss,Pharmacokinetic parameters obtained for group I included: alpha (h(-1)) = 0.38 +/- 0.12; beta (h(-1)) = 0.07 +/- 0.03; K12 (h(-1)) = 0.02 +/- 0.02; K21 (h(-1)) = 0.09 +/- 0.09; K13 (h(-1)) = 0.34 +/- 0.12; Vc (l/kg) = 0.53 +/- 0.23; Vss (l/kg) = 0.62 +/- 0.26; Cl (l/kg.h) = 0.16 +/- 0.06.,[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),[l] / [kg],0.62,168399,DB00563,Methotrexate
,15628946,Cl,Pharmacokinetic parameters obtained for group I included: alpha (h(-1)) = 0.38 +/- 0.12; beta (h(-1)) = 0.07 +/- 0.03; K12 (h(-1)) = 0.02 +/- 0.02; K21 (h(-1)) = 0.09 +/- 0.09; K13 (h(-1)) = 0.34 +/- 0.12; Vc (l/kg) = 0.53 +/- 0.23; Vss (l/kg) = 0.62 +/- 0.26; Cl (l/kg.h) = 0.16 +/- 0.06.,[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),[l] / [h·kg],0.16,168400,DB00563,Methotrexate
,15628946,Eqm,"Eqm was 9.58 x 10(-3), 2.39 x 10(-3), and 1.02 x 10(-3), respectively.",[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),,9.58 x 10(-3),168401,DB00563,Methotrexate
,15628946,Eqm,"Eqm was 9.58 x 10(-3), 2.39 x 10(-3), and 1.02 x 10(-3), respectively.",[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),,2.39 x 10(-3),168402,DB00563,Methotrexate
,15628946,Eqm,"Eqm was 9.58 x 10(-3), 2.39 x 10(-3), and 1.02 x 10(-3), respectively.",[Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15628946/),,1.02 x 10(-3),168403,DB00563,Methotrexate
,8306417,concentration,The mean concentration observed at the end of the infusion was 1016 +/- 143 mumol/l.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),mum,101,170722,DB00563,Methotrexate
,8306417,clearance,The clearance was 49.1 +/- 11.7 ml min-1 m-2.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),[ml] / [(m)^2·min],49.1,170723,DB00563,Methotrexate
,8306417,t1/2 alpha,The decay of the plasma concentration of MTX after completion of the infusion followed a two-compartment model with a t1/2 alpha of 2.66 +/- 0.82 h and a t1/2 beta of 15.69 +/- 8.63 h.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),h,2.66,170724,DB00563,Methotrexate
,8306417,t1/2 beta,The decay of the plasma concentration of MTX after completion of the infusion followed a two-compartment model with a t1/2 alpha of 2.66 +/- 0.82 h and a t1/2 beta of 15.69 +/- 8.63 h.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),h,15.69,170725,DB00563,Methotrexate
,8306417,volume of distribution,The volume of distribution was 0.32 +/- 0.08 l/kg.,Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8306417/),[l] / [kg],0.32,170726,DB00563,Methotrexate
,33595870,volume of distribution,"A 1-compartment open model was selected to estimate the pharmacokinetic parameters; the typical total clearance (L/day) was determined as 1.45 * (body mass index/28 kg/m2 ) * (red blood cells/4.6 × 106 cells/μL) and the volume of distribution was 52.4 L, with an absorption rate of 0.0346/day and a fraction metabolized of 1.03%.",Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595870/),l,52.4,171734,DB00563,Methotrexate
,33595870,absorption rate,"A 1-compartment open model was selected to estimate the pharmacokinetic parameters; the typical total clearance (L/day) was determined as 1.45 * (body mass index/28 kg/m2 ) * (red blood cells/4.6 × 106 cells/μL) and the volume of distribution was 52.4 L, with an absorption rate of 0.0346/day and a fraction metabolized of 1.03%.",Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595870/),1/[d],0.0346,171735,DB00563,Methotrexate
,33595870,fraction metabolized,"A 1-compartment open model was selected to estimate the pharmacokinetic parameters; the typical total clearance (L/day) was determined as 1.45 * (body mass index/28 kg/m2 ) * (red blood cells/4.6 × 106 cells/μL) and the volume of distribution was 52.4 L, with an absorption rate of 0.0346/day and a fraction metabolized of 1.03%.",Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595870/),%,1.03,171736,DB00563,Methotrexate
,10637237,half-life (t(1/2)),The intratumoral half-life (t(1/2)) of 5-FU in these tumors ranged from 18.8 minutes to 42.3 minutes.,Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637237/),min,18.8,173094,DB00563,Methotrexate
,10637237,half-life (t(1/2)),The intratumoral half-life (t(1/2)) of 5-FU in these tumors ranged from 18.8 minutes to 42.3 minutes.,Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637237/),min,42.3,173095,DB00563,Methotrexate
,19138246,V(1),"In the final model, creatinine clearance (CCR, mL/min) and the MTX dose (DOSE10G; 0 when <10 g, 1 when >or=10 g) were the most significant factors that affected the renal clearance (CL(r)) and non-renal clearance (CL(nr)), respectively: CL(r)(L/h) = 5.57 x (CCR/80.0)(0.112), V(1)(L) = 26.9, Q(L/h) = 0.0778, V(2)(L) = 2.27, CL(nr)(L/h) = 0.567 x 3.39(DOSE10G), where V(1) and V(2) are the volumes of distribution of the central and peripheral compartments, respectively, and Q is the inter-compartmental (central-peripheral) clearance.",Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19138246/),l,26,173101,DB00563,Methotrexate
,20478302,Ki,[3H]methotrexate uptake into S2-hOAT3 cells was significantly inhibited by celecoxib in a concentration-dependent manner and the Ki value was 35.3 microM.,Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20478302/),μM,35.3,173915,DB00563,Methotrexate
,20478302,maximum drug concentration (Cmax),"Celecoxib serum concentrations were increased by the increase in celecoxib dosage and the maximum drug concentration (Cmax) was 20.6 microM (celecoxib 200 mg/kg), which did not reach the Ki value obtained in the in vitro study.",Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20478302/),μM,20.6,173916,DB00563,Methotrexate
,3456283,steady state E-MTX,The steady state E-MTX varied between 51 and 202 nmol/l erythrocytes.,Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3456283/),[nM] / [l],51 and 202,174128,DB00563,Methotrexate
,3456283,terminal half-life,A terminal half-life of 2-5 weeks after discontinuation of the drug showed that the erythrocytes functioned as a slow-changing compartment for MTX.,Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3456283/),weeks,2-5,174129,DB00563,Methotrexate
,6698654,total body clearance,A wide range of total body clearance (1.03-5.13 ml/min/kg) was obtained in four subjects.,A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698654/),[ml] / [kg·min],1.03-5.13,175075,DB00563,Methotrexate
,6698654,steady-state volume of distribution,The steady-state volume of distribution of MTX was 0.41-0.95 l/kg.,A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698654/),[l] / [kg],0.41-0.95,175076,DB00563,Methotrexate
,6698654,apparent renal clearance,The mean apparent renal clearance of 7-OH-MTX (0.08-0.13 ml/min/kg) was much smaller compared with that of MTX (0.63-2.62 ml/min/kg).,A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698654/),[ml] / [kg·min],0.08-0.13,175077,DB00563,Methotrexate
,6698654,apparent renal clearance,The mean apparent renal clearance of 7-OH-MTX (0.08-0.13 ml/min/kg) was much smaller compared with that of MTX (0.63-2.62 ml/min/kg).,A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698654/),[ml] / [kg·min],0.63-2.62,175078,DB00563,Methotrexate
,6698654,saliva/serum level ratios,The average saliva/serum level ratios were 0.009 and 0.078 in two patients studied.,A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698654/),,0.009,175079,DB00563,Methotrexate
,6698654,saliva/serum level ratios,The average saliva/serum level ratios were 0.009 and 0.078 in two patients studied.,A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698654/),,0.078,175080,DB00563,Methotrexate
,26809959,peak MTX/PDX concentration,"After PDX administration, his 1-hour peak MTX/PDX concentration increased to 0.58 μmol/L.",Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26809959/),[μM] / [l],0.58,175241,DB00563,Methotrexate
,10782805,terminal half-life,Infliximab in doses of 5 to 20 mg/kg had a mean terminal half-life ranging from 9 to 12 days and was detectable in sera from most patients 8 to 12 weeks after dosing.,Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10782805/),d,9 to 12,175874,DB00563,Methotrexate
,2455425,distribution phase half-life,"The disappearance of methotrexate from the serum fitted a two-compartment model with a distribution phase half-life of 1.18 +/- 0.12 h and an elimination phase half-life of 5.35 +/- 0.62 h following the oral dose and 1.45 +/- 0.22 h and 4.71 +/- 0.32 h, respectively following the intramuscular dose.",Pharmacokinetics of small doses of methotrexate in patients with psoriasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455425/),h,1.18,175887,DB00563,Methotrexate
,2455425,elimination phase half-life,"The disappearance of methotrexate from the serum fitted a two-compartment model with a distribution phase half-life of 1.18 +/- 0.12 h and an elimination phase half-life of 5.35 +/- 0.62 h following the oral dose and 1.45 +/- 0.22 h and 4.71 +/- 0.32 h, respectively following the intramuscular dose.",Pharmacokinetics of small doses of methotrexate in patients with psoriasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455425/),h,5.35,175888,DB00563,Methotrexate
,2455425,elimination phase half-life,"The disappearance of methotrexate from the serum fitted a two-compartment model with a distribution phase half-life of 1.18 +/- 0.12 h and an elimination phase half-life of 5.35 +/- 0.62 h following the oral dose and 1.45 +/- 0.22 h and 4.71 +/- 0.32 h, respectively following the intramuscular dose.",Pharmacokinetics of small doses of methotrexate in patients with psoriasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455425/),h,4.71,175889,DB00563,Methotrexate
,3470165,peak plasma concentration,"When 6-MP was administered alone, both the peak plasma concentration (15 to 150 ng X ml-1) and the AUC (36 to 340 ng X ml-1 X hr) were highly variable.",The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470165/),[ng] / [ml],15 to 150,175961,DB00563,Methotrexate
,3470165,AUC,"When 6-MP was administered alone, both the peak plasma concentration (15 to 150 ng X ml-1) and the AUC (36 to 340 ng X ml-1 X hr) were highly variable.",The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470165/),[h·ng] / [ml],36 to 340,175962,DB00563,Methotrexate
,21656756,area under the concentration-time curve,"Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration-time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m(2) daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m(2) daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m(2) daily ×2 days) combined with ifosfamide or carboplatin.",Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),[mg] / [min·ml],8,176531,DB00563,Methotrexate
,21656756,event-free survival rate,The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98).,Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),%,66.7,176532,DB00563,Methotrexate
,21656756,event-free survival rate,The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98).,Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),%,66.0,176533,DB00563,Methotrexate
,1914082,Ki,"mAMSA appeared to inhibit MTX hydroxylation competitively, exhibiting a Ki of 3 microM.",Inhibition of 7-hydroxymethotrexate formation by amsacrine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914082/),μM,3,176896,DB00563,Methotrexate
,9951428,trough concentration,The methotrexate plasma time course after subcutaneous administration fit a 2-compartment first-order model with biphasic elimination and trough concentration of about 1 nmol/L.,Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951428/),[nM] / [l],1,178135,DB00563,Methotrexate
,9951428,Trough,Trough and peak methotrexate concentrations (mean value +/- SD) were 64 +/- 33 and 206 +/- 64 fmol/mg in the rectal mucosa and 4 +/- 3 and 51 +/- 26 nmol/L in the rectal lumen.,Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951428/),[fmol] / [mg],64,178136,DB00563,Methotrexate
,9951428,Trough,Trough and peak methotrexate concentrations (mean value +/- SD) were 64 +/- 33 and 206 +/- 64 fmol/mg in the rectal mucosa and 4 +/- 3 and 51 +/- 26 nmol/L in the rectal lumen.,Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951428/),[fmol] / [mg],206,178137,DB00563,Methotrexate
,9951428,Trough,Trough and peak methotrexate concentrations (mean value +/- SD) were 64 +/- 33 and 206 +/- 64 fmol/mg in the rectal mucosa and 4 +/- 3 and 51 +/- 26 nmol/L in the rectal lumen.,Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951428/),[nM] / [l],4,178138,DB00563,Methotrexate
,9951428,peak methotrexate concentrations,Trough and peak methotrexate concentrations (mean value +/- SD) were 64 +/- 33 and 206 +/- 64 fmol/mg in the rectal mucosa and 4 +/- 3 and 51 +/- 26 nmol/L in the rectal lumen.,Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951428/),[fmol] / [mg],206,178139,DB00563,Methotrexate
,9951428,peak methotrexate concentrations,Trough and peak methotrexate concentrations (mean value +/- SD) were 64 +/- 33 and 206 +/- 64 fmol/mg in the rectal mucosa and 4 +/- 3 and 51 +/- 26 nmol/L in the rectal lumen.,Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951428/),[nM] / [l],51,178140,DB00563,Methotrexate
,9951428,50% inhibitory concentration,"These methotrexate concentrations were in the range found to be pharmacologically active against Caco-2 cell growth, that is, a 50% inhibitory concentration from 10 to 46 nmol/L.",Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9951428/),[nM] / [l],10 to 46,178141,DB00563,Methotrexate
,31657864,clearance,"The population clearance and volume were 90 mL/min/m2 and 14.4 L/m2 , respectively.",Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31657864/),[ml] / [m2·min],90,178274,DB00563,Methotrexate
,31657864,volume,"The population clearance and volume were 90 mL/min/m2 and 14.4 L/m2 , respectively.",Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31657864/),[l] / [m2],14.4,178275,DB00563,Methotrexate
>,8021736,peak level,"A mean threshold peak level of > or = 1,000 mumol/L for the repeated MTX courses of individual patients was found to correlate significantly to prognosis in study COSS-80 (18% v 64% actuarial 10-year disease-free survival [DFS], P = .0001).",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[μM] / [l],"1,000",178546,DB00563,Methotrexate
> or =,8021736,peak values,"Six courses of HDMTX per patient who achieved peak values > or = 1,000 mumol/L were found to be sufficient for a full effect to be seen in DFS in COSS-80.",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[μM] / [l],"1,000",178547,DB00563,Methotrexate
,8021736,peak values,"In patients who received cisplatin (DDP) as one of the additional drugs to MTX, the peak values and AUC were significantly increased (1,396 v 1,276 mumol/L, P = .011; 6,684 v 5,820 h.mumol/L, P < or = .002) and only a few patients (6%) did not achieve mean threshold MTX peak values.",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[μM] / [l],"1,396",178548,DB00563,Methotrexate
,8021736,peak values,"In patients who received cisplatin (DDP) as one of the additional drugs to MTX, the peak values and AUC were significantly increased (1,396 v 1,276 mumol/L, P = .011; 6,684 v 5,820 h.mumol/L, P < or = .002) and only a few patients (6%) did not achieve mean threshold MTX peak values.",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[μM] / [l],"1,276",178549,DB00563,Methotrexate
,8021736,AUC,"In patients who received cisplatin (DDP) as one of the additional drugs to MTX, the peak values and AUC were significantly increased (1,396 v 1,276 mumol/L, P = .011; 6,684 v 5,820 h.mumol/L, P < or = .002) and only a few patients (6%) did not achieve mean threshold MTX peak values.",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[h·μM] / [l],"6,684",178550,DB00563,Methotrexate
,8021736,AUC,"In patients who received cisplatin (DDP) as one of the additional drugs to MTX, the peak values and AUC were significantly increased (1,396 v 1,276 mumol/L, P = .011; 6,684 v 5,820 h.mumol/L, P < or = .002) and only a few patients (6%) did not achieve mean threshold MTX peak values.",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[h·μM] / [l],"5,820",178551,DB00563,Methotrexate
,8021736,half-life (t1/2),"In addition, following restriction of hydration fluid after the MTX infusion from 4.5 to 3.0 L/m2 per 24 hours, the early MTX half-life (t1/2) and the AUC, but not the MTX peak value, were significantly increased (3.4 v 3.05 hours, and 6,760 v 5,998 h.mumol/L, respectively, P < or = .002).",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),h,3.4,178552,DB00563,Methotrexate
,8021736,half-life (t1/2),"In addition, following restriction of hydration fluid after the MTX infusion from 4.5 to 3.0 L/m2 per 24 hours, the early MTX half-life (t1/2) and the AUC, but not the MTX peak value, were significantly increased (3.4 v 3.05 hours, and 6,760 v 5,998 h.mumol/L, respectively, P < or = .002).",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),h,3.05,178553,DB00563,Methotrexate
,8021736,AUC,"In addition, following restriction of hydration fluid after the MTX infusion from 4.5 to 3.0 L/m2 per 24 hours, the early MTX half-life (t1/2) and the AUC, but not the MTX peak value, were significantly increased (3.4 v 3.05 hours, and 6,760 v 5,998 h.mumol/L, respectively, P < or = .002).",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),h,3.05,178554,DB00563,Methotrexate
,8021736,peak value,"In addition, following restriction of hydration fluid after the MTX infusion from 4.5 to 3.0 L/m2 per 24 hours, the early MTX half-life (t1/2) and the AUC, but not the MTX peak value, were significantly increased (3.4 v 3.05 hours, and 6,760 v 5,998 h.mumol/L, respectively, P < or = .002).",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[h·μM] / [l],"6,760",178555,DB00563,Methotrexate
,8021736,peak value,"In addition, following restriction of hydration fluid after the MTX infusion from 4.5 to 3.0 L/m2 per 24 hours, the early MTX half-life (t1/2) and the AUC, but not the MTX peak value, were significantly increased (3.4 v 3.05 hours, and 6,760 v 5,998 h.mumol/L, respectively, P < or = .002).",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[h·μM] / [l],"5,998",178556,DB00563,Methotrexate
>,8021736,peak serum level,"Individual adaptation of the MTX dose to ensure a threshold peak serum level > or = 1,000 mumol/L does not seem necessary at a fixed dose of 12 g MTX/m2, restriction of hydration fluid to 3 L/m2 per 24 hours, and concomitant use of DDP within the drug regimen.",Methotrexate pharmacokinetics and prognosis in osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021736/),[μM] / [l],"1,000",178557,DB00563,Methotrexate
,3335031,influx rate constant K1,The influx rate constant K1 for [14C]MTX ranged from 1.3 to 8.2 microliters/g/min in the tumor.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μl] / [g·min],1.3 to 8.2,179110,DB00563,Methotrexate
,3335031,Influx rate constants,Influx rate constants in the cortex were 1.3-1.9 microliters/g/min and in the brain adjacent to tumor were 1.7-2.8 microliters/g/min.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μl] / [g·min],1.3-1.9,179111,DB00563,Methotrexate
,3335031,Influx rate constants,Influx rate constants in the cortex were 1.3-1.9 microliters/g/min and in the brain adjacent to tumor were 1.7-2.8 microliters/g/min.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μl] / [g·min],1.7-2.8,179112,DB00563,Methotrexate
,3335031,concentration x time,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],33.4,179113,DB00563,Methotrexate
,3335031,concentration x time,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],15.7,179114,DB00563,Methotrexate
,3335031,concentration x time,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],96.3,179115,DB00563,Methotrexate
,3335031,concentration x time,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],30.3,179116,DB00563,Methotrexate
,3335031,concentration x time,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],266.6,179117,DB00563,Methotrexate
,3335031,concentration x time,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],311.2,179118,DB00563,Methotrexate
,3335031,ratio,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],33.4,179119,DB00563,Methotrexate
,3335031,ratio,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],15.7,179120,DB00563,Methotrexate
,3335031,ratio,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],96.3,179121,DB00563,Methotrexate
,3335031,ratio,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],30.3,179122,DB00563,Methotrexate
,3335031,ratio,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],266.6,179123,DB00563,Methotrexate
,3335031,ratio,The [14C]MTX concentration x time (micrograms/min/g x 90 min +/- SEM) ratio between tumor and cortex after systemic administration was 33.4 +/- 4.1:15.7 +/- 1.9; after arterial administration it was 96.3 +/- 11.7:30.3 +/- 3.1; after arterial administration with barrier disruption it was 266.6 +/- 28.8:311.2 +/- 15.9.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),[μg] / [90·g·min·min],311.2,179124,DB00563,Methotrexate
,3335031,tumor:cortex ratio,The greatest tumor:cortex ratio (3.1:1) occurred with arterial drug administration without barrier disruption.,Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3335031/),,3.1:1,179125,DB00563,Methotrexate
,31267867,V(L),"At the same time, the population pharmacokinetic model of methotrexate was obtained CL(L·h-1) =8.25× e0.167× SNP (SNP: SLCO1B1 388A/A=3; SLCO1B1 388A/G=2; SLCO1B1 388G/G=1); V(L)= 32.8; Ka(h- 1)=1.69.",Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31267867/),,32.8,179357,DB00563,Methotrexate
,31267867,Ka(,"At the same time, the population pharmacokinetic model of methotrexate was obtained CL(L·h-1) =8.25× e0.167× SNP (SNP: SLCO1B1 388A/A=3; SLCO1B1 388A/G=2; SLCO1B1 388G/G=1); V(L)= 32.8; Ka(h- 1)=1.69.",Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31267867/),1·h-,1.69,179358,DB00563,Methotrexate
,7932104,detection limits,"A good linear relationship between peak height and concentration was found for the two compounds in the range 2.5 to 100 ng/ml of the human serum, and the detection limits were about 1 ng/ml for the two compounds.",[Highly sensitive analytical procedure for methotrexate and its main metabolite 7-hydroxymethotrexate in serum by high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932104/),[ng] / [ml],1,180255,DB00563,Methotrexate
,7932104,half-life,"MTX was rapidly absorbed, reached to the maximal level at about 1.4 h and thereafter decreased monoexponentially with a half-life of about 1.4 h.",[Highly sensitive analytical procedure for methotrexate and its main metabolite 7-hydroxymethotrexate in serum by high-performance liquid chromatography]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932104/),h,1.4,180256,DB00563,Methotrexate
,32612964,clearance,Patients receiving Mtx at the dose of 5 g/m2 had lower clearance (4.35 vs.,"Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32612964/),,4.35,180304,DB00563,Methotrexate
,647697,Maximum sensitivity,Maximum sensitivity achieved was 1 X 10(-7) M.,"High-presssure liquid chromatographic determination of methotrexate and its major metabolite, 7-hydroxymethotrexate, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/647697/),M,1 X 10(-7),180543,DB00563,Methotrexate
,24934863,elimination half-life (t ½ elimination),The plasma PEM pharmacokinetics calculated showed an elimination half-life (t ½ elimination) of 3.2 h and distribution half-life (t ½-distribution) of 6 min.,Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.2,180591,DB00563,Methotrexate
,24934863,distribution half-life (t ½-distribution),The plasma PEM pharmacokinetics calculated showed an elimination half-life (t ½ elimination) of 3.2 h and distribution half-life (t ½-distribution) of 6 min.,Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),min,6,180592,DB00563,Methotrexate
,24934863,Clearance (CL),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[l] / [h],5.1,180593,DB00563,Methotrexate
,24934863,central volume of distribution (V(central)),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,23.2,180594,DB00563,Methotrexate
,24934863,peripheral volume distribution (V(peripheral)),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,10.6,180595,DB00563,Methotrexate
,24934863,area under the curve,"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[h·μg] / [ml],186,180596,DB00563,Methotrexate
,24934863,elimination half-life,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.1,180597,DB00563,Methotrexate
,24934863,apparent CL,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[l] / [h],3.2,180598,DB00563,Methotrexate
,24934863,apparent steady-state volume,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,14.2,180599,DB00563,Methotrexate
,24934863,elimination half-life,"The pleura concentrations were only half of simultaneous plasma concentrations, and elimination half-life was 3.15 h.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.15,180600,DB00563,Methotrexate
,23069858,clearance,"The MTX clearance and distribution volume were significantly higher in carriers of at least one copy of the -24T allele as compared with noncarriers: 8.6±2.2 vs 6.7± 2.5 l h(-1), P<0.01 and 30.7±7.7 vs 22.1±8.8 l, P<0.001, respectively.",Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069858/),[l] / [h],8.6,181040,DB00563,Methotrexate
,23069858,clearance,"The MTX clearance and distribution volume were significantly higher in carriers of at least one copy of the -24T allele as compared with noncarriers: 8.6±2.2 vs 6.7± 2.5 l h(-1), P<0.01 and 30.7±7.7 vs 22.1±8.8 l, P<0.001, respectively.",Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069858/),[l] / [h],6.7,181041,DB00563,Methotrexate
,23069858,distribution volume,"The MTX clearance and distribution volume were significantly higher in carriers of at least one copy of the -24T allele as compared with noncarriers: 8.6±2.2 vs 6.7± 2.5 l h(-1), P<0.01 and 30.7±7.7 vs 22.1±8.8 l, P<0.001, respectively.",Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069858/),[l] / [h],6.7,181042,DB00563,Methotrexate
,23069858,distribution volume,"The MTX clearance and distribution volume were significantly higher in carriers of at least one copy of the -24T allele as compared with noncarriers: 8.6±2.2 vs 6.7± 2.5 l h(-1), P<0.01 and 30.7±7.7 vs 22.1±8.8 l, P<0.001, respectively.",Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069858/),l,30.7,181043,DB00563,Methotrexate
,23069858,distribution volume,"The MTX clearance and distribution volume were significantly higher in carriers of at least one copy of the -24T allele as compared with noncarriers: 8.6±2.2 vs 6.7± 2.5 l h(-1), P<0.01 and 30.7±7.7 vs 22.1±8.8 l, P<0.001, respectively.",Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069858/),l,22.1,181044,DB00563,Methotrexate
,11174078,flow rate,"The livers were perfused in a single-pass way at a flow rate of 15 ml/min using a perfusate which consisted of Krebs-Henseleit buffer containing glucose, taurocholate, bovine albumin and erythrocytes.",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],15,181550,DB00563,Methotrexate
,11174078,steady-state biliary clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],1.26,181551,DB00563,Methotrexate
,11174078,hepatic clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],1.30,181552,DB00563,Methotrexate
,11174078,partial metabolic clearance,"During the perfusion with 50 micromol/l MTX, the steady-state biliary clearance (1.26 +/- 0.24 ml/min) in 7 nonpretreated rats accounted for a major proportion of the hepatic clearance (1.30 +/- 0.33 ml/min), metabolism of MTX to 7- OHMTX was minor (partial metabolic clearance = 0.041 +/- 0.023 ml/min).",No effect of phenobarbital pretreatment of rats on methotrexate pharmacokinetics in the isolated liver perfused in a single-pass way. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11174078/),[ml] / [min],0.041,181553,DB00563,Methotrexate
,10528081,apparent terminal half-life,The plasma level of free MTX rapidly declined in a biexponential fashion with an apparent terminal half-life of 0.35 h.,Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528081/),h,0.35,181614,DB00563,Methotrexate
,10528081,apparent terminal half-life,"MTX-BSA conjugates showed the slowest decline with an apparent terminal half-life of 6 h, whereas MTX-L(24)BSA showed a biphasic pattern; a rapid distributive phase with a half-life of 0.567 h and a slow terminal phase.",Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528081/),h,6,181615,DB00563,Methotrexate
,10528081,half-life,"MTX-BSA conjugates showed the slowest decline with an apparent terminal half-life of 6 h, whereas MTX-L(24)BSA showed a biphasic pattern; a rapid distributive phase with a half-life of 0.567 h and a slow terminal phase.",Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10528081/),h,0.567,181616,DB00563,Methotrexate
,8305770,peak concentration,"Mean values for peak concentration, time to peak concentration, and AUC0-infinity were 0.80 mumol/L, 1.2 hours, and 3.0 mumol.h/L, respectively, for Mylan's MTX tablets and 0.81 mumol/L, 1.4 hours, 3.0 mumol.h/L, respectively, for Lederle's MTX.",Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8305770/),[μM] / [l],0.80,181857,DB00563,Methotrexate
,8305770,peak concentration,"Mean values for peak concentration, time to peak concentration, and AUC0-infinity were 0.80 mumol/L, 1.2 hours, and 3.0 mumol.h/L, respectively, for Mylan's MTX tablets and 0.81 mumol/L, 1.4 hours, 3.0 mumol.h/L, respectively, for Lederle's MTX.",Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8305770/),[μM] / [l],0.81,181858,DB00563,Methotrexate
,8305770,time to peak concentration,"Mean values for peak concentration, time to peak concentration, and AUC0-infinity were 0.80 mumol/L, 1.2 hours, and 3.0 mumol.h/L, respectively, for Mylan's MTX tablets and 0.81 mumol/L, 1.4 hours, 3.0 mumol.h/L, respectively, for Lederle's MTX.",Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8305770/),h,1.2,181859,DB00563,Methotrexate
,8305770,time to peak concentration,"Mean values for peak concentration, time to peak concentration, and AUC0-infinity were 0.80 mumol/L, 1.2 hours, and 3.0 mumol.h/L, respectively, for Mylan's MTX tablets and 0.81 mumol/L, 1.4 hours, 3.0 mumol.h/L, respectively, for Lederle's MTX.",Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8305770/),[μM] / [l],0.81,181860,DB00563,Methotrexate
,8305770,time to peak concentration,"Mean values for peak concentration, time to peak concentration, and AUC0-infinity were 0.80 mumol/L, 1.2 hours, and 3.0 mumol.h/L, respectively, for Mylan's MTX tablets and 0.81 mumol/L, 1.4 hours, 3.0 mumol.h/L, respectively, for Lederle's MTX.",Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8305770/),h,1.4,181861,DB00563,Methotrexate
,8305770,AUC0-infinity,"Mean values for peak concentration, time to peak concentration, and AUC0-infinity were 0.80 mumol/L, 1.2 hours, and 3.0 mumol.h/L, respectively, for Mylan's MTX tablets and 0.81 mumol/L, 1.4 hours, 3.0 mumol.h/L, respectively, for Lederle's MTX.",Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8305770/),[h·μM] / [l],3.0,181862,DB00563,Methotrexate
,8305770,Relative bioavailability,Relative bioavailability of generic MTX was 99.2 percent.,Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8305770/),%,99.2,181863,DB00563,Methotrexate
,26555,plasma half-lives,"The mean plasma half-lives in man are: pyrimethamine, 85 hr; metoprine, 216 hr; etoprine, 176 hr.","Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555/),h,85,182163,DB00563,Methotrexate
,26555,plasma half-lives,"The mean plasma half-lives in man are: pyrimethamine, 85 hr; metoprine, 216 hr; etoprine, 176 hr.","Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555/),h,216,182164,DB00563,Methotrexate
,26555,plasma half-lives,"The mean plasma half-lives in man are: pyrimethamine, 85 hr; metoprine, 216 hr; etoprine, 176 hr.","Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555/),h,176,182165,DB00563,Methotrexate
,23647273,plasma concentrations,"Simulation data demonstrated that with 16, 64, 128 and 192 microneedles, mean plasma concentrations of 0.3, 1.4, 2.8 and 4.2 ng/ml, respectively, can be achieved.",Transdermal delivery of methotrexate for pediatrics using silicon microneedles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23647273/),[ng] / [ml],0.3,182316,DB00563,Methotrexate
,23647273,plasma concentrations,"Simulation data demonstrated that with 16, 64, 128 and 192 microneedles, mean plasma concentrations of 0.3, 1.4, 2.8 and 4.2 ng/ml, respectively, can be achieved.",Transdermal delivery of methotrexate for pediatrics using silicon microneedles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23647273/),[ng] / [ml],1.4,182317,DB00563,Methotrexate
,23647273,plasma concentrations,"Simulation data demonstrated that with 16, 64, 128 and 192 microneedles, mean plasma concentrations of 0.3, 1.4, 2.8 and 4.2 ng/ml, respectively, can be achieved.",Transdermal delivery of methotrexate for pediatrics using silicon microneedles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23647273/),[ng] / [ml],2.8,182318,DB00563,Methotrexate
,23647273,plasma concentrations,"Simulation data demonstrated that with 16, 64, 128 and 192 microneedles, mean plasma concentrations of 0.3, 1.4, 2.8 and 4.2 ng/ml, respectively, can be achieved.",Transdermal delivery of methotrexate for pediatrics using silicon microneedles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23647273/),[ng] / [ml],4.2,182319,DB00563,Methotrexate
,1646754,peak concentration,"After an intramuscular dose of 50 mg, plasma MTX levels rose rapidly, reached a peak concentration of 5.8 x 10(-6) M/liter at 1 hour and persisted above 10(-6) M/liter normally considered inhibitory for DNA synthesis, for approximately 7 1/2 hours.",Correlation of plasma methotrexate concentration with human chorionic gonadotropin and therapeutic response to low-dose methotrexate-citrovorum factor in low-medium-risk gestational trophoblastic tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646754/),[M] / [l],5.8 x 10(-6),183905,DB00563,Methotrexate
,12593762,Biliary clearance,3. Biliary clearance of methotrexate in AA rats was 2.30 +/- 0.23 ml min(-1) kg(-1) (mean SD) and significantly lower than in normal rats (8.42 +/- 0.81 ml min(-1) kg(-1)).,Decreased hepatobiliary transport of methotrexate in adjuvant arthritis rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593762/),[ml] / [kg·min],2.30,185014,DB00563,Methotrexate
,12593762,Biliary clearance,3. Biliary clearance of methotrexate in AA rats was 2.30 +/- 0.23 ml min(-1) kg(-1) (mean SD) and significantly lower than in normal rats (8.42 +/- 0.81 ml min(-1) kg(-1)).,Decreased hepatobiliary transport of methotrexate in adjuvant arthritis rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593762/),[ml] / [kg·min],8.42,185015,DB00563,Methotrexate
,12593762,uptake clearance,The uptake clearance of methotrexate in AA rats was also lower than in normal rats (0.138 versus 0.278 ml min(-1) g liver(-1)).,Decreased hepatobiliary transport of methotrexate in adjuvant arthritis rats. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593762/),[g·ml] / [liver·min],0.138,185016,DB00563,Methotrexate
,12593762,uptake clearance,The uptake clearance of methotrexate in AA rats was also lower than in normal rats (0.138 versus 0.278 ml min(-1) g liver(-1)).,Decreased hepatobiliary transport of methotrexate in adjuvant arthritis rats. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593762/),[g·ml] / [liver·min],0.278,185017,DB00563,Methotrexate
,16299240,area under the curve,"Complete bioavailability of aminopterin was confirmed, with a mean area under the curve of 0.52 +/- 0.03 micromol hour/L after oral dosing.",Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299240/),[h·μM] / [l],0.52,185420,DB00563,Methotrexate
,720376,peak serum level,"The peak serum level of methotrexate of 2.32--10(-5) mol/1 was found in children given 500 mg methotrexate/m2 by a 24 h infusion, and another group given 2790 mg/m2 during a 6 h infusion had serum levels as high as 2.16--10(-4) mol/1.",Pharmacokinetics of high-dose methotrexate treatment in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/720376/),mol,2.32,185512,DB00563,Methotrexate
,720376,serum half-life,"The decay of serum concentration of methotrexate after completion of the infusion followed a diphasic curve, with an initial serum half-life of 4.8 h, followed by a second half-life of 34.4 h at distribution equilibrium.",Pharmacokinetics of high-dose methotrexate treatment in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/720376/),h,4.8,185513,DB00563,Methotrexate
,720376,half-life,"The decay of serum concentration of methotrexate after completion of the infusion followed a diphasic curve, with an initial serum half-life of 4.8 h, followed by a second half-life of 34.4 h at distribution equilibrium.",Pharmacokinetics of high-dose methotrexate treatment in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/720376/),h,34.4,185514,DB00563,Methotrexate
,720376,apparent volume of distribution,The apparent volume of distribution was 56.8 litres/m2.,Pharmacokinetics of high-dose methotrexate treatment in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/720376/),[l] / [m2],56.8,185515,DB00563,Methotrexate
,9486490,terminal elimination half-life,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),h,18.2,185873,DB00563,Methotrexate
,9486490,total body clearance,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),[ml] / [h·kg],71,185874,DB00563,Methotrexate
,9486490,volume of distribution,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),[1] / [kg],1.67,185875,DB00563,Methotrexate
,9486490,bioavailability,The p.o. bioavailability was 31-49%.,Tacrolimus pharmacokinetics in BMT patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),%,31-49,185876,DB00563,Methotrexate
,24242937,IC50,"PUR inhibited digoxin efflux transport in MDCK-MDR1 monolayers with an IC50 value of 1.6 ± 0.3 μM, suggesting that the first target of drug interaction was MDR1 in the intestine during the absorption process.",MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242937/),μM,1.6,186679,DB00563,Methotrexate
,8882301,protein binding to serum albumin,A mean protein binding to serum albumin of 42 to 57% is usually reported.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),%,42 to 57,186895,DB00563,Methotrexate
,8882301,steady-state volume of distribution,The steady-state volume of distribution is approximately 1 L/kg.,Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [kg],1,186896,DB00563,Methotrexate
,8882301,elimination half-life,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),h,5 to 8,186897,DB00563,Methotrexate
,8882301,total body clearance,"The usually reported mean values for the elimination half-life and the total body clearance of methotrexate are 5 to 8 hours and 4.8 to 7.8 L/h, respectively.",Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8882301/),[l] / [h],4.8 to 7.8,186898,DB00563,Methotrexate
,25959975,entrapment efficiency,"Drug entrapment efficiency and drug loading capacity were 61.82±6.84%, and 53.68±3.09%, respectively.",Neuropharmacokinetic evaluation of methotrexate-loaded chitosan nanogels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25959975/),%,61.82,187406,DB00563,Methotrexate
,25959975,drug loading capacity,"Drug entrapment efficiency and drug loading capacity were 61.82±6.84%, and 53.68±3.09%, respectively.",Neuropharmacokinetic evaluation of methotrexate-loaded chitosan nanogels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25959975/),%,53.68,187407,DB00563,Methotrexate
,2584317,limit of detection,The limit of detection of the two assays was also similar at 0.01 microM.,Comparison of high-performance liquid chromatography and the Abbott fluorescent polarization radioimmunoassay in the measurement of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2584317/),μM,0.01,187584,DB00563,Methotrexate
,2584317,half-life,The 7-hydroxymethotrexate half-life was 15 h.,Comparison of high-performance liquid chromatography and the Abbott fluorescent polarization radioimmunoassay in the measurement of methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2584317/),h,15,187585,DB00563,Methotrexate
,8509997,renal clearance,"MTX renal clearance was nonlinear, increasing from 0.310 to 0.434 ml/min over the concentration range studied.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),[ml] / [min],0.310,187756,DB00563,Methotrexate
,8509997,renal clearance,"MTX renal clearance was nonlinear, increasing from 0.310 to 0.434 ml/min over the concentration range studied.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),[ml] / [min],0,187757,DB00563,Methotrexate
,8509997,excretion ratios,"Corresponding excretion ratios increased from 0.933 to 1.52, indicative of MTX renal elimination involving the processes of filtration, secretion and reabsorption.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),,0.933,187758,DB00563,Methotrexate
,8509997,excretion ratios,"Corresponding excretion ratios increased from 0.933 to 1.52, indicative of MTX renal elimination involving the processes of filtration, secretion and reabsorption.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),,1.52,187759,DB00563,Methotrexate
,3978622,plasma clearance,The results showed that the plasma clearance (4.02 to 4.68 ml/min/kg) of methotrexate was relatively constant over the concentration range studied.,Clearance studies of methotrexate in dogs after multiple-rate infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978622/),[ml] / [kg·min],4.02 to 4.68,189560,DB00563,Methotrexate
,3978622,renal clearance,"As the plasma methotrexate concentration increased from 1 to 20 or 100 micrograms/ml, renal clearance decreased from 3.60 to 4.28 ml/min/kg to 2.62 to 2.73 ml/min/kg, and nonrenal clearance increased form 0.35 to 0.42 ml/min/kg to 1.38 to 1.74 ml/min/kg.",Clearance studies of methotrexate in dogs after multiple-rate infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978622/),[ml] / [kg·min],3.60 to 4.28,189561,DB00563,Methotrexate
,3978622,renal clearance,"As the plasma methotrexate concentration increased from 1 to 20 or 100 micrograms/ml, renal clearance decreased from 3.60 to 4.28 ml/min/kg to 2.62 to 2.73 ml/min/kg, and nonrenal clearance increased form 0.35 to 0.42 ml/min/kg to 1.38 to 1.74 ml/min/kg.",Clearance studies of methotrexate in dogs after multiple-rate infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978622/),[ml] / [kg·min],2,189562,DB00563,Methotrexate
,3978622,nonrenal clearance,"As the plasma methotrexate concentration increased from 1 to 20 or 100 micrograms/ml, renal clearance decreased from 3.60 to 4.28 ml/min/kg to 2.62 to 2.73 ml/min/kg, and nonrenal clearance increased form 0.35 to 0.42 ml/min/kg to 1.38 to 1.74 ml/min/kg.",Clearance studies of methotrexate in dogs after multiple-rate infusion. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978622/),[ml] / [kg·min],0.35 to 0.42,189563,DB00563,Methotrexate
,3978622,nonrenal clearance,"As the plasma methotrexate concentration increased from 1 to 20 or 100 micrograms/ml, renal clearance decreased from 3.60 to 4.28 ml/min/kg to 2.62 to 2.73 ml/min/kg, and nonrenal clearance increased form 0.35 to 0.42 ml/min/kg to 1.38 to 1.74 ml/min/kg.",Clearance studies of methotrexate in dogs after multiple-rate infusion. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978622/),[ml] / [kg·min],1.38 to 1.74,189564,DB00563,Methotrexate
,8599862,peak plasma concentration (Cmax),"When 6-MP was given alone, the mean peak plasma concentration (Cmax) and area under the curve (AUC) of 6-MP were 72.5 ng/ml and 225.3 h ng ml(-1).",Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599862/),[ng] / [ml],72.5,189721,DB00563,Methotrexate
,8599862,area under the curve (AUC),"When 6-MP was given alone, the mean peak plasma concentration (Cmax) and area under the curve (AUC) of 6-MP were 72.5 ng/ml and 225.3 h ng ml(-1).",Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599862/),[h·ng] / [ml],225.3,189722,DB00563,Methotrexate
,16594642,clearance,"In addition, AMI pretreatment induced a 57% increase in 7E3 clearance (1.13 +/- 0.13 mL h(-1) kg(-1) vs 0.72 +/- 0.08 mL h(-1) kg(-1), P < .05).",Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16594642/),[ml] / [h·kg],1.13,192473,DB00563,Methotrexate
,16594642,clearance,"In addition, AMI pretreatment induced a 57% increase in 7E3 clearance (1.13 +/- 0.13 mL h(-1) kg(-1) vs 0.72 +/- 0.08 mL h(-1) kg(-1), P < .05).",Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16594642/),[ml] / [h·kg],0.72,192474,DB00563,Methotrexate
,3393423,half-lives,"A biphasic plasma-disappearance pattern of methotrexate was observed, with half-lives of 3.5 and 29 hours.",Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3393423/),h,3.5,193196,DB00563,Methotrexate
,3393423,half-lives,"A biphasic plasma-disappearance pattern of methotrexate was observed, with half-lives of 3.5 and 29 hours.",Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3393423/),h,29,193197,DB00563,Methotrexate
over,3393423,final elimination half-life,"The 7-hydroxy metabolite accumulated and showed a very slow rate of elimination, with an estimated final elimination half-life of over 120 hours.",Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3393423/),h,120,193198,DB00563,Methotrexate
,3393423,peritoneal clearance rate,"The mean peritoneal clearance rate of methotrexate was 0.13 l/h (range 0.05-0.20 l/h), dwell times significantly influenced the clearance rate.",Pharmacokinetics of methotrexate in continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3393423/),[l] / [h],0.13,193199,DB00563,Methotrexate
,27410490,apparent bioavailability,The apparent bioavailability was 36.3%-56.7% across single subcutaneous doses.,"Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27410490/),%,36.3,193611,DB00563,Methotrexate
,27410490,t1/2,"Similar to single-dose treatment, ASP2408 concentrations peaked 2 to 3 days postdose, with a median t1/2 of approximately 8 days.","Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27410490/),d,8,193612,DB00563,Methotrexate
,7548777,area under the plasma concentration-time curve (AUC,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml·μg] / [min],173,193771,DB00563,Methotrexate
,7548777,area under the plasma concentration-time curve (AUC,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml·μg] / [min],314,193772,DB00563,Methotrexate
,7548777,terminal half-life (t1/2,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),min,24.0,193773,DB00563,Methotrexate
,7548777,terminal half-life (t1/2,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),min,412,193774,DB00563,Methotrexate
,7548777,mean residence time (MRT,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),min,13.0,193775,DB00563,Methotrexate
,7548777,mean residence time (MRT,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),min,324,193776,DB00563,Methotrexate
,7548777,apparent volume of distribution at steady state (VSS,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml] / [kg],289,193777,DB00563,Methotrexate
,7548777,apparent volume of distribution at steady state (VSS,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml] / [kg],3370,193778,DB00563,Methotrexate
,7548777,total body clearance (CL,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml] / [kg·min],23.1,193779,DB00563,Methotrexate
,7548777,total body clearance (CL,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml] / [kg·min],12.8,193780,DB00563,Methotrexate
,7548777,renal clearance (CLR,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml] / [kg·min],8.38,193781,DB00563,Methotrexate
,7548777,renal clearance (CLR,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml] / [kg·min],3.09,193782,DB00563,Methotrexate
,7548777,non-renal clearance (CLNR,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml] / [kg·min],14.6,193783,DB00563,Methotrexate
,7548777,non-renal clearance (CLNR,"After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I.",Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7548777/),[ml] / [kg·min],9.56,193784,DB00563,Methotrexate
,23729801,maximum plasma concentration,"For the 30-100 mg doses, median maximum plasma concentration values ranged from 4.02 to 4.49 days.","Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23729801/),d,4.02 to 4.49,193938,DB00563,Methotrexate
,23729801,elimination half-life,Mean elimination half-life values ranged from 5.20 to 6.83 days.,"Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23729801/),d,5.20 to 6.83,193939,DB00563,Methotrexate
,8864795,relative recovery,"The relative recovery was independent of methotrexate concentration: 39.3% +/- 2.86% and 39.2 +/- 1.27% for 50 microM and 300 microM, respectively.",In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),%,39.3,194027,DB00563,Methotrexate
,8864795,relative recovery,"The relative recovery was independent of methotrexate concentration: 39.3% +/- 2.86% and 39.2 +/- 1.27% for 50 microM and 300 microM, respectively.",In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),%,39.2,194028,DB00563,Methotrexate
,8864795,bound percentages,"The bound percentages and corresponding total binding capacities were 58.7% +/- 3.13% and 1.44 +/- 0.033 mM-1 and 71.7% +/- 4.38% and 2.18 +/- 0.09 mM-1 for the human and rat plasma, respectively.",In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),%,58.7,194029,DB00563,Methotrexate
,8864795,bound percentages,"The bound percentages and corresponding total binding capacities were 58.7% +/- 3.13% and 1.44 +/- 0.033 mM-1 and 71.7% +/- 4.38% and 2.18 +/- 0.09 mM-1 for the human and rat plasma, respectively.",In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),%,71.7,194030,DB00563,Methotrexate
,8864795,total binding capacities,"The bound percentages and corresponding total binding capacities were 58.7% +/- 3.13% and 1.44 +/- 0.033 mM-1 and 71.7% +/- 4.38% and 2.18 +/- 0.09 mM-1 for the human and rat plasma, respectively.",In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),1/[mM],1.44,194031,DB00563,Methotrexate
,8864795,total binding capacities,"The bound percentages and corresponding total binding capacities were 58.7% +/- 3.13% and 1.44 +/- 0.033 mM-1 and 71.7% +/- 4.38% and 2.18 +/- 0.09 mM-1 for the human and rat plasma, respectively.",In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),1/[mM],2.18,194032,DB00563,Methotrexate
,8864795,affinity constant,For HSA this binding was saturable with an affinity constant of 4.75 +/- 0.66 mM-1.,In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),1/[mM],4.75,194033,DB00563,Methotrexate
,8864795,relative recovery,The in vivo relative recovery of methotrexate was found to be 12.6% +/- 1.8% versus 25.4% +/- 3.3% in vitro.,In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),%,12.6,194034,DB00563,Methotrexate
,8864795,relative recovery,The in vivo relative recovery of methotrexate was found to be 12.6% +/- 1.8% versus 25.4% +/- 3.3% in vitro.,In vitro and in vivo protein binding of methotrexate assessed by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864795/),%,25.4,194035,DB00563,Methotrexate
,2324584,penetration,Pharmacokinetic study revealed high peaks of Ara-C concentration in plasma (6.2 microM immediately after the end of the infusion) and high degree of its penetration into the CNS (5.6 microM at 3 hr after the end of the infusion) suggesting the effective and perhaps a uniform level of Ara-C is achieved throughout the CNS by this therapy.,[Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences]. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324584/),μM,5.6,194604,DB00563,Methotrexate
,25394095,concentration,Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79-455).,"Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25394095/),[ng] / [ml],143,195476,DB00563,Methotrexate
,3431588,half-life (t1/2),"After iv administration of [14C]PTX to rats, the elimination profile of intact drug from plasma was first order with a half-life (t1/2) of 38 minutes.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),min,38,195566,DB00563,Methotrexate
,3431588,plasma t1/2,"Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),h,2.15,195567,DB00563,Methotrexate
,3431588,total body clearance,"Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),[l] / [h·kg],0.625,195568,DB00563,Methotrexate
,3431588,steady-state volume of distribution,"Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),[l] / [kg],1.82,195569,DB00563,Methotrexate
,3431588,absolute bioavailability,"Pharmacokinetic studies in the dog indicated a mean plasma t1/2 (after iv dose) of 2.15 hours, total body clearance of 0.625 liters/hr/kg and steady-state volume of distribution of 1.82 liters/kg; the absolute bioavailability was 0.64.","Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3431588/),,0.64,195570,DB00563,Methotrexate
,18192538,maximum serum concentration (C(max)),"The mean maximum serum concentration (C(max)) for glucarpidase in renally impaired subjects was 2.9 microg/mL, the mean half-life (t(1/2)) was 10.0 hours, and the mean area under the serum concentration-time curve from time zero to infinity (AUC(0-infinity)) was 24.5 microg x h/mL.",Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192538/),[μg] / [ml],2.9,196092,DB00563,Methotrexate
,18192538,half-life (t(1/2)),"The mean maximum serum concentration (C(max)) for glucarpidase in renally impaired subjects was 2.9 microg/mL, the mean half-life (t(1/2)) was 10.0 hours, and the mean area under the serum concentration-time curve from time zero to infinity (AUC(0-infinity)) was 24.5 microg x h/mL.",Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192538/),h,10.0,196093,DB00563,Methotrexate
,18192538,area under the serum concentration-time curve from time zero to infinity (AUC(0-infinity)),"The mean maximum serum concentration (C(max)) for glucarpidase in renally impaired subjects was 2.9 microg/mL, the mean half-life (t(1/2)) was 10.0 hours, and the mean area under the serum concentration-time curve from time zero to infinity (AUC(0-infinity)) was 24.5 microg x h/mL.",Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192538/),[h·μg] / [ml],24.5,196094,DB00563,Methotrexate
,18192538,C(max),"Similar values were found in subjects with normal renal function (mean C(max) 3.1 microg/mL, mean t(1/2) 9.0 hours, and mean AUC(0-infinity) 23.4 microg x h/mL).",Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192538/),[μg] / [ml],3.1,196095,DB00563,Methotrexate
,18192538,t(1/2),"Similar values were found in subjects with normal renal function (mean C(max) 3.1 microg/mL, mean t(1/2) 9.0 hours, and mean AUC(0-infinity) 23.4 microg x h/mL).",Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192538/),h,9.0,196096,DB00563,Methotrexate
,18192538,AUC(0-infinity),"Similar values were found in subjects with normal renal function (mean C(max) 3.1 microg/mL, mean t(1/2) 9.0 hours, and mean AUC(0-infinity) 23.4 microg x h/mL).",Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192538/),[h·μg] / [ml],23.4,196097,DB00563,Methotrexate
,24487484,steady-state serum adalimumab trough concentrations,Mean steady-state serum adalimumab trough concentrations were 7-8 μg/mL at weeks 12 and 24.,"Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487484/),[μg] / [ml],7-8,197115,DB00563,Methotrexate
,6668556,half-life,The disposition kinetics of MTX appeared polyexponential with a small terminal phase having a half-life of 10.2-27.5 hr.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668556/),h,10.2-27.5,197301,DB00563,Methotrexate
,6668556,total body clearance,"An increase in dose not only reduced the mean total body clearance (7.49 vs. 4.26 ml/min/kg) and renal clearance (4.89 vs. 2.76 ml/min/kg), but also prolonged the mean residence time (26.2 vs. 43.3 min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668556/),[ml] / [kg·min],7.49,197302,DB00563,Methotrexate
,6668556,total body clearance,"An increase in dose not only reduced the mean total body clearance (7.49 vs. 4.26 ml/min/kg) and renal clearance (4.89 vs. 2.76 ml/min/kg), but also prolonged the mean residence time (26.2 vs. 43.3 min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668556/),[ml] / [kg·min],4.26,197303,DB00563,Methotrexate
,6668556,renal clearance,"An increase in dose not only reduced the mean total body clearance (7.49 vs. 4.26 ml/min/kg) and renal clearance (4.89 vs. 2.76 ml/min/kg), but also prolonged the mean residence time (26.2 vs. 43.3 min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668556/),[ml] / [kg·min],4.89,197304,DB00563,Methotrexate
,6668556,renal clearance,"An increase in dose not only reduced the mean total body clearance (7.49 vs. 4.26 ml/min/kg) and renal clearance (4.89 vs. 2.76 ml/min/kg), but also prolonged the mean residence time (26.2 vs. 43.3 min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668556/),[ml] / [kg·min],2.76,197305,DB00563,Methotrexate
,6668556,mean residence time,"An increase in dose not only reduced the mean total body clearance (7.49 vs. 4.26 ml/min/kg) and renal clearance (4.89 vs. 2.76 ml/min/kg), but also prolonged the mean residence time (26.2 vs. 43.3 min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668556/),min,26.2,197306,DB00563,Methotrexate
,6668556,mean residence time,"An increase in dose not only reduced the mean total body clearance (7.49 vs. 4.26 ml/min/kg) and renal clearance (4.89 vs. 2.76 ml/min/kg), but also prolonged the mean residence time (26.2 vs. 43.3 min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668556/),min,43.3,197307,DB00563,Methotrexate
,6668556,steady-state volume of distribution (Vss),The steady-state volume of distribution (Vss) of MTX was estimated to range from 0.16 to 0.25 L/kg.,Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668556/),[l] / [kg],0.16 to 0.25,197308,DB00563,Methotrexate
,1891168,clearance,Average clearance decreased from 1.3 l/min for 320 to 0.7 l/min for 960 mg FU/m2.,"Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1891168/),[l] / [min],1.3,197449,DB00563,Methotrexate
,1891168,clearance,Average clearance decreased from 1.3 l/min for 320 to 0.7 l/min for 960 mg FU/m2.,"Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1891168/),[l] / [min],0.7,197450,DB00563,Methotrexate
over,23011175,peak concentration,"To establish the conversion ratio and the best strategy of twice-daily administration of CyA, the authors investigated the serial changes in the blood CyA concentration during the switch from twice-daily intravenous infusion to oral administration while maintaining high-peak concentration (over 1000 ng/mL) and calculated the bioavailability of Neoral, a micro emulsion cyclosporine, in 11 patients.",Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23011175/),[ng] / [ml],1000,197639,DB00563,Methotrexate
,23011175,total area under the concentration-time curve during oral administration (AUCpo),"The total area under the concentration-time curve during oral administration (AUCpo) was nearly the same as AUC during intravenous infusion (AUCiv) (mean ± SD, 7206 ± 1557 ng·h·mL and 7783 ± 897.7 ng·h·mL, respectively).",Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23011175/),h·ml·ng,7206,197640,DB00563,Methotrexate
,23011175,bioavailability,"The bioavailability of Neoral, defined as F = AUCpo × DOSEiv/AUCiv × DOSEpo was 0.58 ± 0.15 (mean ± SD, range: 0.41-0.94).",Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23011175/),,0.58,197641,DB00563,Methotrexate
,7119052,minimum detectable quantities,The minimum detectable quantities with this assay are: methotrexate 4.4 ng (9.8 X 10(-12) mole); 4-deoxy-4-amino-N10-methylpteroic acid 11.9 ng (3.7 X 10(-11) mole); 7-hydroxymethotrexate 30 ng (6.5 X 10(-11) mole); sulfamethoxazole 125 ng (4.9 X 10(-10) mole).,"High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethortrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119052/),ng,4.4,197758,DB00563,Methotrexate
,7119052,minimum detectable quantities,The minimum detectable quantities with this assay are: methotrexate 4.4 ng (9.8 X 10(-12) mole); 4-deoxy-4-amino-N10-methylpteroic acid 11.9 ng (3.7 X 10(-11) mole); 7-hydroxymethotrexate 30 ng (6.5 X 10(-11) mole); sulfamethoxazole 125 ng (4.9 X 10(-10) mole).,"High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethortrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119052/),mole,9.8,197759,DB00563,Methotrexate
,7119052,minimum detectable quantities,The minimum detectable quantities with this assay are: methotrexate 4.4 ng (9.8 X 10(-12) mole); 4-deoxy-4-amino-N10-methylpteroic acid 11.9 ng (3.7 X 10(-11) mole); 7-hydroxymethotrexate 30 ng (6.5 X 10(-11) mole); sulfamethoxazole 125 ng (4.9 X 10(-10) mole).,"High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethortrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119052/),ng,11.9,197760,DB00563,Methotrexate
,7119052,minimum detectable quantities,The minimum detectable quantities with this assay are: methotrexate 4.4 ng (9.8 X 10(-12) mole); 4-deoxy-4-amino-N10-methylpteroic acid 11.9 ng (3.7 X 10(-11) mole); 7-hydroxymethotrexate 30 ng (6.5 X 10(-11) mole); sulfamethoxazole 125 ng (4.9 X 10(-10) mole).,"High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethortrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119052/),mole,3.7,197761,DB00563,Methotrexate
,7119052,minimum detectable quantities,The minimum detectable quantities with this assay are: methotrexate 4.4 ng (9.8 X 10(-12) mole); 4-deoxy-4-amino-N10-methylpteroic acid 11.9 ng (3.7 X 10(-11) mole); 7-hydroxymethotrexate 30 ng (6.5 X 10(-11) mole); sulfamethoxazole 125 ng (4.9 X 10(-10) mole).,"High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethortrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119052/),ng,30,197762,DB00563,Methotrexate
,7119052,minimum detectable quantities,The minimum detectable quantities with this assay are: methotrexate 4.4 ng (9.8 X 10(-12) mole); 4-deoxy-4-amino-N10-methylpteroic acid 11.9 ng (3.7 X 10(-11) mole); 7-hydroxymethotrexate 30 ng (6.5 X 10(-11) mole); sulfamethoxazole 125 ng (4.9 X 10(-10) mole).,"High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethortrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119052/),mole,6.5,197763,DB00563,Methotrexate
,7119052,minimum detectable quantities,The minimum detectable quantities with this assay are: methotrexate 4.4 ng (9.8 X 10(-12) mole); 4-deoxy-4-amino-N10-methylpteroic acid 11.9 ng (3.7 X 10(-11) mole); 7-hydroxymethotrexate 30 ng (6.5 X 10(-11) mole); sulfamethoxazole 125 ng (4.9 X 10(-10) mole).,"High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethortrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119052/),ng,125,197764,DB00563,Methotrexate
,7119052,minimum detectable quantities,The minimum detectable quantities with this assay are: methotrexate 4.4 ng (9.8 X 10(-12) mole); 4-deoxy-4-amino-N10-methylpteroic acid 11.9 ng (3.7 X 10(-11) mole); 7-hydroxymethotrexate 30 ng (6.5 X 10(-11) mole); sulfamethoxazole 125 ng (4.9 X 10(-10) mole).,"High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethortrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119052/),mole,4.9,197765,DB00563,Methotrexate
,1933871,duration of complete responses,The duration of complete responses ranged from 7 to 22 weeks.,"Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933871/),weeks,7 to 22,197934,DB00563,Methotrexate
,20218013,diffusion coefficient,MTX concentration in tumor interstitial fluid equilibrated with that of plasma in about 50 hr using a micropore chamber with a diffusion coefficient of 0.5 microm/min as sampling device.,Pharmacokinetics of methotrexate in solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218013/),[μm] / [min],0.5,198368,DB00563,Methotrexate
,12500426,times of formation,The model-based estimates of the mean times of formation of 7-hydroxymethotrexate from methotrexate ranged from 9.13 to 25.13 h.,System approach to modeling metabolite formation from parent drug: a working example with methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12500426/),h,9.13 to 25.13,198919,DB00563,Methotrexate
,12500426,rates of formation,The model-based estimates of the rates of formation of 7-hydroxymethotrexate from methotrexate reached peak values (ranging from 0.03 to 0.11 h-1) in the time interval 1.5-4.5 h after administration of methotraxate.,System approach to modeling metabolite formation from parent drug: a working example with methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12500426/),1/[h],0.03 to 0.11,198920,DB00563,Methotrexate
,12860493,duration of response,"Of 29 adalimumab recipients who had an ACR20 response, 18 (62.1%) had a duration of response (time from first occurrence of a response to first occurrence of a nonresponse) of 1 to 2 weeks, and 11 (37.9%) had a duration of response of 3 to 13 weeks.","Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860493/),weeks,1 to 2,200178,DB00563,Methotrexate
,12860493,time from first occurrence of a response to first occurrence of a nonresponse,"Of 29 adalimumab recipients who had an ACR20 response, 18 (62.1%) had a duration of response (time from first occurrence of a response to first occurrence of a nonresponse) of 1 to 2 weeks, and 11 (37.9%) had a duration of response of 3 to 13 weeks.","Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860493/),weeks,1 to 2,200179,DB00563,Methotrexate
,12860493,duration of response,"Of 29 adalimumab recipients who had an ACR20 response, 18 (62.1%) had a duration of response (time from first occurrence of a response to first occurrence of a nonresponse) of 1 to 2 weeks, and 11 (37.9%) had a duration of response of 3 to 13 weeks.","Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860493/),weeks,3 to 13,200180,DB00563,Methotrexate
,12860493,apparent terminal half-life,The mean apparent terminal half-life after a single intravenous dose of adalimumab ranged from 15 to 19 days in the 5 dose groups.,"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860493/),d,15 to 19,200181,DB00563,Methotrexate
,12860493,half-life,"In this selected patient population, adalimumab's long half-life of 15 to 19 days supports every-other-week dosing.","Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860493/),d,15 to 19,200182,DB00563,Methotrexate
,18021334,V1/F,"The final pharmacokinetic parameters were CL/F (L/kg/h) = 0.177 x 0.394MULT, V1/F (L/kg) = 0.0501, Q/F (L/kg/h) = 0.056, V2/F (L/kg) = 0.368, ka (h-1) = 0.503, where CL is total body clearance, V1 and V2 is apparent volume of distribution in the central and peripheral compartments, k(a) is absorption rate constant, Q is intercompartmental clearance and MULT = 1 for patients received multiple dosing and zero otherwise.",Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021334/),[l] / [kg],0.0501,200301,DB00563,Methotrexate
,18021334,Q/F,"The final pharmacokinetic parameters were CL/F (L/kg/h) = 0.177 x 0.394MULT, V1/F (L/kg) = 0.0501, Q/F (L/kg/h) = 0.056, V2/F (L/kg) = 0.368, ka (h-1) = 0.503, where CL is total body clearance, V1 and V2 is apparent volume of distribution in the central and peripheral compartments, k(a) is absorption rate constant, Q is intercompartmental clearance and MULT = 1 for patients received multiple dosing and zero otherwise.",Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021334/),[l] / [h·kg],0.056,200302,DB00563,Methotrexate
,18021334,V2/F,"The final pharmacokinetic parameters were CL/F (L/kg/h) = 0.177 x 0.394MULT, V1/F (L/kg) = 0.0501, Q/F (L/kg/h) = 0.056, V2/F (L/kg) = 0.368, ka (h-1) = 0.503, where CL is total body clearance, V1 and V2 is apparent volume of distribution in the central and peripheral compartments, k(a) is absorption rate constant, Q is intercompartmental clearance and MULT = 1 for patients received multiple dosing and zero otherwise.",Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021334/),[l] / [kg],0.368,200303,DB00563,Methotrexate
,18021334,ka,"The final pharmacokinetic parameters were CL/F (L/kg/h) = 0.177 x 0.394MULT, V1/F (L/kg) = 0.0501, Q/F (L/kg/h) = 0.056, V2/F (L/kg) = 0.368, ka (h-1) = 0.503, where CL is total body clearance, V1 and V2 is apparent volume of distribution in the central and peripheral compartments, k(a) is absorption rate constant, Q is intercompartmental clearance and MULT = 1 for patients received multiple dosing and zero otherwise.",Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021334/),1/[h],0.50,200304,DB00563,Methotrexate
,7261249,clearance,Intra-arterial methotrexate showed two-compartment characteristics with a clearance of 79 ml/min/m2 and an apparent volume of distribution of 21.2 l/m2 body surface area.,Pharmacokinetics of methotrexate administered via the hepatic artery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7261249/),[ml] / [m2·min],79,201101,DB00563,Methotrexate
,7261249,apparent volume of distribution,Intra-arterial methotrexate showed two-compartment characteristics with a clearance of 79 ml/min/m2 and an apparent volume of distribution of 21.2 l/m2 body surface area.,Pharmacokinetics of methotrexate administered via the hepatic artery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7261249/),[l] / [m2],21.2,201102,DB00563,Methotrexate
,7261249,half-life of the early phase,The average half-life of the early phase was 1.9 h and the terminal half-life was 14.4 h.,Pharmacokinetics of methotrexate administered via the hepatic artery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7261249/),h,1.9,201103,DB00563,Methotrexate
,7261249,terminal half-life,The average half-life of the early phase was 1.9 h and the terminal half-life was 14.4 h.,Pharmacokinetics of methotrexate administered via the hepatic artery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7261249/),h,14.4,201104,DB00563,Methotrexate
,16120550,C(max) (maximum MTX concentration,"Median (range) bioavailability pk parameters were: C(max) (maximum MTX concentration) 1149.5 microM (692-2,200), AUC(tot) (total area under curve) 6,955.1 micromol*h/l (3,477-12,681).",High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120550/),μM,1149.5,201595,DB00563,Methotrexate
,16120550,AUC(tot) (,"Median (range) bioavailability pk parameters were: C(max) (maximum MTX concentration) 1149.5 microM (692-2,200), AUC(tot) (total area under curve) 6,955.1 micromol*h/l (3,477-12,681).",High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120550/),[h·μM] / [l],"6,955.1",201596,DB00563,Methotrexate
,16120550,total area under curve,"Median (range) bioavailability pk parameters were: C(max) (maximum MTX concentration) 1149.5 microM (692-2,200), AUC(tot) (total area under curve) 6,955.1 micromol*h/l (3,477-12,681).",High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120550/),[h·μM] / [l],"6,955.1",201597,DB00563,Methotrexate
>,16120550,C(max),"C(max)>1,000 microM gave increased histological responses (p < 0.05).",High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120550/),μM,"1,000",201598,DB00563,Methotrexate
>,16120550,AUC(tot),"Toxicity was mild: only two reversible G4 events were observed, related to AUC(tot) >12,000 micromol*h/l (p < 0.001).",High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120550/),[h·μM] / [l],"12,000",201599,DB00563,Methotrexate
,28168347,peak,The cisplatin peak occurred at week 3 (mean 1269 μg/g bone) and the methotrexate peak at week 1 (mean 862.76 μg/g bone).,Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168347/),[μg] / [g],1269,201611,DB00563,Methotrexate
,28168347,peak,The cisplatin peak occurred at week 3 (mean 1269 μg/g bone) and the methotrexate peak at week 1 (mean 862.76 μg/g bone).,Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168347/),[μg] / [g],862.76,201612,DB00563,Methotrexate
,28168347,peak,"Plasma drug levels were found 72 h after surgery, with a peak at 24 h for cisplatin (mean 0.23 μmol/L) and at 30 min for methotrexate (mean 0.92 μmol/L).",Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168347/),[μM] / [l],0.23,201613,DB00563,Methotrexate
,28168347,peak,"Plasma drug levels were found 72 h after surgery, with a peak at 24 h for cisplatin (mean 0.23 μmol/L) and at 30 min for methotrexate (mean 0.92 μmol/L).",Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168347/),[μM] / [l],0.92,201614,DB00563,Methotrexate
,3409236,AUC,"In (a) while the mean AUC for MTX (15815 +/- 1317 microMmin) with mAMSA (+mAMSA) remained essentially unchanged relative to that without mAMSA (-mAMSA) at the same dose (14832 +/- 5151 microMmin), the mean AUC of the metabolite 7-hydroxymethotrexate (7-OH MTX) decreased from 9338 +/- 3057 (n = 6, -mAMSA) to 5794 +/- 1371 microMmin (n = 6, +mAMSA).",Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),μMmin,15815,201798,DB00563,Methotrexate
,3409236,AUC,"In (a) while the mean AUC for MTX (15815 +/- 1317 microMmin) with mAMSA (+mAMSA) remained essentially unchanged relative to that without mAMSA (-mAMSA) at the same dose (14832 +/- 5151 microMmin), the mean AUC of the metabolite 7-hydroxymethotrexate (7-OH MTX) decreased from 9338 +/- 3057 (n = 6, -mAMSA) to 5794 +/- 1371 microMmin (n = 6, +mAMSA).",Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),μMmin,14832,201799,DB00563,Methotrexate
,3409236,AUC,"In (a) while the mean AUC for MTX (15815 +/- 1317 microMmin) with mAMSA (+mAMSA) remained essentially unchanged relative to that without mAMSA (-mAMSA) at the same dose (14832 +/- 5151 microMmin), the mean AUC of the metabolite 7-hydroxymethotrexate (7-OH MTX) decreased from 9338 +/- 3057 (n = 6, -mAMSA) to 5794 +/- 1371 microMmin (n = 6, +mAMSA).",Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),μMmin,9338,201800,DB00563,Methotrexate
,3409236,AUC,"In (a) while the mean AUC for MTX (15815 +/- 1317 microMmin) with mAMSA (+mAMSA) remained essentially unchanged relative to that without mAMSA (-mAMSA) at the same dose (14832 +/- 5151 microMmin), the mean AUC of the metabolite 7-hydroxymethotrexate (7-OH MTX) decreased from 9338 +/- 3057 (n = 6, -mAMSA) to 5794 +/- 1371 microMmin (n = 6, +mAMSA).",Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),μMmin,5794,201801,DB00563,Methotrexate
,3409236,fractional rate conversion,The fractional rate conversion of MTX to this metabolite (fmi) also decreased from 0.60 +/- 0.19 (n = 6) to 0.40 +/- 0.10 (n = 6) (P less than 0.05).,Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),,0.60,201802,DB00563,Methotrexate
,3409236,fractional rate conversion,The fractional rate conversion of MTX to this metabolite (fmi) also decreased from 0.60 +/- 0.19 (n = 6) to 0.40 +/- 0.10 (n = 6) (P less than 0.05).,Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),,0.40,201803,DB00563,Methotrexate
,7981428,area under the plasma concentration-time curve (AUC,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[min·μg] / [ml],639,203006,DB00563,Methotrexate
,7981428,area under the plasma concentration-time curve (AUC,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[min·μg] / [ml],913,203007,DB00563,Methotrexate
,7981428,terminal half-life (t1/2,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),min,48.8,203008,DB00563,Methotrexate
,7981428,terminal half-life (t1/2,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),min,397,203009,DB00563,Methotrexate
,7981428,mean residence time (MRT,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),min,8.40,203010,DB00563,Methotrexate
,7981428,mean residence time (MRT,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),min,325,203011,DB00563,Methotrexate
,7981428,apparent volume of distribution at steady state (Vss,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[ml] / [kg],98.1,203012,DB00563,Methotrexate
,7981428,apparent volume of distribution at steady state (Vss,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[ml] / [kg],2800,203013,DB00563,Methotrexate
,7981428,total body clearance (CL,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[ml] / [kg·min],12.5,203014,DB00563,Methotrexate
,7981428,total body clearance (CL,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[ml] / [kg·min],8.76,203015,DB00563,Methotrexate
,7981428,renal clearance (CLR,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[ml] / [kg·min],4.49,203016,DB00563,Methotrexate
,7981428,renal clearance (CLR,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[ml] / [kg·min],2.78,203017,DB00563,Methotrexate
,7981428,non-renal clearance (CLNR,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[ml] / [kg·min],7.50,203018,DB00563,Methotrexate
,7981428,non-renal clearance (CLNR,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),[ml] / [kg·min],5.99,203019,DB00563,Methotrexate
,7981428,amount of MTX excreted in urine (Xu,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),μg,808,203020,DB00563,Methotrexate
,7981428,amount of MTX excreted in urine (Xu,"After i.v. infusion in 1 min, the plasma concentration of MTX (Cp), the area under the plasma concentration-time curve (AUC, 639 versus 913 micrograms min mL-1), the terminal half-life (t1/2, 48.8 versus 397 min), the mean residence time (MRT, 8.40 versus 325 min), and the apparent volume of distribution at steady state (Vss, 98.1 versus 2800 mL kg-1) were significantly higher; however, the total body clearance (CL, 12.5 versus 8.76 mL min-1 kg-1), renal clearance (CLR, 4.49 versus 2.78 mL min-1 kg-1), non-renal clearance (CLNR, 7.50 versus 5.99 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 808 versus 685 micrograms, p < 0.0948) were significantly lower from treatment II than from treatment I.",The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981428/),μg,685,203021,DB00563,Methotrexate
,15496641,clearance (CL,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.072,203962,DB00563,Methotrexate
,15496641,volume of distribution in the central compartment (V(c),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),l,5.97,203963,DB00563,Methotrexate
,15496641,volume of distribution in the peripheral compartment (V(p),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),l,2.05,203964,DB00563,Methotrexate
,15496641,intercompartment clearance (Q,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.0645,203965,DB00563,Methotrexate
,15496641,first-order absorption rate constant (k(a),"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[1] / [h],0.0282,203966,DB00563,Methotrexate
,15496641,absolute bioavailability,"The following pharmacokinetic parameters (typical value +/- standard error) were estimated: clearance (CL: 0.072 +/- 0.005 L/h), volume of distribution in the central compartment (V(c): 5.97 +/- 0.45 L), volume of distribution in the peripheral compartment (V(p): 2.05 +/- 0.32 L), intercompartment clearance (Q: 0.0645 +/- 0.0093 L/h), first-order absorption rate constant (k(a): 0.0282 +/- 0.0039 1/h), and absolute bioavailability for subcutaneous administration (F: 0.626 +/- 0.056).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),,0.626,203967,DB00563,Methotrexate
,15496641,clearance,"Based on the bioequivalence criteria, the Bayesian-estimated clearance for patients receiving etanercept alone (mean: 0.070 L/h) was comparable to that for patients receiving a combination of etanercept and methotrexate (mean = 0.066 L/h).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.070,203968,DB00563,Methotrexate
,15496641,clearance,"Based on the bioequivalence criteria, the Bayesian-estimated clearance for patients receiving etanercept alone (mean: 0.070 L/h) was comparable to that for patients receiving a combination of etanercept and methotrexate (mean = 0.066 L/h).",Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496641/),[l] / [h],0.066,203969,DB00563,Methotrexate
,10872645,peak levels,"Ventricular cerebrospinal fluid-methotrexate peak levels after blood-brain barrier disruption of the vertebral and the internal carotid arteries territories were 19.3 +/- 2.9 and 8.5 +/- 0.7 micromol/L (P < .001), and the area under the curve from time 0 to infinity was 178.0 +/- 21.3 and 110.0 +/- 12.4 [micromol/L x h, respectively (P < .01).",Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872645/),[μM] / [l],19.3,204431,DB00563,Methotrexate
,10872645,peak levels,"Ventricular cerebrospinal fluid-methotrexate peak levels after blood-brain barrier disruption of the vertebral and the internal carotid arteries territories were 19.3 +/- 2.9 and 8.5 +/- 0.7 micromol/L (P < .001), and the area under the curve from time 0 to infinity was 178.0 +/- 21.3 and 110.0 +/- 12.4 [micromol/L x h, respectively (P < .01).",Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872645/),[μM] / [l],8.5,204432,DB00563,Methotrexate
,10872645,area under the curve from time 0 to infinity,"Ventricular cerebrospinal fluid-methotrexate peak levels after blood-brain barrier disruption of the vertebral and the internal carotid arteries territories were 19.3 +/- 2.9 and 8.5 +/- 0.7 micromol/L (P < .001), and the area under the curve from time 0 to infinity was 178.0 +/- 21.3 and 110.0 +/- 12.4 [micromol/L x h, respectively (P < .01).",Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872645/),[μM] / [h·l],178.0,204433,DB00563,Methotrexate
,10872645,area under the curve from time 0 to infinity,"Ventricular cerebrospinal fluid-methotrexate peak levels after blood-brain barrier disruption of the vertebral and the internal carotid arteries territories were 19.3 +/- 2.9 and 8.5 +/- 0.7 micromol/L (P < .001), and the area under the curve from time 0 to infinity was 178.0 +/- 21.3 and 110.0 +/- 12.4 [micromol/L x h, respectively (P < .01).",Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872645/),[μM] / [h·l],110.0,204434,DB00563,Methotrexate
,10872645,serum peak level,"After intra-arterial infusion was performed without disruption, the serum peak level was higher than that achieved by intravenous treatment (518.2 +/- 67.7 versus 180.6 +/- 31.8 micromol/L; P < .001).",Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872645/),[μM] / [l],518.2,204435,DB00563,Methotrexate
,10872645,serum peak level,"After intra-arterial infusion was performed without disruption, the serum peak level was higher than that achieved by intravenous treatment (518.2 +/- 67.7 versus 180.6 +/- 31.8 micromol/L; P < .001).",Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872645/),[μM] / [l],180.6,204436,DB00563,Methotrexate
,27542957,time to MTX clearance,"Hypoalbuminemia was associated with a significantly longer time to MTX clearance (median 96 vs. 72 h, p = 0.004).",Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27542957/),h,96,206005,DB00563,Methotrexate
,27542957,time to MTX clearance,"Hypoalbuminemia was associated with a significantly longer time to MTX clearance (median 96 vs. 72 h, p = 0.004).",Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27542957/),h,72,206006,DB00563,Methotrexate
,3770040,end-of-infusion concentration,The average end-of-infusion concentration varied from 8 X 10(-7) M for nontoxic patients to 1.45 and 3.12 10(-6) M for moderately and severely toxic patients respectively.,Altered pharmacokinetics and clinical consequences of low dose methotrexate plus cisplatin in the treatment of advanced head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770040/),M,8 X 10(-7),207305,DB00563,Methotrexate
,3770040,end-of-infusion concentration,The average end-of-infusion concentration varied from 8 X 10(-7) M for nontoxic patients to 1.45 and 3.12 10(-6) M for moderately and severely toxic patients respectively.,Altered pharmacokinetics and clinical consequences of low dose methotrexate plus cisplatin in the treatment of advanced head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770040/),M,1.45,207306,DB00563,Methotrexate
,3770040,end-of-infusion concentration,The average end-of-infusion concentration varied from 8 X 10(-7) M for nontoxic patients to 1.45 and 3.12 10(-6) M for moderately and severely toxic patients respectively.,Altered pharmacokinetics and clinical consequences of low dose methotrexate plus cisplatin in the treatment of advanced head and neck cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770040/),M,3.12,207307,DB00563,Methotrexate
,9552066,Peak methotrexate concentrations,"Peak methotrexate concentrations ranged from 3.7 to 55 micromol/L (mean, 17.1 micromol/L) in CSF and 178 to 1,700 micromol/L (mean, 779 micromol/L) in serum.",High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),[μM] / [l],17.1,208573,DB00563,Methotrexate
,9552066,Peak methotrexate concentrations,"Peak methotrexate concentrations ranged from 3.7 to 55 micromol/L (mean, 17.1 micromol/L) in CSF and 178 to 1,700 micromol/L (mean, 779 micromol/L) in serum.",High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),[μM] / [l],"178 to 1,700",208574,DB00563,Methotrexate
,9552066,Peak methotrexate concentrations,"Peak methotrexate concentrations ranged from 3.7 to 55 micromol/L (mean, 17.1 micromol/L) in CSF and 178 to 1,700 micromol/L (mean, 779 micromol/L) in serum.",High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),[μM] / [l],779,208575,DB00563,Methotrexate
,9552066,survival,Median survival in the HD i.v. MTX group was 13.8 months versus 2.3 months in the i.t. MTX group (P = .003).,High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),month,13.8,208576,DB00563,Methotrexate
,9552066,survival,Median survival in the HD i.v. MTX group was 13.8 months versus 2.3 months in the i.t. MTX group (P = .003).,High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552066/),month,2.3,208577,DB00563,Methotrexate
,12207634,steady-state total plasma clearance,"The steady-state total plasma clearance of MTX ranged from 5.0 to 18.2 l h(-1) and was proportional to the renal clearance (r2=0.45, P<0.001) which accounted for 65+/-20% of the former.",Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207634/),[l] / [h],5.0 to 18.2,209483,DB00563,Methotrexate
> or =,12207634,"AUC(24,36 h)","Thirteen of 14 subjects with AUC(24,36 h)> or =700 nmol l(-1) h responded to pharmacotherapy.",Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207634/),[h·nM] / [l],700,209484,DB00563,Methotrexate
<,12207634,"AUC(24,36 h)","Conversely, only 4 out of 10 subjects with AUC(24,36 h)<700 nmol l-1 h were responders (P<0.01, Fisher's exact test).",Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207634/),[h·nM] / [l],700,209485,DB00563,Methotrexate
,12207634,steady state AUC(MTX),The results of this study suggest that a steady state AUC(MTX) values of 700 nmol l(-1)h and higher are associated with a significantly better success rate of antipsoriatic therapy than lower values.,Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207634/),[nM] / [l],700,209486,DB00563,Methotrexate
,2952262,clearance,"Total TMTX clearance was 30.4 +/- 7.6 (SD) ml/min/m2, renal clearance 7.80 +/- 3.9 ml/min/m2, nonrenal clearance 23.2 +/- 7.1 ml/min/m2, volume of distribution 32.8 +/- 16.6 liters/m2, and terminal half-life 13.4 +/- 7.0 h.",Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2952262/),[ml] / [m2·min],30.4,209690,DB00563,Methotrexate
,2952262,renal clearance,"Total TMTX clearance was 30.4 +/- 7.6 (SD) ml/min/m2, renal clearance 7.80 +/- 3.9 ml/min/m2, nonrenal clearance 23.2 +/- 7.1 ml/min/m2, volume of distribution 32.8 +/- 16.6 liters/m2, and terminal half-life 13.4 +/- 7.0 h.",Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2952262/),[ml] / [m2·min],7.80,209691,DB00563,Methotrexate
,2952262,nonrenal clearance,"Total TMTX clearance was 30.4 +/- 7.6 (SD) ml/min/m2, renal clearance 7.80 +/- 3.9 ml/min/m2, nonrenal clearance 23.2 +/- 7.1 ml/min/m2, volume of distribution 32.8 +/- 16.6 liters/m2, and terminal half-life 13.4 +/- 7.0 h.",Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2952262/),[ml] / [m2·min],23.2,209692,DB00563,Methotrexate
,2952262,volume of distribution,"Total TMTX clearance was 30.4 +/- 7.6 (SD) ml/min/m2, renal clearance 7.80 +/- 3.9 ml/min/m2, nonrenal clearance 23.2 +/- 7.1 ml/min/m2, volume of distribution 32.8 +/- 16.6 liters/m2, and terminal half-life 13.4 +/- 7.0 h.",Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2952262/),[l] / [m2],32.8,209693,DB00563,Methotrexate
,2952262,terminal half-life,"Total TMTX clearance was 30.4 +/- 7.6 (SD) ml/min/m2, renal clearance 7.80 +/- 3.9 ml/min/m2, nonrenal clearance 23.2 +/- 7.1 ml/min/m2, volume of distribution 32.8 +/- 16.6 liters/m2, and terminal half-life 13.4 +/- 7.0 h.",Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2952262/),h,13.4,209694,DB00563,Methotrexate
,24708204,Serious adverse event frequencies,Serious adverse event frequencies (5.1% vs. 3.4%) were similar with both formulations.,"Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24708204/),%,5.1,210418,DB00563,Methotrexate
,24708204,Serious adverse event frequencies,Serious adverse event frequencies (5.1% vs. 3.4%) were similar with both formulations.,"Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24708204/),%,3.4,210419,DB00563,Methotrexate
,21084039,apparent clearance (CL/F),"The population typical mean (percent relative standard error (%RSE)) values for apparent clearance (CL/F), apparent volume of distribution (V/F), and absorption rate constant (ka) obtained from the final covariate model were 0.465 l × day-1 (5.1%), 14.3 l (4.4%), and 0.427 day-1 (3.9%), respectively.",Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084039/),[l] / [d],0.465,211017,DB00563,Methotrexate
,21084039,apparent volume of distribution (V/F),"The population typical mean (percent relative standard error (%RSE)) values for apparent clearance (CL/F), apparent volume of distribution (V/F), and absorption rate constant (ka) obtained from the final covariate model were 0.465 l × day-1 (5.1%), 14.3 l (4.4%), and 0.427 day-1 (3.9%), respectively.",Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084039/),l,14.3,211018,DB00563,Methotrexate
,21084039,absorption rate constant (ka),"The population typical mean (percent relative standard error (%RSE)) values for apparent clearance (CL/F), apparent volume of distribution (V/F), and absorption rate constant (ka) obtained from the final covariate model were 0.465 l × day-1 (5.1%), 14.3 l (4.4%), and 0.427 day-1 (3.9%), respectively.",Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084039/),1/[d],0.427,211019,DB00563,Methotrexate
,2715941,rate,The results indicate the MTX is cleared from the plasma at a rate of 84.6 mL/min/m2.,Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),[ml] / [m2·min],84.6,211640,DB00563,Methotrexate
,2715941,terminal half-life,The terminal half-life was approximately 6 h.,Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),h,6,211641,DB00563,Methotrexate
,2715941,volumes of distribution at steady state,"The volumes of distribution at steady state and for the central compartment were 22.2 and 13.5 L/m2, respectively.",Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),[l] / [m2],22.2,211642,DB00563,Methotrexate
,2715941,the,"The volumes of distribution at steady state and for the central compartment were 22.2 and 13.5 L/m2, respectively.",Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),[l] / [m2],22.2,211643,DB00563,Methotrexate
,2715941,central compartment,"The volumes of distribution at steady state and for the central compartment were 22.2 and 13.5 L/m2, respectively.",Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),[l] / [m2],13.5,211644,DB00563,Methotrexate
,2715941,mean residence time,"The mean residence time in the body, in the systemic circulation, and in the periphery were estimated to be 4.7, 3.0, and 1.7 h, respectively, with a peripheral single-pass mean transit time of 6.0 h and an intrinsic mean residence time in the periphery of 7.9 h.",Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),h,4.7,211645,DB00563,Methotrexate
,2715941,mean residence time,"The mean residence time in the body, in the systemic circulation, and in the periphery were estimated to be 4.7, 3.0, and 1.7 h, respectively, with a peripheral single-pass mean transit time of 6.0 h and an intrinsic mean residence time in the periphery of 7.9 h.",Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),h,3.0,211646,DB00563,Methotrexate
,2715941,mean residence time,"The mean residence time in the body, in the systemic circulation, and in the periphery were estimated to be 4.7, 3.0, and 1.7 h, respectively, with a peripheral single-pass mean transit time of 6.0 h and an intrinsic mean residence time in the periphery of 7.9 h.",Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),h,1.7,211647,DB00563,Methotrexate
,2715941,mean transit time,"The mean residence time in the body, in the systemic circulation, and in the periphery were estimated to be 4.7, 3.0, and 1.7 h, respectively, with a peripheral single-pass mean transit time of 6.0 h and an intrinsic mean residence time in the periphery of 7.9 h.",Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),h,6.0,211648,DB00563,Methotrexate
,2715941,intrinsic mean residence time,"The mean residence time in the body, in the systemic circulation, and in the periphery were estimated to be 4.7, 3.0, and 1.7 h, respectively, with a peripheral single-pass mean transit time of 6.0 h and an intrinsic mean residence time in the periphery of 7.9 h.",Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),h,7.9,211649,DB00563,Methotrexate
,2715941,mean absorption time,The mean absorption time was 1.2 h and the oral bioavailability was 0.70.,Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),h,1.2,211650,DB00563,Methotrexate
,2715941,oral bioavailability,The mean absorption time was 1.2 h and the oral bioavailability was 0.70.,Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715941/),,0.70,211651,DB00563,Methotrexate
,7944622,AUCs,The interindividual variability of the AUCs showed a more than five fold range from 77 to 471 min x mumol/l.,Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944622/),[min·μM] / [l],77 to 471,211817,DB00563,Methotrexate
,7944622,AUCs,"In contrast, the intraindividual differences of AUCs between the two visits ranged from 3 to 100 min x mumol/l, reflecting a 3-30% change in nine of 10 patients.",Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944622/),[min·μM] / [l],3 to 100,211818,DB00563,Methotrexate
,18315911,CL,"The final model in this study was: CL=7.0 x [1 + 0.0218 x (WT-31.1)] x EXP (eta(CL)) (L/h); V=32.8 x [1 + 0.0288 x (WT-31.1)] x EXP (eta(V)) (L), where 31.1 (kg) was the average body weight of the population.",[Population pharmacokinetics of high-dose methotrexate administered in 329 children with acute lymphoblastic leukemia]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315911/),[l] / [h],7,212436,DB00563,Methotrexate
,3793260,beta,"The data for MX conformed to a 2-compartment model with overall mean +/- SD for beta, k12, k21, and k13 of 0.225 +/- 0.196, 1.33 +/- 1.44, 0.954 +/- 1.06, and 0.994 +/- 1.28 hr-1, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),1/[h],0.225,213139,DB00563,Methotrexate
,3793260,k12,"The data for MX conformed to a 2-compartment model with overall mean +/- SD for beta, k12, k21, and k13 of 0.225 +/- 0.196, 1.33 +/- 1.44, 0.954 +/- 1.06, and 0.994 +/- 1.28 hr-1, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),1/[h],1.33,213140,DB00563,Methotrexate
,3793260,k13,"The data for MX conformed to a 2-compartment model with overall mean +/- SD for beta, k12, k21, and k13 of 0.225 +/- 0.196, 1.33 +/- 1.44, 0.954 +/- 1.06, and 0.994 +/- 1.28 hr-1, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),1/[h],0.994,213141,DB00563,Methotrexate
,3793260,total body clearance,"The total body clearance, Vc, and V-beta were 0.123 +/- 0.037 l/hr.kg, 0.15 +/- 0.122 l/kg, and 0.965 +/- 0.875 l/kg, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),[l] / [h·kg],0.123,213142,DB00563,Methotrexate
,3793260,Vc,"The total body clearance, Vc, and V-beta were 0.123 +/- 0.037 l/hr.kg, 0.15 +/- 0.122 l/kg, and 0.965 +/- 0.875 l/kg, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),[l] / [kg],0.15,213143,DB00563,Methotrexate
,3793260,V-beta,"The total body clearance, Vc, and V-beta were 0.123 +/- 0.037 l/hr.kg, 0.15 +/- 0.122 l/kg, and 0.965 +/- 0.875 l/kg, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),[l] / [kg],0.965,213144,DB00563,Methotrexate
,3793260,maximum observed concentrations,"With regimens A, B and C, the maximum observed concentrations of MXOH occurred at 9.2, 11.5, and 9.2 hr and the mean +/- SD values of these concentrations were 15.02 +/- 14, 18.96 +/- 13.63, 14.91 +/- 9.95 microM, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),,11,213145,DB00563,Methotrexate
,3793260,maximum observed concentrations,"With regimens A, B and C, the maximum observed concentrations of MXOH occurred at 9.2, 11.5, and 9.2 hr and the mean +/- SD values of these concentrations were 15.02 +/- 14, 18.96 +/- 13.63, 14.91 +/- 9.95 microM, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),,9,213146,DB00563,Methotrexate
,3793260,maximum observed concentrations,"With regimens A, B and C, the maximum observed concentrations of MXOH occurred at 9.2, 11.5, and 9.2 hr and the mean +/- SD values of these concentrations were 15.02 +/- 14, 18.96 +/- 13.63, 14.91 +/- 9.95 microM, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),μM,15.02,213147,DB00563,Methotrexate
,3793260,maximum observed concentrations,"With regimens A, B and C, the maximum observed concentrations of MXOH occurred at 9.2, 11.5, and 9.2 hr and the mean +/- SD values of these concentrations were 15.02 +/- 14, 18.96 +/- 13.63, 14.91 +/- 9.95 microM, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),μM,18.96,213148,DB00563,Methotrexate
,3793260,maximum observed concentrations,"With regimens A, B and C, the maximum observed concentrations of MXOH occurred at 9.2, 11.5, and 9.2 hr and the mean +/- SD values of these concentrations were 15.02 +/- 14, 18.96 +/- 13.63, 14.91 +/- 9.95 microM, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),μM,14.91,213149,DB00563,Methotrexate
,3793260,concentrations,"With regimens A, B and C, the maximum observed concentrations of MXOH occurred at 9.2, 11.5, and 9.2 hr and the mean +/- SD values of these concentrations were 15.02 +/- 14, 18.96 +/- 13.63, 14.91 +/- 9.95 microM, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),μM,18.96,213150,DB00563,Methotrexate
,3793260,concentrations,"With regimens A, B and C, the maximum observed concentrations of MXOH occurred at 9.2, 11.5, and 9.2 hr and the mean +/- SD values of these concentrations were 15.02 +/- 14, 18.96 +/- 13.63, 14.91 +/- 9.95 microM, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),μM,14.91,213151,DB00563,Methotrexate
,3793260,maximum observed concentrations,"With regimens A and C, maximum observed concentrations of MX equal to 231 +/- 67.1 and 204 +/- 69.5 microM occurred at 0.5 and 6 hr, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),μM,231,213152,DB00563,Methotrexate
,3793260,maximum observed concentrations,"With regimens A and C, maximum observed concentrations of MX equal to 231 +/- 67.1 and 204 +/- 69.5 microM occurred at 0.5 and 6 hr, respectively.",Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),μM,204,213153,DB00563,Methotrexate
,3793260,steady-state MX concentration,Only with regimen B was a steady-state MX concentration of 179 microM achieved throughout infusion; this regimen is therefore highly advantageous for high-dose MX treatment.,Pharmacokinetics of methotrexate and its 7-OH metabolite in cancer patients treated with different high-methotrexate dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793260/),μM,179,213154,DB00563,Methotrexate
,15073038,CR rate,The CR rate for 54 patients with active disease was 85%.,"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),%,85,213392,DB00563,Methotrexate
,15073038,clearance,"Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters.","Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),[ml] / [m2·min],109,213393,DB00563,Methotrexate
,15073038,area-under-the-plasma-concentration-versus-time-curve,"Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters.","Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),μmol-min,4871,213394,DB00563,Methotrexate
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB00563,Methotrexate
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB00563,Methotrexate
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB00563,Methotrexate
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB00563,Methotrexate
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB00563,Methotrexate
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB00563,Methotrexate
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB00563,Methotrexate
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB00563,Methotrexate
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB00563,Methotrexate
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB00563,Methotrexate
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB00563,Methotrexate
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB00563,Methotrexate
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB00563,Methotrexate
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB00563,Methotrexate
,17136402,Steady-state clearance,Steady-state clearance (mean+/-standard deviation) for infants aged 0-6 months was 89+/-32 ml/min/m2 compared to 111+/-40 for infants aged 7-12 months (P=0.030).,Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17136402/),[ml] / [m2·min],89,214766,DB00563,Methotrexate
,17136402,Steady-state clearance,Steady-state clearance (mean+/-standard deviation) for infants aged 0-6 months was 89+/-32 ml/min/m2 compared to 111+/-40 for infants aged 7-12 months (P=0.030).,Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17136402/),,111,214767,DB00563,Methotrexate
,17136402,steady-state clearance,In the subgroup of infants aged 0-3 months the mean steady-state clearance was 84+/-30 ml/min/m2 (P=0.026 vs. the 7-12-month group).,Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17136402/),[ml] / [m2·min],84,214768,DB00563,Methotrexate
,7110914,bioavailability,The bioavailability of methotrexate 10 mg tablets has been determined to be 62 +/- 16%.,Bioavailability of methotrexate tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110914/),%,62,214825,DB00563,Methotrexate
,7110914,maximum plasma concentration,After administration of a dose of 30 mg/m2 a maximum plasma concentration of ca. 20.10(-7) mole/l was found after ca. 1.7 h.,Bioavailability of methotrexate tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110914/),[mole] / [l],20.10(-7),214826,DB00563,Methotrexate
,7110914,plasma half-life,The methotrexate plasma half-life was 2.4 h.,Bioavailability of methotrexate tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110914/),h,2.4,214827,DB00563,Methotrexate
,8866922,AUC,"3. There was a statistically, but not clinically, significant decrease in methotrexate AUC (1307 +/- 389 vs 1212 +/- 394 micrograms l-1 h) in the presence of flucloxacillin.",Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866922/),[h·μg] / [l],1307,215450,DB00563,Methotrexate
,8866922,AUC,"3. There was a statistically, but not clinically, significant decrease in methotrexate AUC (1307 +/- 389 vs 1212 +/- 394 micrograms l-1 h) in the presence of flucloxacillin.",Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866922/),[h·μg] / [l],1212,215451,DB00563,Methotrexate
,8866922,clearance,The plasma concentration profiles were best described by a two-compartment model with a mean clearance of 11.9 (+/- 1.7) l h-1 and an initial volume of distribution of 31.2 (+/- 2.6) l.,Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866922/),[l] / [h],11.9,215452,DB00563,Methotrexate
,8866922,volume of distribution,The plasma concentration profiles were best described by a two-compartment model with a mean clearance of 11.9 (+/- 1.7) l h-1 and an initial volume of distribution of 31.2 (+/- 2.6) l.,Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866922/),l,31.2,215453,DB00563,Methotrexate
,3864520,steady-state levels (Css),This approach combined with therapeutic drug monitoring was found to have good performance over a large scale of predicted steady-state levels (Css) (10(-5) to 10(-4) M over 24 to 36 h) corresponding to 17 to 650 mg/h deliveries (root mean squared error : rmse (precision) = 1.54 X 10(-5) M (21.4%) and mean error : me (bias) = 0.043 X 10(-5) M (NS)).,Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864520/),M,10(-5),215667,DB00563,Methotrexate
,3864520,me,However a significative (p less than 0.05) but rather low over-estimation of dosage (me = 7.38 X 10(-5) M (14.8%)) associated to a decrease in the prediction precision (rmse = 13.3 X 10(-5) M (26.6%)) occurred in 5 X 10(-4) M predicted Css over 8 h (970 to 1970 mg/h deliveries).,Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864520/),,7.38,215668,DB00563,Methotrexate
,3864520,rmse,However a significative (p less than 0.05) but rather low over-estimation of dosage (me = 7.38 X 10(-5) M (14.8%)) associated to a decrease in the prediction precision (rmse = 13.3 X 10(-5) M (26.6%)) occurred in 5 X 10(-4) M predicted Css over 8 h (970 to 1970 mg/h deliveries).,Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3864520/),,13.3,215669,DB00563,Methotrexate
,3496173,flow rate,Separation of these compounds was achieved on a Waters Spherical C18 column at a flow rate of 0.8 ml.min-1.,Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),[ml] / [min],0.8,216015,DB00563,Methotrexate
,3496173,apparent half-life,"Mean apparent half-life values for folinic acid and its metabolite were 7.02 +/- 1.81 h and 3.90 +/- 0.86 respectively in the first protocol, 4.80 +/- 1.48 h and 4.74 +/- 1.47 h in the second protocol.",Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),h,7.02,216016,DB00563,Methotrexate
,3496173,apparent half-life,"Mean apparent half-life values for folinic acid and its metabolite were 7.02 +/- 1.81 h and 3.90 +/- 0.86 respectively in the first protocol, 4.80 +/- 1.48 h and 4.74 +/- 1.47 h in the second protocol.",Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),,3.90,216017,DB00563,Methotrexate
,3496173,apparent half-life,"Mean apparent half-life values for folinic acid and its metabolite were 7.02 +/- 1.81 h and 3.90 +/- 0.86 respectively in the first protocol, 4.80 +/- 1.48 h and 4.74 +/- 1.47 h in the second protocol.",Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),h,4.80,216018,DB00563,Methotrexate
,3496173,apparent half-life,"Mean apparent half-life values for folinic acid and its metabolite were 7.02 +/- 1.81 h and 3.90 +/- 0.86 respectively in the first protocol, 4.80 +/- 1.48 h and 4.74 +/- 1.47 h in the second protocol.",Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3496173/),h,4.74,216019,DB00563,Methotrexate
,9218084,Peak concentrations (Cmax),"Peak concentrations (Cmax) varied considerably, ranging from 0.25-0.87 micro M.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),μM,0.25-0.87,216295,DB00563,Methotrexate
,9218084,Cmax,"The mean Cmax values were similar in all patient groups (0.59 +/- 0.12, 0.69 +/- 0.16 and 0.54 +/- 0.18 micro M, P not significant) for Crohn's disease, ulcerative colitis and rheumatoid arthritis, respectively.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),μM,0.59,216296,DB00563,Methotrexate
,9218084,Cmax,"The mean Cmax values were similar in all patient groups (0.59 +/- 0.12, 0.69 +/- 0.16 and 0.54 +/- 0.18 micro M, P not significant) for Crohn's disease, ulcerative colitis and rheumatoid arthritis, respectively.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),μM,0.69,216297,DB00563,Methotrexate
,9218084,Cmax,"The mean Cmax values were similar in all patient groups (0.59 +/- 0.12, 0.69 +/- 0.16 and 0.54 +/- 0.18 micro M, P not significant) for Crohn's disease, ulcerative colitis and rheumatoid arthritis, respectively.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),μM,0.54,216298,DB00563,Methotrexate
,9218084,area under curve in 120 min (AUC0-120),"The mean area under curve in 120 min (AUC0-120) was also similar in all patient groups (32.9 + 11.3, 43.6 + 9.9 and 41.8 + 14.9 ng.min/mL, P not significant) for Crohn's disease, ulcerative colitis and rheumatoid arthritis, respectively.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),[min·ng] / [ml],32.9,216299,DB00563,Methotrexate
,9218084,area under curve in 120 min (AUC0-120),"The mean area under curve in 120 min (AUC0-120) was also similar in all patient groups (32.9 + 11.3, 43.6 + 9.9 and 41.8 + 14.9 ng.min/mL, P not significant) for Crohn's disease, ulcerative colitis and rheumatoid arthritis, respectively.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),[min·ng] / [ml],43.6,216300,DB00563,Methotrexate
,9218084,area under curve in 120 min (AUC0-120),"The mean area under curve in 120 min (AUC0-120) was also similar in all patient groups (32.9 + 11.3, 43.6 + 9.9 and 41.8 + 14.9 ng.min/mL, P not significant) for Crohn's disease, ulcerative colitis and rheumatoid arthritis, respectively.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),[min·ng] / [ml],41.8,216301,DB00563,Methotrexate
,9218084,"time to reach Cmax, (tmax)","The mean time to reach Cmax, (tmax), varied between patient groups (84, 112 and 95 min, respectively, with a significant difference, P < 0.02, between the Crohn's disease and ulcerative colitis groups.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),min,84,216302,DB00563,Methotrexate
,9218084,"time to reach Cmax, (tmax)","The mean time to reach Cmax, (tmax), varied between patient groups (84, 112 and 95 min, respectively, with a significant difference, P < 0.02, between the Crohn's disease and ulcerative colitis groups.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),min,112,216303,DB00563,Methotrexate
,9218084,"time to reach Cmax, (tmax)","The mean time to reach Cmax, (tmax), varied between patient groups (84, 112 and 95 min, respectively, with a significant difference, P < 0.02, between the Crohn's disease and ulcerative colitis groups.",The absorption of low-dose methotrexate in patients with inflammatory bowel disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9218084/),min,95,216304,DB00563,Methotrexate
,29893406,absolute bioavailability,The absolute bioavailability was 93% for SC injection and 30% for the oral route.,Pharmacokinetics of low-dose methotrexate in healthy beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29893406/),%,93,217095,DB00563,Methotrexate
,29893406,absolute bioavailability,The absolute bioavailability was 93% for SC injection and 30% for the oral route.,Pharmacokinetics of low-dose methotrexate in healthy beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29893406/),%,30,217096,DB00563,Methotrexate
,7018678,alpha-phase half-life,"The alpha-phase half-life of LV was about 15 mins, but LV was readily detectable by the assay for 3-4 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),min,15,218709,DB00563,Methotrexate
,7018678,apparent half-life,"The level of mTHFA increased for at least 60 mins, being equimolar with LV by 30 mins, and then decreased slowly with an apparent half-life of 2-3 hrs.",Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7018678/),h,2-3,218710,DB00563,Methotrexate
,8896046,total area under the plasma concentration-time curves,"After 1-min iv infusion of MTX, the plasma concentrations of MTX (except at 1 min) and the total area under the plasma concentration-time curves of MTX (542 versus 297 micrograms min/ml) increased significantly in the U-ARF rats when compared to those in the control rats.",Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896046/),[min·μg] / [ml],542,219016,DB00563,Methotrexate
,8896046,total area under the plasma concentration-time curves,"After 1-min iv infusion of MTX, the plasma concentrations of MTX (except at 1 min) and the total area under the plasma concentration-time curves of MTX (542 versus 297 micrograms min/ml) increased significantly in the U-ARF rats when compared to those in the control rats.",Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896046/),[min·μg] / [ml],297,219017,DB00563,Methotrexate
,8896046,total body clearance (CL),This was due to the significantly slower in total body clearance (CL) of MTX (15.2 versus 27.5 ml/min/kg) in the U-ARF rats than that in the control rats.,Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896046/),[ml] / [kg·min],15.2,219018,DB00563,Methotrexate
,8896046,total body clearance (CL),This was due to the significantly slower in total body clearance (CL) of MTX (15.2 versus 27.5 ml/min/kg) in the U-ARF rats than that in the control rats.,Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896046/),[ml] / [kg·min],27.5,219019,DB00563,Methotrexate
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),%,38,219180,DB00563,Methotrexate
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),,13,219181,DB00563,Methotrexate
higher,739791,concentration ratios lymph,"MTX concentration ratios lymph/plasma were higher than 1.0 (1.0-2.8) in 4 patients, and lower than 1.0 (0.2-0.8) in 2 patients.",Distribution of methotrexate between plasma and peripheral lymph in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/739791/),,1.0,219645,DB00563,Methotrexate
lower,739791,concentration ratios lymph,"MTX concentration ratios lymph/plasma were higher than 1.0 (1.0-2.8) in 4 patients, and lower than 1.0 (0.2-0.8) in 2 patients.",Distribution of methotrexate between plasma and peripheral lymph in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/739791/),,1.0,219646,DB00563,Methotrexate
above,739791,lymph/plasma MTX ratio,"The patients with a lymph/plasma MTX ratio above 1.0 will have high and favourable MTX concentrations for distribution to tumours in peripheral tissue, while in the patients with a low ratio conditions for distribution are less favourable.",Distribution of methotrexate between plasma and peripheral lymph in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/739791/),,1.0,219647,DB00563,Methotrexate
,26833462,terminal half-life,"The most common AEs were headache and nasopharyngitis; there were no injection-site reactions Linear pharmacokinetics of NNC0114-0005 were indicated (mean terminal half-life, 2 - 3 weeks).","Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26833462/),weeks,2 - 3,220080,DB00563,Methotrexate
,10606360,renal clearance,"The mean renal clearance of MTX alone, 7.98+/-2.18 l/h, was virtually unchanged by coadministration of celecoxib (7.94+/-1.61 l/h) or placebo (7.97+/-1.19 l/h).","Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606360/),[l] / [h],7.98,220587,DB00563,Methotrexate
,10606360,renal clearance,"The mean renal clearance of MTX alone, 7.98+/-2.18 l/h, was virtually unchanged by coadministration of celecoxib (7.94+/-1.61 l/h) or placebo (7.97+/-1.19 l/h).","Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606360/),[l] / [h],7.94,220588,DB00563,Methotrexate
,10606360,renal clearance,"The mean renal clearance of MTX alone, 7.98+/-2.18 l/h, was virtually unchanged by coadministration of celecoxib (7.94+/-1.61 l/h) or placebo (7.97+/-1.19 l/h).","Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606360/),[l] / [h],7.97,220589,DB00563,Methotrexate
,27222609,flow rate,"Chromatographic separation of the analytes was performed on the YMC pack ODS AM (150 mm × 4.6 mm, 5 µm) column under gradient conditions with methanol: 2.0 mM ammonium acetate buffer as the mobile phases at a flow rate of 1 mL/min.",Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27222609/),[ml] / [min],1,220894,DB00563,Methotrexate
,27222609,extraction recoveries,"Mean extraction recoveries for baricitinib, methotrexate, and IS of 86.8%, 89.4%, and 91.8% were consistent across low, medium, and high QC levels, respectively.",Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27222609/),%,86.8,220895,DB00563,Methotrexate
,27222609,extraction recoveries,"Mean extraction recoveries for baricitinib, methotrexate, and IS of 86.8%, 89.4%, and 91.8% were consistent across low, medium, and high QC levels, respectively.",Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27222609/),%,89.4,220896,DB00563,Methotrexate
,27222609,extraction recoveries,"Mean extraction recoveries for baricitinib, methotrexate, and IS of 86.8%, 89.4%, and 91.8% were consistent across low, medium, and high QC levels, respectively.",Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27222609/),%,91.8,220897,DB00563,Methotrexate
,28361455,entrapment efficiency,"MTX+ET-ALNE was characterized on the basis of particle size (410 ± 25.4 nm), PDI (0.160), and zeta potential (+38.6 ± 5.6 mV) and evaluated for pH (6.15), drug content (97.7 ± 2.17%), entrapment efficiency (76 ± 4.6%), in vitro release, and in vitro cytotoxicity.","Development of Albumin Coupled, Cholesterol Stabilized, Lipid Nanoemulsion of Methotrexate, and TNF-α Inhibitor for Improved In Vivo Efficacy Against Rheumatoid Arthritis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28361455/),%,76,220938,DB00563,Methotrexate
,22796246,clearance (CL),"Within the study population, the estimated mean MTX clearance (CL) was 7.08 L/h, whereas the mean central compartment volume (V(1)) of MTX distribution was 19.4 L.",ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796246/),[l] / [h],7.08,221041,DB00563,Methotrexate
,22796246,central compartment volume (V(1)),"Within the study population, the estimated mean MTX clearance (CL) was 7.08 L/h, whereas the mean central compartment volume (V(1)) of MTX distribution was 19.4 L.",ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796246/),l,19.4,221042,DB00563,Methotrexate
,421088,oral bioavailability,"Detailed pharmacokinetic analysis in five patients showed high oral bioavailability (mean +/- SE of mean 87.6 +/- 1.5%), indicating that with this regimen oral methotrexate was well absorbed and the first-pass effect low.",Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421088/),%,87.6,221192,DB00563,Methotrexate
,421088,peak plasma methotrexate concentrations,"Oral administration resulted in peak plasma methotrexate concentrations of 8.4 +/- 0.5 mumol/l (382 +/- 23 microgram/100 ml) and was almost as effective as intravenous administration, which achieved peak concentrations of 9.9 +/- 0.4 mumol/l (450 +/- 18 microgram/100 ml).",Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421088/),[μM] / [l],8.4,221193,DB00563,Methotrexate
,421088,peak plasma methotrexate concentrations,"Oral administration resulted in peak plasma methotrexate concentrations of 8.4 +/- 0.5 mumol/l (382 +/- 23 microgram/100 ml) and was almost as effective as intravenous administration, which achieved peak concentrations of 9.9 +/- 0.4 mumol/l (450 +/- 18 microgram/100 ml).",Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421088/),[μg] / [100·ml],382,221194,DB00563,Methotrexate
,421088,peak concentrations,"Oral administration resulted in peak plasma methotrexate concentrations of 8.4 +/- 0.5 mumol/l (382 +/- 23 microgram/100 ml) and was almost as effective as intravenous administration, which achieved peak concentrations of 9.9 +/- 0.4 mumol/l (450 +/- 18 microgram/100 ml).",Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421088/),[μM] / [l],9.9,221195,DB00563,Methotrexate
,421088,peak concentrations,"Oral administration resulted in peak plasma methotrexate concentrations of 8.4 +/- 0.5 mumol/l (382 +/- 23 microgram/100 ml) and was almost as effective as intravenous administration, which achieved peak concentrations of 9.9 +/- 0.4 mumol/l (450 +/- 18 microgram/100 ml).",Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421088/),[μg] / [100·ml],450,221196,DB00563,Methotrexate
,421088,disease-free interval,The disease-free interval in cases of adult sarcoma was 7.4 +/- 1.3 months and the relapse rate 29%.,Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421088/),month,7.4,221197,DB00563,Methotrexate
,30536638,terminal half-life,Model-estimated terminal half-life (9.2 days in children; 9.5 days in adults) and other PK parameters suggest that golimumab PK properties are generally comparable between children and adults with ulcerative colitis.,Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30536638/),d,9.2,221922,DB00563,Methotrexate
,30536638,terminal half-life,Model-estimated terminal half-life (9.2 days in children; 9.5 days in adults) and other PK parameters suggest that golimumab PK properties are generally comparable between children and adults with ulcerative colitis.,Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30536638/),d,9.5,221923,DB00563,Methotrexate
,6690631,terminal half-life,The terminal half-life in plasma (mean +/- SD) was 20.3 +/- 9.2 h.,Persistence of antifolate activity in skin of rats following systemic administration of methotrexate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690631/),h,20.3,224515,DB00563,Methotrexate
,21699456,AUC,"There was substantial inter-individual variability in MTX AUC (median: 795.5 µM*h/L, range 44.8-8326.44).",Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21699456/),[h·μM] / [l],795.5,224886,DB00563,Methotrexate
,20040335,clearance of central compartment (CL1),"The population pharmacokinetic parameters and 95% confidence interval (CI) were obtained as follows: The clearance of central compartment (CL1), apparent volume of distribution of central compartment (V1), the clearance between central and peripheral compartment (CL2), and apparent volume of distribution of peripheral compartment (V2) were 5.04 (3.93 - 6.15) l/min, 16.1 (12.5 - 19.7) l, 0.203 (0.102 - 0.304) l/min and 7.05 (3.86 - 10.20) l, respectively.",Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040335/),[l] / [min],5.04,225255,DB00563,Methotrexate
,20040335,apparent volume of distribution of central compartment (V1),"The population pharmacokinetic parameters and 95% confidence interval (CI) were obtained as follows: The clearance of central compartment (CL1), apparent volume of distribution of central compartment (V1), the clearance between central and peripheral compartment (CL2), and apparent volume of distribution of peripheral compartment (V2) were 5.04 (3.93 - 6.15) l/min, 16.1 (12.5 - 19.7) l, 0.203 (0.102 - 0.304) l/min and 7.05 (3.86 - 10.20) l, respectively.",Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040335/),l,16.1,225256,DB00563,Methotrexate
,20040335,clearance between central and peripheral compartment (CL2),"The population pharmacokinetic parameters and 95% confidence interval (CI) were obtained as follows: The clearance of central compartment (CL1), apparent volume of distribution of central compartment (V1), the clearance between central and peripheral compartment (CL2), and apparent volume of distribution of peripheral compartment (V2) were 5.04 (3.93 - 6.15) l/min, 16.1 (12.5 - 19.7) l, 0.203 (0.102 - 0.304) l/min and 7.05 (3.86 - 10.20) l, respectively.",Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040335/),l,16.1,225257,DB00563,Methotrexate
,20040335,apparent volume of distribution of peripheral compartment (V2),"The population pharmacokinetic parameters and 95% confidence interval (CI) were obtained as follows: The clearance of central compartment (CL1), apparent volume of distribution of central compartment (V1), the clearance between central and peripheral compartment (CL2), and apparent volume of distribution of peripheral compartment (V2) were 5.04 (3.93 - 6.15) l/min, 16.1 (12.5 - 19.7) l, 0.203 (0.102 - 0.304) l/min and 7.05 (3.86 - 10.20) l, respectively.",Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040335/),l,7.05,225258,DB00563,Methotrexate
,20040335,elimination half-life t1/2,"Moreover, some secondary pharmacokinetic parameters were estimated: the elimination half-life t1/2 was 2.34 h (CV = 36.7%), elimination constant k(e) was 0.33 h(-1) (CV = 33.2%), and the area under plasma concentration versus time curve AUC was 582.92 mg x h x l(-1) (CV = 55.9%).",Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040335/),h,2.34,225259,DB00563,Methotrexate
,20040335,elimination constant k(e),"Moreover, some secondary pharmacokinetic parameters were estimated: the elimination half-life t1/2 was 2.34 h (CV = 36.7%), elimination constant k(e) was 0.33 h(-1) (CV = 33.2%), and the area under plasma concentration versus time curve AUC was 582.92 mg x h x l(-1) (CV = 55.9%).",Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040335/),1/[h],0.33,225260,DB00563,Methotrexate
,20040335,area under plasma concentration versus time curve AUC,"Moreover, some secondary pharmacokinetic parameters were estimated: the elimination half-life t1/2 was 2.34 h (CV = 36.7%), elimination constant k(e) was 0.33 h(-1) (CV = 33.2%), and the area under plasma concentration versus time curve AUC was 582.92 mg x h x l(-1) (CV = 55.9%).",Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040335/),[h·mg] / [l],582.92,225261,DB00563,Methotrexate
,30932720,zeta potential,"The particle size, zeta potential and entrapment efficiency of the optimized nanoparticles were found to be 204.90 ± 64 nm, -11.58 ± 4.80 mV, and 88.33 ± 3.74%, respectively.",Design and development of bioinspired calcium phosphate nanoparticles of MTX: pharmacodynamic and pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30932720/),m,-,225656,DB00563,Methotrexate
,30932720,entrapment efficiency,"The particle size, zeta potential and entrapment efficiency of the optimized nanoparticles were found to be 204.90 ± 64 nm, -11.58 ± 4.80 mV, and 88.33 ± 3.74%, respectively.",Design and development of bioinspired calcium phosphate nanoparticles of MTX: pharmacodynamic and pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30932720/),m,11.58,225657,DB00563,Methotrexate
,30932720,entrapment efficiency,"The particle size, zeta potential and entrapment efficiency of the optimized nanoparticles were found to be 204.90 ± 64 nm, -11.58 ± 4.80 mV, and 88.33 ± 3.74%, respectively.",Design and development of bioinspired calcium phosphate nanoparticles of MTX: pharmacodynamic and pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30932720/),%,88.33,225658,DB00563,Methotrexate
,1000510,t1/2,"Within 24 hr after dosages of greater than 24 mg/kg, the rate of tumor cell loss increased to a point characterized by a single exponential (t1/2=8.5 hr).","Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1000510/),h,8.5,225954,DB00563,Methotrexate
,15704189,peak levels,"Modification of the MTX dose to achieve peak levels between 700 and 1,000 micromol/L has been recommended.",Methotrexate levels and outcome in osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704189/),[μM] / [l],"700 and 1,000",226251,DB00563,Methotrexate
,15704189,peak MTX level,"The median peak MTX level (n = 52 patients) was 1,060 micromol/L (range: 410-4,700 micromol/L), with significant intra-patient and inter-patient variability.",Methotrexate levels and outcome in osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704189/),[μM] / [l],"1,060",226252,DB00563,Methotrexate
,1480527,Elimination coefficient ke,Elimination coefficient ke (0.151 + 0.05 h-1) and half-life t0.5 (5.3 +/- 2.9 h) were calculated.,[Pharmacokinetics of urinary excretion of methotrexate (MTX) in patients with malignant tumors]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1480527/),1/[h],0.151,226484,DB00563,Methotrexate
,1480527,half-life t0.5,Elimination coefficient ke (0.151 + 0.05 h-1) and half-life t0.5 (5.3 +/- 2.9 h) were calculated.,[Pharmacokinetics of urinary excretion of methotrexate (MTX) in patients with malignant tumors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1480527/),h,5.3,226485,DB00563,Methotrexate
,15088287,bioavailability,The mean bioavailability after oral MTX was 0.64 (range 0.21-0.96) compared to subcutaneous administration.,Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15088287/),,0.64,226745,DB00563,Methotrexate
,304376,half-lives,"Thus, the plasma clearance over the 50-200-mg/kg range may be represented by a single dose-scalable biexponential model with half-lives of 1.8 +/- 0.1 and 8.4 +/- 0.5 hours.",Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/304376/),h,1.8,226929,DB00563,Methotrexate
,304376,half-lives,"Thus, the plasma clearance over the 50-200-mg/kg range may be represented by a single dose-scalable biexponential model with half-lives of 1.8 +/- 0.1 and 8.4 +/- 0.5 hours.",Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/304376/),h,8.4,226930,DB00563,Methotrexate
,304376,Urinary clearance,Urinary clearance has been determined at 104 +/- 8 ml/minute over the dose range of 50-300 mg/kg and only 60% of the MTX was excreted in the urine by 72 hours.,Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/304376/),[ml] / [min],104,226931,DB00563,Methotrexate
,3836843,affinity constant (Ka),The affinity constant (Ka) of the antibody is 1.8 X 10(9) L/mol.,[Radioimmunoassay of the antitumor drug--methotrexate (MTX)]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3836843/),[l] / [mol],1.8 X 10(9),227576,DB00563,Methotrexate
,3836843,lowest detectable level,The concentration of MTX was measured within 1.5 hours and the lowest detectable level was 0.1 ng using only 10 microliter of serum or other biological fluids.,[Radioimmunoassay of the antitumor drug--methotrexate (MTX)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3836843/),ng,0.1,227577,DB00563,Methotrexate
less,6697425,plasma clearance,"Moreover, the computed dose of MTX had to be increased by a larger amount if the MTX plasma clearance after the identification IV push was low (less than 9 l/h).",Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697425/),l,9,228260,DB00563,Methotrexate
,1233246,overall elimination half-life (MTX T1/2),"The overall elimination half-life (MTX T1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min.",Renal function and the rate of disappearance of methotrexate from serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233246/),h,one to about six,229327,DB00563,Methotrexate
,1233246,overall elimination half-life (MTX T1/2),"The overall elimination half-life (MTX T1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min.",Renal function and the rate of disappearance of methotrexate from serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233246/),min,102,229328,DB00563,Methotrexate
,1233246,overall elimination half-life (MTX T1/2),"The overall elimination half-life (MTX T1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min.",Renal function and the rate of disappearance of methotrexate from serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233246/),min,750,229329,DB00563,Methotrexate
,8046321,elimination capacity,"Galactose elimination capacity decreased from 2.45 (+/- 0.48) mM min-1 to 2.04 (+/- 0.60) mM min-1 after the five planned courses of chemotherapy (P = 0.013, Wilcoxon signed-rank test), without any change in routine liver function tests.",High-dose methotrexate treatment and liver function in patients with osteosarcoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8046321/),[mM] / [min],2.45,229939,DB00563,Methotrexate
,8046321,elimination capacity,"Galactose elimination capacity decreased from 2.45 (+/- 0.48) mM min-1 to 2.04 (+/- 0.60) mM min-1 after the five planned courses of chemotherapy (P = 0.013, Wilcoxon signed-rank test), without any change in routine liver function tests.",High-dose methotrexate treatment and liver function in patients with osteosarcoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8046321/),[mM] / [min],2.04,229940,DB00563,Methotrexate
,3363225,initial elimination half-life,The plasma levels-time profiles revealed a biphasic response with a mean initial elimination half-life of 2.3 +/- 0.2 hours and a terminal elimination half-life of 32.2 +/- 7.2 hours.,Pharmacokinetics of high and moderate intravenous doses of methotrexate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363225/),h,2.3,230495,DB00563,Methotrexate
,3363225,terminal elimination half-life,The plasma levels-time profiles revealed a biphasic response with a mean initial elimination half-life of 2.3 +/- 0.2 hours and a terminal elimination half-life of 32.2 +/- 7.2 hours.,Pharmacokinetics of high and moderate intravenous doses of methotrexate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363225/),h,32.2,230496,DB00563,Methotrexate
,2958611,plasma concentrations,"Median MTX plasma concentrations, measured 42 hours after infusion, were significantly higher in patients with Down syndrome versus control patients (average 0.47 vs 0.24 mumol/L, respectively, P = 0.03).",Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958611/),[μM] / [l],0.47,230580,DB00563,Methotrexate
,2958611,plasma concentrations,"Median MTX plasma concentrations, measured 42 hours after infusion, were significantly higher in patients with Down syndrome versus control patients (average 0.47 vs 0.24 mumol/L, respectively, P = 0.03).",Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958611/),[μM] / [l],0.24,230581,DB00563,Methotrexate
,2958611,clearance,The average MTX clearance was 64.1 mL/min/m2 in Down syndrome vs an average control value of 80.6 mL/min/m2 (P = 0.13).,Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958611/),[ml] / [m2·min],64.1,230582,DB00563,Methotrexate
,2958611,clearance,The average MTX clearance was 64.1 mL/min/m2 in Down syndrome vs an average control value of 80.6 mL/min/m2 (P = 0.13).,Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958611/),[ml] / [m2·min],80.6,230583,DB00563,Methotrexate
,7226169,peak,"The concentration of intact ester reached a peak value of 5.4 microM after 40 minutes, before declining to a steady level of 0.9--1.0 microM over the next 6 hours.",Thymidine 5'-O-pivaloate: evidence for prodrug action in the rat and rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226169/),μM,5.4,231243,DB00563,Methotrexate
,7226169,steady level,"The concentration of intact ester reached a peak value of 5.4 microM after 40 minutes, before declining to a steady level of 0.9--1.0 microM over the next 6 hours.",Thymidine 5'-O-pivaloate: evidence for prodrug action in the rat and rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226169/),μM,0.9,231244,DB00563,Methotrexate
,25298296,total run time,"After a solid-phase extraction procedure, the separation of the analytes and IS was performed on a Chromolith RP₁₈e column using an isocratic mobile phase of 5 m m ammonium acetate (pH 5.0) and acetonitrile at a ratio of 25:75 (v/v) using flow-gradient with a total run time of 3.5 min.",A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25298296/),min,3.5,232174,DB00563,Methotrexate
,23354655,time to progression,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,2.7,232543,DB00563,Methotrexate
,23354655,survival,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,2.7,232544,DB00563,Methotrexate
,23354655,survival,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,7.3,232545,DB00563,Methotrexate
,8033296,binding,Centrifugal ultrafiltration of rat plasma spiked in vitro with MTX (1-100 microM) revealed a mean binding to plasma proteins of 21%.,Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033296/),%,21,233570,DB00563,Methotrexate
,8033296,plasma protein binding,"In rats receiving MTX, plasma protein binding was 23% and the relative drug recovery as assessed with venous microdialysis probes was 18%.",Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033296/),%,23,233571,DB00563,Methotrexate
,8033296,relative drug recovery,"In rats receiving MTX, plasma protein binding was 23% and the relative drug recovery as assessed with venous microdialysis probes was 18%.",Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033296/),%,18,233572,DB00563,Methotrexate
,1634927,steady-state MTX plasma concentration,"During infusion, the steady-state MTX plasma concentration was 11.3 +/- 4.8 mumol/L.",Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),[μM] / [l],11.3,233852,DB00563,Methotrexate
,1634927,initial half-life (t1/2 alpha),The initial half-life (t1/2 alpha) of MTX decreased from 5.8 +/- 2.1 minutes to 0.7 +/- 0.02 minutes after enzyme administration.,Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),min,5.8,233853,DB00563,Methotrexate
,1634927,initial half-life (t1/2 alpha),The initial half-life (t1/2 alpha) of MTX decreased from 5.8 +/- 2.1 minutes to 0.7 +/- 0.02 minutes after enzyme administration.,Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),min,0.7,233854,DB00563,Methotrexate
,1634927,area under the plasma concentration time curve,The postinfusion area under the plasma concentration time curve of MTX was 301 +/- 171 mumol/L/min without CPDG2 compared with 19.6 +/- 6.1 mumol/L/min with CPDG2.,Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),[μM] / [l·min],301,233855,DB00563,Methotrexate
,1634927,area under the plasma concentration time curve,The postinfusion area under the plasma concentration time curve of MTX was 301 +/- 171 mumol/L/min without CPDG2 compared with 19.6 +/- 6.1 mumol/L/min with CPDG2.,Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634927/),[μM] / [l·min],19.6,233856,DB00563,Methotrexate
,19099710,total clearance (CL),The actual values of total clearance (CL) of MTX of 105 infusions were 7.01 +/- 2.06 L/(m(2).h).,[Investigation on individualized adjustment of target range of high-dose methotrexate]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19099710/),[l] / [h·m(2)],7.01,235227,DB00563,Methotrexate
,16549998,peak serum MTX,The mean value of peak serum MTX was 801 micromol/l (range 298-1831) with significant intra- and inter-patient variability.,No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549998/),[μM] / [l],801,235321,DB00563,Methotrexate
,2066764,peak CSF MTX concentration,"Without CPDG2 rescue, peak CSF MTX concentration was 2,904 +/- 340 mumol/L.",Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2066764/),[μM] / [l],"2,904",235670,DB00563,Methotrexate
,6589560,CSF: plasma ratio,"The CSF: plasma ratio of MTX measured during 58 infusions did not exceed 11% in patients with ALL in remission, but was above this value in 13/34 infusions in patients with leukemia of the central nervous system (CNS).","Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589560/),%,11,237004,DB00563,Methotrexate
,3513684,Response rates,"Response rates were 45% on tamoxifen and 38% on CMF, with median durations of 10.4 and 7.9 months, respectively.",Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513684/),%,45,237457,DB00563,Methotrexate
,3513684,Response rates,"Response rates were 45% on tamoxifen and 38% on CMF, with median durations of 10.4 and 7.9 months, respectively.",Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3513684/),%,38,237458,DB00563,Methotrexate
,16513536,blood trough level,The CsA dose was adjusted to maintain the blood trough level between 150 and 200 ng/mL.,"Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),[ng] / [ml],150 and 200,237577,DB00563,Methotrexate
,16513536,trough concentration,"The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 +/- 43 ng/mL, 1498 +/- 387 ng/mL, 3.2 +/- 1.0 hours, and 10,848 +/- 1,991 ng +/- h/mL, respectively.","Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),[ng] / [ml],161,237578,DB00563,Methotrexate
,16513536,peak concentration,"The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 +/- 43 ng/mL, 1498 +/- 387 ng/mL, 3.2 +/- 1.0 hours, and 10,848 +/- 1,991 ng +/- h/mL, respectively.","Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),[ng] / [ml],1498,237579,DB00563,Methotrexate
,16513536,peak concentration,"The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 +/- 43 ng/mL, 1498 +/- 387 ng/mL, 3.2 +/- 1.0 hours, and 10,848 +/- 1,991 ng +/- h/mL, respectively.","Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),h,3.2,237580,DB00563,Methotrexate
,16513536,area under the curve (24 hours),"The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 +/- 43 ng/mL, 1498 +/- 387 ng/mL, 3.2 +/- 1.0 hours, and 10,848 +/- 1,991 ng +/- h/mL, respectively.","Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),[+·ng] / [-·h·ml],"10,848",237581,DB00563,Methotrexate
,29364523,clearance,"A 2-compartment model with a combination of linear clearance (0.419 L/day) and nonlinear clearance (relevant only at low doses; Vmax and Km of 0.155 mg/day and 0.0458 mg/L, respectively) described ABT-122 pharmacokinetics.",Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29364523/),[l] / [d],0.419,238257,DB00563,Methotrexate
,29364523,Vmax,"A 2-compartment model with a combination of linear clearance (0.419 L/day) and nonlinear clearance (relevant only at low doses; Vmax and Km of 0.155 mg/day and 0.0458 mg/L, respectively) described ABT-122 pharmacokinetics.",Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29364523/),[mg] / [d],0.155,238258,DB00563,Methotrexate
,29364523,Km,"A 2-compartment model with a combination of linear clearance (0.419 L/day) and nonlinear clearance (relevant only at low doses; Vmax and Km of 0.155 mg/day and 0.0458 mg/L, respectively) described ABT-122 pharmacokinetics.",Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29364523/),[mg] / [l],0.0458,238259,DB00563,Methotrexate
,29364523,Subcutaneous bioavailability,Subcutaneous bioavailability was 35%-58% across formulations and populations.,Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29364523/),%,35%-58,238260,DB00563,Methotrexate
,26988222,steady-state MTX concentration,The median steady-state MTX concentration at the end of 6-hr infusion was 486 µM/L (range 227-790).,Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988222/),[μM] / [l],486,238828,DB00563,Methotrexate
,26988222,systemic MTX clearance,The median systemic MTX clearance was 4.14 L/h/m(2) (range 1.98-9.35).,Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988222/),[h·l] / [m(2],4.14,238829,DB00563,Methotrexate
,26988222,concentration,The median MTX concentration after 24 h from the beginning of infusion was 3.29 µM/L (range 1.14-100.44).,Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988222/),[μM] / [l],3.29,238830,DB00563,Methotrexate
minor,26988222,clearance,"Moreover, a systemic MTX clearance at the end of infusion minor than 3 L/h/m(2) can predict a delayed elimination (p: 0.0179).",Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26988222/),[h·l] / [m(2],3,238831,DB00563,Methotrexate
,2668915,beta,"The concentration vs time data for total platinum in plasma followed a two-compartment model and the mean (and SE) values for beta, TBC, Vc, and RC were 0.0827 (0.22) hr-1, 2.355 (0.252) liters/hr . m2, 10.74 (0.62) liters/m2, and 2.405 (0.228) liters/hr . m2, respectively.",Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668915/),1/[h],0.0827,239602,DB00563,Methotrexate
,2668915,TBC,"The concentration vs time data for total platinum in plasma followed a two-compartment model and the mean (and SE) values for beta, TBC, Vc, and RC were 0.0827 (0.22) hr-1, 2.355 (0.252) liters/hr . m2, 10.74 (0.62) liters/m2, and 2.405 (0.228) liters/hr . m2, respectively.",Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668915/),[l] / [h·m2],2.355,239603,DB00563,Methotrexate
,2668915,RC,"The concentration vs time data for total platinum in plasma followed a two-compartment model and the mean (and SE) values for beta, TBC, Vc, and RC were 0.0827 (0.22) hr-1, 2.355 (0.252) liters/hr . m2, 10.74 (0.62) liters/m2, and 2.405 (0.228) liters/hr . m2, respectively.",Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668915/),[l] / [h·m2],2.405,239604,DB00563,Methotrexate
,2668915,t 1/2,"The mean (SE) values for t 1/2, TBC, and Vd for free platinum were 1.844 (0.208) hr, 4.583 (1.059) liters/hr . m2, and 11.88 (1.45) liters/m2, respectively.",Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668915/),h,1.844,239605,DB00563,Methotrexate
,2668915,TBC,"The mean (SE) values for t 1/2, TBC, and Vd for free platinum were 1.844 (0.208) hr, 4.583 (1.059) liters/hr . m2, and 11.88 (1.45) liters/m2, respectively.",Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668915/),[l] / [h·m2],4.583,239606,DB00563,Methotrexate
,2668915,Vd,"The mean (SE) values for t 1/2, TBC, and Vd for free platinum were 1.844 (0.208) hr, 4.583 (1.059) liters/hr . m2, and 11.88 (1.45) liters/m2, respectively.",Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668915/),[l] / [m2],11.88,239607,DB00563,Methotrexate
,6961972,bioavailability,"The mean bioavailability (PO/IV) was 42%, but bioavailability was as low as 6% in some cases due to prolonged high serum concentrations after an IV dose, which was not seen with the equivalent PO dose.",Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6961972/),%,42,239698,DB00563,Methotrexate
,6961972,bioavailability,"The mean bioavailability (PO/IV) was 42%, but bioavailability was as low as 6% in some cases due to prolonged high serum concentrations after an IV dose, which was not seen with the equivalent PO dose.",Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6961972/),%,6,239699,DB00563,Methotrexate
,7894696,signal-to-noise ratio,The quantitation limit was 5 ng/ml with a signal-to-noise ratio of 5.,Sensitive determination of methotrexate in monkey plasma by high-performance liquid chromatography using on-line solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7894696/),,5,239963,DB00563,Methotrexate
,14561988,Trough blood concentration (TBC),"Trough blood concentration (TBC) during the first 2 weeks post transplantation was lower in children who developed grade II-IV aGVHD than those developing no GVHD or only grade I (57+/-9 vs 94+/-8 ng/ml, P=0.007), whereas peak blood concentration and area under concentration curve vs time were similar in both groups.",Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561988/),[ng] / [ml],57,240082,DB00563,Methotrexate
,14561988,Trough blood concentration (TBC),"Trough blood concentration (TBC) during the first 2 weeks post transplantation was lower in children who developed grade II-IV aGVHD than those developing no GVHD or only grade I (57+/-9 vs 94+/-8 ng/ml, P=0.007), whereas peak blood concentration and area under concentration curve vs time were similar in both groups.",Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561988/),[ng] / [ml],94,240083,DB00563,Methotrexate
,2532072,response rate,"This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients.",Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2532072/),%,15,240812,DB00563,Methotrexate
,6668557,total body clearance,"Mean total body clearance (from 34.3 to 13.1 ml/min) and mean renal clearance (from 25.6 to 7.6 ml/min) of MTX were found to decrease with increasing steady-state plasma concentrations (from 5.1 to 412 micrograms/ml), whereas nonrenal clearances remained relatively constant.",Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),[ml] / [min],34.3 to 13.1,242530,DB00563,Methotrexate
,6668557,renal clearance,"Mean total body clearance (from 34.3 to 13.1 ml/min) and mean renal clearance (from 25.6 to 7.6 ml/min) of MTX were found to decrease with increasing steady-state plasma concentrations (from 5.1 to 412 micrograms/ml), whereas nonrenal clearances remained relatively constant.",Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),[ml] / [min],25.6 to 7.6,242531,DB00563,Methotrexate
,6668557,steady-state plasma concentrations,"Mean total body clearance (from 34.3 to 13.1 ml/min) and mean renal clearance (from 25.6 to 7.6 ml/min) of MTX were found to decrease with increasing steady-state plasma concentrations (from 5.1 to 412 micrograms/ml), whereas nonrenal clearances remained relatively constant.",Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),[μg] / [ml],5.1 to 412,242532,DB00563,Methotrexate
,6668557,renal clearance,"An essentially steady-state plasma level of 7-OH-MTX was achieved during each MTX infusion, and its renal clearance also decreased (from 37.3 to 6.5 ml/min) with increasing metabolite levels (from 1.8 to 293 micrograms/ml).",Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),[ml] / [min],37.3 to 6.5,242533,DB00563,Methotrexate
,6668557,Plasma protein binding,Plasma protein binding of MTX (56%) and 7-OH-MTX (49%) were independent of concentrations between 0.1 and 300 micrograms/ml.,Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),%,56,242534,DB00563,Methotrexate
,6668557,Plasma protein binding,Plasma protein binding of MTX (56%) and 7-OH-MTX (49%) were independent of concentrations between 0.1 and 300 micrograms/ml.,Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668557/),%,49,242535,DB00563,Methotrexate
,1714790,volume of distribution at steady-state,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [kg],0.398,242987,DB00563,Methotrexate
,1714790,systemic clearance,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [h·kg],0.0956,242988,DB00563,Methotrexate
,1714790,terminal elimination half-life,"The terminal elimination half-life (9.29 hours) of methotrexate was similar to other reported values in adult patients, thus indicating that increases in methotrexate volume of distribution and clearance may offset each other in obesity.",Disposition of high-dose methotrexate in an obese cancer patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),h,9.29,242989,DB00563,Methotrexate
>,12196049,Cp(24h),Cp(24h) >3.5 micro mol/L was confirmed as an indicator of high risk of toxicity.,Pharmacodynamics of high-dose methotrexate in pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196049/),[μmol] / [l],3.5,242996,DB00563,Methotrexate
,7699678,Renal clearance,Renal clearance of MTX at 6 months decreased by a mean (+/- SD) of 23.8 (40.3) cc/min (p = 0.014).,Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699678/),[cc] / [min],23.8,243007,DB00563,Methotrexate
,3839754,half-life,The peak serum level was proportional to the dose administered and was always greater than 10(-4) M. 2 elimination phases were seen: the first had a mean half-life of 2.36 h and the second a mean half-life of 16.14 h.,Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3839754/),h,2.36,243273,DB00563,Methotrexate
,3839754,half-life,The peak serum level was proportional to the dose administered and was always greater than 10(-4) M. 2 elimination phases were seen: the first had a mean half-life of 2.36 h and the second a mean half-life of 16.14 h.,Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3839754/),h,16.14,243274,DB00563,Methotrexate
,3791556,time to peak concentration,"Significant interindividual variability was found in time to peak concentration (30-180 min), peak concentration (0.41-2.77 microM), and to a lesser extent the half-lives (t1/2 alpha: 32.8-86.1 min; t1/2 beta: 43.6-350.0 min; t1/2 absorption: 25.2-60.3 min) and plasma area under the concentration-time curve from zero to infinity (195.6-818.5 microM.min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791556/),min,30-180,244339,DB00563,Methotrexate
,3791556,peak concentration,"Significant interindividual variability was found in time to peak concentration (30-180 min), peak concentration (0.41-2.77 microM), and to a lesser extent the half-lives (t1/2 alpha: 32.8-86.1 min; t1/2 beta: 43.6-350.0 min; t1/2 absorption: 25.2-60.3 min) and plasma area under the concentration-time curve from zero to infinity (195.6-818.5 microM.min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791556/),μM,0.41-2.77,244340,DB00563,Methotrexate
,3791556,half-lives (t1/2 alpha,"Significant interindividual variability was found in time to peak concentration (30-180 min), peak concentration (0.41-2.77 microM), and to a lesser extent the half-lives (t1/2 alpha: 32.8-86.1 min; t1/2 beta: 43.6-350.0 min; t1/2 absorption: 25.2-60.3 min) and plasma area under the concentration-time curve from zero to infinity (195.6-818.5 microM.min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791556/),min,32.8-86.1,244341,DB00563,Methotrexate
,3791556,t1/2 beta,"Significant interindividual variability was found in time to peak concentration (30-180 min), peak concentration (0.41-2.77 microM), and to a lesser extent the half-lives (t1/2 alpha: 32.8-86.1 min; t1/2 beta: 43.6-350.0 min; t1/2 absorption: 25.2-60.3 min) and plasma area under the concentration-time curve from zero to infinity (195.6-818.5 microM.min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791556/),min,43.6-350.0,244342,DB00563,Methotrexate
,3791556,t1/2 absorption,"Significant interindividual variability was found in time to peak concentration (30-180 min), peak concentration (0.41-2.77 microM), and to a lesser extent the half-lives (t1/2 alpha: 32.8-86.1 min; t1/2 beta: 43.6-350.0 min; t1/2 absorption: 25.2-60.3 min) and plasma area under the concentration-time curve from zero to infinity (195.6-818.5 microM.min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791556/),min,25.2-60.3,244343,DB00563,Methotrexate
,3791556,area under the concentration-time curve from zero to infinity,"Significant interindividual variability was found in time to peak concentration (30-180 min), peak concentration (0.41-2.77 microM), and to a lesser extent the half-lives (t1/2 alpha: 32.8-86.1 min; t1/2 beta: 43.6-350.0 min; t1/2 absorption: 25.2-60.3 min) and plasma area under the concentration-time curve from zero to infinity (195.6-818.5 microM.min).",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791556/),min·μM,195.6-818.5,244344,DB00563,Methotrexate
,3791556,area under the concentration-time curve from zero to infinity,"Significant amounts of 7-OH-MTX were detected in plasma, with a mean area under the concentration-time curve from zero to infinity of 208 microM.min compared with 365.6 microM.min for MTX.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791556/),min·μM,208,244345,DB00563,Methotrexate
,3791556,area under the concentration-time curve from zero to infinity,"Significant amounts of 7-OH-MTX were detected in plasma, with a mean area under the concentration-time curve from zero to infinity of 208 microM.min compared with 365.6 microM.min for MTX.",Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3791556/),min·μM,365.6,244346,DB00563,Methotrexate
,15552588,clearance,Preliminary pharmacokinetic investigations of AMI allowed estimation of AMI clearance to be 0.017 mL kg(-1) min(-1) in the rat and 0.043 mL kg(-1) min(-1) in the mouse.,Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552588/),[ml] / [kg·min],0.017,244425,DB00563,Methotrexate
,15552588,clearance,Preliminary pharmacokinetic investigations of AMI allowed estimation of AMI clearance to be 0.017 mL kg(-1) min(-1) in the rat and 0.043 mL kg(-1) min(-1) in the mouse.,Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552588/),[ml] / [kg·min],0.043,244426,DB00563,Methotrexate
,15552588,clearance,"AMF clearance was estimated to be 0.038 and 1.93 mL kg(-1) min(-1) in the mouse and rat, respectively.",Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552588/),[ml] / [kg·min],0.038,244427,DB00563,Methotrexate
,15552588,clearance,"AMF clearance was estimated to be 0.038 and 1.93 mL kg(-1) min(-1) in the mouse and rat, respectively.",Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552588/),[ml] / [kg·min],1.93,244428,DB00563,Methotrexate
,7418714,clearance,This was reflected in a mean clearance value after the 100 mg dose of 31 +/- 16 (SD ml x min(-1) compared with a mean clearance of 62 +/- 19 ml x min(-1) following injection of 25 mg methotrexate.,Dose dependent methotrexate elimination following bolus intravenous injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418714/),[ml] / [min],31,245016,DB00563,Methotrexate
,7418714,clearance,This was reflected in a mean clearance value after the 100 mg dose of 31 +/- 16 (SD ml x min(-1) compared with a mean clearance of 62 +/- 19 ml x min(-1) following injection of 25 mg methotrexate.,Dose dependent methotrexate elimination following bolus intravenous injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418714/),[ml] / [min],62,245017,DB00563,Methotrexate
,7418714,Renal clearance,Renal clearance of methotrexate was markedly lower following the 100 mg dose (18 +/- 6 ml x min(-1) than after 25 mg (53 +/- 19 ml x min(-1).,Dose dependent methotrexate elimination following bolus intravenous injection. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418714/),[ml] / [min],18,245018,DB00563,Methotrexate
,7418714,Renal clearance,Renal clearance of methotrexate was markedly lower following the 100 mg dose (18 +/- 6 ml x min(-1) than after 25 mg (53 +/- 19 ml x min(-1).,Dose dependent methotrexate elimination following bolus intravenous injection. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418714/),[ml] / [min],53,245019,DB00563,Methotrexate
,30584909,PDI,"Optimized formulation depicted 209.6 ± 31.3 nm particle size, 0.209 ± 0.072 PDI and 14.98 ± 1.33 %w/w drug loading.",Novel biosurfactant and lipid core-shell type nanocapsular sustained release system for intravenous application of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30584909/),,0.209,245534,DB00563,Methotrexate
,30584909,drug loading,"Optimized formulation depicted 209.6 ± 31.3 nm particle size, 0.209 ± 0.072 PDI and 14.98 ± 1.33 %w/w drug loading.",Novel biosurfactant and lipid core-shell type nanocapsular sustained release system for intravenous application of methotrexate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30584909/),%,14.98,245535,DB00563,Methotrexate
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,96,245576,DB00563,Methotrexate
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,95,245577,DB00563,Methotrexate
,11695851,plasma protein binding,"2. The extent of plasma protein binding of MA4, PB and MTX was approximately 96, 95 and 65%, respectively, and it did not differ significantly between the male and female rat.",Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),%,65,245578,DB00563,Methotrexate
,11695851,CLrf/GFR,The CLrf/GFR for MTX was approximately 2.5 but did not differ significantly between the male and female.,Sex-related differences in the renal disposition of the acidic metabolite of clentiazem in rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695851/),,2.5,245579,DB00563,Methotrexate
,31232278,clearance (CL),"The mean values of clearance (CL) and distribution volume (Vd) of MTX were 6.53 L/h and 67.88 L, respectively.",Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia . ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31232278/),[l] / [h],6.53,245952,DB00563,Methotrexate
,31232278,distribution volume (Vd),"The mean values of clearance (CL) and distribution volume (Vd) of MTX were 6.53 L/h and 67.88 L, respectively.",Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia . ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31232278/),l,67.88,245953,DB00563,Methotrexate
,6848202,total radioactivity dose,"We investigated its clinical pharmacokinetics in six patients; four of them received by rapid i.v. infusion tracer doses of [N5-methyl-14C]MTHHF ranging from 13 to 16 mg/sq m, and 2 received 150 mg/sq m; the total radioactivity dose was 100 to 200 mu Ci/patient.",Clinical pharmacokinetics of 5-methyltetrahydrohomofolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848202/),[ci·mu] / [patient],100 to 200,248349,DB00563,Methotrexate
,6848202,initial half-life,"The elimination of MTHHF from the plasma followed a triexponential pattern, with a harmonic mean initial half-life of 20.1 min, an intermediary half-life of 4.5 hr, and a terminal half-life of 74.6 hr.",Clinical pharmacokinetics of 5-methyltetrahydrohomofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848202/),min,20.1,248350,DB00563,Methotrexate
,6848202,intermediary half-life,"The elimination of MTHHF from the plasma followed a triexponential pattern, with a harmonic mean initial half-life of 20.1 min, an intermediary half-life of 4.5 hr, and a terminal half-life of 74.6 hr.",Clinical pharmacokinetics of 5-methyltetrahydrohomofolate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848202/),h,4.5,248351,DB00563,Methotrexate
,6848202,terminal half-life,"The elimination of MTHHF from the plasma followed a triexponential pattern, with a harmonic mean initial half-life of 20.1 min, an intermediary half-life of 4.5 hr, and a terminal half-life of 74.6 hr.",Clinical pharmacokinetics of 5-methyltetrahydrohomofolate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848202/),h,74.6,248352,DB00563,Methotrexate
,6848202,apparent volume of distribution,"The apparent volume of distribution was 1.6 liters/kg, suggesting rapid and extensive tissue binding.",Clinical pharmacokinetics of 5-methyltetrahydrohomofolate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848202/),[l] / [kg],1.6,248353,DB00563,Methotrexate
,6848202,total clearance,"This, together with the low total clearance of 0.2 ml/kg/min, contributed to the long half-life of this agent.",Clinical pharmacokinetics of 5-methyltetrahydrohomofolate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848202/),[ml] / [kg·min],0.2,248354,DB00563,Methotrexate
,4018118,M,"However, irradiation resulted in a significant increase of MTX (determined by 125I-radioimmunoassay) in brain tissue per gram wet weight (187.6 +/- 17.9 pmol/g vs 46.4 +/- 29.3 pmol/g in unirradiated brain).",Effect of X-irradiation on the pharmacokinetics of methotrexate in rats: alteration of the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018118/),pm,187,249319,DB00563,Methotrexate
,4018118,M,"However, irradiation resulted in a significant increase of MTX (determined by 125I-radioimmunoassay) in brain tissue per gram wet weight (187.6 +/- 17.9 pmol/g vs 46.4 +/- 29.3 pmol/g in unirradiated brain).",Effect of X-irradiation on the pharmacokinetics of methotrexate in rats: alteration of the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018118/),[pM] / [g],46.4,249320,DB00563,Methotrexate
,1688516,major response rate (CR + MR),The major response rate (CR + MR) was thus 35%.,A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688516/),%,35,250050,DB00563,Methotrexate
,3383986,t1/2 alpha,Plasma platinum elimination was biphasic with a short initial phase (t1/2 alpha 10-31 min) and a long beta-phase (t1/2 beta 65-91 h).,Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383986/),min,10-31,250242,DB00563,Methotrexate
,3383986,t1/2 beta,Plasma platinum elimination was biphasic with a short initial phase (t1/2 alpha 10-31 min) and a long beta-phase (t1/2 beta 65-91 h).,Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383986/),h,65-91,250243,DB00563,Methotrexate
,7226160,half-lives,"In rat serum, levels of MTHHF decreased with half-lives of 7 and 55 mins; for MTX, the corresponding values of half-lives were 14 and 54 mins.",Disposition of 5-methyltetrahydrohomofolate and methotrexate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226160/),min,7,250981,DB00563,Methotrexate
,7226160,half-lives,"In rat serum, levels of MTHHF decreased with half-lives of 7 and 55 mins; for MTX, the corresponding values of half-lives were 14 and 54 mins.",Disposition of 5-methyltetrahydrohomofolate and methotrexate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226160/),min,55,250982,DB00563,Methotrexate
,7226160,half-lives,"In rat serum, levels of MTHHF decreased with half-lives of 7 and 55 mins; for MTX, the corresponding values of half-lives were 14 and 54 mins.",Disposition of 5-methyltetrahydrohomofolate and methotrexate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226160/),min,14,250983,DB00563,Methotrexate
,7226160,half-lives,"In rat serum, levels of MTHHF decreased with half-lives of 7 and 55 mins; for MTX, the corresponding values of half-lives were 14 and 54 mins.",Disposition of 5-methyltetrahydrohomofolate and methotrexate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226160/),min,54,250984,DB00563,Methotrexate
,1993335,maximum measurable concentration,The assay has a standard curve maximum measurable concentration of 1000 micrograms/L and a minimum detectable concentration of 0.1 microgram/L.,"Competitive particle concentration fluorescence immunoassay for measuring 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1993335/),[μg] / [l],1000,251087,DB00563,Methotrexate
,1993335,minimum detectable concentration,The assay has a standard curve maximum measurable concentration of 1000 micrograms/L and a minimum detectable concentration of 0.1 microgram/L.,"Competitive particle concentration fluorescence immunoassay for measuring 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1993335/),[μg] / [l],0.1,251088,DB00563,Methotrexate
,19339090,Time-averaged clearances,"Time-averaged clearances (dose divided by area under the curve, combination of endogenous and dialysis clearance) during treatment with high-flux hemodialysis and continuous multiple-exchange peritoneal dialysis were 0.77 mL/min/kg (0.013 mL/s/kg) and 0.65 mL/min/kg (0.011 mL/s/kg), respectively.",Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339090/),[ml] / [kg·min],0.77,251265,DB00563,Methotrexate
,19339090,Time-averaged clearances,"Time-averaged clearances (dose divided by area under the curve, combination of endogenous and dialysis clearance) during treatment with high-flux hemodialysis and continuous multiple-exchange peritoneal dialysis were 0.77 mL/min/kg (0.013 mL/s/kg) and 0.65 mL/min/kg (0.011 mL/s/kg), respectively.",Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339090/),[ml] / [kg·min],0.65,251266,DB00563,Methotrexate
,19339090,Peritoneal clearance,Peritoneal clearance of methotrexate was estimated to be 0.124 +/- 0.037 mL/min/kg (0.00207 +/- 0.00062 mL/s/kg).,Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339090/),[ml] / [kg·min],0.124,251267,DB00563,Methotrexate
,19339090,Peritoneal clearance,Peritoneal clearance of methotrexate was estimated to be 0.124 +/- 0.037 mL/min/kg (0.00207 +/- 0.00062 mL/s/kg).,Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339090/),[ml] / [kg·s],0.00207,251268,DB00563,Methotrexate
,581360,second phase half-disappearance time,Probenecid pretreatment of the animals prolonged the second phase half-disappearance time of MTX from 5.20 +/- 0.89 to 7.086 +/- 0.23 hours (mean +/- SD).,Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/581360/),h,5.20,251913,DB00563,Methotrexate
,581360,second phase half-disappearance time,Probenecid pretreatment of the animals prolonged the second phase half-disappearance time of MTX from 5.20 +/- 0.89 to 7.086 +/- 0.23 hours (mean +/- SD).,Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/581360/),h,7.086,251914,DB00563,Methotrexate
,581360,half-disappearance times,"Also, the rate of decline of plasma MTX concentrations was slower after treatment with probenecid, with mean half-disappearance times of 7.60 +/- 0.77 and 11.32 +/- 1.08 hours.",Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/581360/),h,7.60,251915,DB00563,Methotrexate
,581360,half-disappearance times,"Also, the rate of decline of plasma MTX concentrations was slower after treatment with probenecid, with mean half-disappearance times of 7.60 +/- 0.77 and 11.32 +/- 1.08 hours.",Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/581360/),h,11.32,251916,DB00563,Methotrexate
,8308768,F,"Mean F for the oral tablet was 0.85, while that for the oral solution was 0.87.","A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308768/),,0.85,252352,DB00563,Methotrexate
,8308768,F,"Mean F for the oral tablet was 0.85, while that for the oral solution was 0.87.","A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308768/),,0.87,252353,DB00563,Methotrexate
,8308768,F,The mean F for sc was 0.97; no statistically significant difference existed between the mean F values for the sc and im routes of administration (p = 0.657).,"A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8308768/),,0.97,252354,DB00563,Methotrexate
,10749518,apparent volume of distribution,"Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans.",Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),l,455,252478,DB00563,Methotrexate
,10749518,elimination half-life,Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals.,Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),h,11,252479,DB00563,Methotrexate
,31673826,Q,"The population pharmacokinetic model obtained was: CL (L/h) = 6.5 × BSA0.62, Vc (L) = 0.36 × Weight, Q (L/h) = 0.41 and Vp (L) = 3.2.",Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31673826/),,0.41,254594,DB00563,Methotrexate
,31673826,Vp (L),"The population pharmacokinetic model obtained was: CL (L/h) = 6.5 × BSA0.62, Vc (L) = 0.36 × Weight, Q (L/h) = 0.41 and Vp (L) = 3.2.",Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31673826/),,3.2,254595,DB00563,Methotrexate
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,319,255424,DB00563,Methotrexate
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,350,255425,DB00563,Methotrexate
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,230,255426,DB00563,Methotrexate
,11488768,Ki,"Daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) at 100 and 500 microM showed significant (P < 0.05) inhibition of DMXAA 6-methylhydroxylation (Ki = 131 and 0.59 microM, respectively), but not glucuronidation.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,131,255427,DB00563,Methotrexate
,11488768,Ki,"Daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) at 100 and 500 microM showed significant (P < 0.05) inhibition of DMXAA 6-methylhydroxylation (Ki = 131 and 0.59 microM, respectively), but not glucuronidation.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,0.59,255428,DB00563,Methotrexate
up to,10213209,half-life,The half-life of the drug was estimated to be up to 3 weeks.,Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10213209/),weeks,3,256516,DB00563,Methotrexate
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],73.6,256672,DB00563,Methotrexate
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],88.3,256673,DB00563,Methotrexate
≥,28822046,Cmin,Median Cmin abatacept concentration was ≥ 10 μg/mL (efficacy threshold) at 3 and 6 months in > 90% of patients across BMI groups with both administration routes.,Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28822046/),[μg] / [ml],10,256751,DB00563,Methotrexate
,32216109,absolute bioavailability,The absolute bioavailability of MTX was 73% following subcutaneous administration but less than 1% following oral administration.,Pharmacokinetics of low-dose methotrexate in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32216109/),%,73,257181,DB00563,Methotrexate
less,32216109,absolute bioavailability,The absolute bioavailability of MTX was 73% following subcutaneous administration but less than 1% following oral administration.,Pharmacokinetics of low-dose methotrexate in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32216109/),%,1,257182,DB00563,Methotrexate
,32216109,plasma clearance,The plasma clearance was 1.54 ml min-1 kg-1 (extraction ratio = 2%).,Pharmacokinetics of low-dose methotrexate in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32216109/),[ml] / [kg·min],1.54,257183,DB00563,Methotrexate
,32216109,extraction ratio,The plasma clearance was 1.54 ml min-1 kg-1 (extraction ratio = 2%).,Pharmacokinetics of low-dose methotrexate in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32216109/),%,2,257184,DB00563,Methotrexate
,28097508,IC50,The IC50 for MTXCHNP for HEK was 26.1 μg/ml and 7.7 μg/ml for RAW 264.7 cells.,Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28097508/),[μg] / [ml],26.1,258066,DB00563,Methotrexate
,28097508,IC50,The IC50 for MTXCHNP for HEK was 26.1 μg/ml and 7.7 μg/ml for RAW 264.7 cells.,Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28097508/),[μg] / [ml],7.7,258067,DB00563,Methotrexate
,28097508,IC50,"In DEXCHNP, the IC50 was 20.12 μg/ml for HEK and 7.37 μg/ml for RAW264.7 cells.",Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28097508/),[μg] / [ml],20.12,258068,DB00563,Methotrexate
,28097508,IC50,"In DEXCHNP, the IC50 was 20.12 μg/ml for HEK and 7.37 μg/ml for RAW264.7 cells.",Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28097508/),[μg] / [ml],7.37,258069,DB00563,Methotrexate
,16052545,terminal half-life,"The mean terminal half-life of AMF was found to be 10.9 +/- 3.3 h and was not dose-dependent, and s.c. bioavailability was 28% +/- 7% at 2.2 g/kg.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),h,10.9,258074,DB00563,Methotrexate
,16052545,bioavailability,"The mean terminal half-life of AMF was found to be 10.9 +/- 3.3 h and was not dose-dependent, and s.c. bioavailability was 28% +/- 7% at 2.2 g/kg.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),%,28,258075,DB00563,Methotrexate
,16052545,survival times,"Median survival times for saline-treated control animals and animals receiving i.p. MTX (1.9, 2.8, 3.8 mg/kg) were 9, 12, 10, and 7 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,9,258076,DB00563,Methotrexate
,16052545,survival times,"Median survival times for saline-treated control animals and animals receiving i.p. MTX (1.9, 2.8, 3.8 mg/kg) were 9, 12, 10, and 7 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,12,258077,DB00563,Methotrexate
,16052545,survival times,"Median survival times for saline-treated control animals and animals receiving i.p. MTX (1.9, 2.8, 3.8 mg/kg) were 9, 12, 10, and 7 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,10,258078,DB00563,Methotrexate
,16052545,survival times,"Median survival times for saline-treated control animals and animals receiving i.p. MTX (1.9, 2.8, 3.8 mg/kg) were 9, 12, 10, and 7 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,7,258079,DB00563,Methotrexate
,16052545,survival time,"AMF, median survival time increased to 17 and 14 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,17,258080,DB00563,Methotrexate
,16052545,survival time,"AMF, median survival time increased to 17 and 14 days, respectively.",Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16052545/),d,14,258081,DB00563,Methotrexate
,32671657,IC50,"In vitro studies demonstrated that PPIs inhibited rOAT3-mediated uptake of MTX, with estimated IC50 values of 2.1-5.2 μM, and a rank order of esomeprazole ≈ lansoprazole ≈ omeprazole > rabeprazole.",Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671657/),μM,2.1-5.2,258778,DB00563,Methotrexate
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.31,259420,DB00563,Methotrexate
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.62,259421,DB00563,Methotrexate
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.71,259422,DB00563,Methotrexate
,31200245,Rf,"The Rf values for MTX, SSZ, MK and HCQ were of 0.31 ± 0.03, 0.62 ± 0.02, 0.71 ± 0.02 and 0.83 ± 0.03; respectively.",Innovative HPTLC method for simultaneous determination of ternary mixture of certain DMARDs in real samples of rheumatoid arthritis patients: an application of quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31200245/),,0.83,259423,DB00563,Methotrexate
,15072460,In vivo recoveries,"In vivo recoveries (reverse dialysis) were significantly different in tumor tissue (C6: 8.0 +/- 3.8%; CNS1: 4.9 +/- 2.5%), and in the contralateral hemisphere (C6: 6.0 +/- 4.0%; CNS1: 3.9 +/- 2.5%) between the two tumors.",Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15072460/),%,8.0,259509,DB00563,Methotrexate
,15072460,In vivo recoveries,"In vivo recoveries (reverse dialysis) were significantly different in tumor tissue (C6: 8.0 +/- 3.8%; CNS1: 4.9 +/- 2.5%), and in the contralateral hemisphere (C6: 6.0 +/- 4.0%; CNS1: 3.9 +/- 2.5%) between the two tumors.",Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15072460/),%,4.9,259510,DB00563,Methotrexate
,15072460,In vivo recoveries,"In vivo recoveries (reverse dialysis) were significantly different in tumor tissue (C6: 8.0 +/- 3.8%; CNS1: 4.9 +/- 2.5%), and in the contralateral hemisphere (C6: 6.0 +/- 4.0%; CNS1: 3.9 +/- 2.5%) between the two tumors.",Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15072460/),%,6.0,259511,DB00563,Methotrexate
,15072460,In vivo recoveries,"In vivo recoveries (reverse dialysis) were significantly different in tumor tissue (C6: 8.0 +/- 3.8%; CNS1: 4.9 +/- 2.5%), and in the contralateral hemisphere (C6: 6.0 +/- 4.0%; CNS1: 3.9 +/- 2.5%) between the two tumors.",Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15072460/),%,3.9,259512,DB00563,Methotrexate
> or =,9469355,serum peak,"After multivariate analysis, performed on patients with localized disease only, MTX serum peak (> or = 700 micromol/L) and histologic subtype were proven to be significant predictive factors of histologic response.","Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469355/),[μM] / [l],700,260230,DB00563,Methotrexate
,9469355,serum peak,A dose adaptation of MTX is recommended to obtain a serum peak of 700 micromol/L or greater when MTX is infused in 6 hours.,"Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469355/),[μM] / [l],700,260231,DB00563,Methotrexate
,2782561,area under the plasma concentration-time curve (AUC),"Total drug exposure to oral methotrexate, as measured by the mean area under the plasma concentration-time curve (AUC), was 2.75 microM.h following the morning dose and 2.77 microM.h in the evening.",Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782561/),h·μM,2.75,260646,DB00563,Methotrexate
,2782561,area under the plasma concentration-time curve (AUC),"Total drug exposure to oral methotrexate, as measured by the mean area under the plasma concentration-time curve (AUC), was 2.75 microM.h following the morning dose and 2.77 microM.h in the evening.",Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782561/),h·μM,2.77,260647,DB00563,Methotrexate
,2782561,AUC,"For 6-mercaptopurine, the mean morning AUC (198 ng.h/ml) was higher than that following the evening dose (167 ng.h/ml) (p greater than 0.05); but compared to the wide interpatient variability observed with this drug, this 20% difference is not likely to be clinically significant.",Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782561/),[h·ng] / [ml],198,260648,DB00563,Methotrexate
,2782561,AUC,"For 6-mercaptopurine, the mean morning AUC (198 ng.h/ml) was higher than that following the evening dose (167 ng.h/ml) (p greater than 0.05); but compared to the wide interpatient variability observed with this drug, this 20% difference is not likely to be clinically significant.",Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782561/),[h·ng] / [ml],167,260649,DB00563,Methotrexate
,21692827,volumes of distribution for the central compartment,"The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹.",Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692827/),l,2.4,263196,DB00563,Methotrexate
,21692827,peripheral compartment,"The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹.",Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692827/),l,1.8,263197,DB00563,Methotrexate
,21692827,systemic clearance,"The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹.",Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692827/),day⁻¹·l,0.23,263198,DB00563,Methotrexate
,21692827,intercompartment clearance,"The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹.",Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692827/),day⁻¹·l,2.3,263199,DB00563,Methotrexate
up to,8194163,peak serum concentration,"The peak serum concentration of 7-OH was up to 939 microM, and concentrations of 7-OH-MTX declined triphasically, showing a t1/2 alpha value of 2.45 min, a t1/2 beta value of 30.5 min, and a terminal half-life (t1/2 gamma) of 240 min.",Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194163/),μM,939,263288,DB00563,Methotrexate
,8194163,t1/2 alpha,"The peak serum concentration of 7-OH was up to 939 microM, and concentrations of 7-OH-MTX declined triphasically, showing a t1/2 alpha value of 2.45 min, a t1/2 beta value of 30.5 min, and a terminal half-life (t1/2 gamma) of 240 min.",Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194163/),min,2.45,263289,DB00563,Methotrexate
,8194163,t1/2 beta,"The peak serum concentration of 7-OH was up to 939 microM, and concentrations of 7-OH-MTX declined triphasically, showing a t1/2 alpha value of 2.45 min, a t1/2 beta value of 30.5 min, and a terminal half-life (t1/2 gamma) of 240 min.",Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194163/),min,30.5,263290,DB00563,Methotrexate
,8194163,terminal half-life (t1/2 gamma),"The peak serum concentration of 7-OH was up to 939 microM, and concentrations of 7-OH-MTX declined triphasically, showing a t1/2 alpha value of 2.45 min, a t1/2 beta value of 30.5 min, and a terminal half-life (t1/2 gamma) of 240 min.",Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194163/),min,240,263291,DB00563,Methotrexate
,8194163,total clearance,"The total clearance value was 14.5 ml min-1 kg, and the postdistributional volume of distribution (V beta) was 5070 ml/kg.",Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194163/),[kg·ml] / [min],14.5,263292,DB00563,Methotrexate
,8194163,volume of distribution (V beta),"The total clearance value was 14.5 ml min-1 kg, and the postdistributional volume of distribution (V beta) was 5070 ml/kg.",Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194163/),[ml] / [kg],5070,263293,DB00563,Methotrexate
,2924373,terminal half-lives,"Plasma concentrations of both drugs declined biexponentially, with terminal half-lives of 90.6 min for MTX and 97.2 min for 7-OH-MTX.",Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924373/),min,90.6,264376,DB00563,Methotrexate
,2924373,terminal half-lives,"Plasma concentrations of both drugs declined biexponentially, with terminal half-lives of 90.6 min for MTX and 97.2 min for 7-OH-MTX.",Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924373/),min,97.2,264377,DB00563,Methotrexate
,2924373,total clearance,"The total clearance values were 9.2 and 9.6 ml x kg-1 x min-1, respectively.",Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924373/),[ml] / [kg·min],9.2,264378,DB00563,Methotrexate
,2924373,total clearance,"The total clearance values were 9.2 and 9.6 ml x kg-1 x min-1, respectively.",Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924373/),[ml] / [kg·min],9.6,264379,DB00563,Methotrexate
,15795592,bioavailability,The mean bioavailability of methotrexate in patients with inflammatory bowel disease was 84% +/- 38%.,The bioavailability of oral methotrexate in children with inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795592/),%,84,265211,DB00563,Methotrexate
,24354889,central volume of distribution,The mean (interindividual standard deviation) estimated central volume of distribution was 2.3 l (36%) and systemic clearance was 0.019 l h(-1) (37%).,Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24354889/),l,2.3,265445,DB00563,Methotrexate
,24354889,systemic clearance,The mean (interindividual standard deviation) estimated central volume of distribution was 2.3 l (36%) and systemic clearance was 0.019 l h(-1) (37%).,Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24354889/),[l] / [h],0.019,265446,DB00563,Methotrexate
,31633515,half-lives,"IGF-MTX concentrations declined rapidly, with half-lives of 5.2 to 14 minutes for the initial distribution phase and 6.5 to 7.5 hours for the terminal elimination phase.",Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633515/),min,5.2 to 14,266048,DB00563,Methotrexate
,31633515,half-lives,"IGF-MTX concentrations declined rapidly, with half-lives of 5.2 to 14 minutes for the initial distribution phase and 6.5 to 7.5 hours for the terminal elimination phase.",Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633515/),h,6.5 to 7.5,266049,DB00563,Methotrexate
> or =,15073863,peak MTX concentrations,Mean peak MTX concentrations > or = 1000 microM were achieved in 135 patients (96%).,High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073863/),μM,1000,266493,DB00563,Methotrexate
>,15073863,peak MTX plasma concentration,"Patients who had a mean peak MTX plasma concentration > 1500 microM were found to have a worse outcome (estimated 5-year EFS, 58.5% +/- 6.7%) compared with patients who had a mean peak concentration < or = 1500 microM (estimated 5-year EFS, 75.5% +/- 6.6%; P = 0.02).",High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073863/),μM,1500,266494,DB00563,Methotrexate
<,15073863,peak concentration,"Patients who had a mean peak MTX plasma concentration > 1500 microM were found to have a worse outcome (estimated 5-year EFS, 58.5% +/- 6.7%) compared with patients who had a mean peak concentration < or = 1500 microM (estimated 5-year EFS, 75.5% +/- 6.6%; P = 0.02).",High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073863/),μM,1500,266495,DB00563,Methotrexate
,7850920,maximal tolerated AUC,"The maximal tolerated AUC was 5 mg ml-1 min, with neutropenia being the dose-limiting toxicity.",A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850920/),[mg·min] / [ml],5,266538,DB00563,Methotrexate
,7850920,AUC,The recommended AUC for phase II study is 4 mg ml-1 min.,A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850920/),[mg·min] / [ml],4,266539,DB00563,Methotrexate
,8823500,elimination half-life,The elimination half-life ranged from 22 to 42 h when he was off dialysis but fell to a median of 5.5 h during dialysis.,Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823500/),h,22 to 42,266747,DB00563,Methotrexate
,8823500,elimination half-life,The elimination half-life ranged from 22 to 42 h when he was off dialysis but fell to a median of 5.5 h during dialysis.,Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823500/),h,5.5,266748,DB00563,Methotrexate
,18719291,biliary clearance,"The biliary clearance, based on the plasma concentration, was 1.6-fold greater in Abcc3(-/-) mice than in wild-type mice (23 and 15 ml/min/kg, respectively, P < 0.05).",Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719291/),[ml] / [kg·min],23,267210,DB00563,Methotrexate
,18719291,biliary clearance,"The biliary clearance, based on the plasma concentration, was 1.6-fold greater in Abcc3(-/-) mice than in wild-type mice (23 and 15 ml/min/kg, respectively, P < 0.05).",Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719291/),[ml] / [kg·min],15,267211,DB00563,Methotrexate
,18719291,fraction of absorption of methotrexate (F(a) F(g)),"Furthermore, a lower fraction of absorption of methotrexate (F(a) F(g)) was suggested in Abcc3(-/-) mice (0.49 and 0.29 in wild-type and Abcc3(-/-) mice, respectively).",Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719291/),,0.49,267212,DB00563,Methotrexate
,18719291,fraction of absorption of methotrexate (F(a) F(g)),"Furthermore, a lower fraction of absorption of methotrexate (F(a) F(g)) was suggested in Abcc3(-/-) mice (0.49 and 0.29 in wild-type and Abcc3(-/-) mice, respectively).",Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719291/),,0.29,267213,DB00563,Methotrexate
,18719291,intrinsic efflux clearance,"This is ascribed to the reduced intrinsic efflux clearance of methotrexate across the serosal membrane (22 and 5.3 mul/min/sac in wild-type and Abcc3(-/-) mice, respectively, P < 0.05).",Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719291/),[mul] / [min·sac],22,267214,DB00563,Methotrexate
,18719291,intrinsic efflux clearance,"This is ascribed to the reduced intrinsic efflux clearance of methotrexate across the serosal membrane (22 and 5.3 mul/min/sac in wild-type and Abcc3(-/-) mice, respectively, P < 0.05).",Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719291/),[mul] / [min·sac],5.3,267215,DB00563,Methotrexate
,8630630,elimination half-life (t1/2),The elimination half-life (t1/2) of meloxicam is approximately 20 h.,A review of the clinical pharmacokinetics of meloxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),h,20,268516,DB00563,Methotrexate
,8630630,total plasma clearance (CL),This is reflected in a total plasma clearance (CL) of 0.42-0.48 1/h.,A review of the clinical pharmacokinetics of meloxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),[1] / [h],0.42-0.48,268517,DB00563,Methotrexate
,15682382,systemic clearance,"The anti-FcRn antibody, 4C9, increased AMI systemic clearance in a dose-dependent manner (from 0.99+/-0.14 mg/h/kg in control animals to 1.27+/-0.05, 1.73+/-0.50, and 1.97+/-0.49 mL/h/kg in animals treated with 3, 15, and 60 mg/kg 4C9; p<0.05).","Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15682382/),[mg] / [h·kg],0.99,269371,DB00563,Methotrexate
,15682382,systemic clearance,"The anti-FcRn antibody, 4C9, increased AMI systemic clearance in a dose-dependent manner (from 0.99+/-0.14 mg/h/kg in control animals to 1.27+/-0.05, 1.73+/-0.50, and 1.97+/-0.49 mL/h/kg in animals treated with 3, 15, and 60 mg/kg 4C9; p<0.05).","Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15682382/),[ml] / [h·kg],1.27,269372,DB00563,Methotrexate
,15682382,systemic clearance,"The anti-FcRn antibody, 4C9, increased AMI systemic clearance in a dose-dependent manner (from 0.99+/-0.14 mg/h/kg in control animals to 1.27+/-0.05, 1.73+/-0.50, and 1.97+/-0.49 mL/h/kg in animals treated with 3, 15, and 60 mg/kg 4C9; p<0.05).","Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15682382/),[ml] / [h·kg],1.73,269373,DB00563,Methotrexate
,15682382,systemic clearance,"The anti-FcRn antibody, 4C9, increased AMI systemic clearance in a dose-dependent manner (from 0.99+/-0.14 mg/h/kg in control animals to 1.27+/-0.05, 1.73+/-0.50, and 1.97+/-0.49 mL/h/kg in animals treated with 3, 15, and 60 mg/kg 4C9; p<0.05).","Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15682382/),[ml] / [h·kg],1.97,269374,DB00563,Methotrexate
,34147089,clearance (CL),Values for clearance (CL) of 4.33 [2.95-5.92] L h- 1 and central volume of distribution of 4.29 [1.81-7.33] L were estimated.,Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34147089/),1·h-·l,4.33,269401,DB00563,Methotrexate
,34147089,central volume of distribution,Values for clearance (CL) of 4.33 [2.95-5.92] L h- 1 and central volume of distribution of 4.29 [1.81-7.33] L were estimated.,Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34147089/),l,4.29,269402,DB00563,Methotrexate
,1437699,Total systemic clearance,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),[ml] / [min],122.6,269567,DB00563,Methotrexate
,1437699,volume of distribution at steady state,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),[l] / [kg],0.49,269568,DB00563,Methotrexate
,1437699,half-life,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),h,3.1,269569,DB00563,Methotrexate
,1437699,mean residence time,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),h,5.0,269570,DB00563,Methotrexate
,1437699,renal clearance,"Total systemic clearance of MTX, given as mean (SD), was 122.6 (25.1) ml/minute, volume of distribution at steady state 0.49 (0.2) L/kg, half-life 3.1 (0.3) hours, mean residence time 5.0 (0.6) hours, and renal clearance 89.1 (36.3) ml/minute.",Pharmacokinetics of low-dose methotrexate in adult asthmatics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437699/),[ml] / [min],89.1,269571,DB00563,Methotrexate
,7139854,half-lives,"Subsequently there was a third phase, with a definite decrease of erythrocyte MTX concentrations with half-lives of 30-40 days.",Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139854/),d,30-40,269885,DB00563,Methotrexate
,15053825,plasma clearance (CL),3. Morphine reduced plasma clearance (CL) of MTX from 0.147 +/- 0.015 to 0.061 +/- 0.009 mL/min per g bodyweight (P < 0.01).,Effects of morphine on methotrexate disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15053825/),[ml] / [g·min],0.147,270319,DB00563,Methotrexate
,15053825,plasma clearance (CL),3. Morphine reduced plasma clearance (CL) of MTX from 0.147 +/- 0.015 to 0.061 +/- 0.009 mL/min per g bodyweight (P < 0.01).,Effects of morphine on methotrexate disposition in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15053825/),[ml] / [g·min],0.061,270320,DB00563,Methotrexate
,15053825,area under the plasma concentration-time curve (AUC(0- infinity )),The area under the plasma concentration-time curve (AUC(0- infinity )) was raised by morphine from 151 +/- 18 to 369 +/- 36 micro g.mL per min (P < 0.01).,Effects of morphine on methotrexate disposition in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15053825/),[ml·μg] / [min],151,270321,DB00563,Methotrexate
,15053825,area under the plasma concentration-time curve (AUC(0- infinity )),The area under the plasma concentration-time curve (AUC(0- infinity )) was raised by morphine from 151 +/- 18 to 369 +/- 36 micro g.mL per min (P < 0.01).,Effects of morphine on methotrexate disposition in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15053825/),[ml·μg] / [min],369,270322,DB00563,Methotrexate
,12081632,Cl,"Ten kinetic profiles obtained after 10 courses of MTX (1.5 g/m2) in seven patients with inflammatory breast cancer were used to establish the population pharmacokinetic parameters (Cl, 8.16 L/h; t1/2, 12.7 h).",Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081632/),[l] / [h],8.16,271476,DB00563,Methotrexate
,12081632,t1/2,"Ten kinetic profiles obtained after 10 courses of MTX (1.5 g/m2) in seven patients with inflammatory breast cancer were used to establish the population pharmacokinetic parameters (Cl, 8.16 L/h; t1/2, 12.7 h).",Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081632/),h,12.7,271477,DB00563,Methotrexate
,3467879,maturation time,The pharmacokinetics demonstrated correspond to a maturation time of the erythroblasts of about 7 days.,Methotrexate pharmacokinetics in age-fractionated erythrocytes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3467879/),d,7,272463,DB00563,Methotrexate
,2277127,maximum plasma concentration Cmax,When compared with a matched group a significantly higher mean value for the maximum plasma concentration Cmax (992 nmol/L +/- 94 SE vs 721 nmol/L +/- 35 SE) for methotrexate was found (P less than .05) after intramuscular administration of 0.2 mg/kg body weight of the drug.,Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277127/),[nM] / [l],992,273929,DB00563,Methotrexate
,2277127,maximum plasma concentration Cmax,When compared with a matched group a significantly higher mean value for the maximum plasma concentration Cmax (992 nmol/L +/- 94 SE vs 721 nmol/L +/- 35 SE) for methotrexate was found (P less than .05) after intramuscular administration of 0.2 mg/kg body weight of the drug.,Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277127/),[nM] / [l],721,273930,DB00563,Methotrexate
